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Abstract 
The physiological changes of pregnancy alter the pharmacokinetics of low molecular weight 
heparins (LMWH). The optimal dosing strategy of LMWH for the treatment of antenatal 
venous thromboembolism (VTE) is not known and this has led to significant variation in 
prescribing practice when women are managed for antenatal VTE with LMWH.  
The aim of this thesis is to describe the pharmacokinetics of enoxaparin during pregnancy 
using the method of population pharmacokinetic (PK) modelling. In addition, pregnant 
women’s thrombin generation and D-dimers are measured and described and their views and 
adherence to enoxaparin are explored.  
Pregnant women prescribed enoxaparin at King’s College Hospital were eligible for 
recruitment. Subjects (n=123) had up to 3 anti-Xa activities drawn per clinic visit (monthly), 
contributing 795 anti-Xa activities for PK modelling purposes. A one compartment model, with 
a combined error model, produced a robust enoxaparin antenatal PK model, with weight, 
baseline lean body weight and gestation found to be significant covariates on enoxaparin 
antenatal PK.  Simulations from the final PK model revealed that a once daily dose of 
enoxaparin is appropriate in this setting.  
D-dimer concentrations were found to increase in line with gestation (r=0.382). Thrombin 
generation was also increased during the antenatal period, with enoxaparin found to 
influence the different thrombin generation parameters in a dose-dependent manner. 
Findings from the adherence aspect of this study revealed that women were highly adherent 
to enoxaparin antentally (mean 97.92%) and demonstrates that women are prepared to inject 
themselves with a parenteral medication, if they feel it is protecting theirs and their unborn 
baby’s health; this belief does impact on adherence to LMWH during the postnatal period, 
where in some women adherence drops (mean 92.75%). 
This study describes the pharmacokinetic profile of enoxaparin during pregnancy and 
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Q inter-compartmental clearance 
RCOG Royal College of Obstetricians and Gynaecologists 
RUV residual unexplained variability 
SD standard deviation 
SE standard error 
SS steady state 
ST start tail 
t time 
t1/2 half-life 
TF tissue factor 
TG thrombin generation 
Tmax time to maximum concentration 
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TTP time to peak 
Vd volume of distribution 
VPC visual predictive check 
vs. versus 
VTE venous thromboembolism  
WFN wings for NONMEM 
Wt total body weight 
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Preface 
A brief history of antenatal venous thromboembolism 
Venous thromboembolism (VTE) is almost five times more common in pregnant women 
compared to women of the same age who are not pregnant [Rodger et al., 2003], and until 
recently has been the commonest cause of direct maternal mortality in the United Kingdom 
[Royal College of Obstetricians and Gynaecologists, 2007; Centre for maternal and child 
enquiries, 2011]. One would therefore expect numerous references to antenatal VTE in the 
historical literature, as it is difficult to imagine how unilateral swelling of the leg, dyspnoea and 
sudden death could have escaped the attention of midwifes and the relatives of pregnant 
women. However, extensive reviews [Anning, 1957; Mannucci, 2002; Dickson, 2004; Bagot 
and Arya, 2008] have found that reference to VTE in general, let alone that associated with 
pregnancy and the post-partum period, prior to the eighteenth century was rare. William 
Smellie’s authoritative textbook on the practice of midwifery from the 18
th
 century contains no 
reference to VTE, although he does describe some pregnant women experiencing difficulty in 
breathing occasionally accompanied by collections of matter in the chest and thorax [Smellie, 
1764]. He perhaps was referring to VTE, but this is speculation. The first reference to VTE is 
widely thought to be the case of Raoul of Normandy, in the 13
th
 century [Dexter and Folch-Pi, 
1974]. This twenty year old man developed oedema in his right ankle, which subsequently 
extended up his thighs; he is reported to have prayed and his symptoms resolved within a 
year. It was some four centuries later that the first detailed description of VTE associated with 
pregnancy and post-partum were reported by Richard Wiseman, the famous Sergeant-
Chirurgical to Kings Charles II [Wiseman, 1676]. He describes the case of a wife of an 
apothecary, who, after a difficult labour developed pain and swelling in the right leg, 
extending from the knee to the hip (developing post-partum deep vein thrombosis (DVT)).  
Prior to 19
th
 century, it was thought that venous thrombosis associated with pregnancy and 
post-partum was due to retention of evil humors in the legs. The 16
th
 century French surgeon 
Ambroise Paré, believed that swelling of the legs during pregnancy was due to the retention 
and concentration of menstrual blood [Mannucci, 2002]. Another widely held view was that 
post-partum thrombosis was due to the retention of unconsumed milk in the legs, 
engorgements laiteaux [Findley, 1912]. Towards the end of the 18
th
 century, Charles White, 
an obstetrician in the then emerging city of Manchester, was one of the first to dispute this 
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humoral thinking and suggested that swelling of the leg during pregnancy was due to 
obstruction, retention and accumulation of lymph in the limb [White, 1784]. He believed this 
was brought about by rupture of the lymphatics from pressure of the fetus’ head and he 
believed that only pregnant and postpartum women could develop this phenomenon and was 
the first to describe phelgmatia alba dolens puerperarium [White, 1801].  Also known as 
phlegmasia dolens, and what would now be recognised as post-partum deep vein 
thrombosis, case reports of phlegmasia dolens  began to be widely reported in the medical 
literature during the nineteenth century [Bacon, 1832; Hodgson, 1835; Johnson, 1842; Winn, 
1852; Crighton, 1871; Barnes, 1880; Elster, 1884; Dixon, 1885; Wilcox, 1897].  
Following the first descriptions of pulmonary embolism by Virchow mid way through the 
nineteenth century [Virchow, 1856], assistant obstetric physician to King’s College Hospital, 
W.S. Playfair began recognising and reporting cases of pulmonary embolism he was 
observing at the time of labour and during the post-partum period [Playfair, 1867; Playfair 
1869]. Very few cases of antenatal pulmonary embolism in the nineteenth century were 
reported, presumably because many would have been sudden and fatal in nature, with the 
condition only gaining recognition mid way through that century. However, of note is a case 
reported in 1872 of an eight month pregnant farmer’s wife in her first pregnancy who 
developed antenatal pulmonary embolism which was successfully managed [Atkinson, 1872]. 
Dr Atkinson describes how this patient woke at 4am in the morning, was violently sick, after 
which she fainted. On examination, she was dyspnoeic (respiratory rate 75) and her pulse 
was found to be rapid and weak. She had visible oedema of the lower extremities, and given 
her signs and symptoms, he concludes that “a clot had come loose and was plugging up one 
of the pulmonary vessels.” He prescribes a mixture containing sprit of sulphuric ether with 
spirit of chloroform, and bottles of hot water to the extremities. For the next few days, she 
rallied, but four days after her initial collapse, she relapsed which passed before Dr Atkinson 
reaches her house. Linseed poultices were then applied to the chest and plenty of 
nourishment ordered. The patient continued in the same state for the next few days, with her 
continued laboured breathing. Eleven days after her initial symptoms, her respiratory rate fell 
to 55, pulse of 120, still coughing, she was perspiring and unable to sleep. Dr Atkinson 
prescribed 15 grains of chloral hydrate, following which, over the next three days, her 
respiratory rate steadily fell to 40. The patient began to recover and by the 2
nd
 May Dr 
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Atkinson discharged her from his care, presumably having delivered her baby successfully. 
The case demonstrates eloquently how patients might have survived VTE, even without the 
treatments available today. 
Following the accidental discovery of heparin by Jay Mclean in 1916 [Mclean, 1916], the 
management of VTE and subsequently antenatal VTE was transformed during the second 
half of the 20
th
 century. Despite this a number of uncertainties remain regarding the optimal 
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Chapter 1 
1.1 Blood coagulation 
1.1.1 An overview 
Coagulation involves a series of complex and inter-linked processes that leads to fibrin 
formation. Haemostasis is coagulation which occurs in a physiological setting and results in 
the sealing of a break in the vasculature, which is essential in protecting its integrity. 
Thrombosis is coagulation in a pathological setting that leads to localised intravascular 
coagulation and potential occlusion of a blood vessel [Key (ed) et al., 2009]. 
When the vessel wall is damaged, exposed collagen in the endothelial matrix attracts and 
binds platelets, causing activation, degranulation and aggregation. In parallel, coagulation is 
activated by the exposure of tissue factor (TF) in the exposed endothelium, resulting in fibrin 
formation, leading to stabilisation of the platelet plug [Sere and Hackeng, 2003; Furie and 
Furie, 2008].  
TF is present in a number of tissues throughout the body [Drake et al., 1989], with highest 
concentrations found in the brain, lung and heart. Low levels are detected in skeletal muscle, 
joints, spleen and the liver. As well as being found in tissues, TF is also expressed on 
vascular smooth muscle cells and the pericyte cells that surround blood vessels. This 
concentration of tissue factor which surrounds the vasculature is referred to as the 
haemostatic envelope. Under normal conditions, the endothelium acts as a barrier to 
separate TF from factor VII and factor VIIa in the circulating blood. TF is also found 
expressed on many non-vascular cells (such as monocytes) and microparticles in the 
circulation. This blood originating TF is thought to participate in coagulation, with coagulation 
reactions occurring on specific cell surfaces, such as activated platelets and TF-bearing cells 
[Furie and Furie, 2008; Chou et al., 2004]. 
The physiological coagulation process can be described under four distinct phases (see 
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1.1.2 Initiation 
When there is a break in the vasculature, platelets adhere to the site of injury [Varga-Szabo 
et al., 2008]. The initiation phase of coagulation is localised to cells that express TF. After 
binding to factor VIIa (from the circulating blood), the TF-VIIa complex activates small 
amounts of factor IX and factor X. Factor IXa moves into association with platelets, where it 
plays a role in the later stages of haemostasis. Factor Xa activates factor V and forms a 
complex with factor Va to convert small amounts of prothrombin (factor II) to thrombin (factor 
IIa) (0.1-1nM). The source of factor V is from the alpha granules of collagen adherent 
platelets [Monkovic et al., 1990]. The thrombin produced promotes local fibrin formation, but 
is not sufficient to provide full blown haemostasis. 
 
1.1.3 Amplification 
The thrombin formed during the initiation phase acts as an amplifier by acting on platelets 
and proteins to facilitate platelet driven thrombin generation. Thrombin interacts tightly with 
platelet glycoprotein Ib [De Marco et al., 1994]. When bound to glycoprotein Ib, thrombin 
undergoes a conformational change, which is thought to protect it from inhibition. The 
conformational change enhances the ability of thrombin to cleave either of two platelet 
protease-activated receptors (PARs). PARs are members of the seven transmembrane 
domain G-coupled family of proteins [Coughlin, 2005]. Cleavage of a PAR creates a new 
amino terminal, which can fold back on itself and bind to a receptor site in the 
transmembrane domain. This binding initiates a signalling cascade. In platelets, cleavage of 
PAR1 leads to signalling that results in platelet activation.  
Platelet activation leads to: 
- platelets undergoing cytoskeletal changes leading to a shape change 
- platelets degranulating, releasing the contents of both alpha and dense granules 
- dense granules release ADP, which promotes further platelet activation 
- alpha granules release partially activated factor V 
von Willebrand factor (vWF), in addition to participating in platelet adhesion, acts as a carrier 
of factor VIII. vWF binds to glycoprotein Ib and brings factor VIII into close proximity to 
thrombin, which is also bound to glycoprotein Ib. The amplification phase results in activated 
platelets that have cofactors Va and VIIIa bound to their surface. 
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Figure 1.1: An overview of blood coagulation, with permission from John Wiley and Sons, in  
Practical Hemostasis and Thrombosis’, Key NS, Makris M, O’Shaughnessy D, and Lillicrap D, 
eds. Wiley-Blackwell, Oxford, 2nd edition, 2009 
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1.1.4 Propagation 
The platelets are now ready for full blown thrombin generation. Factor IXa formed during the 
initiation phase binds to activated platelets, partly through factor VIIIa and partly independent 
of factor VIIIa. The factor IXa/VIIIa complex activates factor X on the platelet surface. This 
platelet surface generated factor Xa moves directly to complex with platelet surface factor Va. 
In the presence of prothrombin, factor Xa is protected from inhibition by antithrombin or tissue 
factor pathway inhibitor (TFPI). Research suggests that factor Xa/Va complexes are very 
stable and in the presence of a new supply of prothrombin, can immediately act to promote 
thrombin generation [Orfeo et al., 2008]. 
The burst of thrombin generation during the propogation phase leads to cleavage of 
fibrinopeptides from fibrinogen, which exposes new binding sites which fit complementary 
sites on other fibrin molecules [Lord, 2007]. These interactions lead to fibrin molecules 
assembling in long, branched chains anchored at the platelet receptor glycoprotein IIb/IIIa. 
This stabilises the initial platelet plug into a fibrin plug. 
In addition to its role in cleaving fibrinopeptides, thrombin generation participates in a positive 
feedback loop by activating factor XI on the platelet surface [Oliver et al., 1999]. This factor 
XIa can activate factor IXa to enhance factor Xa generation. A single thrombin activated 
platelet exposes more than 12,000 copies of GP IIb/IIIa receptors. The thrombin which are 
bound to fibrin are protected from inhibition by antithrombin. This fibrin bound thrombin 
provides an important role in maintaining haemostasis. 
 
1.1.5 Localisation  
Physiologically, a haemostatic plug should seal the break in the vasculature but not continue 
platelet accumulation and thrombin generation to the point that the entire vessel is occluded. 
The endothelial cells produce the coagulation inhibitor, tissue factor pathway inhibitor (TFPI) 
and heparan sulphate. TFPI inhibits the TF-factor VIIa/factor Xa complex, inhibiting the 
initiation of coagulation. Free thrombin and factor Xa are inhibited by antithrombin (AT); the 
inhibitory activity of AT is markedly enhanced by heparan sulphates [Tanaka et al., 2009]. 
Furthermore, free thrombin in the circulation binds to the endothelial surface-bound 
thrombomodulin (TM) and activates the protein C system. This binding of thrombin to TM 
causes a conformational change in thrombin such that it can no longer cleave fibrinogen or 
activate platelets, and thrombin within the thrombin-TM complex is also found to be more 
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sensitive to inhibition by circulating AT than free thrombin [Turpie and Esmon, 2011]. Protein 
C is a vitamin K-dependent protein and is activated after binding to the endothelial protein C 
receptor and interacting with the thrombin-TM complex. Activated protein C (APC), along with 
its co-factor protein S, inactivates factor Va, and factor VIIIa, decreasing the formation of 
factor Xa-factor Va (the prothrombinase  complex) and factor IXa-factor VIIIa (the intrinsic 
tenase complex), resulting in coagulation inhibition [Sere and Hackeng, 2003; Sarangi et al., 
2010]. APC also enhances fibrinolysis by inactivating plasminogen activator inhibitor-1.  
The intact vasculature also has a number of mechanisms which prevents haemostasis and 
ensures localisation and that coagulation only occurs when necessary. Healthy endothelium 
expresses ectonucleotidase (CD39) and produces prostacyclin (PGI2) and nitric oxide (NO), 
which block platelet adhesion to and activation by healthy endothelium [Jin et al., 2005]. 
 
Under physiological conditions, the afore-mentioned mechanisms ensure that thrombus 
formation is a controlled and balanced process; deficiency or impairment of these systems 
may result in a hypercoagulable state. 
 
1.2 Thrombin generation 
The coagulation system is complex and measuring the individual plasma levels or activities of 
individual proteins holds little clinical utility [Castoldi and Rosing, 2011]. Research suggests 
that patients with the same coagulation factor deficiency or thrombophilic defect, often 
experience different bleeding or thrombotic risks, depending on genetic and environmental 
factors also present. In current clinical practice, no valid test for the overall haemostatic 
thrombotic system exists [Hemker et al., 2002]. The clotting times most commonly utilised in 
clinical practice, the prothrombin time and the activated partial thromboplastin time, are of 
limited use as they do not indicate the haemostatic potential in an individual and have been 
developed for a specific use, e.g. the prothrombin time to monitor oral vitamin K antagonist 
therapy [Baglin, 2005]. The current lack of a valid test of the overall haemostatic thrombotic 
system means that it can at times be difficult to judge which patients are at higher risk of 
thrombosis and require intervention, and whether the intervention initiated is actually 
effective. Hence there is a need for global assays which evaluate the overall coagulation 
function that reliably estimates the bleeding or thrombotic risk in an individual patient. 
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Thrombin is central to haemostasis and thrombosis; its formation is influenced by numerous 
coagulation factors and has numerous actions on the blood [Hemker et al., 2002], with no 
process bypassing thrombin. Thrombin can therefore be considered as a central marker of 
haemostasis and can be considered to represent the phenotype of the thrombotic-
haemostatic function of blood [Hemker and Beguin, 2000]. Research into a thrombin 
generation test dates back to work carried out over fifty years ago [Macfarlane and Biggs, 
1953; Pitney and Dacie, 1953]. However the assays developed following this early research 
were labour intensive and imprecise. In the 1980’s Hemker and colleagues re-visited the 
thrombin generation test and developed a method which was reproducible and accurate 
[Hemker et al., 2003]. 
Thrombin generation assays measure the ability of a plasma sample to generate thrombin 
following in-vitro activation of coagulation with tissue factor (TF) or another trigger. As well as 
exploring the initiation phase of coagulation, in contrast to classical coagulation tests, 
thrombin generation assays probe the propagation phase (where the bulk of thrombin is 
formed) and the termination phase (where thrombin formation is shut down and inhibited) 
[Castoldi and Rosing, 2011]. The thrombin generation curve which results, reflects both the 
pro- and anticoagulant reactions that lead to the formation and inhibition of thrombin, and 
show great potential as a global test of plasma coagulability [Baglin, 2005]. Research has 
shown, that in platelet poor plasma (PPP), thrombin generation is diminished in all 
coagulation factor deficiencies and in patients receiving anticoagulant treatment. In platelet 
rich plasma (PRP), thrombin generation is found to be diminished in both congenital and 
acquired platelet related disorders and in those patients receiving anti-platelet drugs. 
Conversely, thrombin generation in PPP is increased in congenital and acquired 
thrombophilias [Hemker et al., 2003].  
1.2.1 Calibrated automated thrombography (CAT) 
The CAT assay [Hemker et al., 2003; Hemker et al., 2006] utilises a fluorogenic substrate (Z-
Gly-Gly-Arg-AMC) to continuously monitor thrombin activity in plasma. As fluorescence is not 
affected by the turbid changes associated with clot formation, the test can be conducted in 
both PPP and PRP. However, appropriate calibration is needed to account for the quenching 
of the fluorescence signal by substrate molecules that have already been converted and by 
the plasma colour, which differs among individuals [Castoldi and Rosing, 2011]. The 
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fluorescence output readings are automatically converted into thrombin generation curves by 
dedicated software. The principle of the fluorescence approach has also been developed with 
chromogenic substrates [Hemker et al., 1993]. However, with the chromogenic approach, the 
turbidity of the emerging clot can affect optical density measurements, so fibrinogen 
containing plasma and PRP cannot be used.  This is not the case with the fluorescence 
approach.  
Each CAT test is typically carried out in triplicate on a microtitre plate, with two tests carried 
out on the same plasma sample. In a set of triplicate wells (the measurement wells), TF and 
synthetic phospholipid vesicles are added to the plasma to initiate coagulation. In the second 
set of triplet wells (the calibrator wells), a known amount of substrate-converting activity is 
added to plasma without activating coagulation. The thrombin calibrator consists of thrombin 
bound to α2-macroglobulin, a form of thrombin that cannot be inhibited by plasma protease 
inhibitors. A mixture of calcium chloride and flurogenic substrate is subsequently dispensed in 
both wells and the developing fluorescence is recorded by a fluorometer. A fluorescence 
tracing in the measurement wells is produced and forms the basis of the thrombin generation 
curve produced. In contrast, the calibration wells containing the flurogenic substrate is 
converted at a constant rate by the added thrombin calibrator. This leads to an initial linear 
fluorescence tracing, whose slope is used to convert the raw fluorescence units (RFU) to 
thrombin concentration units (nM). As more substrate is converted, the fluorescence tracing 
bends with substrate consumption. The thrombin generation curve is eventually calculated by 
taking the first derivative of the fully corrected fluorescence tracing [Castoldi and Rosing, 
2011]. Figure 1.2 illustrates the parameters of the thrombin generation curve. The thrombin 
generation curve can be described in terms of lag time, peak height, area under the curve, 
time to peak and start tail. 
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Figure 1.2: The thrombin generation curve, illustrating the lagtime, peak height, time to peak 
and the endogenous thrombin potential (ETP). Reprinted from Thrombosis Research, Vol 
127; (Supplement 1), Castoldi and Rosing, Thrombin generation tests, s21-s25, Copyright 
2011, with permission from Elsevier  
 
The lag time (LT) is a period when no observable thrombin generation is seen, followed by a 
sudden burst in thrombin generation. The lag phase can be considered as representative of 
clotting times in historical tests and is defined as the time needed for the thrombin 
concentration to reach 1/6 of the peak concentration. The area under the curve, referred to as 
the endogenous thrombin potential (ETP), represents the total enzymatic work performed by 
thrombin and is representative of the bleeding/thrombosis potential within an individual. 
Although ETP and peak height are strongly correlated, peak height is sometimes a more 
sensitive indicator of the plasma thrombin generating capacity [Duchemin et al., 2008]. Short 
lag times and high ETP and peak heights suggest a hypercoagulable state. More recently 
researchers have become interested in calculating the thrombin generation velocity, derived 
from the peak, lag-time and time to peak parameters, as shown in equation 1.1: 
                                                 
           
                      
                        (1.1) 
The CAT assay has demonstrated good reproducibility both in PPP [Spronk et al., 2008] and 
in PRP [Gerotziafas et al., 2005]. The assay also demonstrates reasonably consistent results 
(% coefficient of variance ~ 10-15%) when the same individuals were tested repeatedly over 
a one-year period [Dargaud et al., 2009].  
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1.2.2 Altering CAT assay conditions 
One advantage of CAT is that the experimental conditions can be modified for specific 
purposes. For example, the TF concentration used to trigger coagulation determines the 
extent to which the intrinsic coagulation pathway contributes to thrombin generation and what 
role the tissue factor pathway inhibitor (TFPI)/protein S system plays in inhibiting thrombin 
formation. Alternatively, the addition of thrombomodulin or activated protein C extends the 
sensivity of the assay to the protein C anticoagulant pathway. This means that the shape of 
the thrombin generation curve changes according to the reaction conditions used. Dielis and 
colleagues measured thrombin generation under four conditions (1pMTF +/-TM and 
13.6pMTF +/-APC) as well as assessing the effect of the plasma concentrations of 15 
coagulation related proteins in 140 healthy individuals, in order to determine the individual 
proteins’ influence on the thrombin generation parameters [Dielis et al., 2008]. This study 
reports that the strongest determinants of the ETP were fibrinogen and TFPI at low TF 
concentrations, but prothrombin and antithrombin at high TF concentrations. These 
differences in the plasma concentrations of the assay determinants account for the large 
inter-individual variation reported in thrombin generation parameters in population studies 
and explain why thrombin generation is affected by gender [Dielis et al., 2008 ], age [Dielis et 
al., 2008; Haidl et al., 2006], genetic factors [Segers et al., 2010], body mass index (BMI) 
[Fritsch et al., 2010], pregnancy [Rosenkranz et al., 2008], and other drug use, e.g. oral 
contraceptive use [Tchaikovski et al., 2007]. 
Several epidemiological studies have reported a correlation between elevated thrombin 
generation and the risk of VTE [Dargaud et al., 2006; van Hylckama et al., 2007; Tripodi et 
al., 2008; Besser et al., 2008], with thrombin generation tests performed at low TF in the 
presence of TM being the most predictive, as they are shown to be sensitive to both genetic 
and acquired risk factors for the development of VTE [Castoldi and Rosing, 2011]. 
1.2.3 Assay variability 
Although initial studies using thrombin generation assays to guide clinical decisions are 
encouraging, there are several standardisation problems which need to be overcome before 
they can be used routinely [van Veen et al., 2008]. Factors affecting assay outcome by 
promoting contact activation and the release of platelet micro-particles, include; the method 
of blood collection and plasma preparation and the length for which plasma samples are pre-
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heated in the thrombinoscope [de Smedt and Hemker, 2011]. In addition the variation of 
assay conditions and protocols and the use of different reagents, makes establishing a 
reference range for the thrombin generation parameters difficult, as well comparing results 
between laboratories [Dargaud et al., 2007]. 
Such variability can be reduced by the addition of corn-trypsin inhibitor (CTI), which is 
recommended when thrombin generation is initiated at a low TF concentration [Dargaud et 
al., 2007; Luddington and Baglin, 2004]. Furthermore, inter-laboratory variation can be 
improved by standardising reagents and by normalising ETP of each sample against a 
reference plasma measured in parallel [Dargaud et al., 2007]. 
1.2.4 Thrombin generation in pregnancy 
Accepting that thrombin generation represents the thrombotic-haemostatic system, this assay 
has an important role to play in pregnant women, given the prothrombotic state which ensues 
and as a potential marker for monitoring LMWH during the course of pregnancy. 
Thrombin generation has been evaluated in 150 healthy pregnant women by Rosenkranz and 
colleagues, who found that ETP and peak thrombin generation increased significantly with 
gestational weeks, while the lag time and time to peak thrombin generation remained 
unchanged [Rosenkranz et al., 2008]. A result confirmed by others [Hynes et al., 2009; 
Rosetto et al., 2009]. However in contrast, in a study of 93 pregnant women, Dargaud and 
colleagues [2010] report that the increase in thrombin potential begins early in the first 
trimester, further increases in the second trimester and stabilises by the third trimester. They 
also found that thrombin generation did not correlate with other markers of thrombosis (D-
dimers and prothrombin fragment F1+F2) and suggest that this may be due to thrombin 
generation measurements representing the global coagulation capacity of individuals, whilst 
markers such as D-dimers are markers of ongoing coagulation. 
More recently, a group in Plymouth have reported the results of their pilot study measuring 
thrombin generation in 12 pregnant women prescribed enoxaparin [Ngu et al., 2010]. They 
found that the thrombin generation parameters were highly correlated with anti-Xa levels 
(taken three hours post dose) in particular the time to peak and peak concentration. 
Furthermore, a group in London retrospectively analysed samples for thrombin generation  in 
39 patients receiving LMWH during their pregnancy. The thrombin generation parameters 
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were analysed by anti-Xa activity, according to two groups; group one, > 0.4 IU/mL anti-Xa 
activity, group two, < 0.4 IU/mL. The researchers report that only in patients with therapeutic 
anti-Xa activities (group I), did the ETP, peak height and time to peak differ significantly from 
the control group. In those samples with low anti-Xa activity (group II), no difference was 
found for the ETP or peak height, although the time to peak was significantly different from 
that in the control group [Adamidou et al., 2011]. 
Measuring thrombin generation provides a unique insight into the global thrombotic-
haemostasis system of the patient at a specific time, providing an extremely useful marker for 
women on anticoagulant therapy during pregnancy, when there is substantial activation of the 
coagulation system [Hoke et al., 2004]. 
1.2.5 Hexadimethrine bromide (polybrene) and thrombin generation 
Hexadimethrine bromide is a synthetic polymerised quaternary ammonium salt. During the 
late 1950’s and early 1960’s, it was utilised as an alternative agent to protamine to neutralise 
unfractionated heparin in patients undergoing open heart surgery and in those patients with 
an extracorporeal circulation [Weiss et al., 1958; Keats et al., 1959; Blumberg et al., 1960; 
Lillehei et al., 1960]. Although found to be as effective as protamine, its clinical application 
was short lived following reports of renal toxicity [Haller et al., 1962; Ransdell et al., 1965]. 
Over the last few years the use of polybrene within the laboratory setting has re-emerged. As 
well as those working in the field of gene transfer, reporting successful use of polybrene in 
viral gene transfer across target cell membranes [Davis et al., 2002], a use within the 
anticoagulation laboratory has emerged. Messmore and colleagues [2003] evaluated the 
effectiveness of polybrene to neutralise  unfractionated heparin and LMWH (in-vitro) in 
plasma spiked with unfractionated heparin and enoxaparin at anti-Xa concentrations of 0.5, 
1.0 and 1.5 IU/mL. They found that both unfractionated heparin and enoxaparin were 
completely neutralised, by the addition of polybrene. More recently, Carlo and colleagues 
[2009] tested the use of polybrene for heparin neutralisation in the thrombin generation test. 
They reported that a concentration of 0.025mg/mL polybrene completely neutralised the 
anticoagulant effect of up to 2 anti-Xa IU/mL of both unfractionated heparin and LMWH in 
their thrombin generation experiments. Though these experiments need confirmation from a 
reproducibility point of view, they suggest that it should be possible to neutralise the effect the 
LMWH in plasma being tested for thrombin generation using polybrene, and therefore be able 
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to determine what impact the LMWH has on thrombin generation in-vivo, providing a valuable 
insight. 
1.3 Venous Thromboembolism 
Pulmonary embolism (PE) and deep vein thrombosis (DVT) represent the spectrum of one 
disease, and exemplifies thrombosis in a pathological setting. VTE is a complex (multi-
factorial) disease, involving an interaction between environmental and genetic factors. 
Thrombi commonly form in the deep veins of the calf and then propagate into the proximal 
veins, from where they are more likely to embolise [Tapson, 2008]. Figure 1.3 illustrates the 
pathophysiology of VTE. It’s thought that three-quarters of patients who present with PE have 
evidence of DVT in their legs; in the remaining twenty-five percent of patients, usually the 
whole clot has embolised from the leg. 
Chronic sequelae of VTE include the post thrombotic syndrome and chronic thromboembolic 
pulmonary hypertension [Schulman et al., 2006; Pengo et al., 2004]. Post-thrombotic 
syndrome causes chronic venous hypertension, which leads to limb pain, swelling, hyper-
pigmentation, dermatitis and ulceration [Tovey and Wyatt, 2003]. Symptoms of pulmonary 
hypertension include progressive exertional dyspnoea and exercise intolerance, which can 
lead to chest pain on exertion or syncope as a result of severe pulmonary hypertension and 
the inability of a compromised right ventricle to meet the body’s demands for cardiac output 
[Fedullo et al., 2001]. 
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Figure 1.3: The pathophysiology of VTE - With permission, New England Journal of Medicine 
Copyright © 2010 Massachusetts Medical Society. All rights reserved 
 
1.3.1 Incidence 
The annual estimated incidence of VTE is reported to be around 1 in 1000 of the population, 
and although less common in certain regions e.g. Asia, VTE is a worldwide problem 
[Silverstein et al., 1998]. 
VTE is predominantly a disease of older age [Silverstein et al., 1998; Cushman et al., 2004], 
as it is rare prior to adolescence unless thrombophilia or a central venous catheter are 
present [Heit, 2005]. Incidence rates of VTE increase markedly with age for both men and 
women. The overall age-adjusted incidence rate is higher for men (130 per 100 000) than 
women (110 per 100 000) (male:female sex ratio is 1.2:1). However, the incidence is higher 
in women during the childbearing years, while the incidence rates after 45 years of age are 
generally higher in men. PE accounts for a signficiant proportion of VTE, increasing with age 
for both genders [Heit, 2005].  
 
1.3.2 Survival and recurrence 
Survival after experiencing a PE is worse than for a DVT alone [Heit et al., 1999; Goldhaber 
et al., 1999]. The risk of early death among patients with symptomatic PE is 18-fold higher 
when compared to patients with DVT alone. For almost one-quarter of PE patients, the initial 
clinical presentation is sudden death. Independent predicators of mortality after a VTE 
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include increasing age, male gender, lower body mass index, being in a hospital at VTE 
onset, congestive heart failure, chronic lung disease, serious neurological disease and active 
malignancy [Heit, 2005]. 
VTE frequently recurs, with an estimated 30% of patients developing a recurrence within 10 
years [Heit et al., 2000]. The risk of recurrence changes over time, but is highest within the 
first 6-12 months. Independent predictors of recurrence include the male gender, increasing 
age, high body mass index, presence of neurological disease with extremity paresis and 
active malignancy [Heit, 2005]. For women, VTE during pregnancy and the post partum 
period, or VTE precipitated through oral contraceptive use or gynaecologic surgery are 
associated with a reduced risk of recurrence [Heit et al., 2000]. Provoked VTE through 
surgery, trauma or fracture are reported to have a negligible or reduced risk of recurrence 
[Prandoni et al., 1996]. 
 
1.3.3 Risk Factors 
There are a number of risk factors which pre-dispose a patient to the development of VTE. 
Some of these risk factors are hereditary and some acquired. Table 1.1 lists the common risk 
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Table 1.1: Risk factors for VTE 
Hereditary factors Acquired factors 
Antithrombin deficiency 
Protein C deficiency 
Protein S deficiency 
Factor V Leiden 
Activated protein C resistance without factor V Leiden 
Prothrombin gene mutation 
Dysfibrinogenemia 
Plasminogen deficiency 
Immobility, lower-extremity paresis 
Advanced age 
Previous VTE 
Cancer (active or occult) 
Acute medical illness 
Surgery 
Trauma (major trauma or lower-extremity injury) 
Spinal cord injury 
Pregnancy and postpartum period 
Polycythemia vera 
Antiphospholipid antibody syndrome 
Estrogen-containing oral contraceptives or hormone 
replacement therapy 
Cancer therapy (hormonal, chemotherapy, angiogenesis 
inhibitors, radiotherapy) 
Venous compression (tumor, haematoma, arterial 
abnormality) 
Selective estrogen receptor modulators 
Erythropoiesis-stimulating agents 
Inflammatory bowel disease 
Nephrotic syndrome 
Myeloproliferative disorders 
Paroxysmal nocturnal hemoglobinuria 
Obesity 
Central venous catherisation 
 
1.3.4 Treatment 
Anticoagulant therapy is currently the mainstay of treatment for VTE. The purpose of 
anticoagulant therapy is to prevent thrombus extension during the acute phase and 
recurrence during the chronic phase of treatment [Kearon et al., 2008]. The objective 
evidence for using anticoagulant therapy for this indication stems back to 1960, when Barritt 
and Jordan [1960] compared anticoagulant therapy with placebo in patients with symptomatic 
VTE. In their trial, those patients in the anticoagulant arm received one and a half days of 
unfractionated heparin therapy along with two weeks of oral anticoagulation with the Vitamin 
K antagonist, nicoumalone and this was compared to placebo. They reported that the 
anticoagulant treatment arm markedly reduced recurrence and mortality relative to the 
placebo group. Subsequent studies have unequivocally endorsed the findings from Barritt 
and Jordan’s study, that anticoagulant therapy is superior to placebo [Alpert et al., 1976; 
Kanis, 1974; Kernohan et al., 2007]. 
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There is also strong evidence demonstrating a need to use a form of heparin treatment 
initially, in combination with a vitamin K antagonist, as opposed to vitamin K antagonist 
monotherapy. Brandjes and colleagues [1992] conducted a randomised controlled trial 
comparing a vitamin K antagonist alone to a combination of heparin and vitamin K antagonist 
therapy and found a three-fold increase in the rate of VTE in those patients who had received 
vitamin K antagonist therapy alone. 
The American College of Chest Physicians (ACCP) guidelines for the management of VTE 
state that both heparin and vitamin K antagonist therapy should be started at the time of 
diagnosis (or at the time of clinical suspicion – if there is a delay in conducting the diagnostic 
tests) and to discontinue the heparin after five days provided the INR is >2.0 for at least 24 
hours [Kearon et al., 2008].  
Of the heparins available (unfractionated heparin or Low Molecular Weight Heparins 
(LMWH)), LMWH offers the advantage of a predictable pharmacokinetic response and longer 
elimination half-life relative to unfractionated heparin [Ansell et al., 2008]. This allows body 
weight adjusted doses of LMWH to be administered to patients by subcutaneous injection 
once or twice a day, without laboratory monitoring in the majority of cases. The Cochrane 
collaborative carried out a meta-analysis of fixed dose subcutaneous LMWH versus adjusted 
dose unfractionated heparin for VTE and found that LMWH are associated with fewer 
thrombotic complications (3.6% versus 5.4%; OR: 0.68; 95% CI, 0.55 to 0.840) and less 
major bleeding (1.2% versus 2.0%; OR: 0.57; 95% CI, 0.39 to 0.83) [van Dongen et al., 
2004].  
A meta-analysis of five studies involving LMWH has found no difference in recurrent VTE at 3 
months: (OR, 0.85; 95% CI, 0.48 to 1.49), major bleeding at 10 days: (OR, 1.05; 95% CI, 
0.53 to 2.09), when comparing once daily LMWH with twice daily LMWH, suggesting that a 
once daily dose of LMWH is safe and effective [Couturaud et al., 2001]. 
Options for thrombolysis exist for both DVT and PE. For DVT, catheter –directed 
thrombolysis is sometimes conducted in selected patients with ileofemoral DVT and who 
have a low risk of bleeding. The aim of this treatment being to minimise the risk of post-
thrombotic syndrome. Evidence suggests that catheter-directed thrombolysis is effective in 
improving quality of life [Comerota et al., 2000], although limited facilities and experience 
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means that most patients are not routinely offered such treatment. For PE, thrombolytic 
therapy is usually indicated in patients who are haemodynamically compromised [Kearon et 
al., 2008]. 
Once a patient suffers a VTE event, the duration of warfarin therapy depends on the 
presence of risk factors, whether the VTE was provoked and whether the event was a 
recurrence. Table 1.2 summarises the current recommendations from the American College 
of Chest Physcians [Kearon et al., 2008]: 
Table 1.2: Summary of the ACCP recommendations for VTE management 
Clinical scenario Recommended duration of Vitamin K 
antagonist 
VTE secondary to a transient (reversible) risk 
factor 
3 months treatment 
Unprovoked VTE At least 3 months treatment 
After 3 months, all patients should be evaluated 
for the risk-benefit ratio of long term therapy*. In 
those patients with a first unprovoked VTE that is 
a proximal DVT and in whom the risk of bleeding 
is absent and good anticoagulation control is 
feasible, long term treatment* is recommended. 
Second episode of unprovoked VTE Long term treatment* 
VTE and cancer 3 to 6 months of LMWH, following which 
anticoagulant therapy with a vitamin K antagonist 
or LMWH indefinitely* or until the cancer has 
resolved 
*Patients receiving long term treatment, the risk benefit ratio of continuing anticoagulant treatment should be reassessed at regular 
intervals. 
The advent of the newer oral anticoagulant agents such as the direct thrombin inhibitor, 
dabigatran [Schulman et al., 2009] and the direct factor Xa inhibitors rivaroxaban [Buller et 
al., 2010], apixaban and edoxaban are likely to alter this treatment algorithm in the future. 
 
1.4 Heparin 
1.4.1 The discovery of heparin 
Heparin was discovered accidentally in 1916 at John Hopkins University, Baltimore in 1916, 
when, Jay McLean, a second year medical student at the University was trying to isolate 
thromboplastin from the liver of dogs and instead found a substance, now known as heparin, 
which inhibited the coagulation of blood [McLean, 1916]. Following McLean’s discovery, 
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Howell and Holt carried out further work on the newly identified heparin and objectively 
confirmed the inhibitory action of heparin on coagulation: 
“In shed blood it was found that in mixtures containing 0.1% of heparin, the coagulation is 
prevented entirely. In more dilute solutions the coagulation was delayed in proportion to the 
concentration. When injected intravenously (into dogs), kymographic records showed that 
there was no disturbance of heart rate, blood pressure or respiratory rhythm and no variation 
in rectal temperature.” [Howell and Holt, 1918]. 
Following this breakthrough, it took some 15 years before practical and cost-effective 
methods of extracting purified heparin that could be considered for human administration 
became available, as Howell and Holt’s method of extracting heparin was expensive and 
cumbersome.  
Charles and Scott, in Professor Best’s laboratory in Toronto, were the first to extract heparin 
in a highly purified state in 1933 [Charles and Scott, 1933a; Charles and Scott, 1933b; Scott 
and Charles, 1933]. 
They developed a practical method to extract heparin, which yielded large quantities from 
bovine liver. They also found that heparin was distributed in a number of tissues, not 
exclusively in the liver (table 1.3): 
Table 1.3: Distribution of heparin within various tissues 
Tissue Crude heparin per kilo of tissue Purified heparin per kilo of tissue 
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1.4.2 First in man studies 
The first reported administration of heparin in humans was by Godlowski [1933]; however, he 
used a low potency, impure form and reported low level toxicity with its use. Hedenius and 
Wilander [1936], are reported to have initially self-injected heparin (manufactured by 
Professor Jorpes according to the Charles and Scott method), followed by administration to 
patients, and found that 100mg or more of heparin was needed for heparinising man for a few 
hours.  
It was the great Swedish surgeon, Clarence Crafoord, who recognised the potential clinical 
application of heparin as a prophylactic agent against pulmonary embolism. As early as 1929 
he had approached Professor Jorpes of the Chemistry department at the Karolinska Institute 
in Sweden, asking for Howell’s heparin, so he could use it as a prophylactic agent in his 
patients undergoing surgery. At the time, Professor Jorpes said this was not possible 
because of expense and impurities present after the extraction process [Jorpes, 1959]. 
However in 1935, Professor Jorpes approached Clarence Crafoord, after heparin extraction 
and purification had been made possible by the Scott and Charles method. Crafoord 
immediately started a series of experiments by heparinising patients post-operatively, with 
the help of his colleagues, Wetterdal (Gynaecologist) and Leissner (Obstetrician). In total, 
they treated around 800 patients, and in the case series they treated, one would normally 
have expected a VTE rate of 3-4%, perhaps higher. None of the patients suffered from a VTE 
event [Crafoord, 1937; Crafoord and Jorpes, 1941]. At the same time that Crafoord was 
conducting his experiments on his post-op patients, Gordon Murray in Toronto was assessing 
the prophylactic use of heparin post operatively in a case series amounting to 400 cases. His 
results re-affirmed Crafoord’s findings [Murray, 1941]. 
1.4.3 Unfractionated Heparin 
Unfractionated heparin belongs to the family of sulphated glycosaminoglycans 
(mucopolysaccharides). It is present together with histamine in the granules of mast cells, 
and commercial preparations are extracted from beef lung or porcine intestine. Due to the 
variation in potency seen from the different sources used, unfractionated heparin is assayed 
against an internationally agreed standard, so that doses are specific in units of activity 
[Council of Europe, European Directorate for the Quality of Medicines, 2007]. 
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1.4.4 Pharmacology 
Heparin exerts in anticoagulant effect in vivo and in vitro by activating anti-thrombin. 
Antithrombin inhibits the serine proteases XIIa, XIa, Xa, IXa, and IIa, by binding and inhibiting 
the active serine sites, through an arginine-reactive site on the anti-thrombin. Heparin 
modifies this interaction by binding to the lysine site on anti-thrombin, causing a 
conformational change at the arginine-reactive site that converts anti-thrombin from a slow 
inhibitor of thrombin and Xa to a rapid inhibitor. Anti-thrombin binds covalently to the active 
serine centres of coagulation enzymes; heparin then dissociates and can be re-used 
[Rosenberg and Bauer, 1994]. 
About one-third of a heparin dose administered binds to anti-thrombin, with a 
pentasaccharide fraction (green segment of figure 1.4) [Choay et al., 1981] thought to be 
responsible for most of its anticoagulant effect [Lam et al., 1976; Andersson et al., 1976], as 
















Figure 1.4: The pharmacological action of unfractionated heparin 
 
In addition to its anticoagulant effect, heparin increases vessel wall permeability, inhibits the 
proliferation of vascular smooth muscle cells and suppresses osteoblast formation, whilst 
activating osteoclasts [Hirsh et al., 2008]. 
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1.4.5 Pharmacokinetic profile 
Unfractionated heparin (UFH) has a molecular weight ranging from 3000 to 30, 000 daltons 
(mean 15,000 - ~45 monosaccharide chains) [Johnson and Mulloy, 1976]. The high 
molecular weight moieties are cleared more rapidly than those of a lower-molecular weight 
[Hirsh et al., 2008]. 
In vivo, heparin binds to a number of plasma proteins, which reduces its anticoagulant 
activity, contributing to its variable anticoagulant response [Hirsh et al., 2008]. Heparin is also 
found to bind to endothelial cells [Mahadoo et al., 1977; Glimelius et al., 1978; Barzu et al., 
1985] and macrophages [Friedman et al., 1974], which further complicates its 
pharmacokinetic profile [de Swart et al., 1982]. 
Heparin clearance involves a combination of a rapid saturable and a much slower first-order 
mechanism [Olsson et al., 1963; de Swart et al., 1982; Bjornsson et al., 1982]. The 
mechanism of the saturable phase of heparin clearance is through binding to receptors on 
endothelial cells and macrophages, where it is depolymerised. The slower unsaturable 
mechanism involves renal clearance. At therapeutic doses, heparin is cleared through the 
rapid saturable, dose-dependent mechanism, making its pharmacokinetic profile non-linear, 
with both the intensity and duration of effect rising disproportionately with an increase in the 
dose. As a result, its half life will vary according to the dose (and route) administered, 
increasing from 30 minutes following an intravenous bolus dose of 25 units/kg, to 60 minutes 
with a bolus of 100 units/kg, and 150 minutes with a bolus of 400 units/kg [Olsson et al., 
1963; de Swart et al., 1982; Bjornsson et al., 1982].  
1.4.6 Adverse effects 
UFH can cause hyperkalemia, as it is found to inhibit aldosterone secretion [Oster et al., 
1995]. Although all patients treated with heparin may develop reduced levels of aldosterone, 
most are able to compensate through the renin-aldosterone system. However, some patients, 
e.g. patients with diabetes and those with renal impairment, are thought to have an impaired 
compensatory mechanism and may therefore develop hyperkalemia [Anon (a), 1999]. The 
hyperkalemia is usually transient and resolves once heparin is discontinued. 
Heparin has also been associated with the development of thrombocytopenia. Although the 
reported incidence varies greatly, up to 6% of treated patients are thought to be affected 
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[Derlon et al., 1988; Anon (b), 1990]. There are two types of thrombocytopenia attributed to 
heparin. The first is an acute, but usually mild, fall in platelet count occurring within the first 
four days of starting treatment that resolves without stopping treatment. A direct effect of 
heparin on platelet aggregation appears to be responsible [Martindale, 2011]. The second 
type of thrombocytopenia, the more serious form, has an immunological basis. It usually 
develops between day 5 to 15 of treatment and is associated with thromboembolism, 
complicating treatment [Aster, 1995]. The mechanism appears to be as a result of the 
development of antibodies to a complex formed between heparin and platelet factor-4 (found 
on platelets and endothelial cells), which then causes platelet activation and thrombin 
generation. The reaction is independent of dose or route with reports of thrombocytopenia 
after use of heparin flushes [Keeling et al., 2006] or heparin-coated catheters [Warkentin, 
1997]. 
Osteoporosis is another recognised adverse effect of heparin and is a rare complication of 
long-term heparin therapy – around 2% [Nelson-Piercy, 1998; Bates et al., 2008]. Prophylaxis 
and treatment of VTE during pregnancy is one of the few indications requiring the long term 
use of heparin, so most studies of heparin-induced osteoporosis have been during pregnancy 
[Nelson-Piercy, 1998]. In animal studies, heparin causes a dose dependent loss of bone 
through decreasing rates of bone formation and increased bone resorption [Muir et al., 1996] 
and it is thought this mechanism also applies to humans. Subclinical reduction in bone 
density occurs in up to one-third of patients [Bates et al., 2008]. As the state of pregnancy 
additionally causes bone demineralisation, long term heparin use in this cohort of patients 
puts them at particular risk.  
 
Skin necrosis is a rare complication of heparin therapy and may present as a localised 
reaction at the site of subcutaneous injection or more rarely be related to heparin-induced 
thrombocytopenia [Ulrick et al., 1984; Fowlie et al., 1990]. Very rarely, eczematous plaque 
reactions develop in some patients several days after starting treatment. A type IV 
hypersensitivity reaction has been implicated [Bircher et al., 1990]. 
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1.5 Low molecular weight heparins 
In 1976, two research groups both reported the preparation of LMWH fractions from 
unfractionated heparin, and found progressively less effect on the activated partial 
thromboplastin time ((APTT), the laboratory measure of unfractionated heparin activity), 
whilst still inhibiting factor Xa and exerting an anticoagulant effect [Johnson et al., 1976; 
Andersson et al., 1976]. This finding led to extensive research into fragments of LMWH in the 
late 1970’s and early 1980’s and eventually, to the availability of commercial preparations of 
LMWH in the 1990’s. 
LMWH are also glycosaminoglycans, repeating fragments of unfractionated heparin produced 
by controlled enzymatic or chemical depolymerisation processes that yield chains with a 
mean molecular weight of about 5000 Da (table 1.4) [Weitz, 1997; Baglin et al., 2006]. 
 
Table 1.4: The differences between commercially available LMWH 




Ardeparin Peroxidative depolymerisation 
 
6000 1.9 
Dalteparin Nitrous acid depolymerisation 
 
6000 2.7 
Enoxaparin Benzylation and alkaline depolymerisation 
 
4200 3.8 
Nadroparin Nitrous acid depolymerisation 
 
4500 3.6 























Bemiparin Quaternary ammonium fractionation 
 
2900 9.6 




Similar to unfractionated heparin, LMWH exert their anticoagulant effect through binding to 
anti-thrombin [Rang et al., 2005]. Unfractionated heparin and LMWH interaction with 
antithrombin is mediated by a unique
 
pentasaccharide sequence that is randomly distributed 
along
 
the heparin chains. Approximately one third of the chains of
 
unfractionated heparin, but 
only 15 to 25 percent of the chains
 
of LMWH, contain the pentasaccharide
 
sequence 
[Harenberg, 1990]. By binding to anti-thrombin through this unique pentasaccharide 
sequence, the activity of antithrombin is increased 1000 times [Rosenberg and Bauer, 1994]. 
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The key difference between unfractionated and LMWH is their action on factor IIa (thrombin). 
Any pentasaccharide-containing heparin chain
 
can inhibit the action of factor Xa simply by 
binding to antithrombin
 













to inactivate factor IIa, heparin must bind to both antithrombin
 
and thrombin, 
leading to the formation of a ternary complex [Danielsson et al., 1986]. This ternary complex
 
can be formed only by pentasaccharide-containing heparin chains
 
composed of at least 18 
saccharide units. Whereas most of the
 
chains of unfractionated heparin are at least 18 
saccharide
 
units long, less than half of LMWH are of sufficient length to bind to both 
antithrombin
 
and thrombin [Jordan et al., 1980]. This means that LMWH have a greater 
activity against factor Xa, whereas unfractionated heparins have equivalent activity against 
factor IIa and factor Xa.  
It has also been reported that the tissue-factor-pathway inhibitor (TFPI) contributes to the 
inhibitory
 
activity of LMWH and unfractionated
 
heparin against factor Xa [Abildgaard et al., 
1991]. The TFPI
 
forms a complex with and inactivates factor Xa, followed by an inactivation of 
factor VIIa [Sandset et al., 1988]. Both unfractionated heparin
 
and LMWH are thought to 
release TFPI from the endothelium and enhance its inhibitory activity
 
against factor Xa 
[Sandset et al., 1988; Huang et al., 1993; Broze, 1995]. 
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1.5.1 Pharmacokinetics of LMWH 
LMWH have a more predictable pharmacokinetic profile compared to unfractionated heparin, 
which in clinical terms has meant better bioavailability than unfractionated heparin, a dose-
independent rate of clearance and a longer half life [Bara et al., 1985; Bara et al., 1988; 
Weitz, 1997]. The plasma elimination half life of LMWH is longer than that of unfractionated 
heparin, ranging from 2-4 hours, after intravenous injection (rarely used in clinical practice), to 
three to six hours after subcutaneous injection [Harenberg, 1990; Matzsch et al., 1987; Bara 
and Samama 1988]. Over the last twenty years, LMWH have superceeded unfractionated 
heparin as the heparin of choice in clinical practice. This shift in preference has largely been 
led by the favourable pharmacokinetic profile of LMWH. This profile is more favourable for the 
following reasons [Weitz, 1997]: 
1. Less binding to plasma proteins and to proteins released from activated platelets and 
endothelial cells – leading to a more predictable anticoagulant response 
2. Less binding to endothelium – leading to a better bioavailability 
3. Less binding to macrophages – which means a dose independent clearance and a 
longer half-life 
Unfractionated heparin binds to endogenous plasma proteins, for example histidine-rich 
glycoprotein, polymeric vitronectin and fibronectin. It also binds to platelet factor 4, which is 
released from activated platelets and to high molecular weight multimers of von Willebrand 
factor, which are released from platelets and endothelial cells [Lane, 1989; Sobel et al., 1991; 
de Romeuf and Mazurier, 1993].  This binding reduces the anticoagulant activity of 
unfractionated heparin, as there is less available to interact with antithrombin. Furthermore, 
the unpredictable response that is observed with unfractionated heparin is attributed to the 
wide variability in patients’ plasma concentrations of heparin binding proteins [Young et al., 
1992]. In addition, some of these heparin binding proteins are acute phase reactants, which 
increase in concentration at times of illness, and some, like platelet factor 4 and von 
Willebrand factor, are increased during active coagulation [Weitz, 1997]. 
As LMWH exhibit reduced binding to plasma proteins [Young et al., 1993; Young et al., 1994] 
and the endothelium [Barzu et al., 1985], their bioavailability is improved. Furthermore, the 
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reduced binding of LMWH to macrophages explains why they are not cleared by hepatic 
mechanisms to the same extent as unfractionated heparin and why renal clearance is more 
prominent for these agents. In addition, LMWH are thought to be associated with less 
bleeding than unfractionated heparin. This is because, unlike unfractionated heparin, LMWH 
do not increase microvascular permeability [Blajchman et al., 1989]. LMWH have a lower 
affinity for endothelial cells, platelets and von Willebrand factor, which means that LMWH are 
less likely to interfere with the interaction between platelets and the vessel wall [Salzman et 
al., 1980; Horne and Chao, 1990; Weitz, 1997]. 
The better bioavailability, decreased affinity for heparin binding proteins and dose 
independent clearance makes the anticoagulant response to LMWH more predictable and in 
clinical practice has meant that routine laboratory monitoring is unnecessary, except in 
patients at the extremes of body weight and in those with renal impairment [Samama, 1995; 
Kessler, 1997; Abbate et al., 1998].  
The pharmacokinetic properties of LMWH have been studied and described using anti-Xa 
activity as a biomarker. Following subcutaneous injection, dose-dependent anti-Xa activity is 
found, peaking at between 3-4 hours post dose with anti-Xa activity found up to 12 hours later 
[Andrassy and Eschenfelder, 1996]. It is thought, that the persistence of anti-Xa activity in the 
plasma is central to the pharmacological activity of all LMWH. The area under the plasma 
concentration versus time curve (AUC) for the different LMWH increases with rising doses, 
with repeated doses of LMWH also increasing the AUC [Harenberg et al., 1989; Pedersen et 
al., 1991; Barradell et al., 1992]. Figure 1.6 illustrates the typical anti-Xa activity over time in 
non-pregnant individuals, for the three most commonly used LMWH in the UK, dalteparin, 
enoxaparin and tinzaparin, in addition to unfractionated heparin [Andrassy and Eschenfelder, 
1996]. Enoxaparin and dalteparin have similar anti-Xa profiles, whereas tinzaparin’s profile is 
more closely related to unfractionated heparin. For all four preparations, anti-Xa activity 
converges at the 12 hour point.  
LMWH are found to be confined to the intra-vascular space, and their apparent volume of 
distribution corresponds to that of the plasma. The elimination of LMWH is primarily through a 
non-saturable renal route [Andrassy and Eschenfelder, 1996]. 
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Figure 1.6: Elimination curves of Unfractionated heparin (5000 IU), Dalteparin (5000 IU) – two 
administrations, Enoxaparin (4000 IU) and Tinzaparin (50 IU/kg) [Andrassy K, Eschenfelder V 
[1996], with permission from Elsevier]  
 
1.5.2 Adverse effects of LMWH 
Being derived from unfractionated heparin, the side-effects of LMWH mirror those of 
unfractionated heparin. The two clinically relevant side-effects are HIT and osteoporosis. The 
frequency of HIT is approximately three fold lower with LMWH than with unfractionated 
heparin. This is explained by the fact that the interaction of heparin with platelet factor-4 is 
chain length dependent, and so with LMWH, there is less likelihood of that specific interaction 
occurring. However, although the chance of binding with platelet factor-4 is reduced, LMWHs 
can form complexes with platelet factor-4 that are capable of binding HIT antibodies, 
therefore in patients with HIT antibodies, cross-reactivity with LMWH occurs [Warkentin et al., 
2008]. The risk of osteoporosis is reported to be lower with LMWH when compared to 
unfractionated heparin, although research based on rat models is conflicting. Mätzsch and 
colleagues using a rat model, found that for similar anti-Xa activity, the effect of LMWH and 
unfractionated heparin on experimental bone loss were similar [1990]. However, Monreal and 
colleagues [1990], compared the effects of unfractionated heparin and LMWH on bone loss in 
rats and found both heparin types to cause bone loss, although the effect was greater with 
unfractionated heparin. Muir and colleagues [Muir et al.,1997] found both unfractionated 
heparin and LMWH produced a dose-dependent decrease in bone volume in rats, although 
the effect was greater for unfractionated heparin. The current consensus is that both UFH 
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and LMWH have the potential to produce osteopenia, but the risk is greater for unfractionated 
heparin [Hirsh et al., 2008]. 
1.5.3 LMWH use in UK 
In the United Kingdom, there are four LMWH preparations licensed for clinical use; Bemiparin 
Sodium, Dalteparin Sodium, Enoxaparin Sodium and Tinzaparin Sodium. Of these, 
Dalteparin, Enoxaparin and Tinzaparin are most commonly prescribed in clinical practice and 
is where most clinical experience lies [British Medical Association and the Royal 
Pharmaceutical Society of Great Britain, 2010]. Table 1.5 lists the different licensed 
indications and the associated doses. 
Table 1.5: Doses of LMWH recommended in the UK 
Preparation Prophylaxis of VTE Treatment of VTE Unstable angina and 
STEMI 
Dalteparin 2,500-5,000 IU od 200 IU/kg od 120 IU/kg bd 
Enoxaparin 2,000-4,000 IU od 150 IU/kg od 100 IU/kg bd 
Tinzaparin 3,500-4,500 IU od 175 IU/kg od Not licensed 
   
For each LMWH, a wide spectrum of in-vitro and in-vivo coagulation tests can detect 
measurable pharmacodynamic differences between the LMWH when they are administered 
using equivalent anti-Xa doses. Whilst debate continues on whether LMWH are all the same 
[Prandoni and Nenci, 2003; White and Ginsberg, 2003], clinical experience indicates that any 
differences in effectiveness and safety, if they exist, are small [Baglin et al., 2006], with the 
small number of studies comparing one against another having found no clinically meaningful 
differences between them [White and Ginsberg, 2003]. 
 
1.6 Venous Thromboembolism in Pregnancy 
1.6.1 Epidemiology 
VTE during pregnancy represents a significant cause of maternal morbidity, with an overall 
reported incidence of between 1-2 episodes per 1,000 deliveries [Lindqvist et al., 1999; Heit 
et al., 2005, Jacobsen et al., 2008]. These figures represent a five to ten fold increase in risk 
compared to non-pregnant women of a comparable age [Bates et al., 2008]. Over the last 30 
years, thrombosis and thromboembolism has consistently been reported to be the most 
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common cause of direct maternal mortality in the western world, including the UK, remaining 
relatively constant over this time (table 1.6) [Centre for maternal and child enquiries, 2007]. 
The recently published eighth report of the confidential enquiries into maternal deaths in the 
United Kingdom [Centre for maternal and child enquiries, 2011], describes a significant fall in 
deaths as a result of thrombosis and thromboembolism in pregnant and postpartum women, 
from 41 deaths during the reporting period 2003-2005 to 18 deaths during the period 2006-
2008. This is the first time that thrombosis and thromboembolism is not reported as the 
leading cause of direct maternal death in the United Kingdom. The first Royal College of 
Obstetricians and Gynaecologists (RCOG) guideline for VTE prophylaxis during pregnancy 
and the puerperium was published in 2004, so that it is likely that this significant fall in 
mortality, is as a result of more wide-spread ante and post-natal LMWH thromboprophylaxis.  
Table 1.6: Rates per 100 000 maternities of direct deaths from thrombosis and 
thromboembolism; United Kingdom: 1985-2008 
 Pulmonary embolism Cerebral vein Thrombosis Thrombosis and 
thromboembolism 
 n Rate 95% CI n Rate 95% CI n Rate 95% CI 
1985-87 30 1.32 0.83-1.89 2 0.09 0.02-0.32 32 1.41 1.00-1.99 
1988-90 24 1.02 0.68-1.51 9 0.38 0.20-0.72 33 1.40 1.00-1.96 
1991-93 30 1.30 0.91-1.85 5 0.22 0.09-0.51 35 1.51 1.09-2.10 
1994-96 46 2.09 1.57-2.79 2 0.09 0.02-0.33 48 2.18 1.65-2.90 
1997-99 31 1.46 1.03-2.07 4 0.19 0.07-0.48 35 1.65 1.19-2.29 
2000-02 25 1.25 0.85-1.85 5 0.25 0.11-0.59 30 1.50 1.05-2.14 
2003-05 33 1.56 1.11-2.19 8 0.38 0.19-0.75 41 1.94 1.43-2.63 
2006-08 16 0.70 0.43-1.14 2 0.09 0.02-0.35 18 0.79 0.49-1.25 
 
The increased risk of VTE during pregnancy begins in the first trimester and remains high 
during the second and third trimesters [James, 2009]. A meta-analysis of the risk of 
pregnancy related DVT showed event rates of 21.9%, 33.7% and 47.6% over the three 
trimesters, sequentially [Ray and Chan, 1999]. DVT accounts for 85% of pregnancy-related 
symptomatic VTE [James et al., 2005] and affects the left leg in approximately 90% of cases 
[Chan et al., 2010], due to the gravid uterus and compression of the left common iliac vein by 
the right common iliac artery [Arya, 2011]. Rarely, pregnancy associated DVT presents as 
upper extremity thrombosis which is usually associated with either assisted conception or 
ovarian hyperstimulation syndrome [Arya et al., 2001]. Cerebral venous thrombosis is a rare 
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complication of pregnancy, particularly occurring during the third trimester and after delivery 
[Cantu and Barinagarrementeria 1993]. 
1.6.2 Pathophysiology 
During pregnancy, all three of Virchow’s triad factors associated with venous thrombosis are 
present; hypercoagulability, venous stasis and vascular damage [Virchow, 1846].  
Endothelial damage to pelvic vessels can occur during vaginal or abdominal delivery 
[Goodrich & Wood, 1964]. Venous blood flow velocity is reduced by around 50% by the third 
trimester [Macklon et al., 1997]. Normal pregnancy is accompanied by increased 
concentrations of factors VII, VIII, IX, von Willebrand factor and fibrinogen. Conversely, free 
protein S is reduced during pregnancy [Hellgren and Blomback, 1981; de Moerloose et al., 
1998; Bremme, 2003; Szecsi et al., 2010]. These changes are accompanied by impaired 
fibrinolysis through increases in plasminogen activator inhibitors 1 and 2, the latter being 
produced by the placenta [Greer, 1999]. Collectively, these haemostatic changes occur in 
preparation for delivery, to protect against haemorrhage. 
1.6.3 Risk factors for antenatal VTE 
Aside from the haemostatic and venous alterations during pregnancy, the risk of VTE might 
be further increased by the presence of additional factors. As for non-pregnant individuals, 
previous thrombosis is a strong risk factor for VTE, increasing risk 3 to 4 fold (Pabinger et al., 
2002), with recurrent events accounting for 1 in 5 VTE events in pregnancy. About 50% of 
events are associated with thrombophilia; both acquired and inherited. Table 1.7 lists the 
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Table 1.7: Adjusted odds ratio (OR) for risk of VTE in pregnancy and/or postpartum with 
different thrombophilias (data from Lim et al., 2007 and Robertson et al., 2005). 
Thrombophilia Risk of VTE 
 Odds Ratio 95% CI 
 Lim (2007) Robertson (2005) 
Antithrombin deficiency 10 – unknown 4.7 1.3-17 
Protein C deficiency 2 – unknown 4.8 2.2-10.6 
Protein S deficiency - 3.2 1.5-6.9 
Prothrombin G20210A 
(heterozygous) 
3 -10 6.8 2.5-18.8 
Factor V Leiden 
(homozygous) 
10 – 41 34.4 9.9-120.1 
Prothrombin G20210A 
(homozygous) 
- 26.4 1.2-559.2 
Compound 
heterozygote (Factor V 
Leiden and prothrombin 
G20210A) 
9 – 107 - - 
 
Additional factors include the presence of heart disease, sickle cell disease, diabetes, 
smoking, > 35 years age and obesity [James et al., 2006]. Pregnancy related factors include 
assisted reproduction, hyperemesis, pre-eclampsia, multiple gestation, prolonged labour and 
delivery through caesarean section [Royal College of Obstetrics and Gynaecologists, 2009]. 
1.6.4 Medication use in pregnancy 
It is estimated that approximately 80% of pregnant women in the United States of America 
receive at least one medication during their pregnancy [Andrade et al., 2004] with similar 
figures reported for Europe where 80% of pregnant women in Norway and 70% of pregnant 
women in Italy [Engeland et al., 2008; Gagne et al., 2008] had used a medicine during this 
period. Although there is wide-spread use of medications during pregnancy with antibiotics 
and respiratory drugs most commonly prescribed [Andrade et al., 2004], little research has 
been conducted to assess how effective the medication remains, given the physiological 
changes in pregnancy, with safety often being the primary concern during pregnancy 
following the thalidomide and diethylstilbestrol cases [Ing et al., 1962; Goodman et al., 2011]. 
This has largely meant that when drugs have been prescribed during pregnancy they have 
not been objectively evaluated by the relevant pharmaceutical regulatory bodies, meaning the 
clinician prescribing or recommending the medication, does so, off-label, and as few 
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medications are developed and subsequently evaluated in pregnant women, little information 
on appropriate dosing or efficacy exists [Malek and Mattison, 2010]. Furthermore, little 
information exists on women’s adherence to their medication during their pregnancy. 
Information from a recently published Australian study [Sawicki et al., 2011] suggests that 
adherence to medication used for long term conditions during pregnancy may be affected 
and warrants further investigation.  
1.6.5 Anatomical and physiological changes of pregnancy 
Appreciating the anatomical and physiological changes which occur during pregnancy, 
should help develop appropriate dosing strategies for drugs used by pregnant women. Some 
forty years ago researchers began to recognise that the state of pregnancy altered drug 
disposition, which could then alter the desired outcome [Philipson et al., 1976; Philipson, 
1979]. 
1.6.5.1 Anatomical alterations 
Key anatomical changes which occur in pregnant women include, an increase in body weight, 
an increase in uterine volume and composition, outward growth of the pelvis and 
displacement of the abdominal and chest organs [Hytten, 1975; Hill and Pickinpaugh, 2008; 
Malek and Mattison, 2010]. Growth of the uterus alters the centre of gravity of the pregnant 
woman; the heart enlarges, is elevated and rotated to the left, modifying the 
electrocardiogram; the diaphragm is elevated, decreasing lung volume; breasts enlarge and 
the circumference of the rib cage increases. The growth of the uterus increases vascular 
pressure on tissues below the pelvis, leading to oedema, varicosities and venous stasis. 
1.6.5.2 Physiological alterations 
Physiological changes begin early in pregnancy and can broadly be broken down into 
alterations within the cardiovascular, renal, pulmonary, gastrointestinal and haematological 
systems. The key changes associated with these systems and their implications follow. 
Changes in cardiovascular physiology begin in early pregnancy [Abbas et al., 2005] and 
continue through to the postpartum period. Cardiac output increases from 5 to 7.5 L/min, 
stroke volume increases from 65 to 85 ml and heart rate increases from 75 to 87 beats per 
min [Lindheimer et al., 2009]. During the second half of pregnancy, cardiac output is altered 
according to maternal position; cardiac output falling when standing or lying supine 
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[Lohsiriwat and Imrittha, 2008]. Blood pressure falls by mid pregnancy and then begins to rise 
[Ganzevoort et al., 2004]. Collectively, this leads to decreased vascular resistance and blood 
pressure, increased cardiac output, and stimulation of the renin-angiotensin-aldosterone 
system. 
As the uterus grows, the kidneys are moved upward, with progesterone also acting to dilate 
the ureters. Renal blood flow, glomerular filtration and kidney size increase [Pavek et al., 
2009]. During pregnancy, there is an expansion of the intravascular plasma volume by up to 
60% [Anderson, 2005]. In addition, the glomerular filtration rate (GFR) increases by up to 
50% by the end of the first trimester and this increase is maintained throughout pregnancy 
until the last three weeks, when a decrease in GFR is observed, reaching post-partum levels 
by the last week [Anderson, 2005]. The renal changes occurring during pregnancy often have 
important implications for the pharmacokinetic profiles of medications that may be required 
during pregnancy. 
The tidal volume and inspiratory capacity increase during pregnancy. The respiratory rate, 
vital capacity and inspired reserve volume remains unchanged during pregnancy. The total 
lung capacity, residual volume, expiratory reserve volume and functional reserve capacity are 
decreased during pregnancy [Schatz et al., 2006; Jensen et al., 2008]. These changes 
largely have implications for women who suffer from asthma, which may worsen during 
pregnancy [Tan and Thomson, 2000]. Increased blood flow and oedema in the upper airway 
leads to pregnancy rhinitis in approximately one in five women [Demoly et al., 2003]. 
Gastrointestinal changes include an increased stomach pH due to decreased acid secretion 
and delayed stomach emptying. Furthermore, progesterone decreases gut motility and 
sphincter tone; these changes in part explain the heartburn, nausea and vomiting 
experienced by women duringearly pregnancy [Bynum, 1977; Frederiksen, 2001; Matok et 
al., 2009]. 
Maternal blood volume increases by approximately 50% during pregnancy, beginning early in 
the first trimester and plateauing during the third trimester. The increase is approximately 
1500ml for a singleton and 3000ml for a twin pregnancy [Hytten and Leitch, 1971]. Red cell 
volume increases approximalety 400ml in a singleton pregnancy, however plasma volume 
increases to a greater extent than red cell volume, leading to physiological anaemia [Norwitz 
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et al., 2005; Hartman-Craven et al., 2009]. During pregnancy, levels of factor VII, VIII, X and 
von Willebrand factor increase, while protein S, factor XI and platelets tend to decrease 
[Hellgren and Blomback, 1981; de Moerloose et al., 1998; Bremme, 2003]. Due to these 
haemostatic changes, it is well recognised that a procoagulant state is favoured during 
pregnancy, particularly as term approaches, with substantial haemostatic activation, even 
during uncomplicated pregnancy [Eichinger et al., 1999]. Progesterone mediated venous 
stasis and decreased mobility further increases the risk for the development of pathological 
clots to form. 
1.6.6 Treatment of antenatal VTE 
The standard treatment algorithm described for the management of VTE in Table 1.2, based 
on ACCP guidelines [Kearon et al., 2008], does not apply to the treatment of VTE during 
pregnancy. This is because warfarin (and other Vitamin K antagonists) is known to cross the 
placenta causing fetal wasting, fetal bleeding as well as teratogenic effects [Hall et al., 1980; 
Ginsberg et al., 1989a; Chan et al., 2000]. The most common fetal anomaly reported is 
coumarin embryopathy, consisting of nasal hypoplasia and/or stippled epiphyses. Coumarin 
embryopathy typically occurs after in-utero exposure to vitamin K antagonists during the first 
trimester of pregnancy (particularly weeks six to twelve) [Hall et al., 1980]. Vitamin K 
antagonists are also known to cause fetal CNS abnormalities, which can occur following 
exposure during any trimester. Two patterns of CNS damage have been described; dorsal 
midline dysplasia and ventral midline dysplasia [Hall et al., 1980; Chan et al., 2000]. 
The heparins (unfractionated heparin (UFH) and LMWH, due to their molecular size, do not 
cross the placenta [Flessa et al., 1965; Forestier et al., 1984; Forestier et al., 1987; Ginsberg 
et al., 1989b] and are therefore considered safe [Lepercq et al., 2001] to use for maternal 
indications where anticoagulant therapy is indicated, namely [Greer and Hunt, 2005]: 
(i) Treatment of VTE 
(ii) Thromboprophylaxis (venous and arterial) 
(iii) Thromboprophylaxis for women with mechanical heart valves 
(iv) Prevention of foetal loss during the first trimester and placental dysfunction in  
thrombophilic women 
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As previously discussed, LMWH are preferred over UFH in clinical practice. However, one 
fundamental property of LMWH is lost when they are used during the antenatal period, the 
fixed dose response curve. This is due to the physiological changes which occur during 
pregnancy altering their pharmacokinetic profile. 
In 2001, to account for this, the United Kingdom Royal College of Obstetricians and 
Gynaecologists (RCOG) published guidelines for the management of antenatal VTE, which 
were subsequently updated in 2007. The guidelines suggest that a twice daily LMWH 
regimen should be employed, preferably using enoxaparin or dalteparin, where most 
antenatal clinical experience exists (table 1.8), [RCOG, 2007]. This change to the antenatal 
dosing recommendations compares to a fixed dose of 1.5mg/kg once daily of enoxaparin and 
200 IU/kg once daily of dalteparin when used  in those who are not pregnant [Sanofi-Aventis, 
2009; Pharmacia, 2009]. 
Table 1.8: Doses recommended by RCOG for the management of antenatal VTE 
                           Early pregnancy weight (kg) 
LMWH <50 50-69 70-89 >90 
Enoxaparin 40mg bd 60mg bd 80mg bd 100mg bd 
Dalteparin 5000 IU bd 6000 IU bd 8000 IU bd 10000 IU bd 
Tinzaparin 175 IU/kg od (all weights) 
 
The RCOG recommendations also state that routine anti-Xa (accepted biomarker for LMWH 
therapy) monitoring is not usually required if a weight based approach is used, as most 
women will reach a satisfactory peak anti-Xa response, three hours post dose, of between 
0.5-1.2 IU/mL. The RCOG suggest that anti-Xa monitoring is warranted in those patients at 
the extremes of body weight (<50kg and >90kg), patients with renal disease and those with 
complicating factors, such as recurrent VTE. 
The ACCP pregnancy and postpartum guidelines [Bates et al., 2008] state that the optimal 
dosing strategy for the antenatal management of VTE using LMWH is not well described and 
remains controversial. Their guidance is less prescriptive in comparison to those of the 
RCOG, stating that a once or twice daily approach can be used, with or without anti-Xa 
monitoring. If anti-Xa monitoring is conducted, aim for a concentration of 0.6-1.0 IU/mL when 
a twice daily regimen is used, and slightly higher for a once daily regimen. The authors of the 
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guidelines acknowledge that at present definitive advice cannot be provided because of a 
lack of published evidence. 
Surveys of antenatal anticoagulation practice in the treatment of antenatal VTE in the UK and 
Ireland have found that although LMWH are widely used for this indication the particular 
LMWH used, the dosing strategy employed and the frequency of anti-Xa monitoring is highly 
variable [Voke et al.,2007; Knight et al. 2008]. Voke and colleagues surveyed antenatal VTE 
practice in 25 centres in the UK and Ireland (126 patients) and found that 97% of patients 
were treated with a LMWH. Of these, 66% received a once daily regimen, and anti-Xa 
monitoring was performed in 90% of centres with a wide range of target values (table 1.9). 
More recently Knight and colleagues conducted a case control study evaluating the incidence 
and management of obstetric pulmonary embolism in the UK. In their study of 143 patients, 
134 (97%) were treated with LMWH, with 49% receiving a once daily regimen. 
Table 1.9: Regimen and heparins found to be used in Voke [2007] and Knight [2008] 
LMWH Voke (2007) Knight (2008) 
Once a day LMWH Twice a day LMWH Once a day LMWH Twice a day LMWH 
Dalteparin 23 9 11 14 
Enoxaparin 32 27 32 51 
Tinzaparin 28 3 23 3 
Total 83 (66%) 39 (31%) 66 (49%) 68 (51%) 
 
These studies suggest that despite the RCOG (and ACCP) guidelines for the management of 
antenatal VTE, there is currently no consensus on the management of these patients, with 
many clinicians using a once daily LMWH approach [Patel and Hunt, 2008]. 
The dosing controversies described for the management of VTE, also exist when LMWH are 
used for other antenatal indications, raising some important questions regarding the antenatal 
use of LMWH: (i) given the physiological changes occurring during pregnancy, how frequently 
should LMWH be administered during the antenatal period?; (ii) What weight should be used 
to calculate the dose used during pregnancy? 
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1.7 Pharmacokinetic studies evaluating LMWH during pregnancy 
During pregnancy, the expansion of the intravascular plasma volume by up to 60% and the 
increase in the glomerular filtration rate (GFR), by up to 50% by the end of the first trimester, 
will impact on two key independent pharmacokinetic parameters of LMWH; namely the 
apparent volume of distribution and clearance. The apparent volume of distribution (Vd) of a 
drug provides an estimate of the extent to which a drug distributes into extra vascular tissues. 
The Vd is largely dependent on the physiochemical attributes of the drug, namely, molecular 
size, degree of ionisation, lipid solubility and its ability to cross biological membranes [Hanley 
et al., 2010]. As LMWH are confined to the intravascular space, the increase in the plasma 
volume observed during pregnancy will increase the Vd of the LMWH. The clearance (CL) of 
a drug is inversely related to the steady-state plasma concentration of a drug and determines 
the drug’s maintenance dose. CL is largely influenced by the capacity of the liver and 
kidneys, the principal organs involved in the removal of drugs and their metabolites. As the 
GFR increases during the first trimester, and this increase is maintained throughout the 
remainder of pregnancy, because LMWH are principally cleared through renal clearance, one 
would predict an increase in LMWH CL during pregnancy. 
Having an understanding of how pregnancy affects these two independent parameters could 
help ensure the safe and effective use of LMWH and answer some of the uncertainties 
previously raised.  
1.7.1 Pharmacokinetic studies of LMWH during pregnancy 
Following successful use of unfractionated heparin in pregnant women during the 1970’s and 
1980’s [Hirsh et al., 1970; Bonnar, 1976; Spearing et al., 1978; Anon (c), 1979; de Swiet et 
al., 1980; Bonnar, 1981; Chen et al., 1984; Letsky and de Swiet, 1984], as LMWH therapy 
gained acceptance in antenatal practice through the 1990’s, a number of groups began 
publishing research or information on the pharmacokinetics and use of different LMWH 
during pregnancy [Priollet et al., 1986; Melissari et al., 1992; Gillis et al., 1992; Sturridge et 
al., 1994; Hunt et al., 1997; Nelson-Piercy et al., 1997; Blomback et al., 1998; Casele et al., 
1999; Brennard et al., 1999; Bremme et al., 2000; Ellison et al., 2000; Crowther et al., 2000;  
Leqercq et al., 2001; Rodie et al., 2002; Hunt et al., 2003;  Jacobsen et al., 2003; Sephton et 
al., 2003; Norris et al., 2004; Smith et al., 2004; Ensom et al., 2004; Huxtable et al., 2005; 
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Fox et al., 2008; Lebaudy et al., 2008; Ni Ainle et al., 2008; Simpson et al., 2009; Friedrich et 
al., 2010] (see table 1.10 for a summary of each study).  
Table 1.10: Summary of LMWH PK studies published to date in the pregnancy setting 
 - 64 - 
Study LMWH studied Kinetic findings Summary of results reported 




Case report of a patient with a massive ileo-femerol DVT managed with once daily adjusted dose 
enoxaparin (60-80mg daily) from week 13 of her pregnancy. 
The patient delivers at 34 weeks gestation with no thrombotic or haemorrhagic complications. 
 




Case series, reporting on use of dalteparin use in women undergoing termination of pregnancy (as 
prophylaxis) and in women at risk of VTE during their pregnancy. 
The authors report that dalteparin is safe during pregnancy, but this finding needs further endorsement 
from larger clinical studies. 
 




Case series of 6 pregnant women administered enoxaparin for the treatment and prophylaxis of VTE. In 5 
out of 6 patients, the enoxaparin was successfully used with no complications. The sixth patient relapsed 
after 6 weeks of therapy. 
The authors conclude that LMWH could be considered as a alternative agent to unfractionated heparin 
during pregnancy. 
 





Observational study following 16 women in a total of 18 pregnancies, receiving thromboprophylaxis with 
20mg or 40mg daily. Mean anti-Xa activity with the 40mg dose was 0.102 IU/mL compared with 0.036 
IU/mL with the 20mg dose. The mean concentrations were significantly lower  after 20 weeks gestation. 






Observational study assessing dalteparin in 34 high risk pregnancies. Dalteparin was given to maintain a 
trough anti-Xa level of 0.15-0.2 IU/mL and a peak 2 hour post injection concentration of 0.4-0.6 IU/mL. 
Most women required 5,000 units dalteparin once daily during the first trimester. 
The mean time for a dosage increase was 20.5 weeks gestation into the pregnancy (SD 8.2). 26 of the 34 
women required 5,000 IU twice daily by the end of the pregnancy. 
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Study LMWH studied Kinetic findings Summary of results reported 







Reported on 61 pregnant women at high risk of thromboembolism who were managed with enoxaparin 
(usually 40mg). No correlation was found between the gestational age and anti-Xa levels in this study. 
One of only two studies to date suggesting that there is no link between gestational age and anti-Xa 
concentration. 
 





parameters for the 
5 000 IU dose:  
Cmax 0.21 IU/mL 
AUC 1.97 h/mL 
tmax 3.71 h 
t1/2 4.92 h 
Non compartmental pharmacokinetic study assessing dalteparin (2500 or 5000 IU once daily) in 17 
pregnant women during the third trimester (15 women on 5000 IU once a day and 2 women on 2500 IU 
once a day, due to a lower weight).  
They report that the peak concentration, time to maximum concentration and area under the curve were 
lower in this cohort compared to historical non-pregnant population data they had on file. 
The authors also assessed if administering the dose in the morning or evening made a difference and 
report no difference. 
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Study LMWH studied Kinetic findings Summary of results reported 
Casele et al. (1999)
 
Enoxaparin See table in results 
section 
Non compartmental pharmacokinetic study assessing enoxaparin 40mg (thromboprophylaxis) in 13 
women. Women had serial pharmacokinetic parameters measured at 3 time points (12-15 weeks 
gestation, 30-33 weeks and then 6-8 weeks post-partum). During the first and third trimester, the 
maximum concentration and the last measurable anti-Xa activity level were lower than the measurements 
taken during the post partum period. 








Concentration (12 h after 
dose, IU/mL) 
0.09 + 0.09 0.16 + 0.10 0.19 + 0.09 P<0.05 
Maximum concentration 
(IU/mL) 
0.46 + 0.08 0.40 + 0.08 0.57 + 0.09 P<0.05 
Time to max concentration 
(min) 
185 + 46 229 + 118 192 + 53 NS 
Area under plasma activity 






297 + 79 384 + 158 435 + 118 P<0.05 
Apparent clearance 
(mL/min) 
14.6 + 4.9 11.7 + 3.7 10 + 3.6 P<0.05 
Apparent Vd at SS (L) 4.0 + 0.9 3.7 + 0.9 3.1 + 1.0 P<0.05 
Mean residence time (min) 287 + 56 325 + 44 316 + 32 NS 
 






Retrospective study assessing the efficacy of enoxaparin for prophylactic and treatment indications in 50 
women (57 pregnancies). Women on 40mg enoxaparin once daily, the median peak (3 hours post 
injection) was 0.23 IU/mL (IQR 0.14-0.33 IU/mL); for those on 40mg twice a day, the median peak level 
was 0.38 IU/mL (IQR 0.25-0.53 IU/mL); for those on 60mg twice a day, the median peak level was 0.68 
IU/mL (IQR 0.42-0.98 IU/mL); and for those women on 80mg twice a day, the median peak  level was 0.68 
IU/mL (IQR 0.52-0.77 IU/mL). The authors report that peak plasma anti-Xa levels were not affected by 
gestational age.  
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Study LMWH studied Kinetic findings Summary of results reported 




Report the results from 4 women who had allergies to conventional unfractionated heparin therapy, who 
received dalteparin (varying doses) during their pregnancy. Anti-Xa activity was monitored at various time 
points during pregnancy. 
The authors report that the last measurable anti-Xa activity in the third trimester at 37 weeks was 17 hours 
post dose, compared to 24 hours post dose at 40 weeks gestation, and suggest that there is accumulation 
of dalteparin, as term approaches, with the authors suggesting that this could have implications for how 
LMWH are managed around delivery. 




This prospective study followed 42 patients receiving 4900 IU of reviparin once daily throughout their 
pregnancy. Up to four anti-Xa activities per patient were measured scattered throughout these patients 
pregnancies. The authors report that reviparin is safe to use in an antenatal population and found that anti-
Xa activity was highly correlated with patient’s weight, irrespective of gestational age. 
Though in their study, women were receiving fixed prophylactic doses of reviparin, they suggest that 
women requiring treatment doses of LMWH might need their dose adjusting in line with weight increase, 
given the high correlation between weight and anti-Xa activity found in their study. 







Retrospective review of enoxaparin safety in 604 women in France. 49 cases were actively treated for 
VTE (1mg/kg bd) and 574 cases were treated prophylactically (357 received 20mg daily and 217 received 
40mg daily). 
Eight documented VTE events occurred (5 during pregnancy and 3 post partum). The authors concluded 
that the enoxaparin was well tolerated during pregnancy. 







A case series of 36 VTE episodes antenatally, managed with enoxaparin 1mg/kg bd. Target anti-Xa 
activity (0.4-1.0 IU/mL). In 33 women, the initial dose provided satisfactory peak anti-Xa activity (median 
range 0.44-1.0 IU/mL) and was continued. Three women required a dose reduction, due to their peak 
being above the therapeutic range (1.2, 1.2, 1.1 IU/mL). The authors conclude that routine monitoring with 
this regimen is not required. 






A case series of 25 women (27 pregnancies) assessing the use of unmonitored dalteparin 5,000 IU daily 
increased empirically to 5,000 IU bd at 16-20 weeks. All women had normal renal function and were 
classed as obese. 
The authors report that this regimen worked well and does not require monitoring of anti-Xa activity. The 
authors also comment that many of women were on therapeutic warfarin prior to pregnancy and the 
regime they describe appeared to provide adequate anticoagulation cover. 
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Study LMWH studied Kinetic findings Summary of results reported 






Observational study following the VTE management of 20 women.  
For 9 out of 13 women where treatment was initiated at the time of diagnosis at 100 IU/kg bd, dose 
escalation was required to maintain target anti-Xa activity of 0.5-1.0 IU/mL 2-3 hours post injection. 
6 women started on higher doses (mean 112 IU/kg bd) and the target was reached in all cases. 1 woman 
required a dose reduction (to 100 IU/kg bd) after starting on 133 IU/kg bd. The authors concluded that an 
approximately 10-20% higher dose of dalteparin may be needed during pregnancy compared with non-
pregnant women. 
Sephton et al. (2003)
 
 
Dalteparin Relative to non 
pregnancy, the     
AUC 0-24 was lower 
during pregnancy 
at all gestational 
times – with a 
decrease observed 
as the gestation 
progressed 
A prospective observational study of 24 women suffering from recurrent miscarriage and positive for anti-
phospholipid syndrome. The women were administered 5000 units once daily of dalteparin and serial anti-
Xa levels were measured at 12, 24 and 36 weeks, as well as 6 weeks postpartum.  
The authors report a lower peak anti-Xa levels (and AUC0-24) during the pregnancy phases compared to 
the non-pregnant state. 




Observational study of how anti-Xa activity changes for women at moderate risk of VTE during their 
pregnancy, managed with tinzaparin. 
In 24 women, one of three doses (50, 75 or 100 IU/kg) were given according to the treating physician’s 
assessment of their risk profile. Four hour peak anti-Xa levels were measured throughout pregnancy, with 
additional 24 hour profiles measured at 28 and 36 weeks gestation. 
The authors report that women receiving tinzaparin (50 IU/kg) frequently had peak (4 hour) anti-Xa levels 
below 0.1 IU/mL and that 46% of these patients required dose adjustment. Similarly anti-Xa levels were 
also found to be low over a 24 hour period. They suggest that a starting dose of 75 IU/kg once daily, gave 
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Study LMWH studied Kinetic findings Summary of results reported 






54 women (12 for active VTE treatment and 42 for prophylaxis with tinzaparin). Aim of the study was to 
assess whether a dose adjustment would be required through pregnancy to achieve the target anti-Xa 
activity, four hours post dose (0.3-1.0 IU/mL for treatment and 0.1-0.5 IU/mL for prophylaxis).  
In the treatment and high risk group, the authors report a reduction in peak anti-Xa levels as pregnancy 
progressed, of 0.10 IU/mL. The authors conclude that 175 IU/kg daily used was a sufficient dose for this 
group.  
In the prophylaxis group, three women (20%) required a dose increase from 50 IU/kg to 75 IU/kg to reach 
target levels. The authors endorsed the use of once daily tinzaparin for treatment indications and suggest 
a dose of 75 IU/kg daily for prophylaxis indications for women at moderate risk. 
Ensom et al. (2004)
 
Dalteparin See table in the 
results section for 
pharmacokinetic 
parameters 
calculated by the 
authors 
Compared the pharmacokinetics (non-compartmental analysis) of dalteparin (9) versus unfractionated 
heparin (6) during pregnancy for women with anti-phosphospholipid syndrome.  
Women were randomised to a regime of prophylactic dalteparin (2500 IU od pre-pregnancy, 2500 IU od in 
the first trimester, 5000 IU od in the second trimester and 7500 IU od in the third trimester) or 
unfractionated heparin (5000 IU bd pre pregnancy and during the first trimester, 7500 IU bd during the 
second trimester and 10000 IU bd in the third trimester).  
The authors report that during pregnancy a higher dose of dalteparin would be required compared to the 
non-pregnant state (see table of PK results), whereas for unfractionated heparin, using their dosing 
protocol, no further dose change was required.  




tmax (h) AUC 
(IU.h/mL) 












15.7 + 3.8 
First 
trimester 




















26.4 + 9.7 
Third 
trimester 
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Study LMWH studied Kinetic findings Summary of results reported 







An observational retrospective review of 72 patients requiring thromboprophylaxis during pregnancy with 
enoxaparin due to the presence of thrombophilia. Target anti-Xa was set at 0.2-0.4 IU/mL at 5-6 hours 
post dose. 
The authors report the mean maximum dose required to achieve their therapeutic anti-Xa level was 38.1 
mg every 12 hours (median 35mg, range 30-75mg every 12 hours). 
Following their experience, they suggest a twice daily prophylaxis regimen starting with 30mg bd (or 40mg 
bd if the woman’s gestational age has progressed or if the woman is a larger patient). 
 







A retrospective review of 321 anti-Xa levels in 77 patients requiring thromboprophylaxis during pregnancy. 
They report that anti-Xa levels were more likely to be prophylactic target levels of 0.2-0.4 IU/mL during 
early rather than late pregnancy. 
Lebaudy et al. (2008) Enoxaparin Compartmental PK 
analysis 
A prospective PK modelling study of 75 patients requiring enoxaparin during pregnancy (343 antenatal 
anti-Xa activities measured).  
They report that both clearance and volume of distribution increase by up to 50% during the course of 
pregnancy and suggest that to account for these changes, dose of enoxaparin (and other LMWHs) should 
be normalised for actual body weight. 
Non pregnancy:        Cl = 0.52 +/- 0.03 L/h          Vd = 7.03 +/- 1.05 L 
Pregnancy:                 Cl = 0.78 +/- 0.04 L/h         Vd = 10.5 +/- 1.31 L 
See full details on this study in the introduction later on in chapter 1 and in the discussion section of 
chapter 4. 




A retrospective review of 37 high risk pregnancies being managed on Tinzaparin 175 IU/kg once daily. 
The once daily tinzaparin was well tolerated, although dose modification (based on peak anti-Xa activity 
was required in 45% of patients). 
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Study LMWH studied Kinetic findings Summary of results reported 




A retrospective review of 25 women requiring treatment dose of dalteparin during their pregnancy. They 
found that the dose required to maintain the peak plasma concentration at 4 hours between 0.5-0.8 IU/mL, 
required to be increased, when comparing results from the first trimester to the third trimester. The authors 
suggest that the increase in dose requirement could not be explained by weight increase alone, and that 
anti-Xa levels be monitored during pregnancy and the dose should be adjusted. 




A prospective evaluation of anti-Xa levels in 15 women requiring therapeutic enoxaparin (1mg/kg +/- 20%) 
twice daily during their pregnancy. Three anti-Xa concentrations were monitored; trough, 3-4 hour (peak) 
and 8 hours pose dose.  
The authors considered an anti-Xa activity of between 0.5-1.2 IU/mL as satisfactory. 
Mean anti-Xa activity levels were: trough 0.45 +/- 0.18, peak 0.9 +/- 0.25, and 8-h post dose  0.72 +/- 0.23 
IU/mL. The authors report that trough and 8-h post dose anti-Xa activity levels were sub-therapeutic in a 
substantial number of patients receiving a twice daily regimen of therapeutic enoxaparin. 




A retrospective review of tinzaparin use during the antenatal period from 1267 pregnancies. In 254 
pregnancies, women recieievd tinzaparin for treatment indications, with 94.1% recieiving tinzaparin as a 
once daily indication. In this study, 5 (2%) recurrent VTEs were reported. 
This study provides valuable information on the use of tinzaparin during the antenatal period. 
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Whilst the majority of these studies are observational in nature and they have methodological 
differences in the way they were conducted and the primary objectives set, the studies confirm 
that LMWH clearance is altered antenatally. Little attention in these studies has been given to 
alterations in the Vd of LMWH and what impact (if any), this may have.  
The two studies most commonly cited in this area are the studies by Blomback [1998] and Casele 
[1999]. Blomback and colleagues conducted a non-compartmental pharmacokinetic study of 
dalteparin (2500 or 5000 IU once daily) in seventeen pregnant women during the third trimester. 
In this study, although a measurable anti-Xa concentration was detectable at 16 hours in the 
fourteen women in the study receiving a 5000 IU dose once a day, the maximum concentration 
(Cmax), the time to maximum concentration (tmax) and the area under the curve were significantly 
lower compared with when dalteparin was administered to twelve healthy men and women. 
Casele and colleagues conducted a non-compartmental pharmacokinetic study assessing the 
pharmacokinetics of enoxaparin (40mg) in thirteen women who received thromboprophylaxis 
throughout pregnancy. These women had pharmacokinetic parameters calculated at three time 
points; 12-15 weeks gestation, 30-33 weeks gestation and 6-8 weeks postpartum. During early 
and late pregnancy, the maximum concentration and the last measurable anti-Xa activity were 
lower antenatally than during post-partum period. Both studies imply a higher dose is required 
antenally. More recently Lebaudy et al. [2008] carried out a population pharmacokinetic modelling 
and simulation study assessing enoxaparin during pregnancy and the post-partum period in 
seventy-five women. They found that enoxaparin clearance was higher in the pregnant women 
when compared to non-pregnant women: 0.78 L/hr + 0.03 versus 0.52 L/hr + 0.03 (p=<0.001). 
However, they also report, that the volume of distribution of enoxaparin was influenced by the 
stage of pregnancy, found to be a two-step increase. An initial rise paralleling the woman’s 
increase in body weight during the first two trimesters, followed by an additional increase of 41% 
during the last two months of pregnancy. Lebaudy’s study to date provides the most useful 
information in this area, although the uptake of their recommendations into clinical practice is yet 
to be seen. 
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1.8 Pharmacokinetic analysis 
1.8.1 Non-compartmental pharmacokinetic analysis 
Non-compartmental analysis (NCA) is the pharmacokinetic (PK) analysis of individual 
concentration-time curves, which determine parameters such as maximum concentration (Cmax), 
the area under the concentration-time curve (AUC), time to maximum concentration (Tmax), in 
addition to CL and Vd. NCA summarise the PK data obtained from individuals and generally 
speaking is fast and readily automated, providing estimates of the desired PK parameters. 
Historically, PK analysis has been conducted using NCA, with the pharmaceutical industry 
utilising this method with data obtained from homogenous populations of adults during phase I +/- 
phase II clinical trials informing the dose to be evaluated in phase III studies. The disadvantage 
associated with NCA is that, it makes no attempt to understand or describe the structural or 
mechanistic properties of the system into which the drug is being introduced (like compartmental 
analysis) and is therefore limited in its clinical application, as it is difficult to then predict new 
situations, for example what might happen if the drug being studied was prescribed for a patient 
with moderate renal impairment [Gillespie, 1991]. Furthermore, sources of variability between 
subjects are not explored or identified using this method, further limiting its clinical application.  
1.8.2 Compartmental analysis 
Compartmental PK analysis on the other hand, involves describing drug disposition in terms of 
the drug moving through a series of connected compartments. In this type of analysis, the drug is 
either administered into one of the compartments, either directly, e.g. intravascularly, or indirectly, 
e.g. extravascularly, and from there either distributes into peripheral compartments or is 
eliminated from the body. First order kinetic processes are used to describe the transfer of drugs 
between compartments, with the rate of drug transfer dependent on drug concentration and 
permeability. Drug input (drug administration or absorption) and output (elimination) from the 
system are modelled using different kinetic processes. 
Compartmental analysis does attempt to describe the mechanistic and structural systems into 
which the drug is being introduced, and therefore models from compartmental analyses can be 
used to make predictions into different scenarios, e.g. a different patient population. Furthermore, 
depending on the type of compartmental analysis used, sources of variability can be identified 
and quantified. Compartmental analysis can be further sub-divided into three different 
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approaches; the naïve pooled approach, the standard two-stage approach and nonlinear mixed 
effects modelling. 
1.8.2.1 Naïve pooled approach 
This analysis approach involves pooling all concentration data from the population and treating 
the data, as if it were from one individual [Sheiner and Beal, 1980]. For this approach, data must 
originate from a well-controlled study, i.e. sampling taken at the same time and performed in a 
homogenous population [Ette and Williams, 2004]. This analytical approach provides no 
information on sources of variability in the data and cannot explore relationships between 
parameters and covariates within subjects, and in many ways is similar to NCA. 
1.8.2.2 Standard two-stage approach 
This approach involves two stages of data analysis. Firstly, models are fitted to individual data to 
estimate each subject’s pharmacokinetic parameters. Following this, population parameters are 
then determined, as a mean of the individual values, with individual differences in values 
described by the variances around these means. With a well designed and executed study, it is 
possible to obtain good estimates of population parameters using this approach. This method 
generally requires a homogenous population, in order to obtain reasonable parameter and 
variability estimates, and is usually performed in a small study population, for example 15 patients 
with intense sampling per subject. With this approach, estimates of variance tend to be upwardly 
biased, due to residual unexplained variability (RUV) such as that caused by assay error, not 
being easily distinguished from true between subject variability (BSV) [Sheiner and Beal, 1981]. 
1.8.2.3 Nonlinear mixed effects modelling (NLMEM) 
NLMEM is the most commonly used population modelling analytical method used. It allows 
estimation of both fixed (i.e. CL or Vd) and random (i.e. between subject or residual unexplained 
variability) effects simultaneously, hence the term mixed effects, whilst preserving an individual’s 
data within the population. The method was originally developed by Professor Sheiner in the 
United States, where, the challenges of dosing patients on chronic warfarin therapy, and in those 
with chronic heart failure prescribed digoxin, provided a stimulus for the clinician Sheiner to get 
involved with NLMEM [Sheiner, 1969; Peck et al., 1973]. Following the publication of the seminal 
papers by Sheiner and colleagues [Sheiner et al., 1972; Sheiner et al., 1977], the foundations of 
NLMEM had been laid for application in pharmacokinetic analyses. In the early days, NLMEM 
was viewed with scepticism by the wider statistical community, seen as a pragmatic method of 
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dealing with sparse data and poorly conducted trials [Pillai et al., 2005]. However, the concept has 
stood the test of time and is now an invaluable tool in both the pharmaceutical industry and the 
clinical environment. 
This approach is considered the most robust method of population data analysis as it allows the 
investigation and quantification of variability in model parameters between individuals from data 
which may be sparse, unbalanced and from a heterogeneous population [Sheiner and Grasela, 
1991]. In fact, a heterogeneous population is preferred for this type of modelling, as it provides 
more information on variability [Sheiner and Ludden, 1992].   
The benefit of NLMEM is that data from a range of sources may be analysed, e.g. from highly 
controlled randomised controlled trials to sparse therapeutic drug monitoring data collected in a 
clinic environment, therefore having an important clinical application. Furthermore, unlike the 
naïve or two-stage approach, the approach can allow data from different studies to be combined 
for analysis, even if precision is different between the two studies [Sheiner and Grasela, 1991]. 
1.8.2.4 Population modelling 
Population modelling can be defined as: 
…the application of a mathematical model to describe pharmacokinetic data that arises from more 
than one individual. The process does not require that each study individual provides sufficient 
data to characterise completely their own pharmacokinetic profile. Population analysis methods 
allow borrowing of information between individuals to fill in gaps in the pharmacokinetic profile. In 
doing so, the method allows sparse sampling study designs. The influence of patient 
characteristics, e.g. renal function, on the pharmacokinetic profile can be quantified from the data 
set as well as any remaining unexplained variability between patients. [Duffull et al., 2011]. 
A population model may be written as a mathematical expression describing an observation, in 
terms of two components;  
(i) Structural model, which determines the shape or form of the model, and usually 
describes the fixed effects such as CL or Vd 
(ii) Stochastic (or statistical) model, which describes the degree of uncertainty, for 
example the random effects such as between subject variability, assay error or 
residual unexplained variability 
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1.8.2.4.1 Structural model 
The fixed effects comprises a function of known independent variables and pharmacokinetic 
parameters. Independent variables may include those such as time, dose, and patient factors 
(age, weight, gender) influencing the response and the pharmacokinetic parameters such as CL 
and Vd. Mathematically, a structural model can be expressed as: 
                                                                                                                                                         (1.2)  
Where yij, the j
th
 observation of the i
th
 individual, is a function of the known independent variables 
xij and the predicted individual PK parameters, θij. 
An example of a structural PK model is a one compartment model following IV bolus dosing of a 
drug. In this model, the concentration of the drug can be described with a mono-exponential 
decline from the compartment: 
                                             
 
  
    
  
  
                                                                                            (1.3)                                            
where C is the predicted concentration at time t after dose D. In this example, D and t are the 
known independent variables, whereas CL and Vd are the pharmacokinetic parameters to be 
estimated. 
1.8.2.4.2 Stochastic (statistical) model 
Uncertainty in modelling arises from a variety of sources, for example assay error, between 
subject variability (BSV), inter occasion variability (IOV). As the aim of population modelling is to 
describe variability of individual pharmacokinetic parameters around the typical population value, 
this between subject variability can be expressed as: 
                                                                                                                                        (1.4) 
where θi is the parameter value for the i
th
 individual, θpop is the population parameter value, and ηi 
is assumed to be normally distributed with a mean of zero and variance of ω
2
. When variability in 
a population is assessed to be log-normally distributed, a log-normal distribution may also be 
used: 
                                                            
                                                                              (1.5) 
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The variability that remains once BSV and IOV have been added to the model is referred to as 
residual unexplained variability (RUV) and can be associated with errors in sampling of the assay, 
or can be attributed to model misspecification due to oversimplification of the system. RUV can be 
incorporated into a model as an additive error 
                                                                                                                                         (1.6) 
where ypred,ij is the predicted observation of the model and εij is the random error between the 
observed value with a mean value of zero and variance of σ
2
.  
A proportional or exponentional error can also be used, where 
                                                                 
                                                                          (1.7) 
which approximates a constant coefficient of variation (CCV).   
Both errors terms may also be included together in a combined proportional (εij1) and additive (εij2) 
error term 
                                                                   
                                                                   (1.8) 
1.8.2.5 Estimation methods and software 
Fitting mathematical models to data involves a process of parameter estimation to achieve a set 
of values that best fit the data, i.e. minimising the differences between observations and 
predictions. In non-linear mixed effects modelling, there is no closed form solution to the 
likelihood, therefore approximation and iterative approaches have to be used. A number of 
software packages have been developed for this purpose [Beal and Sheiner, 1989], with 
NONMEM, an acronym for Nonlinear Mixed Effects Modelling, the most widely used, and in 
essence is a regression program that specialises in non-linear systems. 
In NONMEM, nonlinear equations are expressed linearly as Taylor-series approximations of the 
likelihood and an iterative search within the parameter space is performed to obtain the estimates 
of the parameters [Ette and Williams, 2004; Schoemaker and Cohen, 1996]. The simplest 
linearization is by the first-order (FO) method, in which the same parameter values are assumed 
for all subjects during the search for the best parameter combination (Taylor series expansion 
about η = 0), whereas the first-order conditional estimation (FOCE) method linearises with respect 
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to the random effects (η), resulting in a more accurate approximation to the equation [Beal and 
Sheiner, 1992; Schoemaker and Cohen, 1996].  
Final parameter estimates for the model are obtained in NONMEM once the maximum likelihood 
of model to fit the data is achieved, i.e. when the sum of squares has been minimised. This is 
approximated by the objective function value (OBJ) of an extended least squares (ELS) analysis 
which approximates minus twice the natural logarithm of the likelihood. Mathematically, this can 
be expressed as 
                                                  
                         
 
           
    
   
                                             (1.9) 
where Nsub is the total number of subjects, yi is the vector of observations for the i
th
 individual; f is 
a function of xi, a vector of independent variables for the  i
th
, individual and θ, the vector of 
population mean parameter values; J is the Jacobian matrix of the first partial derivatives of the 
model with respect to the random effects; Ω is the variance-covariance matrix of between subject 
effects; Σ is a matrix of the residual variance; and Ι · Ι denotes the determinant of the matrix [Peck 
et al., 1984]. A lower OBJ during the parameter search indicates a better model fit to data. Models 
representing the same data can be compared by determining the difference (Δ) between model 
OBJs. As ΔOBJ is asymptotically and asymmetrically x
2
-distributed, the significance of change 
can be determined according to the x
2
-distribution with the appropriate degree of freedom, for 
example, with one degree of freedom (i.e. one parameter difference between models) a ΔOBJ of 
3.84 or 6.63 indicates a P < 0.05 or < 0.01, respectively. However, it must be remembered, that 
all mathematical calculations for estimating or predicting parameter values are oversimplifications 
of reality. 
1.8.2.6 Covariates 
Covariates are the factors which can explain some of the variability seen during the modelling 
building process, and may be constant, e.g. subject gender, or change with time, e.g. renal 
function, age. They can be considered as the factors which help to describe and understand the 
system into which the drug is being introduced. A catergorical covariate is one that can only be 
described as a discrete value. Unordered catergorical (nominal) covariates include those such as 
sex, race, and smoking status for example. Ordered categorical (ordinal) covariates include those 
such as health or disease status, e.g. progressive cancer stages 0 to IV. Continuous covariates 
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are factors which can be measured on a continuous scale, such as weight, height and age, as 
well as including clinical measures such as creatinine clearance or haemoglobin concentration. 
In a population model, covariates can be defined in terms of their use. For example a mechanistic 
covariate can be regarded as those which explain variability within a population based on 
physiological differences, such as body size on Vd. Due to their physiological basis, their inclusion 
makes a population model useful for predictive purposes into different populations. Empirical 
covariates are descriptive explanations of variability that do not generally have any physiological 
basis, e.g. eye colour. In population modelling, the inclusion of empirical covariates in a model 
cannot be used to predict into new situations, as it can only be considered a description of the 
population from which the data arose. 
1.8.2.7 The model development process 
Generally speaking, irrespective of the purpose of the model or the number of patients involved, 











Figure 1.7: Key steps followed in the PK modelling process, adapted from Bonate [2006] 
Analysis of the problem 
Design and execute experiment 
Collect and format data 
Formulate and fit model 
Check model Validate model 
Interpret and communicate results 
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1.8.3 Advantages of population analysis 
The population approach offers many advantages over traditional pharmacokinetic analysis, often 
including data generated from the population of interest. The approach can accommodate 
unbalanced and sparse data, as well data generated from different sources. Covariate analysis 
allows explanation of subject variability. Collectively, these advantages help to overcome ethical 
barriers that may otherwise prohibit any form of study in the population of interest, e.g. pregnant 
women. Perhaps most importantly, once a model has been developed, if robust enough, can be 
used to simulate “what-if” clinical scenarios. Weaknesses of the population approach include, 
being time consuming, being perceived as complicated and the methodology difficult to 
understand, and that different modellers could develop different models from the same data. 
However, the advantages outweigh the disadvantages, hence why it is a growing discipline 
worldwide [Tucker, 2012].  
1.8.4 Model evaluation and validation 
Population pharmacokinetic models can be considered as either descriptive or predictive [Ette et 
al., 2004]. Descriptive models provide quantitative summaries of the variability in the population 
which was studied [Ette et al., 2003]. For descriptive models, assessment of goodness of fit, 
reliability and stability are important factors in model evaluation. Goodness of fit involves checking 
typical diagnostic plots such as observed versus model individual predicted values, observed  
versus model population predicted values, conditional weighted residuals [Hooker et al., 2007] 
versus time, conditional weighted residuals versus covariates. Parameter reliability addresses the 
issue of confidence in the parameter estimates and hence the model itself. Uncertainty of model 
parameters must be small; the percentage relative standard error for the fixed and random effect 
parameters should not exceed 25% and 50%, respectively [Ette et al., 2004]. 
Predictive models are those that will be extrapolated beyond the population from which the model 
was estimated. For these models, validation would be an added requirement. Predictive models 
require much stronger assumptions about relationships to the underlying population from which 
the data was collected. The key question being, can the model be extrapolated to another group 
of patients.  
Model validation can be split into two groups; external and internal. External validation is the most 
robust. With external validation, the final model is estimated from the index data, the model 
parameters are fixed, and predictions of the drug concentrations are made into test (external) 
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data [Ette et al., 2004]. Internal validation, can include data splitting, cross validation, and 
bootstrapping. Data splitting, involves removing a proportion of data from the original data set, 
before the model is developed. Once the final model is proposed, it is used to predict 
concentrations in the data which was kept aside. The disadvantage of this approach is, that all the 
original data is not used in the modelling process. Cross-validation and bootstrapping have the 
advantage that they use all the data and are therefore not affected by random splitting. Many 
consider bootstrapping as the approach of choice for checking for stability, determination of 
parameter reliability and validation [Miller, 1974; Hinkley, 1977]. 
Cross validation involves removing a part of the available data and the model is fitted to the 
remaining data. The model from the remaining data is fixed, and predictions are made into the 
data that were removed. The process of cross validation provides an estimate of the prediction 
error. The bootstrap is a re-sampling method, first suggested by Efron and Gong [1983]. In the 
bootstrap method, psuedosamples that are distributed according to the same distribution of the 
original samples are repeatedly generated. The process creates a new plausible dataset. Usually, 
> 200 bootstrap data sets are created, and is usually done by re-sampling of subjects with 
replacements – the nonparametric bootstrap. 
1.8.4 Application of population PK analysis  
1.8.4.1 Examples from drug development 
Over the last twenty years modelling and simulation has increasingly become part of the drug 
development process, with both the United States Food and Drug Administration [2004] and the 
European Medicines Agency [2007] recognising the important role the method can play in 
successfully developing and bringing a drug to the market. Examples follow which illustrate how 
the pharmaceutical industry has embraced the discipline of pharmacometrics in recent years. 
Brief examples include: 
- Remifentanil [Egan et al., 2001]. One of the early examples of model-based drug 
development, where the final dose which was licensed, was based on work conducted 
through modelling and simulation and had not directly been studied in clinical trials 
- Nesiritide [Bhattaram et al., 2005]. Dosing for the final registration trial was derived using 
exposure-reponse modelling and simulation to balance benefit versus risk 
- Gabapentin [Lalonde et al., 2007]. Exposure-response modelling provided confirmatory 
evidence of effectiveness and alleviated the need for additional trials 
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- Mycophenolate [Hale et al., 1998]. One of the first fully simulated clinical trials which was 
used to design a registration trial based on early trial data 
- Pralatrexate [Mould et al., 2009]. During phase I studies, patients experienced a high 
incidence of grade 3 and 4 mucositis. Preliminary evaluations of the pharmacokinetics of 
the pralatrexate and its association with mucositis, suggested that its exposure could be 
controlled by body size (either body surface area or weight) based dosing and that pre-
treatment with folic acid and vitamin B12 might minimise the incidence and severity of 
mucositis. The application of modelling was critical in the pharmaceutical development of 
pralarexate, which lead to important suggestions for dose, dosing schedule and pre-
treatment modifications. 
The aforementioned examples illustrate how the pharmaceutical industry are utilising modelling 
and simulation method to improve efficiency and effectiveness in the drug development process. 
1.8.5.1 Examples from clinical practice 
The discipline of pharmacometrics has an important role to play in clinical practice, as the 
methodology can address what-if questions raised from clinical practice, which may not be able to 
be addressed through traditional means. Examples follow, which describe the clinical application 
of pharmacometrics. 
Hawwa and colleagues [2008], applied the methodology to the dosing of 6-mercaptopurine (6-
MP) in paediatric patients with acute lymphoblastic leukaemia (ALL). Conventional dosing 
methods for oral 6-MP was resulting in highly variable drug and metabolite concentrations in the 
paediatric patient population and hence variability in treatment outcomes. They prospectively 





. All patients were genotyped for polymorphisms in three enzymes involved in 6-
MP metabolism. They found that body surface area and thiopurine methyltransferase genotype 
were the two significant covariates which influenced between subject variability in how paediatric 
patients handle 6-MP. Through incorporating these two covariates into the model they developed, 
they were able to suggest a more rational dosing approach for 6-MP.  
In order to develop a better dosing strategy for the paediatric population, Hempel and colleagues 
[2009], were the first group to develop a population pharmacokinetic model of pegylated (PEG)-
asparaginase in a paediatric population being treated for acute lymphoblastic leukaemia. They 
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analysed 1221 serum activities from 168 children. They report that a one-compartmental model 
best fitted the data and found clearance to increase with time according to the following formula: 
                                                                  
                                                                      (1.10) 
where Cli is the initial clearance and t is the time after dose. They also report that a subgroup of 
patients exhibited a higher clearance and suggest this may be related to the development of 
inactivating antibodies.   
Nath and colleagues [2010] explored the pharmacokinetics of total and unbound plasma 
melphalan using the population approach, in order to identify factors which affect melphalan 
disposition and to evaluate the role of melphalan exposure in melphalan-related toxicity and 
disease response. Modelling was performed with total and unbound concentration-time data from 
100 patients who had received a median melphalan dose of 192 mg m
-2
. They found that a two 
compartment model best fitted the data and report that creatinine clearance, fat free mass and 
haematocrit were important determinants of total and unbound CL, reducing inter-individual 
variability in total CL from 34% to 27% and unbound CL from 42% to 30%. They also found that 
total AUC and unbound AUC were significantly higher in patients who had oral mucositis (> grade 
3) and long hospital admissions, providing important information about the relationship between 
melphalan exposure and outcomes.  
Standing and colleagues [2008] developed a population model in paediatric patients receiving 
diclofenac for acute pain in children, as the optimal dosing strategy was not well described. Their 
method involved drawing blood from paediatric subjects at the start and end of surgery and on 
removal of the venous cannula. Data were obtained from 70 children (aged 1 to 12 years), who 
received a diclofenac preoperative oral dose of 1mg kg
-1
. This data was pooled with rich adult 
data from 30 volunteers. As the optimal adult dose of diclofenac is 50mg for acute pain, 
simulation work planned to predict the paediatric dose to achieve a similar AUC to 50mg in adults. 
A one compartment model best fitted the data and they found that allometric scaling was able to 
predict changes in CL and Vd with age, and that a dose of 1mg kg
-1
 diclofenac produces similar 
exposure in children aged 1 to 12, as 50mg in adults, confirming that higher doses were not 
necessary in this population.  
 - 84 - 
1.8.6 Application of population PK analysis in the fields of pregnancy  
Pregnancy is one of the sub-populations where drug therapy is often not formally evaluated due 
to ethical constraints and subsequent information on drug use in this population is derived from 
observational data in the form of case reports.  
Pharmacometrics and the use of modelling and simulation therefore provides an opportunity to 
apply this method in order to optimise drug use in this population, especially when patients are 
using medicines for a range of chronic conditions, for example asthma, HIV and tuberculosis. 
Indeed at the 3
rd
 American Conference on Pharmacometrics in April 2011, the clinical application 
of modelling and simulation in an antenatal population was specifically discussed [van Hasselt et 
al., 2012]. Some examples published in the literature follow. 
Andrew and colleagues [2007] applied modelling and simulation to the problem of developing an 
appropriate amoxicillin dosing strategy for the prevention of anthrax during pregnancy, in 
response to possible bioterrorism attacks on the United States. In their study, sixteen women 
received amoxicillin during 18-22 weeks gestation, 30-34 weeks gestation, as well as 3 months 
postpartum. Single dose amoxicillin pharmacokinetics were evaluated. Amoxicillin renal clearance 
and secretion was found to be higher during pregnancy than postpartum, as one might predict. 
Their simulation work suggested that amoxicillin concentrations required to prevent anthrax may 
be difficult to achieve during pregnancy and that amoxicillin may not be an appropriate antibiotic 
for post-antrax exposure prophylaxis in a pregnant population.  
Tarning and colleagues [2009] conducted a population pharmacokinetic study of lumefantrine in 
pregnant women with uncomplicated multidrug resistant Plasmodium falciparum malaria. Their 
subject population comprised 103 women in the second or third trimester treated with artemether-
lumefantrine (80/480mg) twice daily for 3 days. Patients provided 5 capillary samples for drug 
quantification, with the exact time of sample collection randomly distributed over 14 days. A high 
proportion of women (40%) had day 7 capillary concentrations of <355 ng/mL, a threshold 
previously associated with an increased risk of therapeutic failure in non-pregnant patients. 
Following the modelling process, they found that a two compartment model with first order 
absorption and elimination best fitted the data. In their study, Tarning and colleagues report a high 
treatment failure rate of 16% (95% CI, 9.9-25.1), with their predictive modelling suggesting that a 
twice-daily regimen given for 5 days would be preferable later on in pregnancy and should 
overcome the treatment failures observed. 
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Allegaert and colleagues [2009] applied the population pharmacokinetic approach to cefazolin 
disposition. The antibiotic is recommended as an alternative to penicillin based antibiotics on the 
prevention of perinatal group B streptococcal diseases in pregnant women with a moderate risk of 
a penicillin allergy. They collected 187 plasma samples and 96 amniotic fluid samples from 82 
pregnancies (17-40 weeks gestation). They report cefazolin CL and Vd estimates to be 7.44 L/hr 
and 12 L respectively. On the basis of their results, they suggest that dosing regimens to attain 
higher amniotic fluid concentrations are required for the prevention of group B streptococcal 
infection in this population. 
A study conducted by Hirt and colleagues [2009] evaluated the pharmacokinetics of tenofovir in 
HIV-1 infected pregnant women. Tenofovir is commonly used in resource low income countries, 
as  treatment to prevent mother-child transmission of HIV at the time of birth. Thirty-eight women 
were given tenofovir disoproxil fumerate (TDF 300mg)-emtricitabine (FTC 200mg) tablets; two at 
labour induction and once daily for 7 days postpartum. Maternal, umbilical and neonatal plasma 
tenofovir concentrations were assayed by high pressure liquid chromatography. A two 
compartment model for the mother best fitted the data. The authors found that absorption of 
tenofovir was greater in women who delivered by caesarean section than those delivering 
vaginally. 600mg of tenofovir prior to delivery produces the same concentration as 300mg in non 
pregnant adults. Their simulation work suggested that if the time elapsed between maternal 
administration and delivery is >12 hours, two further tablets of tenofovir should be re-
administered. 
Bouillon-Pichault et al., [2009] investigated the need to increase the lopinavir dose during 
pregnancy in order to achieve pre-determined efficacy concentrations in a HIV pregnant 
population. They obtained lopinavir concentrations from 145 HIV infected women; 74 of which 
were pregnant. A one-compartment model with first-order absorption was found to best fit the 
data. Significant changes in lopinavir PK were observed, with CL increasing as pregnancy 
progressed. The study was able to identify that patients previously treated with protease inhibitor 
were likely to need a dose increase, as their pregnancy progressed. 
These studies clearly demonstrate how the population approach can help to address important 
clinical questions regarding drug use in a pregnant population. 
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1.8.7 Enoxaparin PK modelling studies 
1.8.7.1 PK models of enoxaparin outside of pregnancy 
Enoxaparin has been used routinely in clinical practice for a number of years, and given its wide 
application in the treatment and prevention of VTE, and the management of patients with acute 
coronary syndromes, it is not surprising that clinical uncertainties have arisen around its optimal 
dose in certain sub populations with time, for example its use in the obese and those patients with 
renal impairment. Given these uncertainties, research groups have attempted to address these 
uncertainties using the population approach and compartmental analysis. 
Green and Duffull [2003] applied the population approach to the problem of dosing of enoxaparin 
in patients who are overweight or obese. Enoxaparin dosing is based on total bodyweight and a 
commonly asked clinical question is whether the dose should be capped when treating obese 
patients for the treatment of VTE (1.5 mg/kg once a day) or for acute coronary syndromes (1 
mg/kg every twelve hours). Patients being managed for deep vein thrombosis, acute coronary 
syndromes or prescribed enoxaparin as prophylaxis against VTE were recruited to their study. 
Ninty-six patients were enrolled; thirty-two had a BMI <25kg/m
2
, 31 a BMI of 25-29.99kg/m
2
 and 
33 patients had a BMI of >30kg/m
2
. On average, 3 anti-Xa samples per patient were collected. 
Green and Duffull report that a two compartment model with first order absorption, with 
exponential between subject variability on clearance and volume (central compartment), with an 
additive error model best fitted the data. A covariate analysis showed clearance was best 
described by lean body weight and the central volume by total body weight. The final parameter 
estimates from the covariate model they developed are listed in table 1.11. 
Table 1.11: Green and Duffull’s enoxaparin obesity model 
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Their simulation work suggested that patients over 50 years of age whose total body weight is 
>90kg, or patients under 50 years of age whose total body weight is >120kg are likely to have a 
smoother concentration-time profile and less bruising if a dose of 100 IU kg
-1
 based on lean body 
weight is administered every 8 hours; suggesting that obese patients do require a different dosing 
strategy compared to patients who are normally weighted. 
Green and colleagues [2004] conducted a population pharmacokinetic study in order to 
investigate the influence of glomerular filtration rate on the pharmacokinetics of subcutaneously 
administered enoxaparin. Thirty-eight patients being managed for acute coronary syndromes 
were recruited into the study, with each patient contributing 10 anti-Xa activities. In total, 313 anti-
Xa concentrations were collected for modelling purposes. A two-compartment, with exponential 
between subject variability on Vd and CL and a combined error model, best fitted the data. In their 
analysis, Green and colleagues estimate that 71% of enoxaparin is excreted unchanged through 
the kidneys, and following their simulation work, they suggest the following recommendations on 
dosing enoxaparin for the management of acute coronary syndromes (usual dose 1mg/kg 12
-1
) in 
patients with renal impairment (table 1.12). 
Table 1.12: Green’s enoxaparin renal impairment model 
C-G derived GFR (using IBW) as size descriptor ml 
min
-1 
Enoxaparin dose mg kg
-1










Hulot and colleagues [2005] conducted a population pharmacokinetic modelling study of 
enoxaparin, also addressing the dosing implications for patients with renal impairment, by 
evaluating 532 patients receiving subcutaneous enoxaparin for non-ST-segment elevation acute 
coronary syndrome. Patients were typically prescribed enoxaparin 1mg/kg 12
-1
, however in 
patients with renal impairment, clinicians reduced the dose of enoxaparin according to their 
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clinical judgement. In their study, 34% of patients had a normal renal function, 36% had mild renal 
failure, 20% had moderate renal failure and 10% had severe renal failure. A total 661 anti-Xa 
activities were obtained and modelled using the population approach. A one compartment model 
with first order kinetics with proportional between subject variability on clearance and volume of 
distribution, with an additive error model best fitted the data. Covariate analysis revealed that total 
body weight was a significant covariate for volume and CrCl was a significant covariate for CL. 
Final model parameter estimates are listed in table (1.13). 
Table 1.13: Hulot’s renal impairment model 




 percentiles obtained 
from bootstrapping 
Structural model   
V/F (L) 5.29 +/- 0.55 5.00-6.00 
V (influence of body weight) +1.49 +/- 0.23 1.10-2.00 
CL/F 0.74 +/- 0.03 0.71-0.79 
CL (influence of body 
weight/serum creatinine ratio) 
+0.24 +/- 0.04 0.14-0.27 
CL (factor if female) +0.75 +/- 0.06 0.69-0.80 
Ka (h
-1
) 0.34 +/- 0.05 0.26-0.44 
Statistical model   
Residual variability (σ) (IU/mL) 0.14 +/- 0.02 0.13-0.16 
ISV (V) (%CV) 50 +/- 26 42-61 
ISV (CL) (%CV) 27 +/- 12 26-35 
 
Following their simulation work, aiming for a target peak anti-Xa activity of 0.5-1.2 IU/mL, the 




 is suggested 




. In all cases, like Green and 
colleagues, they suggest a loading dose. In this case, Hulot and colleagues suggest that an initial 
subcutaneous dose of 1mg/kg can be administered whatever the renal function. 
Feng and colleagues assessed the pharmacokinetics of a continuous intravenous infusion of 
enoxaparin in a critical care population [2006]. This was in response to the observations from 
clinical practice, which indicated that unreliable and extensive variability in anti-Xa concentrations 
are found in patients with critical illness, when the standard recommended dose and route of 
administration is used. Feng and colleagues suggest that a continuous IV infusion can overcome 
 - 89 - 
this problem with enoxparin and conducted a study to explore the PK of enoxaparin when 
administered as a continuous IV infusion. In this study, anti-Xa activity from a previous study was 
combined with additional data collected. Three-hundred and sixty-three anti-Xa activities were 
available from patients who received a continuous IV infusion of enoxaparin. A two compartment 
linear model, with a proportional error model for the critical care patients receiving the continuous 
IV infusion of enoxaparin, best fitted the data. Both CrCl and weight were found to significantly 
affect CL and Vd of enoxaparin in this population. Simulation work suggested that the optimal 
doses for patients in the intensive care unit were, 50 IU kg
-1
 per 12 h if CrCl <30 ml min
-1
; 60 IU 
kg
-1
 per 12 h if CrCl is 30-50 ml min
-1
; and 100 IU kg
-1
 per 12 h if CrCl >50 ml min
-1
. 
Bruno and colleagues [2003] conducted a population PK-PD study of data (anti-Xa activity) 
obtained from the TIMI-11A study [Antman et al., 1997]. TIMI-11A was an open label study 
assessing the safety and tolerability of two weight-adjusted enoxaparin regimens in patients with 
unstable angina and non ST elevation MI. Patients received a 30mg intravenous bolus, followed 
by weight adjusted doses of either 1mg/kg
-1
 (309 patients) or 1.25mg/kg
-1
 (321 patients) of 
enoxaparin subcutaneously every 12 hours for a median of 3 days. For the purposes of PK 
analysis, trough and 3-5 hours post dose (peak) anti-Xa activity was drawn, after the third weight-
adjusted dose of enoxaparin and again on the last day of enoxaparin dosing. Bruno and 
colleagues obtained data from 448 patients (71%) of the total study population, providing 788 
anti-Xa activities. Data from 300 patients were randomly selected and modelled, leaving the 
remaining 148 patients’ data as the validation set for the final model produced. A one-
compartment model with between subject variability on drug clearance best fitted the data. 
Following covariate analysis, weight and CrCl were significant covariates which were retained for 
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Table 1.14: Bruno’s enoxaparin model 
 Final Model Bootstrap (n=500) 
Parameter Estimates 95% CI Median 95% CI 
Clearance (L h
-1
) 0.733 0.698 – 0.738 0.734 0.702-0.766 
























V (L) 5.24 4.20 – 6.28 5.19 2.55 – 6.59 
ka (h
-1
) 0.235 0.157 – 0.313 0.232 0.149 – 0.361 
ωCL (%) 26.9 20.9 – 31.8 26.6 20.3 – 31.8 
πCL (%) 21.7 14.9 – 26.8 21.7 12.3 – 27.2 
ωV (%) 56.1 36.4 – 70.6 55.8 34.2 – 77.2 
σ (%) 21.5 16.4 – 25.6 21.3 16.5 – 25.6 
πCL, coefficient of variability of intra-individual variability 
According to this model, a typical patient with a median weight and median CrCl would have an 
enoxaparin clearance of 0.733 Lh
-1





 percentiles of the database (58-117kg) resulted in a change in clearance of 
between -14% and +21%. Patients with a CrCl of 50ml min
-1
 or 30ml min
-1
 would observe a 
enoxaparin clearance decrease of 17% and 27% respectively. The authors conclude that body 
weight and renal function are significantly related to enoxaparin clearance and that a decreased 
clearance will significantly increase the chances of bleeding complications. 
Kane-Gill and colleagues conducted a population PK study of continuous infusion of enoxaparin 
from patients on either a general medical ward or an ICU setting [Kane-Gill et al., 2005]. In their 
study, 48 patients contributed data for PK modelling purposes. Clearance and Vd estimates for 
ICU and ward patients were 0.64 +/-0.34 L/h, 10.6 +/-1.55 L and 1.01 +/-0.39 L/h, 9.08 +/-1.17 L 
respectively. The authors from this small retrospective study conclude, that a continuous infusion 
of enoxaparin is safe and that the PK parameters of enoxaparin of patients on ICU differ from 
those patients on the ward. 
Sanchex-Pena and colleagues conducted a PK modelling study of bolus IV enoxaparin 
administered to patients undergoing percutaneous coronary intervention (PCI) in France [2005]. 
In their study, serial blood samples were taken; before iv bolus of enoxaparin, 10 minutes after 
bolus (start of PCI), at the end of PCI (mean time=45 minutes), 3 hours after PCI and on the 
morning after PCI. A total of 2016 anti-Xa activities were available for modelling purposes from 
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556 patients, who had received a mean IV dose of enoxaparin of 38 +/- 7mg (3830 +/-730 IU). 
The time course of anti-Xa activity was best described by a one compartment model with zero-
order input. Between subject variability was described using an exponential model, and the 
residual error was best described by an additive error model. During covariate modelling, 
bodyweight and to a less degree, CrCl and creatinine influenced CL. In the final model, only body 
weight significantly affected enoxaparin CL. From their simulation work, the authors conclude that 
0.5 mg kg
-1
 i.v. dose of enoxaparin reached anticoagulation levels adequately in patients 
undergoing elective PCI. Their simulation work also suggested that an additional second bolus 
dose could be given in patients with delayed or prolonged procedures. 
Berges and colleagues [2007] conducted a population PK study in elderly patients receiving 
prophylactic enoxaparin 4000 IU sc injection daily as VTE prophylaxis, in order to assess if this 
sub-population would require additional monitoring, due to their age. One hundred and eighty nine 
patients were studied, with 22% weighing <50kg and 50% having the presence of renal 
impairment. Four hundred and fifty one anti-Xa activities were available for PK modelling 
purposes; the authors report a first order input, two compartment model best fitted the data. 
Clearance was significantly related to body weight and CrCl, and weight significantly affected Vd. 
According to their model, around 4% of the population they studied would achieve a peak anti-Xa 
activity of >1.0 IU ml
-1
. The authors conclude that monitoring anti-Xa activity in elderly patients 
treated with enoxaparin at prophylactic doses does not seem necessary to prevent the 
occurrence of major bleeding. 
Finally, Barrass and colleagues [2009] modelled the severity and occurrence of enoxaparin 
related bruising in an Australian population. As part of this study, enoxaparin PK estimates were 
computed for the study population. Patients being managed for PE, DVT, acute coronary 
syndrome (ACS), or atrial fibrillation (AF) were randomised to a dose individualised arm or a 
conventional dosing arm of this prospective study. Patients in the conventional arm received the 
manufacturers recommended doses of enoxaparin. Subjects in the individualised arm were dosed 
according to either their actual weight or lean body weight (LBW). Subjects > 100kg were 
considered obese and dosed on 1.5mg kg
-1
 twice a day, whereas patients <100kg were dosed on 
their actual weight, at a dose of 1mg kg
-1
 twice a day. Patients with a CrCl of < 50ml min
-1
 were 
dosed at a reduced dose after 48 hours. Four samples were collected, one pre-dose, then one at 
15-30, 60-120 and 180-300 min post dose. A total of 349 anti-Xa activities were available for PK 
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modelling purposes. A two-compartment model with first order input and linear elimination best 
described the data. Between subject variability on CL and Vd and Ka was added to the model and 
an additive error model best described residual unexplained variability. Model parameter 
estimates are listed in table 1.15. 
Table 1.15: Barras’ enoxaparin model 










) 0.3 renal (0.14-0.45) 





Vc (L) 3.43 (2.20-4.66) 3.42 (2.07-5.17) 18.3 
Ka (h) 0.26 (0.17-0.35) 0.26 (0.16-0.40) 18.3 
Vp (L) 5.77 (0.75-10.8) 6.42 (3.0-17.8) 44.3 
Q (L h
-1
) 0.31 (0.15-0.47) 0.28 (0.1-0.44) 27.0 
ωCL (% CV) 37.8 (22.3-48.0) 37.4 (28.3-50.9) 32.2 
ωVc (% CV) 35.6 (7-51.0) 34.6 (5.4-52.9) 52.9 
ωKa (% CV) 30.3 (5.3-42.5) 29.8 (1.7-49.8) 49.6 
σ (IU mL
-1
) 0.09 (0.086-0.1) 0.09 (0.083-0.1) 14.5 
 
In the simulation work that Barrass and colleagues conducted, individualised dosing decreased 
the probability of a bleeding or major bruising event when compared to conventional dosing, 
which was most noticeable in those patients who were obese or with renal impairment.  
To date, though enoxaparin modelling has been conducted in heterogeneous populations and 
each were looking to answer specific clinical questions, the common theme emerging from them 
all is that weight (or lean body weight) appears to be a significant covariate for enoxaparin CL. 
1.8.7.2 Antenatal PK model of enoxaparin 
The only compartmental PK analysis of enoxaparin during pregnancy that has been conducted to 
date is that by Lebaudy and colleagues [2008]. They conducted a population pharmacokinetic 
study of 75 pregnant and 38 non-pregnant women (acting as controls), in order to evaluate the 
pharmacokinetics of enoxaparin during pregnancy and the postpartum period. They obtained 343 
anti-Xa activity samples from the pregnant women, up to 49 hours after the last enoxaparin dose 
was administered (samples taken at clinicians discretion). The majority of samples were collected 
during the second and third trimester. They found a one compartment model with first order 
kinetics, with between subject variability on CL and Vd, and an additive error model best fitted the 
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data. They reported that clearance and volume of distribution of enoxaparin increased by 48% 
and 49% respectively in the pregnant women compared to the nonpregnant controls. Their 
median parameter estimates using the population approach are presented in table 1.16. 
Table 1.16: Lebaudy’s pregnancy enoxaparin model 





Structural model   
   Clearance (L/hr) 0.81 +/-0.03 0.763-0.84 
   Ratio effect 0.42 +/-0.12 0.18-0.64 
   Volume of distribution (L) 7.81 +/-1.23 5.7-10.5 
   Gestational age effect 1.41 +/-0.25 1.04-1.86 
   Absorption rate constant (hr
-1
) 0.56 +/-0.12 0.31-0.87 
Statistical model   
   Between subject variability - CL (%CV) 20.3 14.7-24.8 
   Between subject variability - Vd (%CV) 26.0 12.7-37.9 
   Residual unexplained variability (IU/mL) 0.12 +/-0.05 0.09-0.14 
 
In their study, Lebaudy and colleagues found enoxaparin clearance was significantly influenced 
by body weight and serum creatinine and suggested that the best equation to predict individual 
clearance was: 
Cl = 0.781 x [(bodyweight/serum creatinine) / 1.27]
0.423
                                                           (1.11) 
They also report that the volume of distribution of enoxaparin increased from 7.25L in the first 
trimester to 7.83L by the 31
st
 week of pregnancy, thereafter displaying a sharp increase, reaching 
11.4L by the time the baby was delivered. The authors suggest that enoxaparin’s volume of 
distribution during pregnancy was best described by the following equation: 
Vd = 7.81 x (bodyweight / 70) x 1.41 at >31 weeks of amenorrhea                                          (1.12) 
The study has contributed some important findings; although enoxaparin clearance increases 
during pregnancy, it does not increase significantly after the first trimester. On the other hand, 
volume of distribution does continue to increase with pregnancy progression. Therefore, if the 
same dose is administered throughout pregnancy, a reduction in peak anti-Xa activity will be 
observed, however, residual anti-Xa activity will also increase with the progression of pregnancy.  
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There are limitations to the method Lebaudy and colleagues applied the modelling and simulation 
method to this problem. In terms of study design and blood sampling, there was no informative 
sampling strategy; samples were taken at the discretion of the physician, and not optimised using 
d-optimal methods [Mentré et al., 1997]. In terms of the modelling process, no diagnostic plots of 
the final model or model evaluation plots were available for inspection. Furthermore, in the model 
produced, there was a very large unexplained variability (additive error = 120 IU/L). 
Accepting the limitatations, Lebaudy’s study provides an insight into how modelling and simulation 
could be applied to optimise enoxaparin (and other LMWH) use during the antenatal period and 
provides a benchmark for future studies. 
1.9 Hypothesis 
The antenatal dosing strategy of enoxaparin for the treatment and prevention of VTE should be 
the same as in the non-pregnant population. 
1.9.1 Aims of the study 
 To develop a population pharmacokinetic model for enoxaparin during the antenatal 
period 
 To simulate important what-if questions generated from clinical practice from the model 
developed, specifically: 
o Should the dosing strategy of LMWH during pregnancy be once or twice a day 
for the treatment and prophylaxis of VTE 
o Which co-variates significantly affect the PK profile of enoxaparin during 
pregnancy 
 To describe how thrombin generation and d-dimer concentrations are altered during 
pregnancy and the puerperium for women injecting enoxaparin during pregnancy  
 To assess whether polybrene can neutralise the effect of enoxaparin in plasma being 
assayed for thrombin generation 
 To explore women’s views on and adherence to enoxaparin during pregnancy and the 
puerperium 
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Chapter 2 
2.1 Methodology 
The purpose of chapter 2 is to give a broad overview of the methodology adopted for this study. 
Further specific details of methodology are detailed in the relevant results chapters when 
















Figure 2.1: an overview of the methodology adopted for the study 
*Optimal design work to 
inform study design and anti-
Xa sampling points 
Literature review of previous 
work 
Ethics and Trust Research 
and Development approval to 
conduct study 
Recruit eligible patients into 
study and collect required 
data 
Analyse data from thrombin 
generation experiments +/- 
polybrene 
Prepare data for modelling 





Model and simulate PK data 
and explore important “what-
if” factors raised from clinical 
practice 
*Work carried out by Dr 
Green’s laboratory, University 
of Queensland, Australia. 
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2.1.1 Optimal design  
The aim of population pharmacokinetic and pharmacodynamic studies is to obtain accurate 
estimates of the desired parameters in the model being developed. Therefore, although NLMEM 
can model data from studies where data originates from sparse data points, if the study design is 
suboptimal in terms of when the samples were drawn, then the final model developed may be 
inaccurate or imprecise. Therefore, of two approaches of sampling that could be adopted, 
empirical (where the researchers determine the sampling times on when they think is best or is 
practical), or optimal (where pre-determined collection times are determined), optimal design 
methods are the more robust approach  in clinical pharmacokinetic modelling [D’Argenio, 1981; 
Mentré et al., 1997].  
The aim of any optimal design work is to analyse and evaluate information for a particular study 
design that allows selection of a design that allows maximum precision of parameter estimates 
[Duffull et al., 2005]. In this study, optimal design is of particular value, where one anticipates time 
varying changes in the key parameter estimates of CL and Vd as pregnancy progresses. 
Therefore to ensure these are accurately quantified, optimal design work was undertaken by Dr 
Green’s laboratory at the University of Queensland, prior to the commencement of the study [Van 
Hasselt et al., 2009; Van Hasselt et al., 2012]. This work is described here in brief. 
Based on information published in the literature, a semi-physiological model was developed which 
incorporated all relevant physiological variables likely to affect CL and Vd of enoxaparin during 
pregnancy. The performance of the semi-physiological model was then compared to the 
enoxaparin model developed by Lebaudy and colleagues [Lebaudy et al., 2009], in terms of 
estimating volume of distribution and clearance during pregnancy. 1000 individual concentration-
time profiles were then simulated stochastically using both models and the predictions obtained 
from both models were compared. Sampling widows were calculated for both the semi-
physiological and Lebaudy model using optimal design, based on semi-physiological and 
Lebaudy models predicted changes in clearance and volume of distribution of enoxaparin during 
pregnancy. The optimal sampling designs for the semi-physiological and Lebaudy models were 
evaluated by simulating 1000 individual concentration-time profiles under the sampling times of 
interest, following which clearance and volume of distribution were re-estimated. 
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Simulations of the two models were performed in NONMEM (version 7.1.0). D-optimal designs 
were determined using WinPOPT (version 1.2) [Duffull et al., 2008] and the exchange 
optimisation algorithm. 
Dr Green’s laboratory found stochastic simulations of anti-Xa peak and trough concentrations 
using the semi-physiological and Lebaudy models showed comparable concentration-time 
profiles. They also found that the D-optimal time-points and sampling windows for the semi-
physiological and the Lebaudy models were relatively comparable (table 2.1), except for the 
second blood sample (there to determine Ka), where the Lebaudy model predictions suggested a 
later collection of this sample compared to the semi-physiological model. The change in 
parameter estimates over pregnancy resulted in a negligible change of optimal sampling times for 
the Lebaudy model (0.01 hours) and no change in sampling times was found for the semi-
physiological model. Both models showed comparable precision and bias [van Hasselt et al., 
2012]. 
Table 2.1: Differences between the sampling times suggested from the two models evaluated 
Occasion (month)       Sampling times (h) 
 Semi-physiological model Lebaudy model 
0 23.5, 0.585, 3.00 23.5, 1.30, 3.00 
2 23.5, 0.585, 3.00 23.5, 1.30, 3.00 
4 23.5, 0.585, 3.00 23.5, 1.30, 3.00 
6 23.5, 0.585, 3.00 23.5, 1.30, 3.00 
8 23.5, 0.585, 3.00 23.5, 1.30, 3.00 
 
Based on this work, it was decided that the optimal anti-Xa sampling times for this study were, 
just prior to the next dose (trough), one hour post injection and three hours post injection. 
2.1.2 Data Collection 
A prospective cohort study was conducted at the King’s Thrombosis Centre, King’s College 
Hospital. The thrombosis centre at King’s provides expert care for all pregnant women on LMWH 
on an outpatient basis. The LMWH prescribed at King’s is enoxaparin. Clinicians were free to alter 
the doses of enoxaparin through a woman’s pregnancy, if clinically indicated. 
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2.1.2.1 Patient recruitment 
Nulliparous and multiparous women receiving enoxaparin (all indications and doses) were eligible 
to participate in the study. Those women who did not wish to participate in the study, who were 
unlikely to comply with directions or turn up to clinic for follow-up, those who had a documented 
allergy to LMWH, those who had impaired renal function (Creatinine Clearance <60ml/min – using 
the Cockcroft Gault method of calculation [Cockcroft and Gault, 1976]) and women <18 years of 
age were excluded. Eligible patients were invited to participate by a member of the haematology 
medical team, when the patient first attended the haematology outpatient clinic following referral 
and they were given the study information document (see appendix I). Two days following 
attendance at the haematology clinic, the principal researcher telephoned the patient to see if she 
would participate in the study and the patient was then followed up in the haematology clinic, 
usually the following week. Informed written consent (see appendix II for a copy of the consent 
form used) was obtained by the principal researcher. Following recruitment, the information 
outlined in table 2.2 was recorded / collected. 
Table 2.2: Information collected from the women at the initial and subsequent clinic visits 
Demographic Past Medical History 
 
Obstetric information Medication Laboratory 
Date of birth and age Past medical history 
 
Date of last menstrual 
period 
 
Indication for starting 
enoxaparin 
 
Urea and electrolytes  
 
Weight (kg)  
 
Whether there is any 
known thrombophilia  
 
Expected due date 
 
Dose of enoxaparin 
(mg)  
 
Full blood count  
 
Height (cm) Whether there is a 




Medication history  
 











Smoking and alcohol 
  
  INR, aPTT, D-dimers  
 
 
Creatinine clearance was calculated using the Cockcroft-Gault method of calculation [Cockcroft-
Gault, 1976], and for the purposes of this study, the weight inserted into this equation was the 
subject’s baseline lean body weight, calculated on a mechanistically dervived formula [Han et al., 
2007]  
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2.1.2.2 Sample collection  
Anti-Xa levels were drawn in clinic. The anti-Xa sampling strategy (informed by previous optimal 
design work), was based on the following scheme: 
On arrival at 
haematology clinic 
24 hours post previous dose (i.e. trough sample). Following collection of this 
sample, patient injects their enoxaparin in clinic 
  
1 hour after injection Second sample for anti-Xa level drawn 
  
3 hours after injection Third sample for anti-Xa level drawn  
 
Not all women recruited to the study consented to having three anti-Xa activities measured at 
each clinic visit, either because of time or not wishing to have additional venepunctures. In such 
cases, two (trough and one hour post injection) or a single (typically peak) anti-Xa activities were 
drawn at each clinic visit. 
As well as being taught how to self-inject enoxaparin competently, women were also given an 
enoxaparin administration book (How to inject Clexane®, Sanofi-Aventis Ltd) and asked to record 
the time each day they injected the enoxaparin at home. They were instructed to bring the 
completed book with them to their subsequent haematology clinic visits, where the book was 
replaced. 
At subsequent clinic visits (monthly), the patients were reviewed by the haematology doctors and 
the researcher collected and recorded the following information: 
- weight (kg), using electronic scales within the Haematology outpatients, range 2kg-250kg, 
Model: MPP-250, Marsden The Weighing Company 
- height (cm), using electronic scales within the Haematology outpatients, range 50-230cm, 
Model: MPP-250, Marsden The Weighing Company 
- urea and electrolytes  
- full blood count 
- liver function test 
- INR, APTT, D-dimers 
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- changes in any other medications or doses of mecdications the patient is taking 
- anti-Xa level (trough, 1 hour and 3 hour sample) 
 
During the first, second and third trimester, within a week of delivery and eight weeks postpartum, 
each study patient had additional blood samples taken, for the purposes of assessing thrombin 
generation. These samples were taken at the same time as the anti-Xa levels.  
Blood samples were obtained through antecubital venepuncture using a butterfly Terumo® 
Surflo® winged infusion set (21G x ¾”, 0.8 x 19mm UTW tubing, REF: SV-21BL, Terumo Europe 
N.V., Belgium). Thrombin generation samples were drawn through antecubital venepuncture 
using free flow or minimal suction into a 10mL syringe, avoiding vacuum containers, with the first 
5mL of blood drawn being discarded. The blood was then dispensed into 0.109 mol/L sodium 
citrate vacuum container and handled as described in section 2.1.2.4.1. 
2.1.2.3 Sample handling and analysis 
Four samples were collected as part of routine clinical care at each clinic visit; one clotted sample, 
one EDTA sample, and two citrate samples. These were labelled with the patient’s name and 
analysed as follows:  
2.1.2.3.1 Clotted sample 
For determination of urea and electrolytes and liver function. 5mL blood sample collected in 
SST
TM
II Advance Becton-Dickinson Vacutainer®. This sample was then centrifuged on a Rotanta 
46 CSC centrifuge (Hettich Zentrifugen) at 3500g for 10 minutes. The sample was then loaded on 
Siemens Sample Management System and analysed using the Advia 2400 analyser. The results 
were reported on the hospital’s reporting system, under the patient’s name. 
2.1.2.3.2 EDTA sample 
For determination of full blood count. 3mL sample collected in K3E 5.4mg Becton-Dickinson 
Vacutainer®. The sample was loaded onto the Siemens Sample Management System and 
analysed using the Advia 2120 analyser. The results were reported on the hospital’s reporting 
system, under the patient’s name. 
2.1.2.3.3 Citrate sample I 
For determination of INR, APTR and D-dimer. 2.7mL blood (9 vol) sample collected in 0.109M 
(3.2% trisodium citrate) Becton-Dickinson Vacutainer®. Following collection, the sample was 
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centrifuged at 2500g for 7 minutes on a Rotina 38 R centrifuge (Hettich Zentrifugen). The 
prothrombin time and thus the resultant INR was determined using the STA-Neoplastine® CI Plus 
kit (Diagnostica Stago, France). The APTR was determined using the STA-Cephascreen® kit 
(Diagnostica Stago, France). For determination of d-dimers, the STA-Liatest® D-DI kit (immune-
turbidimetric assay of D-dimer (Diagnostica Stago, France)) was used. 
Analysis was conducted on the STA-R evolution (Diagnostica Stago) analyser. 
2.1.2.3.4 Citrate sample II 
For determination of anti-Xa activity, 2.7mL blood (9 vol) sample was collected in 0.109M (3.2% 
trisodium citrate) Becton-Dickinson Vacutainer®. Following collection the sample was centrifuged 
in a Rotina 420 R centrifuge (Hettich Zentrifugen) and double spun for 7 minutes at 2,500g and 
frozen within 1 hour of sample collection. The samples were stored at -40°C until analysed. 
Samples were thawed and analysed in weekly batches using the STA-Rotachrom® Heparin 
colorimetric assay (Diagnostica Stago, France) on the STA-R evolution analyser (Diagnostica 
Stago). Results were reported as IU/mL. 
The principal of the anti-Xa assay is based on measuring the absorbance of residual factor Xa in 
the test sample. Initially a standard curve is constructed by the analysing laboratory, by adding 
known concentrations of LMWH to plasma (which provides the antithrombin), in addition to a fixed 
amount of factor Xa. This addition of LMWH to the reference plasma sample, results in the 
formation of an inactive anti-thrombin-Xa complex and residual Xa. The residual Xa activity is 
what is measured in the assay, and is inversely proportional to the concentration of LMWH and 
can be quantified through the calibration curve; the higher the LMWH in the test plasma, the lower 
the absorbance in the test plasma and vice versa. An example of a typical calibration table which 
informs the calibration curve follows: 
Reference LMWH 
concentration (IU/mL) 
0.00 0.45 0.82 1.54 
Absorbance at 405nm 1017 564 368 154 
 
2.1.2.4 Thrombin generation experiments 
2.1.2.4.1 Plasma preparation 
Platelet poor plasma (PPP) was obtained by centrifugation at 4750g on a Rotina 420 R centrifuge 
(Hettich Zentrifugen) for 10 minutes at room temperature. The supernatant was decanted into a 
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polypropylene tube and centrifugation repeated. The plasma was decanted into a plastic tube, 
capped and immediately frozen. This procedure was performed within 60 minutes of 
venepuncture. The samples were stored at -35
o
C and analysed using calibrated automated 
thrombinography (CAT). 
2.1.2.4.2 Calibrated automated thrombinography 
Thrombin generation was measured with the thrombinoscope assay (Thrombinoscope BV, 
Maastricht, The Netherlands). 20µL of reconstituted PPP reagent (Thrombinoscope BV) was 
added to each test well of an Immulon 96-well microtitre plate (Thermo Labsystems, Franklin, 
Massachusetts, USA) followed by 80µL PPP (thawed and warmed to 37°C immediately prior to 
testing). Final concentrations of tissue factor and phospholipid were 5pmol/L and 4µmol/L, 
respectively. Calibration wells were run in parallel utilising Thrombin Calibrator (Thrombinoscope 
BV) with known thrombin activity instead of PPP reagent. All samples were run in triplicate with 
the calibrator. 20µL of a premixed fluorochrome and calcium reagent (FluCa; Thrombinoscope 
BV) was then added automatically to each well to trigger coagulation. 
Fluorescence was measured with Fluoroskan Ascent (Thermo Electron Corporation Vantaa, 
Finalnd) over time. The Thrombinoscope BV (version 3.0.0.29) software was used to convert the 
fluorescence signal into nmol/L thrombin generated over time. Five parameters were recorded: 
lag time, time to peak, peak thrombin, start-tail and endogenous thrombin potential (ETP). 
Maximum velocity, as a measure of rate of thrombin formation, was calculated by dividing peak 
thrombin by the difference between the time to peak and lag time, with results expressed as 
nmol/L per minute. 
Details on how the polybrene experiments which were run in parallel, are described in the 
relevant section within chapter 6. 
In order to determine the intra- and inter- assay variability from the thrombin generation 
experiments conducted, plasma from the same healthly control (male) was run in each 
experiment for the duration of the study. 
2.1.2.5 Birth and post-partum 
Recruited women were asked to phone or text the principal researcher at the time they went into 
labour, in order for samples to be collected during the post-partum period. When the principal 
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researcher reviewed the patient on the post-natal ward, the plan i.e. dose and duration of 
enoxaparin therapy would be re-confirmed with the patient and obstetric team, following 
consultation with the haematology consultants.  
Patients were then followed up in the haematology outpatient clinic, typically when enoxaparin 
therapy had been discontinued, at 8 weeks post-partum. At this clinic visit, as well as the patient 
receiving a final medical review, a blood sample was collected, where apart from anti-Xa activity, 
all other bloods (UE’s / LFTs / FBC / Coagulation screen / D-dimers and thrombin generation) 
were drawn. 
2.1.2.6 Control group 
In order to assess whether enoxaparin had a significant effect on blood loss and mode of delivery 
of delivery for women injecting enoxaparin antenatally, information on women delivering at King’s 
college hospital, not injecting enoxaparin antenatally was collected from 10 women every week 
(on a Friday) from the post-natal ward from Friday 2
nd
 September 2011 to Friday 2
nd
 March 2012. 
The key comparisons to be made were, age of women, ethnicity, baby’s gender, gestation 
delivered, weight of baby, method of delivery, estimated blood loss at delivery, and APGAR 
scores of baby at delivery.   
2.1.3 Data entry, storage and transfer 
All data was recorded by the principal investigator on a pre-designed study form. At the earliest 
opportunity, the principal investigator transferred the data to an Excel database, with the hard 
copy of the data collection form being filed and stored in a locked office within the haematology 
department at King’s College Hospital. One week after entry of a patient’s data onto the Excel 
database, the data which had been entered was re-checked for any errors. 
Each consented patient was assigned a unique study number comprising of the prefix Preg, 
followed by the year the patient consented to participate in the study, followed by the sequential 
number of the patient in the study. For example the first patient recruited to the study had the 
following study number assigned to them; Preg200901. 
All electronic data collected were password protected and conformed to National Health Service 
confidentiality standards. At the end of data collection, prior to completing the final analysis, 5% of 
inputted data was re-checked for any errors. 
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2.1.4 Population Modelling and Simulation 
Analysis was performed using non linear mixed effects modelling. An overview of the principals of 
this method are described in chapter 1, with further details described in the enoxaparin modelling 
and simulation results chapter 4. 
2.1.5 Ethical approval 
The study received ethical approval from the Isle of White, Portsmouth and South East 
Hampshire Research Ethics Committee (REC reference: 09/H0501/57) in September 2009 (copy 
of approval letter in appendix III), and a copy of the King’s College Hospital Research and 
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Chapter 3  
3.1 Clinical Information on study patients 
Chapter 3 describes from a clinical perspective, background and pregnancy outcome information 
on the women who consented and participated in the enoxaparin study.  
3.1.1 Eligibility and recruitment 
King’s College Hospital has an extensive women’s health service. Specifically, within the obstetric 
department, approximately 5,400 babies are delivered each year, including 1,500 caesarean 
sections. Between 7
th
 September 2009 and 31
st
 December 2011, all pregnant women referred to 
the thrombophilia haematology clinic at King’s College Hospital, prescribed enoxaparin or due to 
commence enoxaparin were eligible to participate in this study. Over this time period, 156 women 
were referred to this clinic. Twenty-nine of these women were not recruited into the study for the 
following reasons; (1) one patient had a previous allergy to enoxaparin and was therefore being 
managed on tinzaparin during the index pregnancy, (2) eight women miscarried prior to informed 
consent being obtained, (3) six women declined to participate, (4) three women were not 
approached to take part in the study, (4) seven women prescribed enoxaparin, attended clinic 
erratically and so were not approached, as any information that would be collected from these 
women was considered too unreliable, (5) four women were moving out-of-area and so were 
referred to their new local provider for ongoing obstetric - haematology care.  
 
3.2.1 Consented patients 
One hundred and twenty-five patients agreed to participate in the study, following informed 
consent. Six of these women were excluded from the final analysis for the following reasons: 
 1 patient who suffered a left proximal deep vein thrombosis during the second trimester of 
her pregnancy, was commenced on enoxaparin treatment dose according to the RCOG 
guidelines. However she developed a troublesome rash at her enoxaparin injection sites 
and her back, soon after the commencement of enoxaparin. She was switched to 
dalteparin, which appeared to help for a short time, but her symptoms re-appeared a few 
weeks later. On switching to tinzaparin therapy for the remainder of her pregnancy, her 
symptoms resolved. 
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 1 patient miscarried prior to her next clinic appointment, so no samples were drawn from 
her. 
 1 patient consented into the study, late in the third trimester. The principal researcher 
found her difficult to bleed and so she was excluded. 
 In the remaining three women, clinicians suspected non-adherence to the enoxaparin, 
and so these women were excluded. 
Excluding the patient who miscarried, the remaining 5 women went on to have live births; two had 
spontaneous vaginal deliveries, two had emergency caesarean-sections and the remaining 
woman delivered by elective caesarean section. 
3.1.3 Study population 
One hundred and nineteen patients had 123 pregnancies (4 women had two pregnancies during 
the study, and will be counted as separate women for the remainder of the thesis).  Five (4%) of 
the 123 pregnancies were twin pregnancies. The mean age for the study population was 33.11 
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   Caucasian 
   Black 
   Asian 











Obstetric history (as a cohort) 
   Gravida 
   Parity 
   Miscarriages 







Primi gravid 26 (21.13) 
Body mass index (kg/m
2
) 
   Underweight     (<18.5) 
   Normal              (18.5-24.9) 
   Overweight       (25-29.9)  
   Obese Class I   (30-34.9) 
   Obese Class II  (35-39.9) 
















Fifty-seven women (46%) had a previous history of thrombosis. Thirty-three women (29%) had a 
history of miscarriages, with nine of these women having laboratory confirmation of anti-
phospholipid syndrome. The results in table 3.1 demonstrate that the cohort of women recruited 
to the study represented a diverse population, particularly with respect to ethnicity and BMI, with a 
significant number of obese class I-III women in the study (27 women (21.95%)). 
3.1.4 Patient outcomes 
Eight of the 123 pregnancies miscarried; five women (4.06%) had first trimester miscarriages and 
2 women (1.62%) had second trimester miscarriages. The remaining patient had a still birth at 39 
weeks gestation. Of the five women who had first trimester miscarriages, four women had a 
history of recurrent miscarriages in the absence of antiphospholipid antibodies. The two women 
suffering from a second trimester miscarriages, one had confirmed antiphospholipid syndrome. 
For the subject who had a still birth at 39 weeks gestation, laboratory, placental histology and 
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post-mortem findings from the neonate could not identify a cause for the still birth. In this case, 
the mother’s indication for the enoxaparin prescription was VTE prevention, due to obesity, parity, 
age and hypertension. 
3.1.5 Indication for enoxaparin and doses prescribed 
Table 3.2 lists information on the women’s indication for antenatal enoxaparin therapy, the range 
of enoxaparin doses prescribed, along with the number of anti-Xa samples each subject agreed to 
contribute for PK modelling purposes. Ninety women were prescribed enoxaparin for prophylaxis 
of VTE; of these, forty-three (47.7%) had no personal history of VTE, but had the presence of 
significant VTE risk factors warranting ante- and postnatal prophylaxis, according to the current 
RCOG prophylaxis guidelines. The twelve women who had ‘other’ indications for antenatal 
enoxaparin were prescribed enoxaparin for the following indications: 
- Seven subjects who had a history of recurrent miscarriages in the absence of 
antiphospholipid syndrome. The weak evidence for using enoxaparin in this 
setting was fully discussed with the patient and the decision to proceed was only 
taken, if the patient wanted to 
- subject 22 had a history of retinal artery occlusion during the post-partum period 
in a previous pregnancy  
- subject 27 had a suspected patent patent foramen ovale and her cardiac team 
requested her to be on treatment dose enoxaparin during her pregnancy, as a 
pre-cautionary measure 
- subject 47 had a stillbirth during a previous pregnancy. Histology findings from 
the placenta reported perivillous fibrin deposition, placental ageing and 
dysmaturity. She was prescribed enoxaparin, as a pre-cautionary measure during 
the index pregnancy 
- subject 72 had a history of intrauterine growth retardation (IUGR) and abruption 
during her last pregnancy. In the index pregnancy, she had a high cardiolipin 
antibody titre and pregnancy-induced hypertension 
- subject 98 had a history of intrauterine growth retardation (IUGR) and pregnancy 
induced hypertension during her last pregnancy. After discussion with the 
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subject, she decided she wanted to inject enoxaparin, as a pre-cautionary 
measure 
Table 3.2: Indication for enoxaparin, dose prescribed and number of anti-Xa samples contributed 
at each clinic visit 
Study patient’s prescribing information Numbers  
n = 123 
(%) 
Indication for enoxaparin 
   Prophylaxis of VTE 
   Treatment of VTE 
   Antiphospholipid syndrome 
   Patients converting from long term warfarin 














Dose of enoxaparin prescribed 
   20mg daily 
   40mg daily 
   60mg daily 
   80mg daily 
   100mg daily 
   120mg daily 
   150mg daily 
   180mg daily 
   40mg twice daily 
   50mg twice daily 
   60mg twice daily 
   80mg twice daily 
   100mg twice daily 
 
2      
81    
2     
5     
8    
3     
1     
1   
8    
1   

















Number of anti-Xa samples patients agreed to contribute per clinic  visit 
   One anti-Xa activity drawn per clinic visit 
   Two anti-Xa activities drawn per clinic visit 
   Three anti-Xa activities drawn per clinic visit 
 
106 
6   






As a cohort, the recruited subjects contributed 795 anti-Xa activities during the ante- and post -
natal period for PK modelling purposes. Specifically, 712 were drawn during the antenatal period, 
with each subject contributing an average of 5.74 anti-Xa antenatal samples (range 1 – 24). 
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Twenty women (16.26%) were prescribed treatment doses of enoxaparin during the course of 
their pregnancies. Clinical reasons for this follow. The remaining 103 women were prescribed 
what would be considered as prophylactic doses of enoxaparin. 
3.1.6 Women suffering from pathological thrombosis during the index pregnancy 
Nine women suffered pathological thrombosis during the index pregnancy and were prescribed 
treatment doses of enoxaparin and referred to the haematology clinic for ongoing management. 
Table 3.3 lists further details on these nine episodes. 
Table 3.3: Details on the 9 women who suffered from pathological thrombosis during the index 
pregnancy 
Subject Indication Gestation at time 
of presentation 
Enoxaparin dose prescribed 
17 DVT (left proximal) 31 weeks 100mg daily antenatally and warfarin 
post-partum 
36 DVT (left proximal) 23 weeks 80mg twice a day ante- and 
postnatally 
96 *DVT (right long saphenous vein) 7 weeks 80mg daily for six weeks, followed by 
40mg daily ante- and postnatally 
117 DVT (left common iliac vein) 25 weeks 80mg daily ante- and postnatally 
18 PE (sub-segmental right lower 
lobe) 
23 weeks 60mg twice a day ante- and 
postnatally 
44 PE (extensive bilateral) 8 weeks 100mg twice a day ante- and 
postnatally 
49 PE (VQ probability high) 23 weeks 80mg twice a day ante- and 
postnatally 
67 PE (bilateral sub-segmental) 22 weeks 150mg daily ante- and postnatally 
79 Axillary vein thrombosis plus right 
proximal subclavian vein 
8 weeks 50mg twice a day antenatally and 
80mg once daily postnatally 
*Not a DVT, but patient was prescribed 6 weeks treatment dose enoxaparin as she had venous malformation. Following a 6 week course of 
enoxaparin, subject 96 was prescribed  prophylactic dose enoxaparin for the remainder of her pregnancy and for 6 weeks post-partum. 
 
3.1.7 Long term warfarin patients switched to enoxaparin during the index pregnancy 
Table 3.4 lists information on the women who were switched to treatment dose enoxaparin, from 
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Table 3.4: Details on the women switched from long-term warfarin to treatment dose enoxaparin 
during the index pregnancy 




16 Recurrent VTE 1.5-2.0 120mg daily 
37 FVL (homozygous). Symptomatic VTE whilst on 
combined oral contraceptive pill 
2-3 100mg daily 
45* Budd-Chiari (Liver transplant in 1998) 2-3 100mg daily 
48 Paroxysmal nocturnal haemoglobinuria 2-3 80mg daily 
53 Budd-Chiari (Liver transplant in 2006) 2-3 100mg daily 
54 Anti-phospholipid syndrome 2-3 100mg daily 
82 AF/Mitral stenosis/Pulmonary hypertension 2-3 100mg daily 
87 Recurrent VTE 2-3 180mg daily 
101* Budd-Chiari (Liver transplant in 1998) 2-3 100mg daily 
115 Anti-phospholipid syndrome and Budd-Chiari 
(Liver transplant in 2005) 
3-4 60mg daily 
*same patient 
One further patient (subject 27), was commenced on treatment dose enoxaparin, following 
referral from the cardiology team with possible patent foramen ovale. She was managed from mid 
way through the second trimester through to 6 weeks post partum with enoxaparin 120mg daily. 
3.1.8 Changes in renal and liver function tests and the full blood count during pregnancy 
At each haematology clinic visit, at birth and at approximately 8 weeks post partum, patients had 
blood drawn for evaluation of full blood count, urea and electrolytes and liver function tests. All 
test results for the cohort of women are listed in table 3.5 (mean, (max, min), median values are 
listed). Alterations in key parameters over the course of pregnancy and the puerperium, i.e. 
haemoglobin, platelet count, creatinine, albumin, mean platelet volume and urea are additionally 
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Table 3.5: Test results according to trimester for the cohort of women followed 
Parameter First Trimester Second 
Trimester 
Third Trimester Within 1 week 
of delivery 
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Parameter First Trimester Second 
Trimester 
Third Trimester Within 1 week 
of delivery 















































85.8 (69.9 – 108.8) 
85.8 

























































































































































Figure 3.1: Changes in creatinine, urea, haemoglobin, albumin, mean platelet volume (MPV) and 
platelets over the course of pregnancy. Please note, trimester 4 refers to within a week of delivery 
and trimester 5 refers to >8 weeks post-partum (red lines represents loess smooth) 
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Figure 3.2 illustrates the change in calculated CrCl and actual weight changes in the cohort of 
women who participated in the study. 
 
Figure 3.2: Changes in creatinine clearance and weight over the course of pregnancy (red line 
represents loess smooth) 
 
3.1.9 Birth and delivery information 
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Table 3.6: Pregnancy outcome information in the recruited women who had live births 
Birth Information Numbers (%) 
Gender 
   Male 








   Vaginal delivery 
   Elective caesarean section 
   Emergency caesarean section 
   Ventouse 













Blood loss at delivery 
  500 mL or less 
 > 500 – 1000 mL 












Baby APGAR score (mean(min-max)) 
  @ 1 minute 








Four women (3.54%) suffered postpartum haemorrhage (PPH) greater than 1000mL. In three of 
these cases, the reason for blood loss was attributed to problems with delivery of the placenta, as 
opposed to the antenatal prescription of LMWH. Greer and Nelson-Piercy’s meta-analysis of 
LMWH use during pregnancy reports an incidence of PPH (>500mL) of 0.94% (95%CI, 0.61-1.37) 
[Greer and Nelson-Piercy, 2005]. In a subsequent study assessing whether LMWH is effective 
during pregnancy and the puerperium in 57 women (82 pregnancies), reported a postpartum 
haemorrhage rate of greater than 1000mL in 9.1% (95%CI, 4.7-16.9) [Roeters van Lennep et al., 
2011]. More recently another group in the Netherlands published the findings of their study which 
spanned 10 years (1999-2009) and followed 88 pregnant women on therapeutic anticoagulation 
[Knol et al., 2012]. In this study, postpartum haemorrhage was defined as > 500mL blood loss for 
vaginal delivery, with severe postpartum haemorrhage defined as > 1000mL for vaginal delivery 
and > 1000mL for caesarean section. The authors found the rate of postpartum haemorrhage to 
be higher in the vaginal delivery group (30% vs 18%, LMWH users vs non-LMWH users), though 
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the risk of severe postpartum haemorrhage in the vaginal delivery groups were not found to be 
different compared to control (5.6% vs 5%, LMWH users vs non-LMWH users). The authors also 
report that the risk of postpartum haemorrhage after caesarean section was 12% amongst LMWH 
users versus 4% in non-users, with the risk higher if delivery was within 24 hours after the last 
dose of LMWH. There are likely to be discrepancies in the reported post-partum haemorrhage 
rate with antenatal LMWH use, as blood loss is estimated at delivery and there will inevitably be 
differences in what is recorded by different midwives and obstetricians. The results from this 
thesis suggest that the incidence of severe post-partum haemorrhage is not increased with the 
use of LMWH. In the remaining post-partum haemorrhage case in this thesis, the patient was 
prescribed enoxaparin for the prevention of VTE, had stopped her enoxaparin for two days prior 
to delivering. She eventually delivered by emergency caesarean section and the blood loss 
recorded was unlikely to be related to enoxaparin.  
3.1.10 Outcomes compared to control group 
Information on 280 pregnant patients who delivered at King’s College Hospital, not prescribed 
antenatal enoxaparin, was collected, in order to assess any differences in the study population 
compared to a typical pregnant population managed at the hospital. This information is presented 
in table 3.7.  
The enoxaparin study population was significantly older than the control group. Unsurprisingly, 
they also had significantly more miscarriages than the control group, given the nature of the 
intervention being offered in the thrombophilia clinic. Study patients were also more likely to 
deliver a little earlier than the control group and may be reflective of the “high risk” pregnancy 
nature of some subjects in the enoxaparin study group. No significant differences were found 
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Table 3.7: Pregnancy outcomes compared to a control group, not prescribed enoxaparin 





Age + sd 30.80 + 6.02 33.07 + 5.48 0.00*  
Ethnicity n (%) 
   Caucasian 
   Black 
   Asian 
































Gestation delivered (weeks) 39.5 38.8 0.0063* 
Blood loss recorded at delivery (ml) 489.46 433.95 NS* 
Delivery Method n (%) 
   Vaginal 
   LSCS (elective) 
   LSCS (emergency) 
   Ventouse 
   Forceps 
 
         126 (45) 
40   (14) 
64   (23) 
37   (13) 





6   (5) 







Twin pregnancies 7     (3) 5   (4) NS** 
Gender 
   Boy 










Baby weight (g) 3237.16 3162.43 NS* 
APGAR score @ 1 minute (mean (min-
max), median) 
8.49 (0-10), 9 8.40 (0-10), 9 NS** 
APGAR score @ 5 minutes (mean 
(min-max), median) 
9.54 (0-10), 10 9.50 (0-10), 10 NS** 
*independent t-test, **Chi-squared test 
Overall, the results from this chapter demonstrate that the population studied in this study 
represented a diverse pregnant population and that the enoxaparin did not appear to have a 
negative impact on the women’s or the baby’s health. 
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Chapter 4  
4.1 Population pharmacokinetic modelling of enoxaparin 
This chapter focuses on the main research question of the thesis; does the antenatal population 
require a higher total daily dose and more frequent dose of LMWH when being managed for acute 
VTE. The specific population pharmacokinetic methods followed during this study are described, 
following which details of how the antenatal enoxaparin model was developed and evaluated are 
described in detail. Following final model evaluation, simulation work central to the research 
question, evaluating once versus twice daily regimens of enoxaparin will be presented. Finally the 
results of the pharmacokinetic modelling work will be discussed in the context of previously 
published work. 
The broad steps of a population pharmacokinetic modelling process were outlined in chapter 1 
(figure 1.7). This figure has been updated and presented as figure 4.1. The shaded boxes 











Figure 4.1 Steps in the population PK development process. Shaded boxes represent areas 
completed thus far in the thesis 
 
Analysis of the problem 
Design and execute experiment 
Collect and format data 
Formulate and fit model 
Check model 
Interpret and communicate results 
Validate model 
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4.1.1 Methods 
4.1.1.1 Data entry and formatting 
Pharmacokinetic analysis was performed using non linear mixed effects modelling, as outlined in 
chapter 1. Raw data from the study (chapter 2 and chapter 3) were initially entered into an excel 
spreadsheet, usually within two days of subjects attending clinic. One week following initial data 
entry, the entry records were reviewed for accuracy. Following completion of data collection, the 
excel spreadsheet was converted to a comma delimited (‘.csv’) file and formatted ready for use in 
NONMEM, software version 7.2.2 (ICON development solutions) [Beal, 1998].  
4.1.1.2 Development of enoxaparin antenatal base model 
The first steps in developing a population model, is to develop a stable base model for the drug 
being evaluated. A base model provides the foundation for subsequent model development. 
Several base models were explored, and the chosen model was the one that best fitted the data 
based upon classical evaluation methods such as assessment of goodness of fit plots, a 
statistical improvement in the fit of the model to the data using the objective function, assessment 
of the precision of the parameter estimates and residual variability. The first order conditional 
method with interaction in NONMEM was used to estimate the base model. 
4.1.1.3 Evaluation of enoxaparin antenatal base model 
Goodness of fit plots allow a visual examination of how well a model is performing. They include 
plots of population / individual observed versus population / individual predicted concentrations of 
the drug being evaluated. A model which is describing the data well, would have population / 
individual observed versus population / individual predicted concentrations, when plotted, being a 
mirror imagine of one another, with no systemic trends and the line of unity running through the 
centre of the points. Goodness of fit plots also include plots of residuals. A residual is the 
difference between observed and model predicted values [Bonate, 2005]. Positive residuals 
indicate the model under-predicting the actual observations, whereas negative residuals indicate 
that the model is over-predicting observations. Residuals are assumed to be normally distributed, 
with a mean of zero; an unbiased model would have a mean value near zero, with residuals +/- 
within 2, considered good. Once again, graphical examination of systematic trends of residuals 
provides a valuable insight into how well a particular model is performing. Historically, weighted 
residuals (WRES) have been the commonly used residual metric in population PK model 
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analysis, for evaluating model misspecification. However, the shift in using the first order with 
conditional estimation (FOCE) in NONMEM has led to a new diagnostic residual tool, the 
conditional weighted residuals (CWRES) [Hooker et al., 2006]. As part of a residual analysis, 
histogram analysis of residuals, in this case CWRES, exhibiting a normal distribution, and QQ plot 
analysis, where there are no departures from normality, provide further evidence that a robust 
base model has been developed. Finally, as well as evaluating the model estimates for the 
pharmacokinetic parameters in question and whether the estimates are reasonable (subjective), a 
non-parametric bootstrap was applied in order to learn about the statistical properties of the 
distribution of the data and to quantify uncertainty in the parameter estimates [Parke et al., 1999], 
i.e. median and standard errors. 
4.1.1.4 Parameterisation of base model with covariates 
Following the establishment of a stable base model, the influence of covariates was then 
explored. When developing a population pharmacokinetic model, identification of covariates that 
can explain variability (typically between subject variability) in the pharmacokinetic parameters is 
one of the primary goals. Appropriately identified covariates can help define optimal dosing 
schedules and explore if covariate specific dosing regimens are necessary to normalise exposure 
across a wide population demographic. Parameterisation of the base model with covariates uses 
both objective and subjective measures to aid in the identification and subsequent retention of 
covariates in the final model, which include a combination of statistical tests, assessment of 
biological, mechanistic and clinical relevance of the covariate, along with prior knowledge of the 
modelled system. A final pharmacokinetic model’s predictive performance is not only dependent 
on the choice of methods used to select covariates, but also incorporation of covariates that 
underlie biological behaviour. For example, a mechanistic covariate is one which is expected to 
describe the parameter of interest as a function of known biological phenomena, e.g. renal 
function on CL for a drug which is renally cleared. On the other hand, empirical covariates are 
descriptive explanations of variability that have no clear physiological basis, e.g. eye colour. The 
utility of descriptive covariates is somewhat limited, compared to mechanistic covariates, 
particularly when consideration to simulation is given. For the purposes of the development of the 
antenatal enoxaparin model, mechanistic covariates were considered for parameterisation of the 
base model. A classical graphical approach was utilised, plotting unexplained variability of CL 
(ETA1) and Vd (ETA2) against each of the covariates which were thought to be influencing the 
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pharmacokinetics of enoxaparin during pregnancy. Trends identified as part of this graphical 
analysis, confirmed the relevance of the covariate being tested and the need for their further 
investigation. Each identified covariate was then tested using a uni-variate stepwise addition into 
the base-model, with a decrease in objective function of at least 6.64 p<0.01 required to consider 
inclusion of the covariate in the intermediate model. Once all relevant covariates had been 
identified and evaluated, they were all simultaneously added to the base model to form an 
intermediate model. A stepwise backward elimination of each individual covariate was then 
conducted, where an increase in the objective function of greater than 10.82 p<0.001, required to 
retain the covariate being evaluated in the final enoxaparin model. 
The first order conditional method with interaction in NONMEM was used to estimate the 
intermediate and final models. The final model developed, was once again formally assessed 
using a non-parametric bootstrap, to assess the statistical properties of the model developed and 
the final model was also formally evaluated using a visual predictive check.  
4.1.1.5 Visual predicted check 
The principle of the visual predicted check (VPC) is to assess graphically whether simulations 
from the final model developed are able to reproduce both the central trend and variability in the 
observed data, when plotted against an independent variable, typically time, and explores the 
predictive capability of the final model [Bergstrand et al., 2011]. Percentiles of the simulated data 
are compared to the corresponding percentiles from the observed data. If the final model is 
describing the original observed data, then the concentrations should lie on top of one another. A 
VPC plot is one of the key plots used in pharmacokinetic modelling to evaluate how well the 
model is performing. 
All graphical analysis performed in sections 4.1.1.3, 4.1.1.4 and 4.1.1.5 used ‘R 2.14.1’ [‘R’, 
2006]. 
4.1.1.6 Simulation 
Following the development of the final enoxaparin antenatal model, the next stage was to 
simulate the important ‘what if’ questions of clinical practice. In the case of this study, this was 
centred on whether pregnant women being managed for VTE needed to receive a total daily dose 
of LMWH which was more than what they would receive outside of pregnancy and whether the 
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dosing interval really needed to be divided, i.e. 1.5mg/kg once daily (used outside of pregnancy) 
versus 1mg/kg twice a day (currently recommended during pregnancy). In order to answer this 
question, the Royal College of Obstetricians and Gynaecologists dosing guidelines (table 4.1 - 
twice daily) and the King’s College Hospital once daily dosing guidelines (table 4.2 - used for non-
pregnant adult patients) for VTE management with enoxaparin were simulated from the final 
model. Both regimens incorporate dose-banding, in order to minimise risk and is currently 
regarded as good clinical practice, in the UK [National Patient Safety Agency, 2010].  
Table 4.1: RCOG antenatal enoxaparin VTE dosing guidelines 






Table 4.2: King’s College Hospital enoxaparin dosing guidelines 









The simulation work was based on women commencing enoxaparin from day 1 of their pregnancy 
and delivering their baby at 40 weeks gestation. The dose of enoxaparin was not altered during 
the pregnancy. For the specific purposes of simulation, an additional weight progression model for 
pregnancy was also developed. The development of the weight model followed the same 
principals of model development, as the main pharmacokinetic model. 
 
4.2 Results: Population pharmacokinetic modelling 
4.2.1 Breadth of anti-Xa activities drawn 
During the course of the study, 123 women contributed antenatal anti-Xa activities that were used 
for the development of the enoxaparin PK model (chapter 3 for details on these women). The 
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recruited pregnant subjects provided 795 anti-Xa activities in total for pharmacokinetic modelling 
purposes, of which 712 were drawn during the antenatal period; the remaining anti-Xa activities 
were from the post-partum period (typically within two days of delivery). Figures 4.2(a and b) 
illustrate at what time points these samples were drawn (i.e. the time after the last dose), and the 
gestational stage at which these anti-Xa activities were collected. 
 
Figure 4.2(a): Scatter-plot of the total anti-Xa activities drawn plotted against time after dose 
 
Figure 4.2(b): Scatter-plot of the total anti-Xa activities plotted against weeks amenorrhea 
Most antenatal samples were drawn during the second and third trimester, though a reasonable 
number of anti-Xa activities (n=104) were also obtained from the first trimester. Figures 4.3 (a - d), 
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Figure 4.3 (a-d): Scatter plot of anti-Xa activities against time-after-dose, split according to 
trimester; first trimester (top left), second trimester (top right), third trimester (bottom left) and 
post-partum (bottom right) 
 
Seventy seven (8.9%) of the anti-Xa activities drawn were reported below the quantifiable level of 
the assay, i.e. <0.01 IU/mL. These individual anti-Xa activities were retained in the data set and 
their values retained as absolute (i.e. negative anti-Xa activity values recorded from the analyser 
were retained in the dataset) and their inclusion will be discussed as part of the base model 
development. 
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4.2.2 Base model development 
Initially, a stable base model, which described the data, was developed. A number of different 
base models were explored, i.e. one and two compartment, with ETA’s (random effects) placed 
on CL, Vd +/- Ka. Table 4.3 lists the different base models initially explored. 
Table 4.3: Base models explored 
Base models explored 
1 compartment with between subject variability on Cl and Vd (combined error model) 
1 compartment with between subject variability on Cl, Vd and Ka (combined error model) 
1 compartment with between subject variability on Cl and Vd (additive error model) 
2 compartment with between subject variability on Cl, and V2 (combined error model) 
2 compartment with between subject variability on Cl, V2 and Ka (combined error model) 
2 compartment with between subject variability on Cl, V2, V3 and Ka (combined error model) 
2 compartment with between subject variability on Cl, V2, V3, Ka and Q (combined error model) 
2 compartment with between subject variability on Cl and V2 (additive error model) 
2 compartment with between subject variability on Cl, V2 and Ka (additive error model) 
 
The parameter estimates for the key base models chosen to evaluate further are listed in table 
4.4. The NONMEM control stream for the one compartment model with between subject variability 
on Cl and Vd is listed in appendix V.  
Table 4.4: Key base models, with associated parameter estimates  
Parameter Estimate  
1 CMT* 
(Model 1) (%SE) 
2 CMT* 
(Model 2) (%SE) 
1 CMT** 
(Model 3) 
CL (l/hr) 1.66 (5.7) 1.64 (5.5) 1.63 
Vd (l) 11.0 (11.5) 4.66 (28.0) 10.6 
Ka (hr
-1
) 0.505 (17.1) 0.21 (24.0) 0.502 
V3 (l) -  4.30  (39.5) - 
Q   (hr
-1
) -  0.358 (47.5) - 
ωCL (%CV) 46 (19.3) 46 (19.5) 47 
ωVd (%CV) 35 (49.9) 49 (63.6) 12 
ωka (% CV) -  -  65 
Proportional error (%) 22 (21) 21 (21) 21 
Additive error (IU/mL) 0.0659 (18) 0.0661 (18) 0.0658 
Objective function -2908.573 -2917.605 -2920.156 
*between subject variability on CL, Vd; **between subject variability on CL, Vd, Ka – minimisation successful, through the 
$COV step did not run for this model. ωX represents between subject variability for parameter x 
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Although the one compartment model with ETA’s on CL, Vd, and Ka (model 3) had a lower 
objective function than the one compartment model with ETA’s on CL and Vd (model 1), model 
3’s $COV step did not run, and so was not considered a stable model. It was likely that the 
standard error around the estimate of between subject variability on Ka could not be well 
estimated, with the model considered to be over-parameterised given the sparse sampling during 
the absorption phase. Furthermore, whilst the two compartment model (model 2) saw a decrease 
in the objective function of -9.032 (p<0.05) relative to model 1, this model was not considered the 
best base model, as the standard error on V3 was greater than 20%, and the standard error on 
between subject variability was greater than 50%. Therefore model 1 was considered the optimal 
base model.  
4.2.3 Handling below limit of quantification (BLQ) data 
Next the BLQ data were considered, which comprised 8.9% of the total dataset of anti-Xa 
activities. The specific question explored was, whether these data needed any special 
consideration. BLQ is not a unique problem to this study and is commonly encountered in the 
pharmacometric field. A number of methods exist in order to handle BLQ data within population 
pharmacokinetic modelling analysis. These include: 
i) Ignoring the data (i.e. remove them from the dataset) 
ii) Setting all the BLQ values to zeros 
iii) Setting all the BLQ values to half the BLQ values, i.e. if the BLQ is 0.01, then all BLQ 
values are set at 0.005 
iv) Use the M3 error method, as developed by Beal [Beal, 2001]. This method assumes 
that all BLQ are normally distributed. Therefore implementing the M3 method in 
NONMEM would involve sampling from this normal distribution of BLQ. This method 
has gained wide credibility within the pharmacometrics field 
v) Obtaining extrapolated values from the analyser of the assay and including these in 
the dataset as absolute values (including negative values) 
As bias could be introduced into the model if the BLQ were ignored, converted to zero or 
converted to half the BLQ values [Bergstrand and Karlsson, 2009], options four and five were 
specifically explored.  
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The M3 method was explored on the data. Appendix VI lists the NONMEM control stream code 
for the M3 method. Table 4.5, presents the parameter estimates obtained from this method. 
Table 4.5: Pharmacokinetic parameter estimates when using the M3 error method 
Parameter Estimate 
CL (l/hr) 1.50 
Vd (l) 14.3 
Ka (hr
-1
) 0.649       
ωcl (%cv) 43 
ωVd (%cv) 36 
Proportional error (%) 54           
Additive error (IU/mL) 0.025 
Objective function -2923.835* 
*minimisation terminated due to rounding error, therefore %SE estimates were not obtained 
Minimisation was not successful with the M3 method. This perhaps is not unsurprising, as 
Bergtrand and Karlsson [2009], have already stipulated that with the M3 method, the number of 
successful minimisations and how often the $COV runs, may fall. The M3 error model was 
rejected, as although the additive error decreased, the proportional error with this method went up 
significantly (54% compared to 22% in model 1). The decision to reject the M3 error model was 
further vindicated by recent work from Keizer and colleagues, which has evaluated different 
methods of handling BLQ data, including incorporation of BLQ, as a continuous data source 
[Keizer et al., 2010]. They found that when BLQ is incorporated as a continuous dataset and 
represents less than 10% of the total data (as is the case here), all BLQ methods showed similar 
performance. It was therefore decided to retain the BLQ in the data set as a continuous 
(extrapolated) data source, where the actual extrapolated values were those extracted from the 
laboratory analyser (including negative anti-Xa activities obtained). 
4.2.4 Inter occasion variability 
One question which needed to be considered in this study was whether inter occasion variability 
should be incorporated into the model developed. This is because it is recognised that 
pharmacokinetic parameters can vary over time in the same individual. In some situations, this 
may be linked to physiological processes, for example the effect of age, and in such situations, 
age would be incorporated into a final pharmacokinetic model to account for this. However in 
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some situations, individual pharmacokinetic parameters may change randomly between study 
occasions [Karlsson and Sheiner, 1993]. Within population pharmacokinetics, three levels of 
random effects are usually identified, firstly, between subject variation, the second is within 
subject variation and finally residual unexplained variability. Incorporating inter-occasion variation 
into a final model allows further assessment of within subject variability, by evaluating inter- 
occasion variability for the same subject. Work by Karlsson and Sheiner [1993], has 
demonstrated that although inter occasion variability can be ignored in the model development 
process, if it is, it can lead to significant bias on the fixed-effects parameters; which ones and by 
how much, depending on the design of the study and the model produced. With respect to the 
random-effect parameters, the effect of ignoring or not incorporating inter occasion variability into 
the model, can inflate the estimated residual error variance. Indeed only by extracting inter-
occasion variability, do you truly identify residual error. This is important to consider for this study 
as each subject in this study would have anti-Xa activity drawn on a number of occasions over the 
course of their pregnancy. However, the gravid state is a special situation; the primary purpose of 
the pharmacokinetic model being developed in this sub-group was to understand the 
pharmacokinetic changes as pregnancy progresses. Therefore, one expects inter occasion 
variability which can closely be linked to the physiological changes of the gravid state and 
therefore should be considered as a fixed effect rather than a random effect. Therefore inter 
occasion variability was investigated as a diagnostic tool to determine appropriate fixed effect 
changes in clearance and volume of distribution (figures 4.4 (a) and (b)) during pregnancy. These 
plots took the first ETA values for each subject in each trimester, for both CL and Vd and show 
that CL did not change significantly over the course of pregnancy, whereas, Vd did show a 
change in trend between the second and third trimester and again between the third trimester and 
within a week of delivery, suggesting that this needed to be accounted for in the final model, with 
respect to Vd. 
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Figures 4.4(a): ETA of CL (IOV) versus trimester (trimester 4 refers to within a week of delivery); 
redline represents the median values at each time point and the blue line is the reference line 
 
Figures 4.4(b): ETA of Vd (BOV) versus trimester (trimester 4 refers to within a week of delivery); 
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4.2.5 Goodness of fit evaluation of the base model  
A one compartment model, with exponential between subject variability on CL and Vd (model 1), 
with a combined additive and proportional error model, was the base model taken forward. 
Following this, standard goodness of fit plots of the one-compartment model were produced to 
graphically evaluate the model (figures 4.5-4.14); blue lines in the plots represent the line of 
identity and the red lines represent the linear regression line. Concentration of anti-Xa activity is in 
IU/mL. For figures 4.5 and figure 4.6, the model is not able to predict negative anti-Xa activities, 
as only positive concentrations can be predicted by the population and individual model, which 
explains the ‘tail’ observed at the bottom of figures 4.5 and 4.6. 
 
Figure 4.5: Observed versus population predicted values 
Within figure 4.5, the population model is under-predicting at higher concentrations. 
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Figure 4.6: Observed versus individual predicted values 
 
Figure 4.7: Conditional weighted residuals (CWRES) versus population predictions 
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Figure 4.8: Conditional weighted residuals (CWRES) versus time after dose 
 
Figure 4.9: Conditional weighted residuals (CWRES) versus time 
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Figure 4.10: Conditional weighted residuals (CWRES) versus gestation 
 
Figure 4.11: Histogram of conditional weighted residuals (CWRES), blue line represents actual 
standard deviation 
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Figure 4.12: Q-Q plot of conditional weighted residuals (CWRES) 
 
Figure 4.13: Histogram of ETA1 (CL), blue line represents actual standard deviation 
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Figure 4.14: Histogram of ETA2 (Vd), blue line represents actual standard deviation 
For this base model, shrinkage on ETA1 (CL) was 19.1% and ETA2 (Vd) was 35.2%. The 
goodness of fit plots provided confirmation and reassurance that the one compartment model was 
describing / capturing the observed data well and was a stable base model to take forward.  
Next a 1000 non-parametric bootstraps were run on the base model. Appendix VII lists the 
specific code used for completing this, using Wings for NONMEM for version 7.2.2 (available at 
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Table 4.6: Non-parametric bootstrap results compared with the parametric model estimates 













CL (l/hr) 1.66         (1.48-1.84) 1.67  (1.49-1.89) 
Vd (l) 11.0        (8.53-13.97) 11.20 (3.3-18.93) 
Ka (hr
-1
) 0.505   (0.335-0.675) 0.515 (0.15-0.89) 
ωcl (%cv) 46          (18-74) 46  (38-57) 
ωVd (%cv) 35          (2-70) 35  (14-65) 
Proportional error (%) 22           (8-36) 22 (17-53) 
Additive error (IU/mL) 0.0659 (0.0644-0.0674) 0.065 (0.04-0.08) 
 
The results from the bootstrap provided further confirmation of the appropriateness of the one 
compartment base model. 
4.2.6 Covariate analysis 
A full covariate analysis was then instigated. The following mechanistic covariates were tested; 
age, ethnicity, weight, lean body weight (baseline), creatinine and creatinine clearance.. 
Graphical analyses of random effects (ETAs) of CL versus covariates are illustrated in figures 
4.15-4.20. 
 
Figure 4.15: ETA1 (CL) versus age 
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Figure 4.16: ETA1 (CL) versus creatinine clearance 
 
Figure 4.17: ETA1 (CL) versus ethnicity (1 refers to the Caucasian population, 2 refers to the 
Africian-Caribbean population, 3 refers to the Asian population and 4 refers to the ‘other’ 
population), the width of the boxes indicates the relative number of subjects 
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Figure 4.18: ETA1 (CL) versus LBW 
 
 
Figure 4.19: ETA1 (CL) versus weight 
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Figure 4.20: ETA1 (CL) versus creatinine 
 
Based on this analysis, trends can be seen with weight, creatinine, baseline lean body weight and 
creatinine clearance. No trend was observed on age, and so was not considered relevant on CL 
and not investigated further. The ethnicity box-plots shows a slight trend on with groups 3 and 4 
(Asian and ‘other’ group), however the number of subjects in these two group were too small for 
further consideration. Gestation was not formally investigated on CL during the antenatal period, 
as the inter-occasion variability plot (figure 4.4(a)) demonstrated minimal impact during 
pregnancy. 
Graphical analyses of random effects (ETAs) of Vd versus covariates are illustrated in figures 
4.21 to 4.24. 
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Figure 4.21: ETA2 (Vd) versus age 
 
Figure 4.22: ETA2 (Vd) versus ethnicity (1 refers to Caucasian population, 2 refers to African-
Carribean population, 3 refers to Asian population and 4 refers to ‘other’ population); The width of 
the box-indicates the relative number of subjects in each group 
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Figure 4.23 ETA2 (Vd) versus lean body weight 
 
Figure 4.24: ETA2 (Vd) versus weight 
Based on this analysis, weight and baseline lean body weight demonstrated trends with the 
random effects (ETAs) of Vd and warranted further investigation. Due to a lack of trend, age was 
not considered relevant and not considered further. Ethnicity once again showed a slight trend 
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with groups 3 and 4 (Asian and ‘other’), however, like for CL, the numbers were considered too 
small, to consider this trend formally. Gestation was retained as a covariate for Vd, as the inter-
occasion variability plot (figure 4.4(b)) clearly showed a change with the progression of 
pregnancy.  
The identified covariates were next added to the base model in a uni-variate fashion. Each 
covariate was coded, so that it was centred around the median or mean of the covariate being 
evaluated, as is usual practice in PK modelling. For example creatinine (CRE) was centred 
around the value 60. Table 4.7 describes how each covariate was coded and tested. 
Table 4.7: How the different covariates were coded for evaluation into the base model 
Covariate CL Vd 
CrCl/110 CL x (CrCl/110) 
theta1 
- 
Wt/80 CL x (Wt/80) 
theta2 
Vd x (Wt/80) 
theta3 
Gest/MGest CL x (GEST/MGEST) 
theta4 
Vd x (GEST/MGEST) 
theta5 
CRE/60 CL x (Cre/60) 
theta6 
- 
LBW/42 CL x (LBW/42) 
theta7 
Vd x (LBW/42) 
theta8 
For gestation, centring occurred on MGEST, which represented the specific gestation at delivery for each subject 
Table 4.8 presents the change in objective function with the uni-variant addition of each covariate 
into the base model. A decrease on objective function of 6.64 (p<0.01) was required for the 
inclusion of the covariate into the intermediate model. 
Table 4.8: Uni-variate addition of covariates to base model 
Model Covariate OBV ∆OBV Minimisation 
successful? 
Base -  -2908.57 - - 
105 CL x (CrCl/110)
0.733 -2040.14 -31.57 Y 
80 CL x (Wt/80)
1.22
  -2959.66 -51.79 Y 
104 CL x (GEST/MGEST)
0.0666 -2923.01 -15.14 Y 
82 CL x (LBW/42)
1.78 -2944.63 -36.76 Y 
92 CL x (CRE/60)
-0.453 -2919.12 -11.25 Y 
84 Vd x (GEST/MGEST)
0.261 -2923.49 -15.62 Y 
83 Vd x (Wt/80)
1.47 -2942.46 -34.59 Y 
85 Vd x (LBW/42)
1.43
  -2921.06 -13.19 Y 
∆OBV represents the change in the base model objective function with the addition of the covariate 
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CrCl/110 and CRE/60 both significantly dropped the objective function on CL, and therefore a 
case could be made to have either included in an intermediate model. However, it made no 
physiological sense to have both included; therefore as CRE is already considered as part of CrCl 
(in the Cockcroft-Gault equation) and the objective function drop was greater with CrCl than with 
CRE, CRE was dropped as a covariate at this stage of the model building process. The other 
covariate which required special consideration was how weight and baseline lean body weight 
would be incorporated into the intermediate and final models. Both were found to be significant 
covariates for both CL and Vd.  
Based on the uni-variate covariate analysis, four competing models were developed and tested, 
table 4.9. 
Table 4.9: Addition of covariates in different combinations, led to four competing models 
Model Intermediate Model Description OBV 
 
401 LBW/42 + CrCl + Gest/MGest on CL 
LBW/42 + Gest/MGest on Vd 
 
-3039.899 
402 Wt/80 + CrCl + Gest/MGest on CL 
Wt/80 + Gest/MGest on Vd 
 
-3051.622 
403 LBW/42 + CrCl + Gest/MGest on CL 
Wt/80 + Gest/MGest on Vd 
 
-3040.002 
404 Wt/80 + CrCl + Gest/MGest on CL 
LBW/42 + Gest/MGest on Vd 
-3051.039 
 
Although intermediate model 402 has the lowest objective function, intermediate model 404 was 
the model chosen to take forward, as enoxaparin is a hydrophilic drug and it made physiological 
sense to have LBW on Vd, compared to model 402 which had weight on both CL and Vd; 
furthermore the objective function difference between both models was only -0.583.  
A backward elimination of covariates from the intermediate model 404 in a uni-variate fashion was 
then conducted (table 4.10). An increase in the objective function of greater than 10.82 (p<0.001) 
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Table 4.10: Backward elimination of covariates from model 404 (full model) 
Model Covariate removed OBV ∆OBV Retain? 
404 Full model -3051.039 - - 
431 CrCl on CL -3047.004 4.035 N 
432 Gest/MGEST on CL -3028.797 22.242 Y 
433 Wt/80 on CL -3010.590 40.449 Y 
434 Gest/MGEST on Vd -3010.948 40.091 Y 
435 LBW/42 on Vd -3036.259 14.780 Y 
436 Model 431 – GEST/MGEST on CL -3017.235 29.769 Y 
437 Model 431 – LBW/42 on Vd -3032.720 14.284 Y 
∆OBV represents the change in the final model objective function with the removal of each covariate. 
CrCl was not retained in the final model, as its exclusion from the final model caused an increase 
in objective function of only 4.035. Following this, the two covariates with the smallest increases in 
objective function, following their removal from the final full model (404), were re-evaluated to 
ensure their continued relevance. Therefore model 431 became the final model and gestation on 
CL and lean body weight on Vd were removed singularly, and they both continued to demonstrate 
their relevance in the final model, with ∆OBJ changes of 29.769 and 14.284 respectively. 
Therefore the final antenatal enoxaparin model was model 431. 
The final pharmacokinetic model for enoxaparin during pregnancy can be represented 
mathematically as: 
CL = POPCL x GESTCL x (Wt/80)
FACWTCL
      (4.1) 
Vd = POPVd x GESTV x (LBW/42)
FACLBWV
      (4.2) 
where during pregnancy: 
GESTCL=1          (4.3) 
GESTV=(GEST/MGEST)
FACGESTV
       (4.4) 
and post delivery: 
GESTCL=(GEST/MGEST)
FACGESTCL2
       (4.5) 
GESTV=(GEST/MGEST)
FACGESTV2
       (4.6) 
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4.2.7 Evaluation of the final model 
In order to evaluate the final model (NONMEM code: appendix VIII), a nonparametric bootstrap 
was completed; the specific code used for this in listed in appendix IX. This along with the final 
model parameter estimates are presented in table 4.11. 
Table 4.11: Bootstrap results of the final PK model developed 







CL   (l/hr) 1.60 (1.47-1.73) 1.60 1.48-1.74 
 
V     (l) 13.2 (10.93-15.47) 13.4 10.3-15.8 
 
Ka   (hr
-1
) 0.578 (0.428-728) 0.586 0.43-0.77 
 
ωCL (%cv) 31 (11-51) 31 24-38 
 
ωV   (%cv) 29 (1-57) 26 5-41 
 
FACGESTV 0.357 (0.212-0.502) 0.359 0.235-0.503 
 
FACGESTV2 -5.49 (-2.73(-)-8.25) -5.37 -28.79-0.78 
 
FACGESTCL2 -4 (-2.76(-)-5.24) -4.26 -9.28-(-)1.55 
 
FACWTCL 1.06 (0.78-1.34) 1.06 0.76-1.39 
 
FACLBWV 1.25 (0.47-2.03) 1.27 0.42-2.03 
 
Add error (IU/mL) 0.0660 (0.06449-0.06751) 0.0656 0.0536-0.0761 
 
Prop error (%) 18 (4-32) 18 12-24 
 
  
The inclusion of these covariates in the final model led to a decrease in between subject 
variability in CL from 46% to 31% (a drop of 15%) and a decrease in between subject variability in 
Vd from 35% to 29% (a drop of 6%). Figures 4.25 (a and b), and 4.26 (a and b) illustrate the ETA 
trend change, with the covariate being incorporated into the final model; before (top), after 
(bottom). 
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Figure 4.25 (a) and (b): ETA1 (CL) versus weight, before (top) and after (bottom) inclusion into 
the final model 
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Figure 4.26 (a) and (b): ETA2 (Vd) versus LBW, before (top) and after (bottom) inclusion into the 
final model 
 
The plots demonstrate the relevance of including these covariates into the final model, as with 
their inclusion, the systematic trends observed in random effects are removed. 
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4.2.8 Visual predictive check of final PK model 
Finally a visual predictive check (VPC) was conducted to ensure the final model developed was 
capturing the observed data. The ‘R’ code for the VPC plot is available in appendix X. For all 
VPCs, 100 datasets that mirrored the demographics of subjects in this clinical study were 






 prediction intervals 
from the simulated concentrations were plotted against time after dose, with the observed data 
superimposed. Figure 4.27 illustrates the VPC from the final model, with the red lines 













 percentiles from the simulated data set. As can be seen, the 
final model is describing the observed data extremely well. Figures 4.28 (a-d) demonstrate the 
VPC’s when broken down by trimester. 
  
Figure 4.27: VPC of dose normalised plasma concentrations versus time after last dose 
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Figure 4.28: VPC breakdown according to each trimester; 1
st





 trimester ((c)bottom left) and postpartum ((d)bottom right) 
 
The overall VPC and the trimester specific VPC’s confirm that a robust final enoxaparin antenatal 
model had been developed. 
4.2.9 Simulation work 
The aim of the simulation work was to simulate the important ‘what if’ questions of clinical 
practice. As part of this, a weight model, describing weight changes over the course of pregnancy 
needed development. The evolution of this weight model followed the same method principles of 
development and evaluation as the enoxaparin antenatal model. 
4.2.9.1 Developing a weight model 
In the first instance, a sub-data file was created from the main file, which listed each subject’s 
weight at each clinic visit, from initial recruitment to when they attended the haematology clinic 
around eight weeks post-partum for their final clinic visit. Within the data file, each weight entry 
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had an associated gestation time listed (weeks amenorrhea), along with the subject’s baseline 
ethnicity and lean body weight.  
Initially, three different weight models were explored as suitable base models, differing in the error 
structure within each model; additive, proportional and combined (additive and proportional)). For 
all three models, an ETA was added to the exponent describing gestational weight change over 
pregnancy (FACGESTWT1), with a further ETA added onto baseline weight (BSWT). The OBJ 
function and parameter estimates from these three models are listed in table 4.12. 
Table 4.12: Results of weight models with three error structures 
Base weight model 10 Additive error          
(% SE) 
11 Proportional error                    
(%SE) 
12 Combined error 
(%SE) 
OBJ 3193.211 2999.237 2979.109 
Baseline weight θ1  82.3 (2.1) 83.1 (2.2) 83.1 (2.2) 
FACGESTWT1 θ2  0.0569 (8.3) 0.0709 (7.9) 0.0692 (8.8) 
FACGESTWT2 θ3 -0.313 (7.3) -0.350 (7.0) -0.345 (7.2) 
ωBSWT (CV%) 25 (15.0) 25 (14.8) 25 (14.8) 
ωFACGESTWT1 (CV%) 31 (23.1) 60 (22.2) 63 (23.1) 
Additive error (kg) 10.1 (31.3) -  3.32 (29.3) 
Proportional error (%) -  3 (9.7) 2 (44.0) 
 
As there was little to choose between these three models, all three were considered for covariate 
analysis.  
Next consideration was given to covariates and which ones should to be included in the final 
weight model developed. Based on observations in clinic, whereby different ethnic groups 
appeared to have different weight categories, e.g. patients from a south Asian origin were smaller 
(in terms of weight) than those of African-Caribbean origin; which could be significant. Age was 
not explored as a covariate, even though it might be in other settings, due to the tight age range 
of the population followed in this study (mean age 33 (range 18-46)). Figure 4.29 illustrates the 
weight differences between the four different ethnic groups (1 refers to Caucasian, 2 refers to 
African-Caribbean, 3 refers to Asian and 4 refers to ‘other’ group). 
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Figure 4.29: box-plot of the first recorded weight for each of subject within each ethic group (1 
represents the Caucasian group, 2 represents the African-Caribbean group, 3 represents the 
Asian group and 4 represents the ‘other’ group) 
 
As illustrated by figure 4.29, the Asian group weight is much lower (in terms of the spread), 
relative to the Caucasian and African-Caribbean groups. This suggested that ethnicity should be 
considered for the weight model and so was added as a covariate to the three base models with 
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Table 4.13: Results with the incorporation of ethnicity into the base model 
Model 19 – Additive (SE%) 19 – Proportional (SE%) 19 – Combined (SE%) 
OBJ 2959.284 2979.305 2950.785 
Caucasian θ1 79.6  (3.0) 79.6  (3.1) 79.6  (3.0) 
Black θ2 91.5  (3.7) 91.6  (3.8) 91.6  (3.7) 
Asian θ3 69.6  (4.0) 69.6  (4.0) 69.6  (4.0) 
Other θ4  85.5  (6.3) 85.5  (6.3) 85.6  (6.3) 
FACGESTWT1 θ5 0.0768  (8.0) 0.0787  (7.0) 0.0782  (7.5) 
FACGESTWT2 θ6 -0.322  (9.2) -0.342  (7.6) -0.335  (8.1) 
ωBSWT (%) 23  (15.9) 23  (15.9) 23  (15.9) 
ωFACGESTWT1 (%) 5  (17.5) 4  (19.5) 4.5  (18.0) 
Additive error (kg) 5.63  (9.6) -  3.95  (65.1) 
Proportional error (%) -  3.05  (9.9) 1.5  (26.3) 
 
Although the combined error model was the model with the lowest objective function, the standard 
errors around the additive and proportional errors were large, relative to the singular additive and 
proportional error models. Therefore the additive error model was the model chosen to take 
forward, as it demonstrated a lower objective function relative to the proportional error model.  
Next each ethnic group was tested in this additive error model, with an ETA added on each ethnic 
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Table 4.14: Assessment of each ethnic group in a uni-variate fashion 
Model 30 - Asian                    
(SE %) 
31 - Caucasian             
(SE %) 
32 - African-              
Caribbean (SE %) 
33 - Other                
(SE %) 
 
OBJ 2756.768 2759.749 2760.830 2760.649 
Caucasian θ1 79.5 (3.0) 79.4 (3.0) 79.5 (3.0) 79.5 (3.0) 
Black θ2 91.4 (3.7) 91.4 (3.7) 91.4 (3.7) 91.4 (3.7) 
Asian θ3 69.8 (4.0) 69.7 (4.0) 69.7 (4.0) 69.7 (4.0) 
Other θ4  85.3 (6.4) 85.4 (6.4) 85.3 (6.4) 85.4 (6.3) 
FACGESTWT1 θ5 0.0735 (9.2) 0.0734 (9.3) 0.0735 (9.3) 0.0734 (9.3) 
FACGESTWT2 θ6 -0.319 (9.2) -0.318 (9.2) -0.318 (9.2) -0.318 (9.2) 
ωBSWTEthn1 (%) 24 (16.1) 22 (23.6) 23 (20.2) 24 (16.4) 
ωBSWTEthn2 (%) 11 (44.5) 25 (21.4) 23 (25.3) 21 (66.1) 
ωFACGEST1 (%) 4 (29.8) 4 (30.1) 4 (30.2) 4 (30.2) 
Additive error (kg) 11.4 (49.5) 11.4 (49.5) 11.4 (49.5) 11.4 (49.5) 
 
Weight model 30 (with a separate ETA on the Asian group) was the best performing model and 
so was the weight model used for the purposes of simulation. For completeness, a VPC plot 
analysis of this model was completed (figure 4.30). 
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 percentiles from the simulated data set 
Overall, the weight model is performing well, demonstrated by the median observed and 





values, and are likely to be reflective of the large variation in weight gain and loss observed in 
some women during pregnancy. 
4.2.9.2 Simulations 
Next simulations based on the the final enoxaparin antenatal model developed were done, and 
compared once daily enoxaparin (according to the King’s College Hospital non-pregnancy 
guidelines) to twice daily enoxaparin (according to the RCOG antenatal VTE guidelines). The 
simulations assumed that the dose was not altered through pregnancy and all doses were taken 
(injected). Figure 4.31 (a) and (b) illustrates the three hour anti-Xa activity of enoxaparin when 
women are given these two regimens from day one of their pregnancy and they continue to 
receive this dose and dosing regimens until they deliver at 40 weeks gestation. 
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Figure 4.31 (a) and (b): 3 hour anti-Xa activity of enoxaparin during pregnancy, once (top) versus 
twice a day (bottom). RCOG target anti-Xa activity represented by grey horizontal lines (0.5-1.2 




 percentile anti-Xa concentrations 
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These plots demonstrate that with both regimens, the three hour anti-Xa activity decreases with 
gestational age. However, they also demonstrate that for both regimens, the 3 hour peak activity 
remains within the RCOG desired range of 0.5-1.2 IU/mL (grey horizontal lines) throughout 
pregnancy. This suggests that the once daily dosing regimen would be acceptable in this setting, 
based on current recommendations. However, historically, it’s thought that LMWH CL increases 
during pregnancy, and so pregnant women need to receive a higher and/or more frequent dose. 
Therefore, the more important concentration to evaluate, is the trough concentration, i.e. before 
the next dose is due, to assess if LMWH activity exists, before the next dose is injected. When the 
trough anti-Xa activities are simulated for the two regimens, the results presented in figure 4.32 
(a) and (b) are found, suggesting that the majority of women will posses residual anti-Xa activity 
before the next dose is injected. 
 





 percentile anti-Xa concentrations 
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 percentile anti-Xa concentrations 
 
Combining the results and figures 4.31 and 4.32, the 3 hour and trough plots for once versus 
twice daily are illustrated in figures 4.33 (a) and (b). 
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Figure 4.33 (a) and (b): 3 hour and trough anti-Xa activity; once (top) versus twice daily (bottom) 






 percentile 3 hour anti-Xa activity 







concentrations associated with just the trough activity 
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The trough activity of both the once and twice daily regimens increases with the progression of 
pregnancy. Most of the women on the once daily regimen have measurable anti-Xa activity at the 
trough time point and demonstrates that once daily enoxaparin would be adequate for this 
purpose in this setting.  
4.2.9.3 Percentage of women with a trough concentration <0.01 IU/mL with these regimes 
The simulation work shows that there will be a percentage of women who would not have a 
measurable anti-Xa activity at the trough time point. The number of women this would apply to 
was quantified in ‘R’ and presented in table 4.15.  
Table 4.15: % of women who have enoxaparin concentrations BLQ 
Gestation (weeks) Once daily regimen (% <0.01 IU/mL) Twice daily regimen (% <0.01 IU/mL) 
1 44.87 18.53 
6 33.98 9.18 
12 29.51 6.99 
18 29.67 6.01 
26 24.39 4.87 
32 24.06 4.87 
36 23.25 4.55 
37 25.28 5.53 
38 25.36 5.77 
39 23.65 4.14 
40 21.62 4.30 
 
The clinical implications of not having a measurable anti-Xa activity at the trough time point are 
not known. For the once daily group, approximately 25% of women will have a trough activity 
below 0.01 IU/mL compared to 5% of women in the twice daily group. On the other hand, the 
results also demonstrate that the majority of women will have anti-Xa activity when the next dose 
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4.3 Discussion 
The results from this study demonstrate that both CL and Vd of enoxaparin are significantly 
altered during the antenatal period. The estimates for enoxaparin CL and Vd are markedly 
different to previously published enoxaparin compartmental models published from a non-
pregnant population (table 4.16), and demonstrate the impact the physiological changes of 
pregnancy has on enoxaparin PK. It should be noted that the study by Green and colleagues 
[2003] had a higher CL and Vd value, relative to the other studies; this is likely because they were 
specifically assessing enoxaparin PK in an obese population and therefore the higher fixed effects 
parameter estimates are reflective of this.  
Table 4.16: Estimates for enoxaparin Vd and CL from other pop PK studies of enoxaparin 
Study Compartmental or non-
compartmental 
CL (L/hr) Vd (L) 
Casele (1999) Non-compartmental 0.6 3.10 
Green (2003) Compartmental 1.03 16.77 
Hulot (2005) Compartmental 0.74 5.29 
Bruno (2003) Compartmental 0.73 5.24 
Lebaudy (2008)* Compartmental 0.52 7.03 
Barrass (2009) Compartmental 0.72 9.20 
*Only other population PK study of enoxaparin during pregnancy 
Some of the compartmental analysis completed to date, e.g. Green and colleagues [2003] and 
Barrass and colleagues [2009] have described enoxaparin PK in terms of a two compartment 
model. Although a two compartment base model was initially explored in this thesis, a one 
compartment model was found to describe the data sufficiently well, and the decision to pursue to 
a one compartment model was further ratified by the VPC of the final model produced. Indeed the 
only other compartmental PK analysis of enoxaparin during the antenatal period was also a one 
compartment model [Lebaudy et al., 2008]. 
The findings from this thesis report CL and Vd to increase to as much as 1.6 L/hr and 13.2 L 
during pregnancy, and suggest, due to the measurable trough activity (and therefore persistence 
of anticoagulation), that a once daily dose of enoxaparin is an appropriate dosing regimen for the 
management of antenatal VTE. 
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The concern during pregnancy has always been that CrCl increases and so therefore does CL, 
and therefore compensation is required in the dose or dosing strategy of LMWH to counter this. 
The results from this thesis demonstrate that Vd also increases significantly during pregnancy and 
because of this, half life of enoxaparin is actually prolonged. This is the second study to 
demonstrate this formally. The compartmental PK study by Lebaudy and colleagues [2008] had 
similar findings to this thesis and they are the only group to date to comment on the significance 
of the Vd in this setting. In their study they found that the trough anti-Xa activity increased with the 
progression of pregnancy, attributing this to changes in Vd. Clearance and Vd are independent 
PK parameters, and the fact that Vd rises during pregnancy, prolongs the half life of enoxaparin, 
particularly if renal elimination of enoxaparin has stabilised, which is what is thought to occur, with 
CrCl reaching a plateau around 15 weeks gestation. Table 4.17 compares the PK model 
estimates between Lebaudy’s model and those from this thesis. 
Table 4.17: Comparison between the model results in this thesis with Lebaudy’s model 
Parameter This thesis Lebaudy Model 
Estimate (SE%) Estimate (+/-SD) 
CL   (l/hr) 1.60        (4) 0.81 (0.03) 
V     (l) 13.2        (9) 7.81 (1.23)  
Ka   (hr
-1
) 0.578      (13) 0.56 (0.12) 
ωCL  (%cv) 31           (21) 20.3 
ωV   (%cv) 29           (49) 26 
FACGESTV 0.357      (21) - 
FACGESTV2 -5.49       (26) - 
FACGESTCL2 -4            (16) - 
FACWTCL 1.06        (14) - 
FACLBWV 1.25        (31) - 
FACCLLebaudy - 0.42 (0.12) 
FACVLebaudy - 1.41 (0.25) 
Add error (IU/mL) 0.0660     (18) 0.12 
Prop error (%) 18            (30) - 
FACVLebaudy and FACCLLebaudy are exponents that Lebaudy and colleagues had on CL and Vd 
Lebaudy’s model provides a good comparator for this thesis’ study, and the reproducibility of the 
Vd finding by two independent groups should provide reassurance to those working in the field 
that such a finding is not by chance. In their study, Lebaudy’s simulation work described that after 
administration of identical doses of enoxaparin, pregnant women showed a 22% reduction in peak 
anti-Xa activity compared to non pregnant women. They were the first to demonstrate that 
because CL of enoxaparin does not change significantly after the first trimester, the area under 
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the curve of anti-Xa activity does not change significantly further during pregnancy for a constant 
dose and go onto suggest that whereas peak anti-Xa activity will decrease with the progression of 
pregnancy, the residual anti-Xa activity will increase as pregnancy progresses, a finding which is 
endorsed and supported by the results from the study in this thesis.  
It must be remembered though, that Lebaudy’s model does have a number of limitations; the anti-
Xa sampling strategy was left to the clinician’s discretion, and was not based on D-optimal design. 
As described in chapter 2, it is well recognised, that a study based on D-optimisation is more 
robust, in terms of the information that the study will provide. The study in this thesis was based 
on D-optimal design and was more likely to capture the gestation related changes in Vd and CL. 
Furthermore, Lebaudy’s study describes an un-physiological rise in Vd, where a big shift in Vd is 
incorporated into their model at 31 weeks gestation, which is not what actually happens in 
practice, and not what was observed during the course of this study. Finally, relative to this study, 
the number of anti-Xa activities and number of women recruited in Lebaudy’s model was half the 
number recruited during this study; 343 versus 712 anti-Xa activities and 72 versus 123 women 
recruited. Accepting these limitations from Lebaudy’s model however, the results from the study in 
this thesis add weight to Lebaudy’s group stipulation, that trough anti-Xa activity will increase with 
the progression of pregnancy and this needs to be considered in the current dosing schedule 
recommendations in national / international guidelines. 
Closer examination of early clinical studies evaluating LMWH PK, have demonstrated the Vd 
effect, even though the authors were unaware of this, at the time. For example in Sturridge and 
colleagues [1994] observational study evaluating 18 pregnancies in women receiving 
thromboprophylaxis with enoxaparin 20mg or 40mg once daily, mean peak anti-Xa activity was 
reported as 0.102 IU/mL and 0.036 IU/mL with the 40mg and 20mg dose respectively. They go 
onto to describe how the concentration was significantly lower after 20 weeks gestation, which 
could be attributed to Vd as well as an increase in CL. Hunt and colleagues [1997] observational 
study of using dalteparin in 34 pregnancies initially dosed at 5,000 IU daily, aimed to maintain a 
trough anti-Xa activity of 0.15-0.2 IU/mL and a 2-hour peak of 0.4-0.6 IU/mL. In this study, the 
authors report that the majority of women required a dose change to 5,000 IU twice daily from 
around 20 weeks gestation to reach these target peak levels; this again can be attributed in part 
to a Vd effect as opposed to just an increase in CL. Perhaps the most compelling evidence comes 
from Casele and colleagues [1999] seminal study assessing the PK of prophylactic enoxaparin 
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during pregnancy in 13 women. The authors of this study reported a lower area-under the 
concentration-time curve during pregnancy than during the post-partum period. Closer 
examination of the detailed results from this study reveal some interesting findings, as presented 
in table 4.18. 
Table 4.18: Casele and colleagues findings in their antenatal enoxaparin study 
Parameter 12-15 weeks 30-33 weeks 6-8 weeks PP 
Anti-Xa activity 12 h after dose (IU/mL) 0.09 +/- 0.09 0.16 +/- 0.10 0.19 +/- 0.09 
 
Maximum concentration (IU/mL) 0.46 +/- 0.08 0.40 +/- 0.08 0.57 +/- 0.09 
 
Mean residence time (min) 287 +/- 56 325 +/- 44 316 +/- 32 
PP = post-partum 
The 12 hour activity increases at 30-33 weeks gestation, compared to 12-15 weeks gestation, 
maximum concentration has decreased by 30-33 weeks gestation, although the mean resident 
time has increased at 30-33 weeks gestation, compared to 12-15 weeks gestation. These 
changes can be explained by an increase in Vd.  
Interestingly, groups worldwide continue to publish their experience of LMWH in the antenatal 
population and continue to suggest that an increase in the dose of LMWH is required in response 
to a falling peak anti-Xa activity, with the progression of pregnancy. In a recently published study, 
De Sancho and colleagues [2012], describe a retrospective review of pregnant women prescribed 
LMWH from January 2001 to December 2010. Seventy-six women had 89 pregnancies and they 
found doses of LMWH needed to be adjusted in 75% of women managed on therapeutic doses of 
LMWH (aiming for a peak anti-Xa of 0.6-1.1 IU/mL) and in 45% of women managed with 
prophylactic dose LMWH (aiming for a peak anti-Xa activity of 0.2-0.5 IU/mL). In light of the 
findings from this thesis and coupled with the findings from Lebaudy and colleagues, this strategy 
has to be wrong when the anti-Xa activity is considered in the context of Vd.  
It is thought that persistence of anti-Xa activity is central to LMWH pharmacological action; this 
being the case, perhaps the focus of monitoring should be centred on trough monitoring, as 
opposed to peak activity during pregnancy. Such a monitoring strategy would help to identify the 
women with no anti-Xa activity, and who might then benefit from a dose increase. 
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4.3.1 Assumptions made during the PK modelling process  
As part of the PK modelling process, a number of assumptions have been made. It is important 
that they are considered as part of the wider results. Firstly, an assumption that the patient 
population in this study, from which a simulation data-set was created, is representative of a 
typical obstetric population. The simulation work also assumes all the women begin their 
enoxaparin from day 1 of pregnancy and deliver at 40 weeks gestation. Next, an assumption is 
made that the assay is 100% accurate from which the results were obtained. Finally, the 
simulation work assumes that women are 100% adherent to the enoxaparin, and that they inject 
enoxaparin at the same time each day, during the course of their pregnancy. In reality, this would 
not be the case and indeed observing women during the course of this study, was not the case, 
with variation in time administered. Some of these assumptions would account for some of the 
residual unexplained variability observed in the final model developed. 
4.3.2 Strengths of this study and the final model 
This study is the largest pharmacokinetic study of LMWH in a pregnant population completed to 
date, and one of only a few which has studied information from the first trimester. Particular 
strengths include the number of patients recruited, the number of anti-Xa activities drawn and 
modelled and the negligible complication rate. A further particular strength of the study is in its 
multi-disciplinary nature, with different disciplines and experts working together (haematologists, 
obstetricians, PK modeller, and a pharmacist) to achieve a common objective.  
4.3.3 The clinical case for a once daily dosing strategy for antenatal VTE 
An Australasian expert group statement on the management of antenatal VTE [Mclintock et al., 
2012], recommends LMWH over UFH as the agents of choice. With respect to LMWH dosing, i.e. 
once versus twice a day, they suggest that there is currently insufficient evidence to favour one 
dose regimen over the other. They do however recommend that women with PE or more 
extensive DVT (i.e. iliofemoral thrombosis), should receive initial treatment with twice daily LMWH 
for at least 8-12 weeks, after which a reduction to once daily may be considered. They also 
suggest that women who suffer from a PE should be monitored closely as inpatients for the first 
couple of days following diagnosis. Their guidelines go on to recommend that there is insufficient 
evidence to recommend monitoring of anti-Xa levels to guide dosing in women on therapeutic 
dose LMWH, as there are no data of clinical benefit from dose adjustment. However if a level is 
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aimed for, they suggest 0.5-1.0 IU/mL for a twice daily regimen at four hours post dose, whilst 
acknowledging that the target is less clear for a once daily regimen (1.0-2.0 IU/mL at four hours 
post dose).  The results from this thesis demonstrate that the 3 hour anti-Xa activity will decrease 
with the progression of pregnancy, due to the increase in the Vd. The results also demonstrate 
that residual anti-Xa activity increases with the progression of pregnancy, again due to the 
increase in the Vd. Therefore monitoring peak target anti-Xa activities during pregnancy seems 
counter-initiative, as if you did adjust the dose to reach a target peak anti-Xa activity, you run the 
risk of over anticoagulation and ultimately put the patient at risk of bleeding.  
4.3.3.1 Thrombus regression: once versus twice daily 
Meta-analysises of LMWH in the treatment of VTE outside of pregnancy have concluded that 
treatment with LMWH increases the frequency of thrombus regression [Leizorovicz et al., 1994; 
Lensing et al., 1995; van den Belt et al., 2000]; a fundamental aim of LMWH therapy in the 
management of VTE. A previously published study by Breddin and colleagues [2001], conducted 
a open-label, multicentre study, with blinded adjudication at end points, whereby patients with 
acute deep vein thrombosis were randomly assigned to one of three treatment regimens; 
intravenous unfractionated heparin for a week, twice a day reviparin for one week, or reviparin 
once a day for four weeks; patients recruited to all three arms received a total of 90 days 
treatment, with a vitamin K antagonist started on day 1 of the unfractionated heparin and twice a 
day reviparin group and from day 20 for the once a day reviparin group. The reviparin dose 
administered was one injection every 12 hours, or as one injection every 24 hours, based on 
patients weight; 7000IU for a weight of 35-45kg, 8400IU for a weight between 46-60kg and 
12,600IU for a weight of more than 60kg. The primary end point was a change in the 
venographically determined thrombus size between baseline and day 21, using the Marder score 
[Marder et al., 1977]. This score allocates points to each of the involved deep segments of the 
lower limb; if all the veins in one leg are occluded, the total score is 40, with partially occluded 
veins given a lower score. Patients are considered to have a response when their scores had 
decreased by at least 30%. In the study, 40.2% (129 patients) had thrombus regression 
(response to treatment) in the unfractionated heparin group, compared to 53.4% (175 patients) 
receiving reviparin twice daily, and 53.5% (167 patients) receiving reviparin once daily. Table 4.19 
lists the numbers of patients who were judged to have not responded.  
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Table 4.19: Results from Marder and colleagues reviparin study 




Reviparin TWICE daily 
n=388 (%) 
Reviparin ONCE daily 
n=374 (%) 
Recurrence  24    (6.4) 7   (1.8) 13   (3.5) 
No venographic changes 
seen 
167  (52) 140  (42.7) 128  (41) 
Deterioration (increase 
in Marder score of at 
least 30%) 
25   (7.8) 13 (4) 17   (5.4) 
 
Clearly the LMWH was more effective in this study compared to unfractionated heparin, with this 
study demonstrating a correlation between clinical outcome and change in thrombus size, and 
although the twice daily dose of reviparin has the best outcomes, the once daily dose has 
extremely good outcomes and is considered as efficacious as the twice daily dose. The results 
demonstrate objective efficacy of both once and twice daily doses of reviparin, which is further 
endorsed by a comprehensive Cochrane review [van Dongen et al., 2004]. 
4.3.3.2 Lessons from the early cardiology dose-ranging twice a day trials of enoxaparin 
The dose ranging trial of enoxaparin for unstable angina, originate from the TIMI 11A trial 
[Antman et al., 1997]. This was a phase II trial whose objective it was to compare the safety and 
tolerability of two weight-adjusted regimens of enoxaparin in patients with unstable angina / non-
Q-wave myocardial infarction (NSTEMI), as the optimal dose in patients with arterial disorders 
had not been established. This study was an open label study, with the original plan in the study 
for an ascending dose, to evaluate a weight-adjusted dose of enoxaparin of 1.25mg/kg every 12 
hours (dosing schedule 1) in the first cohort of patients studied and then 1.5mg/kg every 12 hours 
(dosing schedule 2) in the second cohort of patients. However, after 321 patients had been 
enrolled in dosing schedule 1, the trial had to be reconfigured, as a descending dose-ranging trial, 
with the second cohort (309 patients) receiving 1.0mg/kg every 12 hours (now dosing schedule 
2). This was because routine monitoring of the major haemorrhage rate by the trial safety 
committee found a major haemorrhage rate of 6.5% (21 patients) at day 14. Major haemorrhage 
in the new dosing schedule 2 occurred in six patients (1.9%) at day 14. In both dosing tiers the 
majority of episodes of major bleeding occurred at instrumental sites, with only small numbers 
attributed to spontaneous bleeds. Further analysis of anti-Xa activities from this trial are presented 
in table 4.20. 
 - 168 - 
Table 4.20: Results from TIMI 11A enoxaparin dose ranging study 
Anti-Xa activity 
(IU/mL) 
Dose tier 1  
(1.25mg/kg every 12 hours) 
Dose tier 2  















 weight adjusted 
dose 
    
      Trough 0.5 (n=14) 0.6 (n=202) 0.7 and 1.0 (n=2) 0.5 (n=162) 
      Peak 1.8 (n=14) 1.4 (n=213) 1.2 and 1.9 (n=2) 1.0 (n=161) 
Last weight 
adjusted dose 
    
      Trough 0.6 (n=7) 0.8 (n=106) 0.3 and 1.5 (n=2) 0.6 (n=43) 
      Peak 2.0 (n=4) 1.6 (n=99) 1.0 and 1.8 (n=2) 1.1 (n=44) 
 
The authors from this study concluded that the 1.0mg/kg weight adjusted dose was well tolerated 
and this work then formed the basis of the larger phase III trial the TIMI 11B trial [Antman et al., 
1999]. They also suggest that with the twice daily regimen, there was no accumulation of the 
LMWH. What can be extrapolated for the antenatal population? Antman’s study provides valuable 
information, informing us that increasing the dose of enoxaparin above 1mg/kg twice a day can 
increase the risk of haemorrhage. So in an antenatal setting, if a patient is prescribed a twice daily 
regimen and the dose is adjusted to maintain a peak level, potentially the risk of bleeding 
(particularly at instrumental sites) is run, as a drop in peak anti-Xa activity is inevitable with the 
increase in Vd; once again providing weight to the thinking that trough activity is a better time 
point to monitor in this setting.  
The TIMI IIB trial [Antman et al., 1999], was a phase III study which randomised patients with 
unstable angina or NON-Q-wave MI to intravenous UFH for > 3 days followed by subcutaneous 
placebo injections or uninterrupted  therapy with enoxaparin during both the acute and chronic 
phase, of 30mg IV bolus, followed by subcutaneous injections of 1.0mg/kg every 12 hours and an 
outpatient phase of 40mg bd (for patients weighing less than 65kg) and 60mg bd (for patients 
weighing > 65kg). The authors of this study conclude that enoxaparin is superior to UFH for 
reducing a composite end point of death and serious cardiac ischemic events during the acute 
management of UA/NON-Q-wave MI, without causing a significant increase in the rate of major 
haemorrhage. However, interestingly, when you analyse the patients who suffered from major 
 - 169 - 
and minor haemorrhage at 72 hours and at the end of the time period of hospitalisation, more 
patients significantly suffered from minor bleeds compared to those patients in the unfractionated 
heparin arm (table 4.21). 
Table 4.21: Bleeding results from the TIMI IIB trials 
 Treatment Group  
Time point UFH (n=1926) Enoxaparin (n=1938)     p 
72 h    
    Major haemorrhage (%) 14 (0.7) 16 (0.8) 0.714 
    Minor haemorrhage (%) 45 (2.3) 99 (5.1) <0.001 
End of initial hospitalisation    
    Major haemorrhage (%) 19 (1.0) 29 (1.5) 0.143 
    Minor haemorrhage (%) 48 (2.5) 176 (9.1) <0.001 
 
As with many other unfractionated heparin trials, only around 40-50% in this study had aPTT 
values in the target range, so it is difficult to know whether the increase in minor haemorrhage 
seen with the enoxaparin arm was truly because of the enoxaparin or not, as if all the UFH 
patients were in range, might a similar number of events have been observed? The minor 
haemorrhages in most cases were due to ecchymosis at the subcutaneous site or a haematoma 
at the site of a sheath inserted for cardiac catherisation. Whilst accepting the fact, that the 
majority of patients in this study are older and not directly comparable to a pregnant population 
from a physiological point of view, the message that can be discerned from this large and 
influential study is that giving a twice daily enoxaparin dose, might increase the risk of minor 
haemorrhage.  
Considering all of these factors, more weight is given to the camp supporting a once daily 
regimen of LMWH in the pregnancy setting for antenatal VTE. Indeed none of the women 
managed in this cohort who were managed with once daily enoxaparin suffered from any 
recurrences or complications during the course of this study; including the 10 pregnancies in 
women on long-term warfarin who were switched to enoxaparin during the index pregnancy.Table 
4.22 is a reminder of the specific clinical details of these women. 
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Table 4.22: Women switched from warfarin to once daily enoxaparin 
Patient Indication Target INR 
range 
Enoxaparin dose prescribed 
16 Recurrent VTE 1.5-2.0 120mg daily 
37 FVL (homozygous). Symptomatic VTE whilst 
on combined oral contraceptive pill 
2-3 100mg daily 
45* Budd-Chiari (Liver transplant in 1998) 2-3 100mg daily 
48 Paroxysmal nocturnal haemoglobinuria 2-3 80mg daily 
53 Budd-Chiari (Liver transplant in 2006) 2-3 100mg daily 
54 Anti-phospholipid syndrome 2-3 100mg daily 
82 AF/Mitral stenosis/Pulmonary hypertension 2-3 100mg daily 
87 Recurrent VTE 2-3 180mg daily 
101* Budd-Chiari (Liver transplant in 1998) 2-3 100mg daily 
115 Anti-phospholipid syndrome and Budd-Chiari 
(Liver transplant in 2005) 
3-4 60mg daily 
*same patient 
4.3.4 Mechanical valve prophylaxis during pregnancy 
Managing pregnant women with a mechanical heart valve in-situ, has to be one of the most high 
risk and difficult challenges that clinicians can be faced with in obstetric care. The anticoagulation 
management of these women is highly controversial and each case should be considered on a 
case-by-case basis on their particular management, depending on co-morbidities, valve type and 
specific circumstances [Patel and Hunt, 2008]. During pregnancy, the risk of valve thrombosis is 
least with coumarin anticoagulation throughout pregnancy (4%) and increased markedly with the 
use of unfractionated heparin, with the risk of life-threatening thrombosis of 29-33% and a 
mortality of between 7-15% [Chan et al., 2000; Sadler et al., 2000]. Information relating to the use 
of LMWH has been variable. Current ACCP guidelines [Bates et al., 2012] on this matter suggests 
one of three approaches should be adopted: 
(i) Adjusted twice daily dose of LMWH throughout pregnancy to keep the 4 hour post 
injection, between 1-1.2 IU/mL 
(ii) Aggressive adjusted dose UFH throughout pregnancy, administered by subcutaneous 
injection every twelve hours to keep the mid-interval aPTT at least twice control or to 
attain an anti-Xa activity between 0.35-0.70 IU/mL 
(iii) UFH or LMWH (as above) until 13 weeks gestation, changing to warfarin, until the 
middle of the third trimester, and re-converting back to UFH or LMWH 
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Regarding LMWH specifically, in 2002, Sanofi Aventis changed the warning label for enoxaparin, 
stating that it was not recommended in patients with prosthetic heart valves. This was prompted 
by a South African study which compared the effectiveness of enoxaparin with a combination of 
warfarin and unfractionated heparin. The safety committee terminated the study after only 12 
patients were enrolled, due to two deaths from prosthetic valve thrombosis in the enoxaparin 
group, prompting concerns about its use during pregnancy for this indication, and implying the 
same for other LMWH. However, subsequent experience [James et al. 2006; McLintock et al., 
2009] suggests that LMWH is by no means inferior to unfractionated heparin, with McLintock 
reporting worse outcomes in those women non-adherent to the prescribed treatment, an issue 
which is explored further in chapter 7 of this thesis. 
The study in this thesis was not designed to deal with optimising the dosing of LMWH in the 
obstetric population with mechanical heart valves in-situ. Indeed, none of the 123 patients who 
were recruited to this study had a mechanical heart valve in-situ, reflecting in part the low 
incidence of rheumatic fever in the young Western population. However, the results found from 
this study have implications for the recommendations made in the international ACCP guidelines. 
Firstly, the study of this thesis has undoubtedly demonstrated that as pregnancy progresses, Vd 
increases, with a reduction in peak anti-Xa activity, if the dose is kept the same throughout 
pregnancy. Furthermore, the trough anti-Xa activity increases with the progression of pregnancy. 
This being the case, if the peak anti-Xa activity is titrated against a set target, in this case 1.0-1.2 
IU/mL four hours post injection, then there is the risk of over-anticoagulation in this setting and 
increasing the risk of haemorrhage, as has been reported in the literature [McLintock, ISTH 2012]. 
This is because, during pregnancy, it is inevitable that having such a target, will lead to a dose 
increase, which perhaps might not be necessary, when the trough is taken into account. The 
problem in this area is further complicated by the fact, that it is not known, what minimum level of 
anticoagulation with LMWH is required to prevent valve thrombosis. If this was known, current 
treatments could be used much more effectively for this population. During the course of this 
study, the median 3 hour anti-Xa activity in the simulation work, decreased from 1 to 0.6 IU/mL for 
women on the once daily dose and 0.9 to 0.5 IU/mL for women on the twice daily dose of 
enoxaparin; in both cases, a drop of 0.4 IU/mL. Assuming the same drop for Cmax, then 
hypothetically speaking, the dose would definitely have been increased, if ACCP guidelines were 
to be followed to the letter. 
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It is becoming more apparent that trough activity might be a better marker for dose adjustments in 
this setting. In this study, a percentage of patients were found to have no trough anti-Xa activity; 
this was the case for both once and twice daily regimes. The literature is littered with case reports 
of patients who have suffered valve thrombosis despite a prescription for LMWH, and perhaps by 
measuring the trough activity, and identifying women with negligible trough activity in this setting, 
would identify the women who would benefit from a dose increase, as opposed to increasing the 
dose for all. Future research should focus on this, with key opinion leaders in this setting are 
already suggesting their personal practice is likely to focus more on trough activity in the future 
[McLintock, ISTH 2012]. 
Finally, the issue of medication adherence needs to be factored into this setting. Only McLintock’s 
study to date, has commented on this, and found that those women who had worse outcomes on 
LMWH had poor adherence. Perhaps, the lack of efficacy reported in the literature of LMWH 
could be related to this very issue, as from a scientific point of view, why would vitamin K 
antagonists be better than LMWH in this setting. The issue of medication adherence certainly 
deserves further attention and is explored in detail in this study in chapter 7 of the thesis. 
Clearly the management of women with mechanical valves in-situ is complex and requires special 
attention. Until further work is published to move the management of these women forward, the 
consensus of managing each woman on a case by case basis seems appropriate. The results 
from this thesis do however suggest that caveats should be added to the current four hour ACCP 
recommendations in order for all risks, both thrombotic and haemorrhagic, to be considered.  
4.3.5 VTE prophylaxis during the antenatal period 
VTE prophylaxis has been a real success story in obstetric care over the last decade. Since the 
introduction of the first RCOG guidelines for the prevention of VTE during pregnancy and 
puerperium in 2004, the number of women dying or suffering from VTE has been on the decline, 
suggestive of the good work of those involved in identifying and managing this risk during the 
antenatal period. How do things look, when women are administered once daily LMWH in this 
setting? Figure 4.34 is a simulated profile of three hour and trough anti-Xa activity over the course 
of pregnancy, according to ROCG once daily dosing guidelines based on weight (table 4.23).  
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Table 4.23: Current RCOG suggested doses for enoxaparin for VTE prophylaxis 
Weight (kg) Enoxaparin 
<50 20mg daily 
50-90 40mg daily 
91-130 60mg daily* 
131-170 80mg daily* 
>170 0.6mg/kg/day* 
High prophylactic (intermediate) dose 40mg 12-hourly 
*may be given in two divided doses 
 
Figure 4.34: Simulation of prophylactic dosing of enoxaparin according to current Royal College of 
Obstetricians and Gynaecologists recommendations  
 
As can been seen, with prophylactic dosing of LMWH, a large number of women are below a 
quantifiable level of anti-Xa activity, before the next dose is due. Table 4.24 lists the percentage of 
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Table 4.24: % of women BLQ when dosed according the current RCOG antenatal prophylaxis 
guidelines 













The findings from this study provides compelling evidence that a once daily dose, for those 
weighing 91kg or more, is appropriate and there is no need to split the dose. The suggested 
changes to the guidelines would have the additional benefits of reducing the injection burden for 
pregnant women, which would be welcome, particularly, as a recent small study [Revell and 
Smith, 2011] suggested that 41% of women would meet the threshold for postpartum 
thromboprophylaxis in the UK if the current RCOG guidelines are followed to the letter. 
The clinical case for once daily dosing, coupled with the population PK case for once daily dosing, 
provides strong evidence for a need for a change in practice. 
 
4.4 Conclusion 
The aim of this study was to characterise the pharmacokinetic profile of enoxaparin during the 
antenatal period, using the method of non-linear mixed effects modelling. A robust enoxaparin in 
pregnancy model was developed. Simulation work, comparing once versus twice a day 
enoxaparin for the treatment of VTE provides compelling evidence that a once daily dose of 
enoxaparin is appropriate. The implications of these findings are discussed further in chapter 8. 
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Chapter 5  
5.1 D-dimer concentrations during pregnancy 
Chapter 5 focuses on the measurement and meaning of D-dimer concentrations during 
pregnancy and the puerperium. After providing background information on the role and meaning 
of D-dimer concentrations in general, information related to the measurement of D-dimer 
concentrations within an antenatal context will be discussed. The observational D-dimer 
concentrations from pregnant women followed during this study are then presented and 
discussed in the context of previously published work. 
5.1.1 D-dimer measurements 
5.1.2 Background 
Though not considered a global coagulation assay, D-dimer concentrations provide a valuable 
insight into individual’s active coagulation. When a fibrin clot is degraded by the fibrinolytic 
enzyme, plasmin, the final product which results are D-dimers and they provide compelling 
evidence of the activation of the fibrinolytic system, in response to coagulation activation (figure 
5.1).  
Thrombin











Figure 5.1: diagrammatic representation of the formation of D-dimers 
Over the last twenty years, clinical studies have demonstrated that measuring D-dimers 
concentrations for patients suspected of VTE is an appropriate screening strategy for acute 
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thrombosis; D-dimer concentrations demonstrate high specificity and sensitivity, with high 
negative predictive value, reported in the region of 98% [Bounameaux et al., 1991; Wells et al., 
2003]. Bounameaux and colleagues [1991] prospectively evaluated the clinical utility of D-dimer 
testing for the diagnosis of acute pulmonary embolism. In their study, they reported a sensitivity of 
98% and a specificity of 39% for the assay, at a D-dimer cut-off point of 500 μg/L or above, giving 
positive and negative predictive values of 44% and 98% respectively. Following completion of 
their study, they concluded that plasma measurement of D-dimers had a definite role to play in 
the diagnostic work-up of patients with suspected acute PE, and suggested that a concentration 
below 500 μg/L can confidently rule out the diagnosis. Wells and colleagues [2003] evaluated the 
utility of D-dimer testing in patients presenting with suspected acute DVT. In their study, patients 
were randomly assigned to two groups; group 1 (control group) comprising patients who 
underwent ultrasound imaging alone, or group 2, who underwent D-dimer testing followed by 
ultrasound imaging, unless the D-dimer test was negative. Over one thousand patients were 
enrolled to the study and the overall prevalence of DVT or PE was 15.7% in the cohort of patients 
recruited. Of the patients who had DVT ruled out by the initial diagnostic strategy, there were two 
confirmed cases of VTE in the D-dimer group and six cases in the control group. Wells and 
colleagues demonstrated that the utility of D-dimer testing resulted in a significant reduction in the 
use of ultrasonography, from a mean of 1.34 test per patient in the control group to 0.78 in the D-
dimer group (p=0.008) and concluded that DVT can be ruled out safely in patients who have 
negative D-dimer results.  
In clinical practice today, D-dimer concentrations are considered a routine test in the diagnostic 
work-up of suspected VTE, with the recently published National Institute for Health and Clinical 
Excellence guidance on VTE incorporating D-dimer testing, as part of the routine diagnostic work-
up of individuals suspected of VTE [National Institute for Health and Clinical Excellence, 2012]. 
In addition to identifying a prothrombotic state and confirmation of an acute VTE episode, D-dimer 
testing has been investigated as a marker of identifying patients who are at higher risk of VTE 
recurrence and whom might benefit from long term anticoagulation following an acute VTE 
episode [Palareti et al., 2003]. In their study, Palareti and colleagues assessed the predictive 
value of D-dimers for recurrent VTE in subjects with a previous unprovoked VTE event (in 
subjects with and without inherited thrombophilia). Five hundred and ninty-nine patients were 
followed for 870.7 patient years. They found that an increased D-dimer concentration at 1 month 
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after discontinuation of oral anticoagulation therapy was associated with a higher rate of 
subsequent recurrence in all subjects; though debate continues on whether this alone is enough 
to warrant long-term anticoagulation. The other important and increasing utility of D-dimer testing, 
is when the concentrations are raised, in the absence of VTE (confirmed by objective testing). In 
such situations a grossly elevated D-dimer concentration could represent the presence of cancer 
and warrants further investigation [Adam et al., 2009]. Both these examples exemplify the wider 
utility of D-dimer testing other than in the diagnosis of VTE. 
5.1.3 D-dimer assays: principle of assay 
Commercial D-dimer assays available, use monoclonal antibodies that detect an epitope that is 
present in the factor XIIIa-cross-linked fragment D domain of fibrin, but not in fibrinogen 
degradation products or non-cross-linked fibrin degradation products. Different commercial 
assays have their own reported specificity [Adam et al., 2009]. The test principles for D-dimers 
are based on either a rapid ELISA (enzyme linked immunosorbent assay) or latex agglutination 
tests. Both these test methods have their own advantages; ELISAs have the greatest sensitivity, 
whilst the agglutination tests are reported to have the greatest specificity [Kelly and Hunt, 2002]. 
The STA® - Liatest® D-Di kit (Stago Diagnostica, France) is used at King’s College Hospital, 
utilising the immune-turbidimetric method to quantitatively determine D-dimer concentrations. The 
test principle involves a beam of monochromic light to traverse a suspension of microlatex 
particles to which specific antibodies have been attached by covalent bonding. If the wavelength 
of the light is much greater than the diameter of the latex particles, the light is only slightly 
absorbed. In the presence of the antigen being tested for, in this case D-dimers, the antibody-
coated latex particles agglutinate to form aggregates of diameters greater than the wavelength of 
the light; more of the latter is absorbed. This increase in light absorption is a function of the 
antigen level present in the test sample [Stago Diagnostica, 2011]. 
5.1.4 D-dimer concentrations use during pregnancy 
Although D-dimer testing is considered a part of routine clinical practice, in those patients 
suspected of VTE during the gravid state, the utility of D-dimer concentrations as a screening tool 
for thrombosis is somewhat lost. This is because historically pregnant women have been 
excluded from clinical studies evaluating D-dimer testing, due to the fact that early studies 
[Gafney et al., 1987] assessing D-dimers during pregnancy demonstrated D-dimer concentrations 
to rise, even during uncomplicated pregnancy, due to a pro-thrombotic state being favoured, and 
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so the usual reference ranges used in routine clinical practice, were found not to apply in the 
gravid state.  
This has led the Royal College of Obstetricians and Gynaecologists (RCOG) to stipulate in their 
guidelines for the management of antenatal VTE, that a positive D-dimer is not necessarily 
consistent with VTE, suggesting that further objective testing is required [Royal College of 
Obstetricians and Gynaecologists, 2007]. Indeed, recent expert clinician reviews on the 
management of antenatal VTE, suggest that D-dimer testing, from a reference range view point, 
cannot be considered as part of the usual diagnostic algorithm for VTE during pregnancy, with 
both clinical experts offering alternative comprehensive diagnostic algorithms to successfully 
diagnose antenatal VTE [Arya, 2010; Middeldorp, 2011].  
5.1.5 Studies of D-dimer concentrations during uncomplicated pregnancy 
A small number of studies evaluating D-dimer concentrations in uncomplicated pregnancy have 
been published. Chabloz and colleagues [2001] measured D-dimer concentrations from 144 
pregnant women with uncomplicated pregnancies. A total of 519 samples were drawn from these 
women. They reported a gradual rise in D-dimer concentrations over the course of pregnancy, 
peaking at the time of delivery (table 5.1).  
Table 5.1: D-dimer concentrations during uncomplicated pregnancy reported by Chabloz and 
colleagues 
Trimester 1 2 3 At delivery 






139-602 291-1231 489-2217 678-5123 
 
The authors suggest that given this pattern observed during uncomplicated pregnancy, it might be 
possible to propose a new reference range for D-dimer concentrations, according to the trimester 
of pregnancy.  
In a further small observational study comparing alterations in D-dimer concentrations, 
endogenous thrombin potential (ETP) and fragment 1+2 during pregnancy, 50 healthy women 
had serial D-dimer concentrations measured through their pregnancy [Dargaud et al., 2010]. The 
authors also found that D-dimer concentrations gradually rose during pregnancy; with the majority 
of women having results within the normal reference range during the first trimester, followed by a 
significant rise during the second and third trimesters.  
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Another study of 50 women with uncomplicated pregnancy, evaluated D-dimer concentrations 
serially; preconception and then again at 12, 24, and 36 weeks gestation along with a final 
measurement at 4 weeks post-partum [Kline et al., 2005]. This is one of the few studies to assess 
D-dimer concentrations preconception and during the post-partum period. The headline results 
from this study are presented in table 5.2. 






Pre-conception 50 0.429 0.486 
First trimester 32 0.579 0.363 
Second trimester 31 0.832 0.456 
Third trimester 23 1.159 0.573 
Four weeks post-partum 18 0.605 0.433 
a Number of patients for each time point 
Once again, they demonstrated that during uncomplicated pregnancy, D-dimer concentrations 
rise to >0.50mg/L in all trimesters and that by the third trimester, D-dimer concentrations will 
almost certainly be abnormal if a threshold of 0.50mg/L is used.  
Murphy and colleagues [2011] drew D-dimer concentrations from 694 ‘low risk’ pregnant women 
in their study. Women were sampled at different time points during their pregnancy and within two 
days of delivery (table 5.3).  








<12 weeks              163 101 39 499 
19-21+6                  167 282 131 628 
28-36+6                  98 475 225 1033 
38-40+6                  102 661 343 1513 
Day 2 postpartum  164 480 193 1746 
a Number of patients for each time point 
Again, the same pattern as previously reported by other groups, was found.  
Finally, the largest study evaluating D-dimer concentrations in pregnancy to date, is that 
conducted by Szecsi and colleagues [2010]. In their study, 801 women had serial haemostatic 
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tests drawn (including D-dimer concentrations). The authors report that D-dimer concentrations 
increased progressively, peaking at the first day postpartum. Detailed analysis of their results 
found that, mid way through the second trimester, more than 25% of women have D-dimer levels 
at or above 0.5mg/L, and that by week 36-42, virtually all the women’s D-dimer concentrations 
were above the traditional cut-off point (table 5.4).  
Table 5.4: D-dimer concentrations reported by Szecsi and colleagues 
Gestation 






















0.2 -1.4 0.3-1.7 0.3-3.0 0.4-3.1 0.7-7.6 0.5-10.9 
a Number of patients for each time point 
Clearly all these published studies to date demonstrate a pregnancy related rise in D-dimer 
concentrations. The question is can this be harnessed in clinical practice, in order to establish a 
pregnancy-specific D-dimer concentration range to exclude antenatal VTE. 
Morse [2004] was one of the first to suggest that this might be possible and in his study, 
measured D-dimer concentrations in 48 pregnant women, with concentrations drawn at 16, 26 
and 34 weeks gestation in the same women. As per previous studies, a rise in D-dimer 
concentrations was reported. In the discussion of his results, Morse suggests that it should be 
possible to work out a pregnancy specific D-dimer concentration level, in order to safely use the 
test in the diagnosis of pregnancy-associated PE and DVT. This concept has now been taken 
forward by Chan and colleagues [2011] who recruited pregnant patients who presented to 
Canadian hospitals with suspected DVT over an eight year period. Plasma samples for D-dimers 
were collected at the time of presentation and analysed using five different commercially available 
D-dimer assays [Vidas®, Asserachrome®, IL Test®, Sta-Lia®, Innovance®]. A receiver operating 
curve (roc) analysis was conducted to determine a pregnancy specific cut-off point for D-dimer 
tests. A ROC curve is a plot which illustrates the performance of a variable, in this case the D-
dimer assay, as its discrimination threshold is varied. Two hundred and twenty eight women 
contributed data in their study. Of these, fifteen were diagnosed with a DVT, an incidence rate of 
6.6% (95% CI 4-10.6).  
The specific D-dimer concentrations from the Sta-Lia® test (used at King’s College Hospital) are 
presented in table 5.5.  
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Table 5.5: D-dimer concentrations using the Sta-Lia® test 



















+Ve 4 10.27 
 (12.8) 
5.40    
(2.0-18.5) 




















a Number of women 
The receiver operator curve (ROC) analysis found that the area under the ROC curve ranged 
from 0.82 and 0.87 for all five D-dimer assays, demonstrating that all the assays were able to 
discriminate between pregnant women with and without DVT. The authors also found that the 
sensitivities of all five assays were 100% when the standard D-dimer cut-off point was used, 
however, the specificity was poor (range, 6-23%). Using new optimal cut-off points [1.89μg/mL for 
the Vidas assay, 1.51μg/mL for the Asserachrome assay, 0.57μg/mL for the IL assay, 1.38μg/mL 
for the Sta-Lia assay, and 1.50μg/mL for the Innovance assay], the specificity increased 
substantially to 61-79%, with a small reduction in sensitivity in four of the assays (range 93-100%) 
and a modest reduction in the fifth assay (IL test) of 80%. The authors conclude that setting a 
higher threshold for D-dimers for the initial screening of VTE during pregnancy is safe and 
effective, based on a negative predictive value of 98% and a sensitivity of 60%.  
Whilst this study has demonstrated the possible utility of D-dimer testing for the diagnosis of VTE 
in the antenatal setting, one published case report of a patient with antenatal VTE with a normal 
D-dimer does provide a note of caution [To et al., 2008]. In this isolated report, the initial VTE 
event was diagnosed during the first trimester and the patient was prescribed full dose LMWH 
therapy according to the RCOG guidelines. On re-presentation during the third trimester, where 
the patient was reported to be non-compliant, the patient was found to have a normal D-dimer 
concentration. D-dimers do have a long half-life and the patient injecting the LMWH early on 
during their pregnancy and then on and off thereafter, may well have suppressed to a certain 
degree, any expected rise during the third trimester. This is speculation however, and the case 
serves as a reminder that D-dimer concentrations should not be used in isolation, for the initial 
screening of antenatal VTE.  
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Overall, the evidence published to date demonstrates that D-dimer concentrations do indeed 
increase during pregnancy and although historically they have not been regarded as a useful test 
to exclude antenatal VTE, they could hold an important clinical utility, if a pregnancy specific 
reference range can be established.  
5.1.6 D-dimer concentrations in women with antenatal medical complications 
Accepting the rise in D-dimers during pregnancy, are there differences in the rise observed, 
depending on the underlying antenatal medical complication during pregnancy? Few studies have 
assessed this. Gafney and colleagues [1987] assessed D-dimer concentrations during the third 
trimester of their pregnancy, in women with evidence of pre-eclampsia and compared the results 
to a control pregnant group, at the same stage of their pregnancy. In this small study, compared 
to the 14 controls, the 24 women with pre-eclampsia had much higher elevations of D-dimers, and 
the authors suggest that a clear distinction between the pre-eclamptic women and the non-pre-
eclamptic women can be observed. 
Nolan and colleagues [1993], evaluated D-dimer concentrations in four groups of women; 17 
normal women, 14 with preterm labour, 17 women with pre-eclampsia at term and 14 patients 
with abruption placentae during the third trimester. As in previous studies, D-dimer concentrations 
were raised in line with gestational age. Those subjects with preeclampsia, preterm labour and 
abruption placentae had mean D-dimer concentrations significantly greater than those of controls 
(p<0.003), suggesting that D-dimer concentrations might indeed hold a utility of identifying women 
at higher risk of pre-eclampsia, pre-term labour and abruption placentae. Though an interesting 
signal emerges from this study, clearly, studies with higher patient numbers are required before 
the results from this study can be accepted into wider clinical practice. 
Finally, Francalanci and colleagues [1995] collected D-dimer measurements from 37 pregnant 
women with intra-uterine growth retardation (IUGR) and 22 women with gestational hypertension, 
in order to test the hypothesis that women with these antenatal complications can be identified 
through an elevated D-dimer concentration. The IUGR patients were divided into two groups 
according to gestational age; < 30 weeks (group A) and > 30 weeks (group B). Two control 
groups of 37 and 22 normal matched pregnant women were also followed. In group A IUGR 
patients, D-dimer plasma concentrations were significantly higher than matched controls 
(p=<0.05). However, in group B IUGR patients, no significant differences were found between the 
active and the control groups. In the gestational hypertension cohort of patients, the subjects had 
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higher D-dimer concentrations than the controls (p<0.05), but the authors noted that 15 out of the 
22 subjects had a D-dimer concentration lower than the mean + 2 standard deviations of controls. 
The authors suggest that using a ELISA D-dimer assay, as utilised in their study, it is not possible 
to discriminate IUGR and gestational hypertension women when compared to matched controls.  
The results published to date, exploring the utility of D-dimer concentrations for discriminating for 
antenatal complications contradict one another, and due to their observational nature provide little 
firm direction of the place of D-dimer concentrations in this setting. However, these studies do 
demonstrate the general rise of D-dimer concentrations during pregnancy. In order to answer 
whether D-dimer concentrations could be an appropriate biomarker for IUGR or pre-eclampsia 
further larger controlled studies need to be conducted. 
5.1.7 The impact of LMWH on D-dimer concentrations during pregnancy 
As the gravid state represents a pro-thrombotic state, and D-dimer concentrations rise during 
pregnancy, is the rise in D-dimer concentrations altered by women who are injecting LMWH? 
Only one study published to date has assessed this [Hoke et al., 2004]. In this study, 61 women 
prescribed LMWH thromboprophylaxis throughout pregnancy due to a history of VTE, hereditary 
thrombophilia and/or previous pregnancy related complications, had their D-dimer concentrations 
measured at set times during their pregnancy. Dalteparin or enoxaparin were prescribed at a 
dose range of 4000 to 7500 anti-factor Xa IU daily, commenced as soon as possible after a 
positive pregnancy test. These results were then compared to a control group comprising 113 
healthy pregnant women without a need for thromboprophylaxis. The authors found that D-dimer 
concentrations in both subjects and controls increased significantly from the first to the second 
trimester (p<0.0001), as well as from the second to the third trimester (p<0.0001). The authors 
also describe that the D-dimer levels were significantly higher (p<0.0001) among subjects 
compared with controls. The results are interesting from two viewpoints; firstly despite being 
prescribed prophylactic LMWH, substantial activation of coagulation is seen during pregnancy, i.e. 
the prophylactic doses of LMWH do not dampen down the increase in D-dimers one expects to 
observe. Secondly, those women prescribed LMWH had significantly higher D-dimer 
concentrations throughout pregnancy compared to women in the control group. This suggests 
that pregnant women identified at risk of VTE or pregnancy-related complications do indeed have 
higher activation of coagulation compared to a relatively healthier pregnant control group, not at 
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risk. Hoke’s work begs the questions of whether treatment doses of LMWH alter the increase in 
D-dimer concentrations observed. 
 
5.2 Aim and method 
As very little has been published on how the D-dimer concentrations of pregnant women injecting 
LMWH (both prophylactic and treatment doses), the aim of this sub-study was to describe D-
dimer concentrations in the cohort of women followed during the course of this study. 
Chapter 2 provides full details on the methodology for this aspect of the study, and the specific D-
dimer assay used. In brief, women recruited to this study had D-dimer concentrations measured 
at each clinic visit, typically every month during their pregnancy. Additionally, D-dimer 
concentrations were measured at delivery and > 8 weeks post-partum, when anticoagulant 
therapy had ceased. 
For the purposes of analysis, the D-dimer concentrations were grouped into 5 time points; first, 
second and third trimester, within a week of delivery and > 8 weeks of delivery. The D-dimer 
concentrations were reported as median and interquartile ranges (IQR), for the cohort as a whole, 
and then further analysed at these time points, according to the dose of enoxaparin prescribed 
(prophylaxis or treatment dose). Friedmans mean rank test was used to assess if statistically 
significant differences existed between the different time points, with the Wilcoxon pair test used 
to assess significance between specific pairs of trimester timepoints. 
Furthermore, in order to assess if ethnic differences existed between the African-Caribbean and 
Caucasian populations, the median values of those women prescribed prophylactic enoxaparin 




Over the course of the study, 815 separate D-dimer concentrations were drawn from the women 
(table 5.6). An increase in D-dimer concentrations was found in line with gestational week, with 
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the concentrations peaking at the time of delivering, falling back to ‘baseline’ levels by 8 weeks 
postpartum (table 5.6, figures 5.2 and 5.3). 
Table 5.6 The overall D-dimer results from this study for the cohort of women followed 
Pregnancy time point n  Median Interquartile range 
First trimester 88 315 245-467 
Second trimester 240 620 450-970 
Third trimester 287 990 690-1550 
Within a week of delivery 102 1497 2225-3910 
> 8 weeks postpartum 98 335 230-482 
n represents the number of D-dimer samples at each trimester time point 
Although the standard deviations for the results are large and demonstrates much inter-patient 
variability, a clear pattern is observed in line with gestational age.  
 
 
Figure 5.2: Scatter plot of log D-dimer concentration versus weeks amenorrhea (red line 
represents the loess smooth) 
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Figure 5.3: Box plot illustration of the D-dimer concentrations, according to each trimester 
(trimester 4 and 5 represent within a week of delivery and >8 weeks post partum respectively) 
 
A significant positive correlation is observed between the D-dimer concentrations and pregnancy 
gestational age; r=0.382 (Pearson’s correlation), p=0.000. Thirty-six women had consecutive D-
dimer concentrations measured from the first trimester through to > 8 weeks of delivery. 
Friedmans mean rank test demonstrates statistically significant differences between the five 
different time points assessed (n=36, df=4, p=0.000). As many women did not book until after the 
first trimester had passed, when the analysis is re-run excluding the first trimester (which results 
in more women being considered in the analysis), the same result is found; Friedmans mean rank 
test (n=75, df=3, p=0.000) confirming the finding that statistically significant differences do exist 
between the time points. 
A Wilcoxon pair test was conducted comparing results between each trimester. Significant (<0.05) 
differences were found when each trimester pair, except when the first trimester was compared 
with the > 8 weeks post-partum time point (perhaps unsurprisingly). 
Sections 5.3.1 and 5.3.2 illustrate how the overall results change when women on prophylactic 
and treatment doses of enoxaparin are considered as separate groups.  
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5.3.1 Women prescribed prophylactic doses of enoxaparin 
In total 619 D-dimer concentrations were drawn from women prescribed prophylactic enoxaparin. 
The correlation between D-dimer concentrations and gestational age was found to increase to 
r=0.441 (Pearson’s correlation), p=0.000. Table 5.7 describes the D-dimer concentrations for 
women on prophylactic doses on enoxaparin, and figure 5.4 illustrates the D-dimer concentration 
rise pattern observed, which largely mirrors the cohort of women overall. 
Table 5.7: D-dimer concentrations for the cohort of women prescribed prophylactic doses 
Pregnancy time point N Median Interquartile range 
First trimester 64 335 270-487 
Second trimester 193 620 465-955 
Third trimester 225 1020 735-1625 
Within a week of delivery 79 2360 1790-4130 
> 8 weeks postpartum 78 365 256-525 
n represents the number of D-dimer samples at each trimester time point 
 
 
Figure 5.4: The rise in D-dimer concentrations in women prescribed prophylactic doses of 
enoxaparin; trimester 4 and 5 refers to within a week of delivery and > 8 weeks post-partum 
respectively 
 
Twenty-six women had serial D-dimer concentrations measured consecutively from the first 
trimester through to > 8 weeks post-partum. Friedmans mean rank test demonstrated statistically 
significant differences between the five different time points (n=26, df=4, p=0.000). When this 
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analysis is re-run excluding trimester one results, this result is repeated; Friedmans mean rank 
test (n=58, df=3, p=0.000) providing further confirmatory evidence that statistically significant do 
exist between each time point. 
A Wilcoxon pair test was conducted comparing results between each trimester. Significant (<0.05) 
differences were found when each trimester pair, except when the first trimester was compared 
with the > 8 weeks post-partum time point, mirroring the results from the overall cohort of women. 
 
5.3.2 Women prescribed treatment doses of enoxaparin 
Women prescribed treatment doses of enoxaparin did exhibit a different pattern of D-dimer 
concentrations relative to those women on prophylactic doses. The strength of the relationship 
between D-dimer concentrations and gestational weeks went down to r=0.212 (Pearson’s 
correlation), though still statistically correlated. The rise in D-dimer concentrations for this sub-
group of women was also much smaller, relative to women prescribed prophylactic doses of 
enoxaparin (table 5.8, and figure 5.5), illustrating an enoxaparin effect. 
 
Table 5.8: Specific results from women prescribed treatment doses of enoxaparin 
Pregnancy time point N Median Interquartile range 
First trimester 24 270 230-422 
Second trimester 47 480 350-1180 
Third trimester 62 850 545-1270 
Within a week of delivery 23 1610 440-2450 
> 8 weeks postpartum 20 260 220-325 
n represents the number of D-dimer samples at each trimester time point 
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Figure 5.5: The D-dimer concentrations of women prescribed ‘treatment’ dose enoxaparin during 
their pregnancy (trimester 4 and 5 refers to within a week of delivery and > 8 weeks post-partum 
respectively)  
 
Ten women prescribed treatment dose enoxaparin had serial D-dimer concentrations 
consecutively measured from the first trimester through to > 8 weeks of delivery. Friedmans mean 
rank test demonstrated statistically significant differences between the five different time points 
(n=10, df=4, p=0.000). When the analysis was re-run excluding the 1
st
 trimester results, this result 
is repeated; Friedmans mean rank test (n=17, df=3, p=0.000) confirming the finding that 
statistically significant do exist between each time point. 
A Wilcoxon pair test was conducted comparing results between each trimester. Significant (<0.05) 
differences were found between the following time points: second and third trimesters and within 
a week of delivery and > 8 weeks postpartum. 
5.3.3 The influence of ethnicity on D-dimer concentrations 
Two ethnic groups, Caucasians and African-Caribbeans, formed the majority of patients recruited 
to this study, reflecting the location of the hospital in South London.  Sub-group analysis between 
these groups, excluding women on treatment doses, revealed no significant differences (Mann 
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Table 5.9: Medium D-dimer concentrations (IQR) for the Caucasian and African-Caribbean ethnic 
groups of women prescribed prophylactic doses of enoxaparin  
Time point Ethnicity p-value* 
 Caucasian African - Caribbean 






























Median (IQR) D-dimer values presented; *Mann-Whitney U independent rank-sum test 
These results demonstrate that ethnicity does not appear to impact significantly on D-dimer 
results during pregnancy and, if a pregnancy-specific D-dimer concentration cut-off is established 
in the future, ethnicity would not need special consideration for this assay. This mirrors current 
clinical practice in the non-pregnant population.  
 
5.4 Discussion and implications for practice 
In line with previously published studies, this study has demonstrated substantial activation of the 
fibrinolytic system during pregnancy, as assessed through D-dimer concentrations. D-dimer 
concentrations were found to significantly rise over the course of pregnancy, peaking at the time 
of delivery, before dropping back to baseline concentrations by eight weeks post-partum. Despite 
the fact that the women were prescribed enoxaparin therapy during the course of their pregnancy, 
the rise in D-dimer concentrations was not suppressed, a finding endorsing that of Hoke and 
colleagues [2004], where women were prescribed prophylactic doses of enoxaparin. When the D-
dimer concentrations of women prescribed treatment and prophylactic doses are compared, more 
differences at the different pregnancy time points were observed for women prescribed 
prophylactic doses of enoxaparin compared to women prescribed treatment doses. This suggests 
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that although the increase in D-dimer concentration is not suppressed, the D-dimer concentration 
is influenced by enoxaparin in a dose dependent manner.  
Ethnic differences between the subjects did not appear to influence the D-dimer pattern to any 
significant degree and if an antenatal specific D-dimer concentration is established, the results 
here suggest that ethnicity would not need special consideration. It must be remembered though, 
that this study’s data is observational in nature and others have reported differences in D-dimer 
concentrations between the African-Caribbean and Caucasian population outside of pregnancy 
[Pieper et al., 2000; Cushman et al., 2003; Khaleghi et al., 2008]. On the other hand, a recent 
study by Roberts and colleagues comparing D-dimer concentrations between patients who 
suffered a first deep vein thrombosis and controls from a Caucasian and African-Caribbean 
population found no significant differences in D-dimer concentrations between the two groups, 
outside of a pregnancy setting, as well as when the two control groups were compared [Roberts 
et al., 2012]. The predictable nature of the results from the cohort of women prescribed 
prophylactic doses provides further compelling evidence that it should be possible to develop a 
pregnancy specific D-dimer normal concentration reference range, which could then be used as 
an initial VTE screening test during pregnancy, for women suspected of VTE. 
5.4.1 Strengths, limitations and future work 
The strength of this sub-study are, the number of D-dimers samples measured, the serial 
measurement nature of D-dimer concentrations in the cohort of women followed, and it is only the 
second study to assess D-dimer concentrations in pregnant women, prescribed concurrent 
LMWH.  
The study is limited due to its observational nature. It would have been more meaningful if D-
dimer concentrations were also measured in a concurrent control group. Work is currently 
underway at King’s College Hospital specifically assessing this issue. It must be borne in mind 
though, that during the course of this study, much inter-individual variability was observed. Future 
studies might also focus on identifying what factors cause this variability (e.g. the presence of a 
specific thrombophilia or antenatal complication). Furthermore, if a pregnancy specific reference 
range for a specific assay is developed, it must be remembered that the initial presentation of 
antenatal VTE is variable and challenging, and that D-dimer concentrations should not be used in 
isolation, but in conjunction with other confirmatory testing, as is the case outside of pregnancy 
[National Institute for Health and Clinical Excellence, 2012]. 
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Chapter 6  
6.1 Thrombin generation during pregnancy 
The focus of chapter 6 is the measurement of thrombin generation as pregnancy progressed in 
the cohort of women recruited during the course of the enoxaparin in pregnancy study. After 
discussing some further background to thrombin generation testing, specific questions around 
assaying thrombin generation within a pregnant population prescribed LMWH are posed. The 
methodology for this aspect of the study is described, following which, the results are presented 
and discussed. In addition, work aimed at neutralising enoxaparin in the women’s plasma during 
in-vitro thrombin generation, using polybrene, is also presented and discussed. 
 
6.1.1 Background 
In chapter one, reference to how thrombin generation is central to coagulation is explained. The 
capacity to generate thrombin and the enzymatic work that thrombin does, determines an 
individual’s blood coagulability [Baglin, 2005]. In clinical practice, to have a test which determines 
an individual’s coagulation potential is extremely useful, as it can help to determine which patients 
might benefit from long-term anticoagulation and/or identify patients who are at higher risk of 
pathological thrombosis. An assay such as thrombin generation has the potential to provide a 
meaninful pharmacodynamic marker for patient’s prescribed anticoagulant therapy. Excellent 
reviews already exist on the background to thrombin generation testing and the clinical potential 
that exist [Hemker at al., 2005 Baglin, 2005, van Veen et al., 2008]; although much has been 
promised, the clinical benefits and utility of the test are yet to be realised in widespread clinical 
practice. Why might this be the case? 
6.1.2 Limitations of TG testing 
A number of reasons can be attributed as to why the application of thrombin generation has yet to 
be incorporated into wide-spread clinical practice. Different methods and reagents used in 
thrombin generation testing can yield different results and influence the total amount of thrombin 
generated, making comparisons between laboratories and studies difficult to assess. For example 
the concentration of tissue factor (TF) used as the trigger for the assay can influence the path of 
thrombin generation that actually gets assessed. The positive feedback activation of thrombin by 
the intrinsic pathway can only be seen at low TF concentrations [Keularts et al., 2001; van Veen 
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et al., 2008]. TF concentrations of 1 pmol/L in platelet poor plasma (PPP) are required to observe 
the effects of Factor XI, an observation which is lost at concentrations >5 pmol/L. Dielis and 
colleagues [2008] investigated the determinants of thrombin generation in a normal population at 
two tissue factor concentrations with or without thrombomodulin or activated protein C. Their 
results showed that thrombin generation is determined by different coagulation factors or 
inhibitors, depending on the specific experimental conditions. 
Furthermore, a number of studies have reported significant contact factor activation with the 
thrombin generation assay [Luddington and Baglin, 2004; Tappenden et al., 2007; van Veen et 
al., 2008]. This is problematic as contact factor activation can give falsely elevated levels of 
thrombin generation, obscuring the true result. Research suggests that contact factor activation is 
more likely when low tissue factor concentrations are used as the trigger in the assay. To 
overcome this, some advocate the addition of corn trypsin inhibitor (CTI) to the assay reagents to 
minimise contact factor activation; the addition of CTI has the added benefit of reducing variability 
observed in the final results [Baglin, 2005; van Veen et al., 2008].  
Additionally, when thrombin generation is assessed using platelet poor plasma (PPP), the 
phospholipid concentration in the test plasma can influence the final results obtained. During 
thrombin generation experiments, if the phospholipid concentration present is not adequate, the 
reaction could become rate limiting. Research has revealed that a phospholipid concentration of 
between 3-5 μmol/L is sufficient, and been proven not to be rate-limiting [Chantarangkul et al., 
2003; Hemker et al., 2003; Gerotziafas et al., 2005]. The fact that the test can be conducted in 
PPP and platelet rich plasma (PRP) complicates matters, as samples from the same patient with 
these two different methods of preparation will yield different thrombin generation results. In PRP, 
the ETP and peak height are found to be lower when compared to the same subject’s sample 
tested under PPP conditions. In PRP, the lag-time is more prolonged in comparison to the same 
sample tested under PPP conditions. Furthermore, under PRP conditions, the platelet count in the 
test plasma can also impact on the thrombin generation result obtained. This is found to be the 
case when the platelet count is < 100 x 10
9
/L [Hemker et al., 2003]. Once above 200 x 10
9
 / L, 
dependence on platelet numbers is thought to be minimal. Under PRP, under the aforementioned 
conditions, thrombin generation is also dependent upon concentrations of factor VIII, IX and XI 
[Hemker et al., 2003]. 
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Finally, not all aspects of the coagulation pathway can be evaluated with a single set of reagents 
in the thrombin generation assay; for example evaluation of the protein C pathway requires a 
special set of reagents. Standard thrombin generation assays are not sensitive to the actions of 
the protein C pathway, as thrombomodulin is not present. However, the protein C pathway can be 
assessed in-vitro by the addition of truncated human recombinant thrombomodulin (sTM) [van 
Hylckama Vlieg et al., 2007]. The addition of thrombomodulin makes the thrombin generation test 
sensitive to deficiencies in protein C, protein S, factor V Leiden and conditions associated with 
acquired protein C resistance [van Veen et al., 2008], providing a different slant to the thrombin 
generation experiment, but also demonstrating that a single set of experimental conditions cannot 
evaluate all aspects of thrombin generation. 
The other important issue to consider, unrelated to the reagents and experimental conditions of 
the test, is one of variability within the test, both intra-assay, inter-assay variability, as well as 
inter-patient variability. The variability results for both PPP and PRP, from 4 individuals who had 
their thrombin generation assayed over 9 consecutive weeks are listed in table 6.1.  
Table 6.1: Inter-assay and intra-assay variability of thrombin generation in 4 healthy controls 
Conditions of 
experiment 
TG parameter CV (%) 
  Inter-individual Intra-individual Experimental* 
PPP ETP 15 4.5 2.5 
 Peak 13 5.5 4.5 
 Lag Time 47 8.1 5 
PRP ETP 19 7.4 3 
 Peak 34 10.3 3.5 
 Lag Time 24 9.4 7 
*Experimental CV was determined on 36 identical samples measured simultaneously 
Intra-assay variability was found to be 8%. The inter-individual variability was reported as 17.5%, 
and suggests that significantly different endogenous thrombin potentials exist between individuals 
[Hemker et al., 2006]. Others have also reported similar variability results; Dargaud and 
colleagues [2008] assayed thrombin generation in 12 healthy volunteers every three months for 1 
year using CAT, at 3 different tissue factor concentrations (0.5, 1 and 5pM). They report intra-
individual variability of 11% over the course of the year. Experts in the use and application of the 
thrombin generation assay have proposed that variability between laboratories could be improved 
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by assaying a reference plasma in each thrombin generation experiment and using the same 
reference plasma across all laboratories, allowing normalisation of the results and a meaningful 
comparison between the laboratories [Dargaud et al., 2010]. This approach has gained further 
credence with the publication of a further multi-centre study [Dargaud et al., 2012]. 
Thrombin generation assays can be performed by numerous methods and reagents and 
depending on how they are performed, will have different sensitivities for various haemostatic or 
thrombotic defects. Results from the assay cannot therefore be interpreted without detailed 
information on how the test was conducted. Currently, multi-centre studies are difficult in the 
absence of international standards of thrombin and tissue factor. It must be borne in mind that 
even when a standardised test is available, it is unlikely to be suitable in all situations and 
depending on the clinical situation under investigation and the specific objectives of the study, the 
right set of reagents will need to be employed. 
6.1.3 What is the influence of anticoagulant therapy on the thrombin generation test? 
A number of studies have been published which describe the pharmacodynamic effect of 
anticoagulant therapy on the thrombin generation test, under different experimental conditions. 
Most of these studies have involved in-vitro spiking of the anticoagulant in question within the 
experiments, with few actually measuring thrombin generation in patients prescribed 
anticoagulants. 
When evaluating the impact of the oral anticoagulant warfarin on thrombin generation, the 
endogenous thrombin potential (ETP) exhibits a moderate hyperbolic relationship and negative 
correlation with the INR in patients prescribed warfarin therapy [Jackson et al., 2003; Altman et 
al., 2007]. Studies assessing the impact of unfractionated heparin (UFH) [Al Dieri et al., 2004], 
LMWH [Al Dieri et al., 2006; Gerotziafas et al., 2007] and the direct Xa inhibitor, danaparoid [Stief, 
2007] on thrombin generation have been conducted. These studies suggest that UFH, tinzaparin 
and danaparoid have a more profound effect on thrombin generation relative to LMWH, due to 
their significantly greater anti-IIa effect, and therefore imply that thrombin generation tests might 
not detect all the significant activity of LMWH; depending on the molecular weight of LMWH, and 
the dose prescribed, the anti-thrombin activity and hence the thrombin generation effect will vary.  
Studies assessing the newer oral anticoagulants, rivaroxaban and dabigatran, on thrombin 
generation suggest a concentration dependent effect of these agents on the thrombogram 
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parameters [Gerotziafas et al., 2007; Wienen et al., 2007]. Interestingly, in their study, Gerotziafas 
and colleagues found that the concentration of rivaroxaban required to decrease the lag-time and 
time to peak to 50% (IC50), is lower than that required to produce the same effect on the peak 
height and ETP, suggesting that certain parameters of the thrombogram are more sensitive to the 
effects of rivaroxaban than others. 
Details on the three studies which provide the most information on the effect of LMWH on the 
thrombogram are described in detail.  
Al Dieri and colleagues [2006] tested the hypothesis that the ETP is a sensitive detector of 
heparin’s effect, both LMWH and UFH. In 12 healthy male volunteers, average age 25 years 
(range:18-30), with a mean body weight of 80kg (range:60-95kg), a mono-centric, randomised, 
double-blind, four-period cross-over trial was conducted. All patients were administered a single 
subcutaneous injection of 9 000 anti-Xa IU of either heparin (UFH, a medium molecular weight 
heparin (MMWH), certoparin or enoxaparin), followed by a wash-out period of one week, before 
the next agent was administered. Blood samples assessing thrombin generation were drawn at 
t=0, 0.5, 1.5, 2, 3, 4, 5, 8, 10 and 24 hours, following the administration of each agent. Anti-Xa 
activity was performed by amidolytic assays and thrombin generation was measured using a 
validated chromogenic method. In their experiments using PPP, 30 pM of recombinant TF and a 6 
μM concentration of phospholipid was employed. The authors’ aim was to assess ETP inhibition 
relative to time zero, along with the activity of factor IIa and factor Xa.  
The authors found that the course of anti-Xa and anti-IIa activities in plasma following the four 
heparin agents showed significant inter-individual variability in the order of ~40-50% for UFH and 
~30-40% for the other three. Interestingly, the authors also report that the highest heparin levels 
were found in the volunteer with the lowest weight (60kg), and the lowest in volunteer with the 
highest weight (98kg), confirming the strong relationship which exists between weight and heparin 
concentrations. The authors headline results were, that as the concentration of the heparin in 
plasma changes with time, so does the ETP; this is interesting, as it confirms that an individual’s 
propensity to generate thrombin is dynamic, not static, and will change with an ever changing 
heparin concentration in the plasma. Al-Dieri and colleagues report that a hyperbola curve is 
generated in relation to heparin activity and ETP inhibition. IC50 values, that is to say, the heparin 
concentration which reduces the ETP value registered at time zero by 50%, was calculated for 
each of the four agents in relation to both their IIa and Xa activity. In terms of anti-Xa values, the 
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IC50 was variable and increased with the molecular weight of the heparin, i.e. the higher the 
molecular weight, the lower the concentration required (table 6.2).  
Table 6.2: Anti-IIa and anti-Xa activity of the four agents evaluated by Al-Deiri and colleagues 
[2006] 
 UFH MMWH Certoparin Enoxaparin 
aIIa (IU mL
-1
) 0.10 +/- 0.01 0.10 +/- 0.01 0.09 +/- 0.01 0.06 +/- 0.01 
aXa (IU mL
-1
) 0.10 +/- 0.01 0.12 +/- 0.01 0.29 +/- 0.04 0.36 +/- 0.04 
 
The authors of the study stipulate that ETP is not yet validated for the control of anticoagulant 
therapy, and go onto suggest that a therapeutic window could be possible with this parameter. A 
traditional INR range of 2-4 corresponds to ETP inhibition of 17-40% [Odegard et al., 1976]. 
Studies also suggest that in congenital clotting factor deficiency, bleeding is seen at a ETP 
inhibition of 20-30% [Al Dieri et al., 2003; Gouin-Thibault et al., 2003; Ip et al., 2001; Alhenc-Gelas 
et al., 1994].  
In a further study, Gerotziafas and colleagues [2007], assessed the inhibition of thrombin 
generation induced by the low molecular weights bemiparin, enoxaparin, nadroparin, dalteparin, 
and tinzaparin in PRP and compared their effects to that from unfractionated heparin and 





, and a TF trigger concentration of 6pM. The PRP was spiked with increasing 
concentrations of the agents being assessed to evaluate their effects on thrombin generation. 
Thrombin generation was assayed according to the CAT method, as described by Hemker and 
colleagues [2000]. The different LMWH agents influenced the different parameters of the 
thrombogram in their own unique way. When considering the lag-time and the time to peak, at a 
concentration 0.2 IU/mL of anti-FXa, bemiparin, enoxaparin, nadroparin and dalteparin did not 
appear to significantly affect these parameters, relative to control samples. Tinzaparin, the LMWH 
most closely related to UFH, did significantly prolong the lag-time and time to peak as compared 
to control samples. UFH samples, at the equivalent anti-Xa activity, also prolonged the lag-time 
and time to peak. A doubling of concentration to 0.4 IU/mL, bemiparin, enoxaparin, nadroparin 
and dalteparin prolonged both the lag-time and time to peak by about 20%. Further increases in 
the concentration led to further prolongation, suggesting a dose- dependent effect; it is interesting 
to note however, the influence of both UFH and tinzaparin at the low concentration were 
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measurable on the thrombogram relative to the other four LMWH. The key parameters considered 
important with the thrombogram are the peak height, ETP and the thrombin generation velocity. 
When considering the rate of TG velocity, a similar picture to the lag time and time to peak 
emerges, that is to say, at low concentrations UFH and tinzaparin exert a significant effect, and 
other LMWH reduced the thrombin generation velocity by less than 20%. Further increases in 
heparin concentrations led to more marked effects, as one would anticipate. When evaluating the 
ETP and peak height parameters of the thrombogram, the concentration of the LMWH, exhibited 
a dose dependent effect, with concentrations of 0.2 IU/mL of bemiparin, enoxaparin, nadroparin 
and dalteparin not significantly modifying the peak or ETP values as compared to controls. At 
concentrations > 0.4 anti-FXa IU/mL, the LMWHs induced a significant concentration dependent 
reduction of the ETP and peak concentration; as per the lag-time and time to peak results, the 
bemiparin required an even higher concentration to achieve the same result. Once again, 
tinzaparin and UFH exhibited a similar concentration-dependent inhibition of peak and ETP at 
concentrations >0.2 anti-FXa IU/mL. 
The authors of this study were able to identify three distinct groups of LMWH, in terms of how 
they influenced the thrombin generation test. Significantly higher concentrations of bemiparin 
(group 1) than of enoxaparin, nadroparin, and dalteparin (group 2) were required to inhibit 
thrombin generation by 50%. Enoxaparin, nadroparin and dalteparin were less active than 
tinzaparin (group 3). Tinzaparin inhibited thrombin generation by 50% at similar concentrations to 
those of UFH. This classification of LMWH was valid for each separate thrombin generation 
parameter. The important results from this study suggest that anti-Factor IIa activity, which is a 
major determinant of the ETP and prolongation of TG, and that ETP underestimates the potency 
of the anti-FXa activity of LMWH. The authors suggest that future research needs to be 
conducted in patients prescribed LMWH in order to evaluate how much and for how long each 
phase of thrombin generation has to be inhibited in order to achieve the ‘desired’ antithrombotic 
effect. 
Green and colleagues [2010] assessed the thromboprophylaxis effect of dalteparin or rivaroxaban 
in those patients who had undergone elective hip or knee replacements. They did this by 
measuring thrombin generation pre-operatively, peri-operatively and 24 hour post-operatively, 
with the thromboprophylaxis agent being assessed, commencing 6-8 hours post-operatively. They 
report that patients prescribed dalteparin exhibited a variable thrombin generation response after 
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surgery, whereas the effects of rivaroxaban were more consistent. Good correlations between 
rivaroxaban levels and the various parameters of the thrombogram were found, with rivaroxaban 
found to inhibit thrombin generation more, in relative terms, than dalteparin, at 24 hours post 
surgery.  
Finally a small in-vitro study assessed the inter-individual variability of seven LMWH on CAT 
[Hacquard et al., 2011]. In this study, samples were drawn from 12 healthy volunteers and the 
prepared plasma was then spiked with varying concentrations of the LMWH. The authors report a 
concentration dependent inhibition of thrombin generation, with large inter-individual variability of 
the effect observed. 
The overall messages that emerge from these studies are that there is large inter-individual 
variability in the response to LMWH, when assessed through the thrombin generation assay, and 
that different LMWH will have differing effects on the thrombin generation assay, depending on 
their molecular weight and thus their factor IIa to factor Xa specificity. The studies conducted to 
date, specifically using enoxaparin, suggest that the full anticoagulant effect of enoxaparin is not 
seen in the thrombin generation assay. 
6.1.4 Studies assessing thrombin generation during pregnancy 
Very few studies have been conducted which have assessed thrombin generation during 
pregnancy, with even fewer which have evaluated thrombin generation in women prescribed 
LMWH during pregnancy. Details of these studies, with specific experimental conditions, are 
described. 
6.1.4.1 Thrombin generation during healthy pregnancy 
Eichinger and colleagues [1999] were the first group to assess thrombin generation during 
pregnancy, and their study was a prospective study evaluating thrombin generation in healthy 
pregnant women, with and without Factor V Leiden. Thrombin generation (reported as ETP), was 






 weeks gestation and 3 months post-partum). The 
ETP was determined using a chromogenic assay, using 120 pM recombinant TF concentration, 
as a trigger for the assay. They also followed a control group in their study, which comprised 91 
healthy individuals (33 male, 58 female, aged 55+/-11 years, median 56 years), so their ETP 
results were expressed as a percentage of normal controls. The pregnant women recruited, 
comprised 113 women (102 with no FVL, and 11 with FVL). The authors found that ETP levels in 
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the pregnant women with and without FVL did not increase over the course of pregnancy (p=0.2), 
despite evidence of substantial activation of the fibrinolytic system, with increases observed in 
Fragment 1+2, Thrombin-Antithrombin complex and D-dimer concentrations. This finding is 
surprising and is likely to be related to the high TF concentration (120 pM) used as a trigger in the 
study, masking the true thrombin generation pattern of pregnancy. A subsequent smaller study 
[Ku et al., 2003], also used a high concentration of the trigger and reported no difference in ETP 
over the course of pregnancy. Both these studies demonstrate the importance of choosing the 
right TF concentration in evaluating thrombin generation in a pregnant population.  
Rosenkranz and colleagues [2007] assessed thrombin generation in 150 healthy pregnant 
women, aged 18-38 years of age at different gestational ages, contributing a single sample at a 
routine maternity visit. A sub-group of 20 women were recruited twice, once in the first trimester 
and again in the third trimester. Thrombin generation was measured by means of calibrated 
thrombinography in PPP with a 5 pM TF and 4 μM phospholipid concentration. 
The authors found that the ETP and peak height increased significantly with gestational age, 
while the lag-time and time to peak remaining unchanged. According to their results, the level of 
ETP significantly increased from the first to the second trimester, as well as from the first to the 
third trimester, with no significant difference found between the second and third trimester. A 
limitation of this study is the fact that the majority of women provided only a single sample during 
their pregnancy, so it’s difficult to conclude whether the pattern of ETP described is true or not, 
particularly as numbers were small. When analysing the specific results from the sub-group of 
women contributing samples in the first trimester and repeated again in the third trimester, the 
authors report significant increases in ETP and peak height levels, with the lag-time and time to 
peak remaining unchanged, providing relative confirmatory evidence of the wider study results. 
Accepting the limitations of this study, the results suggest that during normal pregnancy, thrombin 
generation increases from the first to the second trimester, after which a plateau is reached. 
Dargaud and colleagues [2010] followed 93 pregnant women, with a mean age of 29.8 years 
without a history of VTE or known thrombophilia. Results were obtained from twenty-eight of 
these women in the first trimester, 33 during the second trimester and 32 during the third 
trimester. The study authors also recruited a control group in their study, which comprised 50 
healthy women, with a mean age of 27.7 years. The thrombin generation assay method employed 
as part of this study was CAT, using the standard TF trigger concentration of 5pM and a 
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phospholipid concentration of 4μM. The study authors report that the ETP was significantly 
increased amongst the pregnant women, compared to the non-pregnant control group. They 
found that the ETP was already raised by the first trimester (p<0.0001), with a further rise seen 
during the second trimester (p=0.03), after which it settled through to delivery (p=0.67). These 
results provide further evidence of how thrombin generation is altered during normal pregnancy 
and confirm the findings of Rosenkranz and colleagues [2007] earlier study. 
More recently, Wulfkuhle and colleagues [2011] have presented an abstract of their pilot study of 
thrombin generation during normal pregnancy in young nulliparous women. In this small study, 16 
women were recruited and had their thrombin generation measured pre-conception, during early 
pregnancy, during the 3
rd
 trimester and during the post-partum period (exact times not listed by 
the authors). For thrombin generation assessment, the study authors used a modified fluorogenic 
substrate thrombin generation assay, initiated with 5pM TF and 20μM phospholipid concentration. 
Unlike previous studies, the authors report the maximum level of thrombin generation (MaxL). 
They found the maximum level of thrombin generation increased with the progression of 
pregnancy (pre-conception MaxL 86.3 nM versus early pregnancy MaxL 223.7 versus late 
pregnancy 322.5 MaxL), and subsequently decreased during the post-partum period. Though the 
authors report an increase in thrombin generation from early pregnancy to late pregnancy, as they 
did not measure thrombin generation during the second trimester, given the findings of other 
groups, its perhaps inappropriate to conclude that thrombin generation increases progressively 
during pregnancy, as if it could well be that it reaches a maximal level by the second trimester, 
something which was not evaluated through data collection in Wulfkuhle’s study.  
The studies published to date on the thrombin generation pattern during pregnancy are 
conflicting. Accounting for differences in reagents and methods employed, the conclusion that can 
be drawn from them are that thrombin generation, as reflected through the ETP increases during 
pregnancy; there appears to be a significant increase from the first to the second trimester 
following which the ETP stabilises through to delivery. By approximately six weeks post partum, 
thrombin generation concentrations will have reached pre-pregnancy values again. 
6.1.4.2 Thrombin generation of women prescribed LMWH during pregancy 
To date, five studies have been published in the form of 4 abstracts and a short report, which 
describes thrombin generation results from pregnant women, prescribed concurrent LMWH or 
who have their plasma spiked, in-vitro, with LMWH.  
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Hynes and colleagues [2009] were the first to report their results in this setting. In their study, they 
assayed thrombin generation, using CAT, presumably using 5pM TF and 4μM phospholipid 
concentration (not described in their abstract), from healthy pregnant women and women with risk 
factors for thrombosis. ETP was assayed at 12, 28 and 36 weeks gestation and 6 weeks 
postpartum. According to the patient’s VTE risk, tinzaparin (50 IU/kg) was commenced for women 
at risk of thrombosis, at the clinician’s discretion. The study authors report the ETP to be 
significantly elevated during pregnancy compared to non-pregnant samples, and report that these 
values fall by six weeks postpartum to non-pregnancy values. This is interesting, as despite the 
prescription of tinzaparin in the pregnant women at risk of thrombosis, a rise in ETP over the 
course of pregnancy occurs. 
Ngu and colleagues [2010], assessed thrombin generation, using CAT, in pregnant women 
prescribed enoxaparin for various obstetric indications, with doses ranging from 40mg once daily 
to 1mg/kg twice a day. In this abstract report, it appears as if thrombin generation was measured 
once during the subject’s pregnancy, at various gestational ages (7-30 weeks, median 29 weeks). 
All samples were measured at 3 hours post enoxaparin injection, with the aim of assessing the 
specific influence of enoxaparin on the thrombogram parameters. The authors report that all 
parameters of the thrombogram correlated with the measured anti-Xa activity, with the strongest 
correlation seen with peak height and time to peak parameters. The study authors conclude that 
all parameters of thrombin generation are affected in a dose-dependent manner, and suggest that 
time to peak and peak height are the most sensitive thrombin generation parameters, with 
respective to enoxaparin. 
In a retrospective study of 66 high risk pregnancies, contributing 144 samples, Adamidou and 
colleagues [2011] measured thrombin generation using an ‘in-house’ fluorogenic method, with 
ETP, peak height and time to peak expressed as a % of normal controls. LMWH was 
administered to 39 pregnant women, with a further 27 women acting as a control group. The 
study authors report significant differences in all the thrombin generation parameters between the 
two groups. The group of women who had anti-Xa activity of >0.4 IU/mL, had significantly different 
ETP, peak and time to peak parameters compared to the control group. However, in those 
women who had an anti-Xa activity of <0.4 IU/mL, no difference in ETP or peak was found 
compared to the control group, although the time to peak parameter was found to be significantly 
different in this group, compared to controls. 
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The largest study that has been published to date is that by Hron and colleagues [2010]. In this 
prospective study, 113 healthy pregnant women and 61 pregnant women receiving LMWH 
heparin prophylaxis were followed. Those prescribed LMWH were receiving either enoxaparin or 
dalteparin at a dose range of 4000-7500 anti-factor Xa IU subcutaneously, with subsequent dose 
changes left to the physician’s discretion.  All subjects had samples drawn in the first, second and 
third trimester of their pregnancies, and thrombin generation was assayed in PPP using a 
chromogenic assay (Siemens Healthcare). The concentration of TF and phospholipid used was 
not disclosed by the assay manufacturers. In women with and without anticoagulation, ETP levels 
did not change significantly from the first to the second trimester (p=0.18). However, the ETP did 
decrease significantly during the third trimester. Interestingly, those women prescribed 
anticoagulation had higher ETP levels than healthy women not prescribed anticoagulation 
therapy, across all three trimesters. The authors conclude that LMWH thromboprophylaxis did not 
completely attenuate coagulation activation during pregnancy. It is difficult for the authors to 
explain their findings, as they contradict what others have reported and their findings are not what 
you might expect to observe. The fact that the concentrations of TF and phospholipids are not 
known to the study authors makes it difficult to utilise the results of this study, given what is known 
about sensitivity of the thrombin generation assay to alterations of assay conditions and reagents.  
Finally, Rossetto and colleagues evaluated the effect of LMWH in pregnant women through the 
in-vitro addition of nadroparin to the women’s plasma [Rossetto et al., 2012]. Twelve healthy 
pregnant women in the first trimester of their pregnancy had blood drawn and thrombin generation 
was performed on PPP using CAT, using a 5pM TF concentration and a phospholipid 
concentration of 4μmol/L. The final nadroparin concentration in the plasma was 0.3 IU/mL and the 
results were compared to results obtained from 12 healthy non-pregnant women. Before the 
addition of LMWH, ETP and peak height were higher in the pregnant population than in the 
controls (p=<0.003). After spiking the women’s plasma, a statistically significant reduction of ETP, 
both in cases and controls was observed. The same pattern was also observed for the peak 
height. The authors report that the proportional reduction in peak height was the same for both 
the subjects and the controls, however, the effect observed on ETP was lower in subjects, when 
compared to controls. This perhaps suggests that during pregnancy, the relationship between 
anti-Xa activity and peak height is stronger than that between anti-Xa activity and ETP. From their 
small study, they suggest that there might be a need to give a higher dose of LMWH during 
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pregnancy, as despite the addition of LMWH, the ETP in the plasma of pregnant women did not 
reach the levels observed in plasma of non-pregnant women after the addition of the same 
amount of LMWH. The authors make an interesting point, however it is important to bear in mind 
that it is known that thrombin generation is increased during pregnancy, so a lowering effect is 
what is required, as opposed to reaching a non-pregnant value as suggested by the authors. 
Clearly further work is required before any significant change in practice would be recommended.  
The message which emerges from these five studies is that some (if not all) of the thrombin 
generation parameters could be influenced by a concurrent LMWH prescription in a pregnant 
population, depending on the dose prescribed. Thrombin generation assays therefore potentially 
provide a meaningful pharmacodynamic marker in pregnant women prescribed LMWH.  
 
6.2 Objectives and Method 
Chapter 2 described the details of how thrombin generation was assayed for the cohort of women 
recruited during this study. In brief, a TF concentration of 5 pM was used as the trigger for 
coagulation, coupled with 4 μM of phospholipid, in PPP, using CAT. Depending on when women 
were recruited during the study, they had their thrombin generation assayed in each trimester, 
within a week of delivery (typically day 0 or day 1 following birth) and > 8weeks post-partum. The 
specific objectives of this sub-study were to: 
 Describe the thrombin generation profiles of pregnant women receiving enoxaparin (dose 
range 20mg-180mg) during their pregnancy 
 Explore the relationship between the enoxaparin concentration and its influence on the 
different parameters of the thrombogram at different pregnancy time-points and post-
partum 
 Compare the results from Caucausian women and African-Caribbean women who were 
prescribed prophylactic doses of enoxaparin 
 Compare how the thrombin generation profiles of the pregnant women followed are 
altered, when the CAT assay conditions are altered by the addition of polybrene, which is 
thought to neutralise enoxaparin in the plasma 
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Units for the different parameters of the thrombogram 
The specific units for the different parameters of the thrombogram in the results section which 
follows are: the lag-time, time to peak and the start tail are recorded in minutes. The peak is in 




Continuous data are reported as means and standard deviations. The means of continuous 







 trimesters, within a week of delivery and > 8 weeks postpartum), using the repeated measures 
ANOVA with a Greenhouse-Geisser correction. Post-hoc analysis was conducted using 
Bonferroni correction. Differences between the Caucasian and African-Caribbean populations are 
described at each pregnancy time point, as means and standard deviations. The means between 
the two groups at each time point were assessed using the independent t-test. Evaluation of 
correlations between anti-Xa activity and each thrombin generation parameter, a two-way 
Pearson’s correlation was run. Significance was considered when p<0.05.  
 
6.3 Results 
6.3.1 Internal thrombin generation variability 
A healthy control (male subject, aged 36-37 years) was bled every eight weeks from the 16
th
 April 
2010 to the 24
th
 January 2012. Eight plasma samples were obtained from the control on each 
occasion and one sample was run in each thrombin generation experiment, from the 20
th
 April 
2010 (exp 17) to the 21
st
 February 2012 (exp 125), 79% of total thrombin generation experiments 
completed as part of this study. For each batch, the control plasma sample were analysed within 
8 weeks of the sample being drawn. 
The intra-assay and inter-assay coefficient of variance was calculated for each thrombin 
generation parameter for this control (table 6.3); the mean (+/-sd) thrombin generation for each 
parameter are listed. 
 
 
 - 206 - 
Table 6.3: Intra-assay and Inter-assay variability in the male healthy control 
Parameter Mean SD Intra-assay %CV Inter-assay %CV 
Lag time 3.13 0.6 4.5 7.6 
ETP 1116 226 1.6 11.8 
Peak height 206 49 3.9 13.7 
Time to peak 6.32 1.1 4.0 7.5 
Start tail 20 2.3 2.1 5.1 
Velocity* 69 27 - - 
*velocity intra and inter assay %CV not computed, as it is a secondary parameter derived from primary parameters 
These results are similar to previously reported variances for the assay and demonstrate an 
appropriate laboratory technique to consider the results for further evaluation.  
6.3.2 Overall thrombin generation results for the cohort of women 
The 123 women recruited to the study provided 498 individual thrombin generation profiles; 414 
(83%) of the profiles were drawn from women prescribed prophylactic doses of enoxaparin with 
the remaining 84 profiles from women prescribed treatment doses of enoxaparin.  
Considering the results overall, the different parameters of the thrombogram were altered during 
pregnancy and the postpartum period. Table 6.4, lists the alterations in these parameters, as 
pregnancy progressed. 
Table 6.4: Overall TG parameter results for the cohort of women 
TG Parameter       1
st
 T 
       n=58 
     2
nd
 T 
      n=117 
     3
rd
 T 
     n=132 
Within 1 week   
of delivery   
n=93 
>8 weeks pp 
n=98 
Lag time 4.27   (3.81) 3.53   (1.26) 3.88   (2.46) 3.14   (1.32) 3.13   (1.34) 
ETP 1391  (795) 1757  (706) 1692  (631) 1857  (633) 1293  (409) 
Peak height 208    (141) 277    (136) 262    (116) 356    (127) 261     (80) 
Time to Peak 8.09   (5.18) 7.05   (3.27) 7.36   (3.91) 5.57   (2.83) 5.68    (1.58) 
Start tail 27.3   (9.7) 26.4   (6.9) 26.6   (6.8) 24.2   (5.8) 20.6    (2.79) 
Velocity 77      (65) 107    (71) 96      (59) 175    (75) 109     (45) 
 sd in brackets; T refers to trimester, pp refers to post-partum. n refers to the number of samples analysed in each trimester (some women 
had two or three profiles drawn around a dose of enoxaparin in each trimester). 
 
The standard deviations on the thrombin generation parameters reflect the hetergenous cohort of 
women followed and is additionally reflective of the differing doses of enoxaparin prescribed. 
The samples drawn at > 8 weeks post delivery provide an insight into what the cohort of women’s 
baseline thrombin generation was prior to their pregnancy by which point the majority of women 
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had discontinued their anticoagulation therapy and all the pregnancy related changes, with 
respect to coagulation factors, would have subsided. Using the >8 week post-partum values as a 
reference point; a rise in ETP is seen over the course of pregnancy, despite a prescription of 
enoxaparin. A similar pattern is also observed for the peak height. It must be remembered though, 
that these samples were drawn from a heterogeneous group of pregnant women and the samples 
were drawn at different time points (post dose), from pregnant women on different doses of 
enoxaparin.  
The pregnant women in this study can be split into two broad groups; treatment and prophylactic 
dosing groups. How are the parameters of the thrombogram altered, when the results are sub-
analysed according to these two groups? 
6.3.2.1 Thrombin generation parameters of women on prophylactic and treatment doses 
Table 6.5 presents the thrombin generations results from the women (414 profiles) prescribed 
prophylactic doses of LMWH during the course of their pregnancy. Table 6.6 presents the 
thrombin generation results from the women prescribed treatment doses of LMWH. 
 
Table 6.5: Thrombin generation results from the cohort of women prescribed prophylactic doses 
of enoxaparin 
TG Parameter       1
st
 T 
      n=49 
     2
nd
 T 
     n=101 
     3
rd
 T 
     n=110 
Within 1 week   
of delivery  
n=75 
>8 weeks pp 
n=79 
Lag time 4.35   (3.82) 3.38   (0.83) 3.53   (0.97) 2.92   (0.92) 2.89   (0.57) 
ETP 1473  (730) 1905  (564) 1803  (481) 1945  (550) 1345  (355) 
Peak height 222    (137) 306    (118) 287    (95) 378    (107) 269     (67) 
Time to Peak 8.30   (4.88) 6.50   (1.76) 6.69   (1.84) 5.09   (1.39) 5.48    (0.96) 
Start tail 28.3   (7.2) 26.5   (4.2) 26.2   (5.7) 24.3   (3.8) 20.5    (2.65) 
Velocity 79      (65) 117    (68) 107    (56) 187    (68) 111     (41) 
 sd in brackets; T refers to trimester, pp refers to post-partum. n refers to the number of samples analysed in each trimester (some women 
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Table 6.6: Thrombin generation results from the cohort of women prescribed treatment doses of 
enoxaparin 
TG Parameter       1
st
 T 
       n=9 
     2
nd
 T 
      n=16 
     3
rd
 T 
     n=22 
Within 1 week   
of delivery  
n=18 
>8 weeks pp** 
n=19 
Lag time 3.83   (3.98) 4.50  (2.57) 3.67   (5.37) 4.10   (2.14) 4.16   (2.64) 
ETP 941  (1015) 820   (809) 1141  (952) 1497  (824) 1078  (547) 
Peak height 129    (146) 95     (103) 135    (131) 266    (164) 232     (117) 
Time to Peak 6.96   (6.81) 10.5  (6.89) 10.7   (7.99) 7.55   (5.46) 6.53    (2.94) 
Start tail 21.5   (17.90) 24.9  (15.9) 28.8   (13.1) 23.9   (10.8) 21.1    (3.36) 
Velocity 60      (61) 28     (35) 42      (51) 122    (83) 104     (61) 
 sd in brackets; T refers to trimester, pp refers to post-partum. n refers to the number of samples analysed in each trimester (some women 
had two or three profiles drawn around a dose of enoxaparin in each trimester).**some women were taking warfarin when this sample was 
drawn 
 
The results demonstrate that differences between the two groups. The ETP rise over pregnancy 
for women on treatment doses of enoxaparin is more attenuated , relative to those women 
prescribed prophylactic doses. It is also interesting to observe how the peak height parameter is 
much lower in the women prescribed treatment doses of enoxaparin, relative to those prescribed 
prophylactic doses. An influence of enoxaparin on the lag time, time to peak, and start tail is also 
observed and will be explored further on in this chapter. Examining the results from the women 
prescribed prophylactic doses, where all anticoagulant therapy had been stopped by eight weeks 
postpartum, one can see that ETP is already higher by the first trimester, with a further rise seen 
during the second trimester, after which it settles through to delivery, where it peaks. The other 
observation which stands out is the wide standard deviations of the results, illustrating the wide 
inter-patient variability in these parameters, with the variation being more pronounced in those 
women prescribed treatment doses of enoxaparin. 
6.3.2.2 Correlation of anti-Xa activity and the thrombin generation parameters 
Previous work assessing the anticoagulant effect in the thrombin generation test has 
demonstrated thrombin generation is not a static parameter, but is dynamic and can change with 
an ever changing concentration of anticoagulant in the plasma. In order to better understand this 
in the antenatal population, anti-Xa activity was correlated for the cohort of women overall, 
followed by women prescribed prophylactic and treatment doses separated out. These results are 
presented in table 6.7. Pearson’s correlation was used (two-way), and significance was 
considered at p<0.05. 
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Table 6.7: Correlation between anti-Xa activity and the different thrombin generation parameters 
Correlation between anti-
Xa activity and TG 
parameter 
Cohort overall Prophylaxis group Treatment group 
Lag time 0.267 0.313 0.030** 
ETP -0.590 -0.438 -0.615 
Peak -0.694 -0.587 -0.747 
Time to peak 0.397 0.481 0.137** 
Start tail -0.004** 0.324 0.290 
Velocity -0.642 -0.577 -0.785 
**non-statistically significant 
The lag time, time to peak and the start tail are all positively correlated with anti-Xa activity, whilst 
the ETP, peak height and velocity are negatively correlated. The parameters where the strength 
of the relationships are strongest are between the ETP, peak height and velocity parameters of 
the thrombogram and anti-Xa activity. For those women prescribed treatment doses of 
enoxaparin, the strength of these correlations increase, relative to those women receiving  
prophylactic doses (-0.6 vs. -0.4 for ETP, -0.7 vs. -0.5 for peak, and -0.78 vs. -0.58 for velocity), 
treatment versus prophylaxis groups respectively. It is interesting to observe that the lag-time and 
the time to peak in the treatment group of patients were not significantly positively correlated, as 
might one anticipate. Detailed analysis of each thrombin generation parameter follows. 
6.3.2.3 Lag time 
The lag time is when no observable thrombin generation is seen and can be considered as being 
representative of historical clotting times, as it is the time taken until thrombin generation reaches 
1/6 of the peak concentration.  
When lag time is compared across trimesters and gestations for the study women overall, a 
decrease in this time is observed as pregnancy progresses. Figures 6.1 (a) and (b) show the 
overall trend in lag time for the study women overall.  
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Figure 6.1 (a) left: Scatter-plot of the lag-times versus weeks amenorrhea for the cohort of women 
recruited. Red line represents the loess smooth 
Figure 6.1 (b) right: Box plots of the lag-times, according to when the lag-time was assessed. 
Trimester 4 and 5 refers to within a week of delivery and > 8 weeks post partum 
 
Thirty women had results for all five time points and the mean lag-times did not significantly differ 
between the five antenatal and postnatal time points (F(1.373, 39.807)=0.699, p=0.452). When 
the lag time results are analysed into those from women prescribed prophylactic doses and those 
women prescribed treatment doses, the results diverge and confirm in part the relationship that 
exists between this parameter and the enoxaparin dose prescribed. There appears to be more 
inter-patient variation from those women on treatment doses compared to those on prophylactic 
doses (figures 6.2 (a) and (b)).  
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Figure 6.2 (a) left: a box-plot of the lag-times from the women prescribed prophylactic doses of 
enoxaparin (trimester 4 and 5 refers to within a week of delivery and > 8 weeks post partum) 
Figure 6.2 (b) right: a box plot of the lag-times from the women prescribed treatment doses of 
enoxaparin (trimester 4 and 5 refers to within a week of delivery and > 8 weeks post partum) 
 
For women prescribed treatment doses (n=8), no significant differences were found between the 
five pregnancy and postnatal time points and the lag-time (F(1.152, 8.066)=0.245, p>0.05). 
Women prescribed prophylactic doses and whom had TG results for all five time points (n=22), 
significant differences were found between the time points (F(2.684, 56.261)=3.732, p<0.05). 
Post-hoc analysis demonstrated significant differences between the > 8 weeks postpartum 
samples and the samples drawn in the first, second and third trimester, where a prolongation of 
the lag-time was observed. 
6.3.2.4 Endogenous Thrombin Potential (ETP) 
The ETP represents the area under the thrombin generation curve. A high ETP value is thought to 
suggest a greater thrombogenic potential in an individual and the greater an individual’s 
propensity to form a clot. A primary aim of anticoagulant therapy would be to reduce the ETP. 
Figure 6.3 (a) and (b) illustrates the overall ETP pattern for the whole cohort of women followed 
and confirms a favoured pro-thrombotic state during pregnancy, despite a prescription of 
enoxaparin. 
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Figure 6.3 (a) left: Scatter-plot of the ETP versus week’s amenorrhea for the cohort of women 
recruited. Red line represents the loess smooth 
Figure 6.3 (b) right: Box plots of the ETP, according to when the ETP was assessed. Trimester 4 
and 5 refers to within a week of delivery and > 8 weeks post partum 
 
The mean ETP did significantly differ between the five antenatal and postal time points (F(2.198, 
63.738)=7.501, p<0.001). Post-hoc analysis revealed specific differences between the > 8 weeks 
post-partum time point and the second and third trimester and the ETP at the time of delivery. A 
statistically significant difference was not found between the first trimester and the > 8 weeks 
postpartum time point.  
When the results were split according to those women receiving prophylactic and those women 
receiving treatment doses, a clear distinction can be seen (box plot figures 6.4 (a) and (b)). Once 
again, the treatment (right) dose women have greater variation in response compared to the 
prophylactic (left) group. 
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Figure 6.4 (a) left: a box-plot of the ETP from the women prescribed prophylactic doses of 
enoxaparin (trimester 4 and 5 refers to within a week of delivery and > 8 weeks post partum) 
Figure 6.4 (b) right: a box plot of the ETP from the women prescribed treatment doses of 
enoxaparin (trimester 4 and 5 refers to within a week of delivery and > 8 weeks post partum) 
 
The mean ETP concentrations are lower for women on treatment doses, as one might predict. For 
women prescribed prophylactic doses, a rise in ETP is observed from the first trimester to the 
second and third trimesters; the ETP remains relatively static during pregnancy for women on 
treatment doses, with a jump observed at the time point of delivery.  
Detailed analyses from the eight women who had thrombin generation samples at all five time 
points, prescribed treatment doses of enoxaparin, found that mean ETP concentrations in these 
women did not statistically differ between the time points (F(1.556, 10.891)=1.550, p>0.05). For 
the twenty two women in the prophylaxis group, the mean ETP concentrations did statistically 
differ between the five time points (F(2.312, 48.561)=9.072, p<0.05). Post-hoc analysis  revealed 
that specific differences were between the > 8 weeks post-partum time point and the second and 
third trimesters and at the time of delivery, mirroring the result seen for the cohort of women as a 
whole. 
6.3.2.5 Peak height 
The peak height was assessed for the cohort of women as a whole. The pattern which emerges is 
an increase from the first to the second trimester, following which peak height appears to stabilise 
to the third trimester, with a jump observed at the time of delivery, before a drop at the > 8 weeks 
post-partum time point (figures 6.5 (a) and (b)).  
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Figure 6.5 (a) left: Scatter-plot of the peak for the cohort of women recruited. Red line represents 
the loess smooth 
Figure 6.5 (b) right: Box plots of the peak, according to when the peak was assessed. Trimester 4 
and 5 refers to within a week of delivery and > 8 weeks post partum 
 
Interestingly, the ‘fall back’ at the eight week post partum time does not reach the level seen 
during the first trimester and certainly demonstrates an impressive enoxaparin pharmacodynamic 
effect during the first trimester. Statistically significant differences did exist between the five time 
points (F(2.230, 64.684)=7.881, p<0.05). Post hoc analysis using a Bonferroni correction revealed 
that specific differences lie between the results obtained at the time of delivery and the results 
from the first and second trimester and the > 8 weeks post partum time points. No statistically 
significant differences were found between the third trimester and the time of delivery, though the 
difference was approaching significant (p=0.063). 
Once again, when the prophylaxis and treatment groups of women were analysed separately 
(figures 6.6 (a) and (b)).   
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Figure 6.6 (a) left: a box-plot of the peak from the women prescribed prophylactic doses of 
enoxaparin (trimester 4 and 5 refers to within a week of delivery and > 8 weeks post partum) 
Figure 6.6 (b) right: a box plot of the peak from the women prescribed treatment doses of 
enoxaparin (trimester 4 and 5 refers to within a week of delivery and > 8 weeks post partum) 
 
No statistically significant differences were found for the 8 women prescribed treatment doses of 
enoxaparin,  who had repeated measures of peak height throughout their pregnancy and at the    
> 8 weeks post-partum time point(F(1.689, 11.820)=3.290, p=0.079). For the 22 women 
prescribed prophylactic enoxaparin with results at all five time points,  statistically significant 
differences between the five time points (F(2.375, 49.877)=5.209, p=0.006) were found. A post-
hoc analysis however, was unable to identify at which time points the differences lie. 
6.3.2.6 Time to Peak (tt Peak)  
The time to peak parameter is, as the name suggests, the time it takes for peak thrombin to be 
reached. Thrombin generation studies do not always report this parameter, however, in this the 
context of this study, it is worth considering, as one would anticipate an increase in the time to 
peak thrombin in those patients prescribed anticoagulant therapy. When the results of tt Peak are 
assessed for the women as a group, a general decrease in this parameter is seen with the 
progression of pregnancy; once again implying the effect of enoxaparin is greatest during the first 
trimester (figure 6.7 (a) and (b)). 
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Figure 6.7 (a) left: a scatter-plot of the time to peak for the cohort of women recruited. Red line 
represents the loess smooth 
Figure 6.7 (b) right: a box plots of the time to peak, according to when the time to peak was 
assessed. Trimester 4 and 5 refers to within a week of delivery and > 8 weeks post partum 
No significant differences existed between the five time points and the time to peak parameter for 
the 30 women, with results at all the time points (F(1.692, 49.058)=2.445, p=0.105).  
When women prescribed treatment doses are separated from those subjects prescribed 
prophylactic doses, differences are observed between the two groups (figures 6.8 (a) and (b)).  
 
Figure 6.8 (a) left: a box-plot of the time to peak from the women prescribed prophylactic doses of 
enoxaparin (trimester 4 and 5 refers to within a week of delivery and > 8 weeks post partum) 
Figure 6.8 (b) right: a box plot of the time to peak from the women prescribed treatment doses of 
enoxaparin (trimester 4 and 5 refers to within a week of delivery and > 8 weeks post partum) 
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The tt Peak is much longer for the women prescribed treatment doses (right), as one would 
anticipate.No significant differences between the five pregnancy time points with respect to the 
time to peak for women prescribed treatment doses. For those women, prescribed prophylactic 
doses, significant differences were found between the five pregnancy time points; (F(2.715, 
57.021)=6.181, p=0.001). A post-hoc analysis revealed significant differences between the > 8 
weeks post-partum time point and the first, second and third trimesters. No significant differences 
were found between the samples drawn at delivery and the > 8 week post-partum time point.  
6.3.2.7 Start Tail 
The start tail is the time at which thrombin generation has begun to diminish. Overall, for the 
cohort of women, a downward trend in the start tail is observed with the progression of pregnancy 
(figures 6.9 (a) and (b)). When patients are prescribed anticoagulant therapy, one would 
anticipate a prolongation in the start tail time. Significant differences did exist between the five 
pregnancy time points (F(2.953, 85.632)=3.093, p=0.032). Post-hoc analysis revealed significant 
differences between the > 8 week post-partum time point and the results from the third trimester 
and within 1 week of delivery, but not at the trimester 1 and trimester 2 time points. 
 
Figure 6.9 (a) left: a scatter-plot of the start tail, for the cohort of women recruited. Red line 
represents the loess smooth 
Figure 6.9 (b) right: a box plot of the start tail, according to when the start tail was assessed. 
Trimester 4 and 5 refers to within a week of delivery and > 8 weeks post partum 
Once again enoxaparin’s effect appeared to be greater during the first trimester than during the 
second and third trimester. When the data are split into those women prescribed treatment (right) 
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and prophylactic doses (left), a difference in response is observed (figures 6.10 (a) and (b)).
 
Figure 6.10 (a) left: a box-plot of the start tail from the women prescribed prophylactic doses of 
enoxaparin (trimester 4 and 5 refers to within a week of delivery and > 8 weeks post partum) 
Figure 6.10 (b) right: a box plot of the start tail from the women prescribed treatment doses of 
enoxaparin (trimester 4 and 5 refers to within a week of delivery and > 8 weeks post partum) 
No significant differences in the start tail for the 8 women who had results from all five time points, 
prescribed treatment doses of enoxaparin were found. Interestingly, significant differences 
between the five pregnancy time points, for those women prescribed prophylactic doses of 
enoxaparin were found (F(2.252, 47.291)=11.953, p=0.000). A post-hoc analysis revealed that the 
specific differences were between the > 8 weeks post-partum time point and the other four time 
points. 
6.3.2.8 Thrombin generation velocity 
Thrombin generation velocity is the final parameter to consider and is thought by many to be an 
important parameter; the faster the TG velocity the larger the thrombin generation potential. The 
overall pattern observed for the women in the study is an increase from the first to the second 
trimester, after which it stabilises through the third trimester. A ‘jump’ is observed at the time of 
delivery, before dropping back by eight weeks postpartum (figure 6.11 (a) and (b)).  
Significant differences were found between the five pregnancy time points (F(2.310, 
66.995)=12.005, p=0.000). A post-hoc analysis revealed that the differences were between the 
results from the time of delivery, and the other four time points.   
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Figure 6.11 (a) left: Scatter-plot of the TG velocity, for the cohort of women recruited. Red line 
represents the loess smooth 
Figure 6.11 (b) right: Box plots of the TG velocity, according to when the TG velocity was 
assessed. (Trimester 4 and 5 refers to within a week of delivery and > 8 weeks post partum) 
Closer scrutiny of differences between women on prophylactic versus women on treatment doses 
demonstrated differences. Women prescribed treatment doses (right), show a ‘suppression’ of 
velocity during pregnancy, compared to those prescribed prophylactic doses (left). Both groups 
had a jump in velocity at the time of delivery. Once again, a strong relationship appears to exist 
between the dose of enoxaparin prescribed and the effect observed (figures 6.12 (a) and (b)). 
 
Figure 6.12 (a) left: a box-plot of the TG velocity from the women prescribed prophylactic doses of 
enoxaparin (trimester 4 and 5 refers to within a week of delivery and > 8 weeks post partum) 
Figure 6.12 (b) right: a box plot of the TG velocity from the women prescribed treatment doses of 
enoxaparin (trimester 4 and 5 refers to within a week of delivery and > 8 weeks post partum) 
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For women receiving prophylactic doses statistically significant differences between the five time 
points were found (F(2.333, 48.983)=7.784, p=0.001). A post-hoc analysis found significant 
differences between the first and third trimester and results from the time of delivery. No 
differences were found between the second trimester and the results from the time of delivery, 
although the results were approaching significance (p=0.052). For women prescribed treatment 
doses of enoxaparin, significant differences between the five time points assessed were found 
(F(1.762, 12.332)=4.752, p=0.033). However a post-hoc analysis was unable to identify where the 
specific differences were.  
Overall, the results demonstrate increased thrombin generation during the antenatal period, 
despite the enoxaparin prescription, and an influence of enoxaparin on the thrombogram 
parameters, in a dose dependent manner. 
6.3.2.9 Are there ethnic differences between the women’s profiles? 
The Caucasian and African-Caribbean ethnic groups represented the majority of ethnic origin 
groups in the cohort of women recruited during the course of this study. The thrombin generation 
results from these two groups of women prescribed prophylactic doses of enoxaparin were also 
compared and contrasted.  
Table 6.8 lists these results according to each trimester (mean +/- SD of each parameter). 
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  n=34 v 8 n=67 v 24 n=75 v 27 n=45 v 23 n=47 v 24 
Lag time Caucasian  
A-C 
4.11   (1.74) 
3.27   (0.81) 
3.49   (0.83) 
3.18   (0.74) 
3.62   (0.98) 
3.34   (0.77) 
3.03   (1.09) 
2.73   (0.61) 
2.98   (0.57) 
2.72   (0.51) 
ETP Caucasian 
A-C 
1296  (651)* 
2126  (754) 
1806  (557)* 
2129  (556) 
1784  (451) 
1810  (432) 
1944  (578) 
1911  (540) 
1306  (356) 
1402  (336) 
Peak height Caucasian 
A-C 
193    (124)* 
323    (146) 
284    (114)* 
356    (112) 
280    (92) 
301    (96) 
379    (119) 
367    (91) 
256    (60) 
286    (63) 
tt Peak  Caucasian 
A-C 
8.27   (3.6) 
6.61   (2.2) 
6.83   (1.8)* 
5.89   (1.3) 
6.95   (1.9) 
6.22   (1.6) 
5.23   (1.6) 
4.88   (1.0) 
5.65   (0.9)* 
5.15   (0.9) 














65       (56) 
123     (79)* 
103    (62)* 
148    (71) 
100     (53) 
119     (60) 
187    (76) 
183    (62) 
101     (34)* 
123     (40) 
*Significance at <0.05 level; A-C refers to the African-Caribbean population, C refers to Caucasian population. n=number of samples in 
each trimester (Caucasian vs African-Caribbean). SD in brackets. ‘T’ represents trimester. 
When assessing those women receiving prophylactic enoxaparin during the first trimester, there 
are significant differences between the two ethnic groups for the mean ETP, peak and velocity 
parameters with the African-Caribbean group having higher values for these relative to their 
Caucasian counterparts. These differences seem to subside with the progression of pregnancy 
and re-emerge at the > 8 weeks postpartum point, when time to peak and velocity were found to 
be significantly different. It is difficult to draw a firm conclusion from these results, due to a lack of 
a control group and the heterogeneous nature of women who were followed, however the results 
do suggest an ethnic difference in thrombin generation over the course of pregnancy, although 
this difference does not remain static, and appears to change with the progression of pregnancy. 
It must be remembered though, that in the cohort of women followed in this study, the African-
Carribean women tended to be heavier relative to their Caucasian counterparts. It is well 
recognised that obesity in itself can increase thrombin generation, so further objective work is 
required before a definitive conclusion that women from African-Carribean origin will have an 
altered thrombin-generation profile relative to their Caucasian counterparts. 
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6.3.2.10 The dynamic state of thrombin generation 
Eleven women in the study had three anti-Xa samples drawn at each clinic visit. Though the 
numbers were small, it provided an opportunity to observe how the thrombin generation 
parameters altered with time, around a single dose of enoxaparin. Overall, the thrombogram 
parameters appear to change directly in proportion with the anti-Xa activity. Table 6.9 lists the 
mean parameter results of women injecting prophylactic doses of enoxaparin at three time points, 
trough, one hour post and 3 hours post dose. 





Lag time ETP Peak Time to 
Peak 














































SD in brackets 
The lag time, peak, the time to peak, and the start tail, peak and the thrombin generation velocity 
follow the anti-Xa activity, i.e. the larger the anti-Xa activity, the longer the times for the lag-time, 
time to peak and start tail, and the lower the peak and thrombin generation velocity parameters. 
Interestingly, the ETP does not appear to correlate with the anti-Xa activity. It seems to drop at 1 
hour post dose, but then appears to recover by 3 hours post dose. At first glance this is an 
unexpected result, however, this observation is likely to be caused, by the prolongation of the lag 
time, time to peak and start tail, which will increase the area under the curve, hence the ETP. 
Therefore it would seem sensible to be wary of this artefact when comparing the thrombin 
generation ETP parameter around a dose of an anticoagulant.  
One of the study patients was on treatment dose of enoxaparin (1mg/kg bd) and had three anti-
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0.30 4.22 1770 228 8 28 60 
1 hour post 0.40 4.89 756 63 10 35 11 
 
3 hour post 0.51 5.11 957 65 12 37 10 
 
Once again, a similar pattern is observed, whereby, the lag time, time to peak, start tail all 
increase with an increase in anti-Xa activity and the peak and thrombin generation velocity 
decreases with an increase in anti-Xa activity. The ETP values appear to be recovering with an 
increasing anti-Xa activity, however, this effect is likely to be related to the prolongation of the lag 
times, time to peak and start tails, causing an increase in ETP seen, as was observed previously.  
Though the results from this aspect of the analysis are based on small numbers and confounded 
by many variables, the message which emerges appears to be that the thrombin generation 
parameters will alter with an ever changing concentration of enoxaparin in the plasma and these 
alterations are predictable. If a standard % inhibition or prolongation is established for each of the 
thrombin generation parameters at a given time point post dose, such as IC50, then such a 
parameter could be used to assess objectively the effect the enoxaparin is exerting on the 
subject’s plasma [Gerotziafas et al., 2007]. 
  
6.4 Discussion 
Overall, the results from assaying the thrombin generation of women prescribed enoxaparin 
during their pregnancy suggest that thrombin generation, as measured by CAT, has already 
increased by the first trimester, further increases during the second trimester, after which it 
stabilises through to delivery. By eight weeks post partum it appears to drop back and 
demonstrates the prothrombotic state which ensues during a gravid state. These results agree 
with those presented by Dargaud and colleagues [2010], who suggested the same pattern of ETP 
increase. The results from this thesis do not endorse the thrombin generation pattern described 
by Eichinger and colleagues [1999] , who described no thrombin generation increase during 
pregnancy in women with and without factor V Leiden and reported that ETP does not increase 
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during pregnancy. Ku and colleagues also reported a similar finding from their small study [Ku et 
al., 2003]. As previously stated, both Eichinger and Ku’s studies used an extremely high TF 
trigger concentration in their thrombin generation experiments. It is likely that this high 
concentration of TF was masking the thrombin generation rise, demonstrating the importance of 
experimental conditions in the execution of thrombin generation studies. Wulfkuhle and 
colleagues [2011], report that the maximum level of thrombin generation increases as pregnancy 
progresses and then drops back down post-partum. However, this study did not measure 
thrombin generation during the second trimester, so it is difficult for the authors to conclude 
without doubt whether thrombin generation would have peaked already by the second trimester, 
as already discussed. Rosenkranz and colleagues, report a similar pattern of ETP increase as 
observed by Dargaud and colleagues and during this thesis. They report that ETP is significantly 
different between the first and second trimester and between the first and third trimester of 
pregnancy. However, the difference between the second and the third trimester was not 
significant. This coupled with the results from this thesis, provide more weight that the true pattern 
of thrombin generation increase during pregnancy is as described by Rosenkranz and Dargaud’s 
studies. Epidemiology studies describe the incidence of antenatal VTE to be equally distributed 
across all three trimesters.  If Wulfkuhle’s pattern of thrombin generation were true, then one 
might anticipate an increase in the incidence of antenatal VTE, in line with gestation, which is not 
the case, providing weight that Rosenkranz’s, Dargaud’s and the results presented in this thesis, 
is the correct thrombin generation pattern rise during pregnancy. More recently, Ismail and 
colleagues have published the results of evaluating the effect of tinzaparin on thrombin generation 
post elective caesarean section [Ismail et al., 2012]. In their study, anti-Xa activity, tissue factor 
pathway inhibitor (TFPI) and thrombin antithrombin complex (TAT) and ETP were measured in 20 
healthy women who received 4,500 IU tinzaparin 6 hours post caesarean section, in 20 women 
who received 4,500 IU tinzaparin 10-12 hours post delivery and in 20 women post spontaneous 
vaginal delivery. Prior to delivery, TAT levels at 6 hours post delivery were significantly higher in 
the caesearean section groups than the spontaneous vaginal delivery groups. The authors also 
found that TAT levels were significantly reduced up to 24 hours following LMWH, despite a falling 
anti-Xa activity. They also found that peak thrombin and ETP were significantly reduced following 
LMWH prophylaxis and reverted to pre-delivery levels 10 hours post LMWH. Though this study 
was conducted in women during the postnatal period, their findings mirror many of those 
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presented in this thesis, in terms of the influence of LMWH on the different thrombin generation 
parameters. 
The women in this study were self-injecting enoxaparin, and an argument could be made that the 
presence of enoxaparin is distorting the true pattern of thrombin generation in the pregnant 
women. However, as observed in the results, the prophylactic doses of enoxaparin appear to alter 
the thrombin generation parameters in a consistent manner, allowing the typical thrombin 
generation pattern to be described, though the confounding factor of women injecting enoxaparin 
must be born in mind. 
Indeed a clear influence of enoxaparin on the thrombogram can be seen in this study, as has 
been reported by earlier smaller studies. In their study, Ngu and colleagues [2010], reported that 
all parameters of the thrombogram correlated well with anti-Xa activities with the most sensitive 
parameters being the peak height and the time to peak parameters. Adamidou and colleagues 
[2011] report the time to peak to be the most sensitive parameter in pregnant women injecting 
enoxaparin with anti-Xa activities greater and less than 0.4 IU/mL. Unsurprisingly, the results from 
this thesis suggest that a treatment dose of enoxaparin has more of a profound effect on thrombin 
generation compared to prophylactic doses, with strong negative relationships existing between 
the ETP, peak and velocity parameters of thrombin generation and anti-Xa activity. With respect 
to the lag time, time to peak and start tail; these relationships were positive. The results agree 
with the small studies of Ngu and Adamidou, and with the patient numbers in this study, provide 
invaluable insight into these relationships. The next steps would be to define by how much 
thrombin generation is to be inhibited at a set time point with prophylactic and treatment doses of 
LMWH, for individual LMWH, in order to tailor treatment to individual patients.  
This aspect of the enoxaparin study is limited by the fact that it is observational, it has no control 
group, women were prescribed enoxaparin, and the women that were followed were a 
heterogeneous group of women, from active pathological thrombosis to asymptomatic VTE 
prophylaxis. Future thrombin generation studies would be well served to explore sub-groups of 
women in a controlled manner in order to identify if thrombin generation patterns are different in 
different groups of women. It would also be good to have confirmation of the pattern in ETP / peak 
height, with a study which follows a control group. 
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The results from this study also found that thrombin generation does indeed alter with time when 
a dose of enoxaparin is administered. This change is largely reflected in the start tail, time to 
peak, lag time, thrombin generation velocity and the peak height parameters of the thrombogram. 
The ETP results, with respect to this, are misleading; as initial inspection of the results suggest 
that ETP begins to recover by 3 hours post dose. But this is likely to be an artefact of measuring 
area-under curve, where the lag time and time to peak have increased in a dose dependent 
manner, thereby increasing the ETP, i.e. not that the ETP is recovering. This should be borne in 
mind, when reviewing thrombin generation results of patients on anticoagulant therapy where 
thrombin generation repeatedly measured, over a single dose. 
Finally, other groups have reported thrombin generation to be altered by age, obesity, and other 
medical co-morbidities. These factors were not controlled in this study, and future studies might 
well look to control these variables, in order to discern the specific impact of covariates on 
thrombin generation during pregnancy. Obesity is of particular interest, as evidence published in 
the UK over the last 10 years identifies this sub-group of women as a growing cohort and that as 
well as an increasing risk of VTE, these women are at increased risk of bleeding [Modder and 
Fitzsimons, 2010]. More recently, ethnicity has also been identified as an independent factor 
influencing thrombin generation [Roberts et al., 2012]. Evidence already exists which 
demonstrates that the African-Caribbean ethnicity is associated with an increased risk of both first 
and recurrent venous thromboembolism [White et al., 2004; White et al., 2005]. In their study, 
Roberts and colleagues [2012] evaluated thrombin generation in African-Caribbeans compared to 
Caucasians in patients with a first DVT, and healthy volunteers. Thrombin generation was 
measured in a case-control study of 80 patients who had completed anticoagulation therapy for a 
first DVT (50 Caucasians and 30 African-Caribbean) and 66 controls. In the DVT group, peak 
thrombin, ETP and maximum velocity were all significantly higher in the African-Caribbeans than 
the Caucasian group. Within the control group, peak thrombin and maximum velocity were also 
increased in the African-Caribbean group compared to the Caucasian group. In the pregnancy 
sub-study, significant differences in some of the thrombin generation parameters were found 
during the first and second trimester and at the > 8 weeks post-partum time point. No differences 
were found during the third trimester and at the time of delivery. The ethnicity results assessed in 
this thesis were from women prescribed prophylactic doses; and at first glance might suggest that 
the enoxaparin is ‘equalling’ out thrombin generation over the course of pregnancy. However, a 
 - 227 - 
case could be made that enoxaparin has a constant and consistent effect on thrombin generation 
over the course of pregnancy, and so a true pattern is seen, i.e. African-Caribbeans having a 
higher TG than their Caucasian counterparts in the first and second trimester, after which the 
Caucasian group ‘catch-up’ and they begin to separate out again by eight weeks post-partum. 
The results certainly provide confirmatory evidence of the findings from Roberts and colleagues 
and explain some of the findings from the last CMACE report [CMACE, 2011]. In the last CMACE 
report, 5 women died during the antenatal period, of which 3 were from a African-Caribbean 
ethnic group, with all 3 dying during the first trimester. The results here demonstrate how much 
more TG has increased in the first trimester for the African-Caribbean population and may in part 
explain why this ethnic group dominates the death/incidence rate during the first trimester. Of 
course the increases incidence in this sub-group could also be dependent on other factors, 
particularly obesity or social, e.g. language barriers. However, further research should focus on 
understanding the exact mechanism behind this and further explore what has been found in this 
thesis.  
Strengths of this sub-study include the patient numbers recruited and tested, the fact that the 
same women were tested on multiple occasions through their pregnancy and during the post-
partum period, the fact that thrombin generation was measured 8 weeks post delivery (when most 
women were off anticoagulant therapy), providing a baseline value for each women. This allowed 
the evaluation of how much thrombin generation had increased during the antenatal period. Other 
strengths, include the number of African-Caribbean patients followed in this study, providing 
valuable information on this particular sub-group. Finally, a major strength of this study is that it 
involved in-vivo work, i.e. was conducted on plasma from women actually injecting the 
enoxaparin, not plasma spiked with LMWH. Limitations in this sub-study are, that not all women 
had thrombin generation assayed at all five pre-determined time points, and that exact impact of 
obesity on thrombin generation was not controlled, therefore its not known whether the ethics 
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6.5 Can polybrene neutralise enoxaparin in the thrombin generation assay? 
6.5.1 Background 
Polybrene (hexadimethrine bromide) is a synthetic polymerised quaternary ammonium cation. As 
described in chapter one, during the late 1950’s and early 1960’s, the compound was utilised as 
an unfractionated heparin neutralising agent for patients undergoing open cardiac surgery and in 
those patients with an extracorporeal circulation. Its use in clinical practice was short-lived, 
however, due to significant reports of renal toxicity. 
The requirement of reversing or neutralising anticoagulant agents is not new and stems back to 
work by Chargaff and Olson [1937]. Chargaff and Olson were the first to demonstrate the 
neutralising effect of protamine on unfractionated heparin. Over the years, with an increase in the 
use of anticoagulant therapy in patients, a need has arisen to have a safe and effective reversing 
agent, particularly in an emergency setting. Protamine sulphate achieves this for the heparins by 
competing with antithrombin for binding to heparin [Okajima et al., 1981]. Protamine has a 
stronger affinity for binding to heparin than antithrombin, therefore causing antithrombin to 
dissociate from the heparin-antithrombin complex, and thus reversing the anticoagulant effect. 
The binding of protamine to heparin is through an electrostatic means, whereby the polycation 
protamine binds to the polyanion heparin to form a stable complex with no anticoagulant activity 
[Ando et al., 1973]. Polybrene, also a polycation, is also thought to exert its heparin neutralising 
effect through electrostatic means. Protamine sulphate fully reverses both the anti-IIa and anti-Xa 
fractions of unfractionated heparin, and the anti-IIa fraction of LMWH, but does not fully reverse 
the anti-Xa effect of LMWH [van Veen et al., 2011]. The inability of protamine sulphate and thus 
polybrene to fully reverse the anti-Xa fraction of LMWH is thought to be due to a reduced sulphate 
charge in ultra low molecular weight fragments present in LMWH but not in unfractionated heparin 
[Crowther et al., 2000]. 
The neutralisation of enoxaparin in-vitro holds an important clinical utility for the study in this 
thesis. The lack of a control group and the fact that the thrombin generation samples were drawn 
at different time points in the thrombin generation aspect of this study meant that it was difficult to 
assess what exact impact the enoxaparin has had on the women’s thrombin generation. If a 
suitable LMWH neutralising agent could be established for the thrombin generation assay, then a 
valuable insight could be obtained.  
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This aspect of the sub-study was inspired by an abstract presented at the Interntional Socity of 
Thrombosis and Haemostasis (ISTH) conference by Carlo and colleagues [2009]. In their study, 
Carlo and colleagues initially evaluated whether polybrene influenced the thrombin generation 
assay, in itself. They found that polybrene, at concentrations between 0-5mg/mL, did influence the 
thrombin generation assay. This influence was found to be in an inhibitory form; particularly 
influencing the peak height and ETP. Carlo and colleagues found that at a concentration of 
0.1mg/mL, the peak height and ETP are inhibited by 38% and 32% respectively by polybrene. 
The group then spiked normal pool plasma with UFH and dalteparin (at an anti-Xa concentration 
range of between 0-2 IU/mL), and measured thrombin generation using CAT in order to assess 
whether the addition of polybrene to the samples would effectively neutralise the heparin effect. 
They report that a polybrene concentration of 0.025 mg/mL effectively neutralised the effect of 
UFH and LMWH up to a concentration of 2 IU/mL of anti-Xa activity and would be effective in 
evaluating the pharmacodynamic effect of LMWH on the thrombogram. They go onto to report 
that at a polybrene concentration of 0.025 mg/mL, the specific influence of polybrene on the 
thrombin generation parameters was less than 10%.  
In a further earlier study, Messmore and colleagues [2003] evaluated the effectiveness of 
polybrene neutralisation in normal pool plasma. They conducted their experiments, inspired by 
the fact that some samples arriving in their hospital laboratory were from patients on heparin 
based treatments and wanted to develop a means of neutralising the heparin effect from the 
plasma.  They spiked plasma with enoxaparin and UFH at the following anti-Xa concentrations; 
0.5, 1.0, 1.5 IU/mL and then measured anti-Xa activity before and after the addition of polybrene 
to these samples, at a concentration of 0.1 mg/mL. They found polybrene reversed the anti-Xa 
activity of both UFH and enoxaparin, demonstrating that the desired effect can be achieved in-
vitro, at therapeutic heparin concentrations. 
Using Carlo’s study as a template and inspired by the clinical use of polybrene in UFH reversal 
from the late 1950’s and early 1960’s, the thrombin generation profiles of recruited pregnant 
women recruited during this study were additionally assayed with polybrene, in order to establish 
whether enoxaparin’s specific pharmacodynamic effect could be discerned.  
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6.5.2 Aim 
 The aim of this sub-study was to: 
 Evaluate whether polybrene could neutralise the effect of enoxaparin in the thrombin 
generation profiles of the women recruited to the study 




Dr Carlo (Diagnostica Stago, France) was personally contacted to obtain details of how her group 
had conducted their polybrene study. Dr Carlo’s kindly sent the following description for 
conducting their experiments [personal communication, 18/09/2009];  
Initially a stock solution of 10mg/mL of polybrene, by dissolution of the polybrene powder (Sigma 
Aldrich) in distilled water is prepared. From the stock solution, prepare a dilution of 1mg/mL 
polybrene solution. Depending on the specific experimental conditions and reagents going to be 
used in the thrombin generation assay (e.g. either PPP, PPP low, PPP high, micro-particles or 
PRP), reconstitute the appropriate reagent vial with 850µL of distilled water and make up to 1mL 
with 150µL of the polybrene 1mg/mL solution. Then wait for stabilisation of the reconstituted vial 
for 30 minutes at room temperature. The reagent is then ready to use in the thrombin generation 
test and executed normally (as previously described), and contains 0.15mg/mL of polybrene, 
which is 0.025mg/mL in the final test (20µL of trigger + 80µL of sample + 20µL of FluCa).  
For reasons explained in the next section, the final concentration of polybrene that was utilised in 
this study was 0.0125mg/mL, not 0.025mg/mL. Furthermore, in order to ensure that the PPP 
reagents were not wasted during each experiment, Dr Carlo’s instructions were amended as 
follows: 
i) A stock solution of polybrene 10mg/mL was freshly prepared for each experiment 
(made fresh prior to each thrombin generation test, usually weekly). 
ii) A diluted solution of polybrene 1mg/mL was prepared from the stock solution. 
iii) A vial of PPP was reconstituted with 500μL of di-ionised water and left to stand for 2 
minutes. 250μL was then withdrawn from the PPP vial and added to a new tube. A 
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further 250μL of de-ionised water was added to the original PPP vial (with no 
polybrene). To the second tube of 250μL of PPP, 215μL of di-ionised water was 
added, along with 35μL of the polybrene 1mg/mL solution. This was then left to stand 
for 30 minutes before using in the thrombin generation assay. 
 
6.5.3.1 Concentration of polybrene used in the experiments 
Following commencement of the thrombin generation experiments, the research team found that 
the polybrene concentration suggested by Carlo and colleagues’ study might be too high for the 
in-vivo samples being assayed, as no apparent reversal effect was being observed for women 
prescribed prophylactic doses of enoxaparin and the ETP and peak parameters were being 
inhibited significantly; the research team therefore conducted a small in-vitro study to evaluate 
whether an alternative lower concentration of polybrene 0.025 mg/mL should be used. 
6.5.3.2 In-vitro study of differing polybrene concentrations 
The plasma from a healthy control (male, aged 36) was spiked with enoxaparin at the following 
anti-Xa activities: 0.05, 0.10, 0.15, 0.20, 0.30, 0.40, 0.60, 0.80, 1.0 IU/mL. Thrombin generation 
was then evaluated, using CAT, in these samples with and without the addition of polybrene at 
the following polybrene concentrations; 0.025, 0.01875, 0.0125, 0.00625 mg/mL. 
In the absence of polybrene, a strong negative relationship existed between the enoxaparin anti-
Xa activities and the ETP and peak height parameters of the thrombogram (r=-0.952, p=0.01 and 
r=-0.872, p=0.01). With the addition of polybrene concentrations, all four polybrene concentrations 
neutralised enoxaparin at higher anti-Xa activities (>0.30 IU/mL). At lower enoxaparin anti-Xa 
activities (<0.30 IU/mL), PB neutralised enoxaparin’s effect in a concentration dependent manner, 
with the two higher PB concentrations (0.025 and 0.01875mg/mL) inhibiting TG. By the lowest 
anti-Xa activity, all four PB concentrations were inhibiting TG. Figures 6.13 (a) and (b) illustrate 
the thrombin generation curves of the spiked plasma at two different enoxaparin anti-Xa activities; 
0.05 IU/mL and 0.60 IU/mL. The effect of polybrene does change with anti-Xa activity, being more 
effective in terms of neutralising enoxaparin at higher enoxaparin concentrations than lower 
concentrations. This has implications for women for this study, as women in this study were 
prescribed varying doses of enoxaparin and so the polybrene effect will be variable, dependent on 
the anti-Xa activity at a given moment in time in the plasma. 
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Figure 6.13 (a): Thrombin generation curves of plasma samples spiked with 0.05 IU/mL of 
enoxaparin, with the addition of polybrene at differing concentrations 
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Figure 6.13 (b): Thrombin generation curves of plasma samples spiked with 0.60 IU/mL of 
enoxaparin, with the addition of polybrene at differing concentrations 
 
The research team therefore decided to use half the concentration that Dr Carlo reported in their 
study, i.e.  0.0125 mg/mL, as this concentration appeared to be able to neutralise therapeutic 
concentrations of enoxaparin, whilst having a minimal impact itself on thrombin generation.  
In order to better determine the impact of 0.0125 mg/mL polybrene on plasma, as has already 
been described by Carlo and colleagues, the same healthy control had their thrombin generation 
assayed in each of the thrombin generation experiments conducted for the enoxaparin in 
pregnancy study from the period 20
th
 April 2010 to 21
st
 February 2012 (experiments 17 to 
experiments 125), 79% of total thrombin generation experiments. Table 6.11 illustrates the 
thrombin generation results from this healthy control, with and without polybrene, with an 
indication of what impact the polybrene had on each thrombin generation parameter.  
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These results clearly demonstrate a significant influence of polybrene on the thrombin generation 




Table 6.12 represent the thrombin generation results, when the results with and without polybrene 
are compared. The table represent the whole cohort of women, i.e. women receiving prophylactic 
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Table 6.12: The thrombin generation results for the cohort of women in this study, with and 
without polybrene 0.0125mg/mL 









LT with PB 
4.27   (3.81) 
4.87   (2.85) 
3.53   (1.26)** 
4.18   (1.38) 
3.88   (2.46)** 
4.20   (1.43) 
3.14   (1.32)** 
3.73   (1.88) 
ETP 
ETP with PB 
1391  (795)** 
1666  (610) 
1757  (707)** 
1922  (480) 
1692  (631)** 
1889  (522) 
1857  (633)** 
1926  (542) 
Peak 
Peak with PB 
207    (141)** 
247    (104) 
277    (136)** 
301    (93) 
262    (117)** 
296    (82) 
356    (127)** 
371    (100) 
tt Peak 
tt Peak with PB 
8.09   (5.17) 
8.45   (3.47) 
7.05   (3.27) 
7.41   (2.07) 
7.36   (3.91) 
7.34   (2.01) 
5.57   (2.83) 
5.99   (2.39) 
Start tail 
Start tail with PB 
27      (9.72) 
28      (5.71) 
26      (6.96) 
26      (4.41) 
27      (6.88) 
26      (4.47) 
24      (5.82) 
25      (4.79) 
Velocity 
Velocity with PB 
77      (65) 
85      (50) 
107    (71) 
107    (51) 
96      (57)** 
105    (44) 
174     (75) 
175     (58) 
SD in brackets. **p<0.05, n=number of samples evaluated. Results from the > 8 weeks PP not presented, as women were no longer 
injecting enoxaparin 
Overall, the results demonstrate an increase in all thrombogram parameters with the addition of 
polybrene to the subjects’ plasma. The ETP and peak were significantly increased in the 
polybrene samples, compared to the original samples, across all four time points where women 
were injecting enoxaparin, suggesting a polybrene neutralising effect, however, the polybrene 
consistently appeared to prolong the lag time at all time points. If the polybrene was truly 
neutralising the effect of enoxaparin, one would anticipate a shortening of the lag time. Overall, 
the tt Peak parameter increased with the polybrene samples; not as expected, as one would 
predict a shortening of this time with polybrene. This pattern is largely repeated with the start tail. 
Finally, the thrombin generation velocity parameter increased across all four time points where 
patients were injecting enoxaparin, in line with the ETP and peak, and suggesting once again, a 
potential polybrene neutralising effect. 
The results clearly demonstrate that the polybrene is exerting a neutralising effect on the women’s 
plasma. However the results are variable depending on which thrombin generation parameter is 
evaluated, and overall the results appear to suggest that the neutralisation of enoxaparin in-vivo is 
not complete. 
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In order to further evaluate the overall result, they have once again been split, according to 
women injecting prophylactic or treatment doses of enoxaparin. Results for women on prophylaxis 
are presented in table 6.13, whilst the results for women on treatment doses are presented in 
table 6.14. In both cases, significant differences are highlighted (**) in these tables. 
Table 6.13: Thrombin generation results from women prescribed prophylactic enoxaparin, with 










At delivery  
n=75 
LT 
LT with PB 
4.35   (3.82) 
4.45   (2.25) 
3.38   (0.82)** 
3.92   (0.85) 
3.53   (0.97)** 
4.00   (1.00) 
2.92   (0.92) ** 
3.40   (0.92) 
ETP 
ETP with PB 
1473  (730)** 
1701  (507) 
1905  (564) 
1955  (477) 
1802  (481)** 
1889  (460) 
1945  (551) 
1957  (504) 
Peak 
Peak with PB 
222    (137)** 
254    (96) 
306    (118) 
313    (88) 
288    (95)** 
303    (74) 
378    (107) 
383    (90) 
tt Peak 
tt Peak with PB 
8.30   (4.88) 
7.98   (2.89) 
6.50   (1.75)** 
7.02   (1.52) 
6.70   (1.84)** 
7.05   (1.57) 
5.09   (1.39) ** 
5.57   (1.15) 
Start tail 
Start tail with PB 
28.3   (7.16) 
27.6   (4.89) 
26.6   (4.2) 
26.4   (3.9) 
26.2   (4.7) 
26.1   (4.4) 
24.3   (3.88) 
24.1   (3.26) 
Velocity 
Velocity with PB 
79      (65) 
84      (51) 
118    (68) 
112    (50) 
107    (56) 
108    (42) 
187    (68) 
182    (52) 
sd in brackets. **p<0.05, n=number of samples at the respective time point 
 
As with the ‘overall’ group, the lag time is prolonged in the polybrene group. The ETP increases 
by varying amounts at the different time points sampled. The peak height increases by varying 
amounts at the different time points sampled. Apart from during the first trimester, the time to 
peak is increased in the polybrene samples. The start tail is consistently found to decrease with 
the polybrene samples, and apart from the second trimester and within one week of delivery, the 
velocity increases. 
At first glance, it appears as if the results provide no useful information. They do however 
demonstrate that polybrene can neutralise enoxaparin, even for patients on prophylactic doses, 
depending on the enoxaparin anti-Xa activity at a given moment in time, but this effect does not 
appear to be complete. The other useful piece of information to discern is the result demonstrates 
the previous in-vitro work, that polybrene exerts its own effect on the thrombin generation test.  
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Table 6.14: Thrombin generation results of patients prescribed treatment doses of enoxaparin 










LT with PB 
3.82   (3.97) 
7.17   (4.53) 
4.50   (2.57) 
5.90   (2.62) 
5.66   (5.37) 
5.16   (2.51) 
4.09   (2.14) 
5.13   (3.62) 
ETP 
ETP with PB 
942    (1015)** 
1470  (1030) 
820    (809)** 
1711  (460) 
1141  (952) ** 
1889  (776) 
1497  (824)** 
1800  (681) 
Peak 
Peak with PB 
129    (146)** 
210    (140) 
95      (103)** 
231    (97) 
135    (131) ** 
261    (111) 
266    (164)** 
321    (130) 
tt Peak 
tt Peak with PB 
6.96   (6.81) 
10.98 (5.21) 
10.5   (6.89) 
9.89   (3.19) 
10.7   (7.99) 
8.7     (3.14) 
7.55   (5.46) 
7.79   (4.59) 
Start tail 
Start tail with PB 
21.5   (17.9) 
32.6   (8.1) 
24.9   (15.9) 
29.9   (5.96) 
28.8   (13.0) 
27.9   (4.5) 
23.9   (10.8) 
27.6   (8.30) 
Velocity 
Velocity with PB 
60      (62)** 
92      (38) 
28      (35)** 
66      (45) 
42      (52)** 
85      (52) 
122    (83)** 
147    (74) 
sd in brackets. **p<0.05, n=number of samples at the respective time point 
 
For all pregnancy time points, apart from the third trimester, the lag time was longer in the PB 
samples, suggesting that irrespective of enoxaparin plasma concentration, the polybrene effect on 
thrombin generation will prolong the lag time. The ETP is increased in all the polybrene samples 
and during the first, second and third trimesters, the enoxaparin effect observed appears to be 
greater than 50% at these time points. This really does demonstrate the application of the 
possibilities of a neutralising agent in this setting. A similar result is also observed for the peak 
height parameter; the effect is once again more profound during the first, second and third 
trimesters. During the second and third trimester, the time to peak is shortened, but otherwise is 
more prolonged, showing a variable response. The start tail is on the whole more prolonged in 
those samples with polybrene. Finally the velocity of thrombin generation is prolonged 
significantly during the first, second and third trimesters, and at the time of delivery.  
These results demonstrate the concentration dependent effect of polybrene, exerting what 
appears to be more of a neutralising effect on plasma derived from subjects receiving treatment 
doses of enoxaparin. The ETP, peak height and velocity are the parameters that appear to be 
most sensitive to the polybrene effect. At the time of delivery, the effect of polybrene appears to 
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be less pronounced. This is likely to be related to the fact, that the concentration of enoxaparin in 
the plasma was likely to have been less than at other time points, hence the effect observed. 
Clearly the PB is exerting an effect on these samples and neutralising part of the enoxaparin 
present, but this effect is not complete.  
Before any firm conclusions can be drawn, further investigation of what the exact binding 
relationship is between polybrene and enoxaparin  is required, along with what influence albumin 
in the plasma might be having on this relationship, i.e. assessment of the hypothesis, that 
although polybrene neutralisation might be complete in-vitro, it is not complete in-vivo, due to the 
presence of albumin (and other plasma proteins).  
6.5.5 Discussion 
The results demonstrate that it is possible to neutralise to a certain degree, enoxaparin’s 
pharmacodynamic effect in the thrombin generation assay with polybrene. However, this effect is 
dependent on the concentration of LMWH at a given moment in time and the effect is not 
complete, with polybrene found to exert its own effect on the thrombin generation profiles tested. 
The results should not come as a surprise, given what has previously been reported by Carlo and 
colleagues [2009]. Over the years, many groups have compared and contrasted the effects of 
polybrene and protamine as heparin neutralising agents. Sie and colleagues [1989] evaluated the 
effectiveness of protamine sulphate and polybrene in neutralising dermatan sulphate and heparin 
in plasma and in saline. Protamine sulphate and polybrene were both found to neutralise heparin 
in-vitro in a predictable fashion, with polybrene found to be as potent as protamine sulphate in 
plasma and twice as potent as protamine sulphate in saline. When dermatan sulphate in saline 
was considered, both protamine sulphate and polybrene readily neutralised the dermatan 
sulphate, but in plasma both agents were approximately five times less active than when 
compared to saline, with the study authors suggesting that this observation may involve a non-
specific interaction with plasma proteins. 
Cumming and colleagues [1986] investigated the effects on the activated partial thromboplastin 
time (APTT) when heparin in plasma was neutralised with protamine or polybrene. Both 
polycations exhibited clot promoting activity at low concentrations and acted as anticoagulants in 
their own right at higher concentrations. At a plasma heparin concentration of 4 IU/mL, protamine 
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was the most effective neutraliser, while at a plasma heparin concentration of 10 IU/mL, 
polybrene was the most effective. 
Jacobsen and colleagues [2006] investigated the effect of polybrene on neutralising the effects of 
heparin in plasma from patients who were being tested for lupus anticoagulant. Lupus 
anticoagulant positive patients were given 5000 IU intravenous unfractionated heparin and their 
plasma was drawn just before and five minutes after the injection.  They found the lupus ratio to 
be slightly lower when polybrene was added to plasma without heparin. The patient’s lupus ratios 
returned to the lupus ratios before any additions of heparin and they conclude that the addition of 
polybrene at a final concentration of 7.9 µg/mL in test plasma can determine the presence of 
lupus anticoagulant, irrespective of the presence of unfractionated heparin at a concentration of 
0.0-1.3 IU/mL. 
The messages which emerge from these studies is that polybrene can neutralise the effect of 
heparin in plasma, but the effect is concentration dependent and it will not completely reverse the 
LMWH effects in-vivo. Therefore it is unsurprising that in this study, complete neutralisation was 
not seen.  
6.5.5.1 Effect observed with treatment and prophylactic doses 
It has been speculated that an INR of between 2-4 corresponds to ETP and peak inhibition by 20-
40% [Odegard et al., 1976]. The polybrene experiments gave an opportunity to assess this 
principle, in those women managed on treatment doses of enoxaparin during pregnancy. This 
analysis found that ETP and peak were significantly inhibited. This clearly demonstrates the 
effectiveness of treatment doses of enoxaparin and demonstrates the potential clinical utility of 
the thrombin generation assay in titrating drug therapy. As one might anticipate, the effect of 
enoxaparin on thrombin generation is dose related, with much lower inhibition observed for those 
women prescribed prophylactic doses of enoxaparin. This is important, as currently we do not 
know the level at which to inhibit the TG parameters, in order to get a prophylactic effect from 
LMWH. Establishing a prophylactic range would help and overcome a question commonly asked 
in clinical practice, about what the optimal level of thromboprophylaxis is, and perhaps help 
overcome prophylaxis failure seen in clinical practice. 
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6.5.5.2 Are there alternative neutralising agents that could be used? 
Accepting that polybrene does not completely neutralise the effect of LMWH in plasma, is there 
any other compound that might be 100% effective at achieving the desired effect in the thrombin 
generation assay? Protamine could be tried, but given the plethora of literature which suggests 
that it works in a similar way to polybrene and the fact that protamine exerts its own anticoagulant 
effect in excess, exploring protamine’s use in this setting is unlikely to be fruitful. Reagents that 





, whole blood coagulation is evaluated 
(www.rotem.de), and can then be compared by the use of HEPTEM®. In the HEPTEM assay 
(heparinase modified TEM), coagulation is triggered via the instrinsic pathway. During the assay, 
heparinase rapidly degrades heparin and allows for the assessment of haemostasis in 
heparinised patients. The results from HEPTEM are compared to INTEM. The heparinise present 
in the reagent is Heparinase I from falvobacteria (www.rotem.de). This system works well in this 
setting and could be explored as an option in the thrombin generation test setting, although 
whether the heparinises could break down enoxaparin further, because of its low molecular 
weight, and thus neutralise the enoxaparin effect is debatable. If pursued, the key will be 
establishing the concentration to use in the thrombin generation test, but certainly deserves 
further consideration. 
6.5.6 Summary and future work 
This chapter set out to explore the thrombin generation profiles of women injecting enoxaparin 
during their pregnancy. The results confirm that thrombin generation is already raised by the first 
trimester, with a further rise seen during the second trimester, after which thrombin generation 
stabilises through to delivery. By eight weeks post partum, baseline (non-pregnancy) thrombin 
generation levels will be reached. Future work should focus on comparing the thrombin 
generation profiles of women with pre-eclampsia, IUGR, at high risk of VTE and compare the 
changes in thrombin generation profiles, to a control group. This might help identify a further 
important clinical utility of the thrombin generation assay. 
As one might predict, the dose of enoxaparin strongly influenced the thrombin generation test, in 
a dose-dependent manner. Though polybrene did reverse the effects of enoxaparin to a certain 
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degree, it was not complete and was more apparent with higher plasma concentrations of 
enoxaparin, as assessed through anti-Xa activity. 
Given the strong correlations between the dose of enoxaparin and the effect observed on 
thrombin generation parameters, future work should focus on developing an appropriate means of 
reversing the LMWH anticoagulant effect from subject’s plasma. Given the inter-individual 
differences between the patients, this could help determine a reference range of % inhibition of 
ETP or peak that could be used to titrate drug therapy. The results in this sub-study also 
demonstrate a ethnicity specific pattern of thrombin generation changes over the course of 
pregnancy; this area certainly warrants further investigation, along with investigating other ethnic 
group responses. The obese pregnant population continues to present an ever present challenge, 
as clinicians try to balance the risk of VTE and bleeding concurrently. Specific studies assessing 
thrombin generation in the obese (with and without LMWH) would additionally be of value to 
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Chapter 7  
7.1 Women’s views on and adherence to enoxaparin 
The focus of chapter 7 is to explore women’s views onand adherence to enoxaparin during 
pregnancy and the puerperium. Following a discussion about medication adherence in general, 
adherence to medicines during pregnancy will be discussed, before describing how pregnant 
women’s views were explored during the course of this study. The results of this work are then 
presented, followed by a discussion of the relevance of the results, in the context of previously 
published work. 
7.1.1 Medication adherence 
7.1.1.1 Background 
Research suggests that up to 50% of patients with chronic conditions who are prescribed 
medications do not adhere to their medication as prescribed; this not only has a negative impact 
on the individual in question from a health point of view, but also on society, due to the waste of 
resources [Cutler and Everett, 2010]. 
Medication adherence can be defined as: 
The extent to which the patient’s behaviour matches agreed recommendations from the 
prescriber [Horne et al., 2005].  
The term adherence emphasises the need for agreement and that the patient is free to decide 
whether or not to adhere to the prescriber’s recommendation. Non-adherence can broadly be 
divided into two categories, intentional and unintentional non-adherence [Horne, 1993; Haynes et 
al., 2002a; Haynes et al., 2002b]. Unintentional non-adherence, is when the patient has every 
intention of adhering to their medication, but is unable to. Reasons for this include physical 
disability, inhibiting them from accessing the medicine, as well as forgetfulness, sensory disability 
(e.g. poor eyesight) or lack of understanding [Meichenbaum and Turk, 1987]. Intentional non-
adherence is when a patient makes a conscious decision not to follow treatment advice. It is 
intentional non-adherence which is the focus of this chapter. 
Medicine taking by patients is a complex behaviour. Research over the last twenty years has 
demonstrated that intentional non-adherence is influenced by the patient’s perception of their 
illness and treatment, in particular, the patient’s specific beliefs about the necessity of the 
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medicines prescribed and their perceived concerns about the potential adverse effects, which all 
influence their medication taking behaviour [Horne, 1997; Horne and Weinman, 1999]. 
Specifically, patients evaluate whether or not to take a medicine, based on whether the proposed 
treatment makes sense to them, in the context of their illness beliefs. Patient’s personal beliefs 
about, and experiences of, their illness will influence whether they follow treatment advice. 
Leventhal and colleagues [1992] conceptualised the common-sense model which suggests that 
patients form a map when challenged with ill-health before deciding on the most appropriate 
course of action, including whether to access healthcare and ultimately whether or not to take any 
prescribed treatment. This map is based on five key components of their condition [Leventhal et 
al., 1992]: 
1. Identity (what is it?) 
2. Timeline (how long will it last?) 
3. Cause (what caused it?) 
4. Consequences (how will it, has it affected me?) 
5. Cure/control (can it be cured or controlled?) 
Utilising this model, it is unsurprising that adherence rates are lower in patients who suffer with 
asymptomatic illness. In asymptomatic illness, e.g. hypertension, where no relief of symptoms is 
required, the intervention offered, e.g. beta-blocker therapy, may lead to negative symptoms and 
impact on the patient’s adherence. Research has shown that adherence in patients with the same 
illness or condition varies, and this demonstrates patient’s individual subjective response to ill-
health [Horne et al., 2005]. Furthermore external factors, such as friends, relatives and the media 
can all impact on how much an individual adheres to their prescribed treatment [Nunes et al., 
2009]. 
Horne and colleagues have further developed Leventhal’s model, focusing particularly on 
medications, by proposing the perceptions and practicalities model of adherence [Horne et al., 
2005] (figure 7.1). 
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Figure 7.1: The practicalities and perceptions model of adherence [Horne et al., 2005] 
The model incorporates both concepts of intentional and non-intentional adherence. 
7.1.1.2 Measures of adherence 
There are two methods in which adherence to medication can be assessed; directly and 
indirectly. Direct methods include collecting samples of blood, urine or other body fluids and 
testing them for the presence of the medicine. Indirect methods on the other hand, use measures 
such as self reports from patients, pill counts, prescription reordering, pharmacy refill records and 
a therapeutic effect to form the assessment of adherence [Nunes et al., 2009]. All measures of 
adherence have their own advantages and disadvantages. Direct measures provide objective 
evidence of drug in the system, but can be expensive to conduct and depending on the drug 
being tested, may not reliably be able to indicate continuous adherence. Pill counts and 
prescription reordering are crude measures of adherence, as the patient may not have actually 
taken the medicine, even though they have collected or ordered it from the pharmacy. Self-
reporting is the most convenient method for reporting adherence in a clinical context. Self-
reporting has the advantages of being simple, inexpensive, relatively quick and easily applied to a 
clinical setting. The advantage of self-reporting is that important information gathered about 
behavioural factors in medicines use and what is leading to non-adherence in an individual can be 
deciphered. The disadvantages are, that self-reporting is associated with over-estimation of 
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adherence, can be inaccurate due to recall bias and errors in self-observation, and the manner in 
which information is obtained from patients, particularly around how questions are asked, can 
affect the answers received [Nunes et al., 2009]. 
7.1.1.3 Medication usage during pregnancy 
Over the last thirty years, medication use amongst pregnant women has increased substantially. 
A retrospective American study of 152,531 pregnant women, spanning the period 1996-2000 
[Andrade et al., 2004], found that 82% (124,695), had a drug or medical product (vitamin or 
mineral) dispensed in the 270 days leading up to delivery. In 82,974 (54%) of these cases, it was 
a vitamin or mineral supplement that was dispensed, whilst in 98,182 (64%) cases, a drug other 
than a vitamin or mineral supplement was dispensed. A further study from America, which 
assessed medication use during pregnancy with a particular focus on prescription drugs, 
spanning the period 1976-2008, reported that the use of prescribed medication amongst the 
pregnant population had increased by more than 60% over this period, with 50% of pregnant 
women admitting to the use of a prescription only medicines during their pregnancy [Mitchell et 
al., 2011]. Similar increases in prescription and over the counter medication use has been 
reported in Europe, Australia and South Africa [Aviv et al., 1993; Refuuerzo et al., 2005; Engeland 
et al., 2008; Gagne et al., 2008; Broussard et al. 2010; Crespin et al., 2011;  Sawicki et al., 2011].  
7.1.1.4 Medication adherence during pregnancy 
Despite the widespread use of medication during pregnancy, only a small body of research has 
been published which has explored the issue of medication adherence during pregnancy. 
Teratogenic risk is a factor considered before women decide whether or not to take a medicine / 
vitamin / mineral. Research has shown that women often over-estimate this risk [Sanz et al., 
2001; Nordeng et al., 2010]. In the study conducted by Sanz and colleagues, the teratogenic risk 
of fourteen specific medicines were perceived to be higher by pregnant women than the actual 
risk. This perception could lead to abrupt withdrawal of medication, as has been observed in the 
field of psychiatry [Einarson et al., 2001; Bonari et al., 2005]; conversely, the gravid state can also 
lead to improved medication adherence; for example in the field of HIV. Studies report adherence 
to highly active anti-retroviral therapy during pregnancy to increase, seen as an attempt by 
mothers to prevent vertical transmission of infection to the fetus [Ickovics et al., 2002; Vaz et al., 
2007; Mellins et al., 2008]. Adherence to fertility drugs during in-vitro fertilisation treatment is also 
found to be complete, presumably because of a strong desire for a successful pregnancy 
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outcome [Smith and Williams 2010]. The most comprehensive antenatal adherence study 
published to date is an Australian study by Sawicki and colleagues [2011]. In this study, all 
pregnant women attending their 36 week antenatal clinic visit were asked to complete a 61 item 
questionnaire, which included assessment of adherence using the Morisky scale [Morisky et al., 
1986]. Eight hundred and nineteen patients, with a mean age of 30.8 years, mostly born in 
Australia, comprised the study population. Of these, 322 (39.3%) reported a chronic health 
condition during pregnancy, most commonly asthma (104; 12.7%), which required a medication. 
The commonly used medications by the study population are listed in table 7.1. Non-adherence 
was reported by 107 (59.1%) of subjects.  
Table 7.1: Medications prescribed in the cohort of women followed in Sawiciki’s study 
Medicine Number (%) 
Iron therapy 68  (8.3) 
Medicines for chronic airway conditions 64  (7.8) 
Vitamins and minerals 59  (7.2) 
Anti-diabetics 43  (5.2) 
Anti-Depressants 12  (1.5) 
Cardiovascular drugs 11  (1.3) 
Antithrombotics 10  (1.2) 
Thyroid therapy 10  (1.2) 
Corticosteroids for systemic use 6  (0.7) 
Anti-inflammatories and anti-rheumatics 6  (0.7) 
Analgesics 5  (0.6) 
Dermatologicals 3  (0.4) 
Other (e.g. antibiotics, antifungals) 21  (2.6) 
 
Clearly, the gravid state introduces a new level of complexity to the perceptions and practicalities 
model that Horne and colleagues have developed, as pregnant mothers have additional 
considerations on what impact any medication prescribed might have on their developing fetus 
and depending on the known risk, whether the medicine warrants consumption (figure 7.2).  
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Figure 7.2: Adapted practicalities and perceptions model of adherence for pregnancy  
7.1.1.5 Medication adherence study objectives 
An assessment of adherence was important during the course of this study, not only because 
pharmacokinetic interpretation requires a knowledge of whether the medicine was actually taken, 
but also because prophylaxis of VTE during pregnancy can be viewed as an analogous situation 
to an asymptomatic health condition, whereby patients are told they are at risk, and then 
prescribed medication, in this case, a parenteral medication, which significantly impacts on the 
rest of their pregnancy and for up to six weeks postpartum. It is easy to comprehend why a 
patient might therefore omit or miss doses, particularly if they have never experienced 
symptomatic VTE. Furthermore, the dosing of LMWH during pregnancy, as already discussed in 
this thesis, is controversial. Therefore, gaining an insight into the adherence behaviour of 
pregnant women prescribed LMWH, would support any recommendations made on the optimal 
dosing strategy for this population.  
Therefore, as part of this study, women’s views on and adherence to enoxaparin during 
pregnancy and the puerperium were explored. 
The specific objectives of this sub-study were: 
- Monitor and calculate adherence rates to enoxaparin during both the antenatal and 
postnatal periods 
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- Explore and understand women’s views of having to inject the enoxaparin during their 
pregnancy and the postnatal period and what impact this has on their adherence to the 
enoxaparin prescribed.  
7.2 Method 
7.2.1 Assessment of adherence 
Adherence in this study was assessed by means of self-report. As outlined in chapter 2, at each 
clinic visit, recruited women were given a diary (How to inject Clexane®, Sanofi-Aventis Ltd) and 
asked to record the time they injected each day. At the time of consenting the women, the 
pharmacokinetic nature of the study was explained and recruited women were advised that if, for 
whatever reason, they missed or omitted a dose or doses, they should record that in their diary. 
This diary was collected and replaced at each clinic visit. Concurrent laboratory (anti-Xa, and 
thrombin generation) monitoring was used to provide further objective information about whether 
adherence might be a problem.   
7.2.2 Assessing beliefs about medications 
Women’s beliefs about medication use in general and enoxaparin specifically, were explored 
using the beliefs about medication (BMQ) instrument [Horne et al., 1999]. This validated tool 
explores patient’s perceived harm and overuse of medication in general and the perceived 
necessity and concerns associated with a specific medicine prescribed. The other most 
commonly used instrument in the adherence field is the 4-item Morisky Scale, which was 
originally developed to assess adherence in relation to anti-hypertension medication [Morisky et 
al., 1986]. The research team decided to use the BMQ for the purposes of this study, as the 
instrument allowed more of a detailed exploration of the patient’s beliefs about medications 
relative to the Morisky scale.  
The BMQ consists of 18 items, 8 designed to measure overuse and harm of medicines in general 
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Table 7.2: BMQ general (overuse and harm) questions 
BMQ general questions Overuse or harm sub-
scale question 
Doctors use too many medicines Overuse 
People who take medicines should stop taking their treatment for a while every 
now and again 
Harm 
Most medicines are addictive Harm 
Natural remedies are safer than medicines Overuse 
Medicines do more harm than good Harm 
All medicines are poisons Harm 
Doctors place too much trust on medicines Overuse 
If doctors had more time with patients they would prescribe fewer medicines Overuse 
 
Table 7.3: BMQ specific (necessity and concerns) questions 
BMQ specific questions Necessity or 
concerns sub-scale 
question 
My health at present, depends on my medicines Necessity 
Having to take medicines worries me Concern 
My life would be impossible without my medicines Necessity 
Without my medicines I would be very ill Necessity 
I sometimes worry about the long-term effects of my medicines Concern 
My medicines are a mystery to me Concern 
My health in the future will depend on my medicines Necessity 
My medicines disrupt my life Concern 
I sometimes worry about becoming too dependent on my medicines Concern 
My medicines protect me from becoming worse Necessity 
 
Responses to the BMQ, are measured on a five point likert scale, ranging from strongly agree (5) 
to strongly disagree (1). Sub-scale scores for overuse and harm in general, and necessity and 
concerns specifically, are then computed to gauge subject’s beliefs about taking a particular 
prescribed medicine, as well as the broader context of their general beliefs about medication 
taking.  
When applied to a particular population or setting, the necessity and concerns questions are re-
worded to fit a particular medicine. For example, the question, Having to take medicines worries 
me, would be re-worded to, Having to take prednisolone worries me, in the case of an asthmatic 
patient prescribed prednisolone.  
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7.2.2.1 Adapting the BMQ for a pregnant population 
The BMQ has not previously been applied to a pregnant population, therefore, as part of this 
study; it was adapted to meet the study objectives. Specifically, the first part of the questionnaire, 
listing the general overuse and harm questions was modified to reflect the context of pregnancy 
(e.g. doctors use too many medicines was changed to doctors use too many medicines during 
pregnancy). Furthermore, a series of additional questions were added to provide further 
information about this specific context. Table 7.4 lists the additional questions used in section one 
of the adapted BMQ. 
Table 7.4: Additional questions added to the general section of the adapted BMQ  
Question 
Over-the-counter medicines from a chemist are safer than prescription medicines during pregnancy 
Before considering to take a medicine during pregnancy, I like to know about the safety of that medicine to 
me and my unborn baby 
Most medicines are safe when taken during pregnancy if prescribed by a doctor 
When deciding on whether to take a medicine whilst I am pregnant, I place a higher priority on the impact 
the medicine will have on the health of my unborn baby than to any effects the medicine may have on me 
 
The necessity and concerns questions from the BMQ were adapted for the context of enoxaparin 
generally (for example ‘my health at present depends on my medicines’ was altered to ‘my health 
at present depends on enoxaparin’), and then specifically in the context of pregnancy, to assess 
whether women’s responses changed when they focussed on the impact of being pregnant (see 
table 7.5). 
Table 7.5: Questions repeated within the specific section of the adapted BMQ in the context of 
pregnancy 
Specific BMQ questions repeated in the context of pregnancy 
My current pregnancy depends on enoxaparin 
Having to take enoxaparin during pregnancy worries me 
My current pregnancy would be impossible without enoxaparin 
Without taking enoxaparin during this pregnancy I would be very ill 
I sometimes worry about the long term effects of enoxaparin on my unborn baby 
Any pregnancies in the future will depend on me taking enoxaparin 
Enoxaparin is protecting my pregnancy 
 
As the BMQ had not been used in a obstetric setting before, it did not capture information relating 
to women’s views and concerns around child delivery, pain relief and breast-feeding issues and 
what role enoxaparin may have in protecting the unborn baby’s health. Therefore, a series of 
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additional questions were constructed, which explored these specific issues, which were identified 
by the research team that might be important for pregnant women, based on previous clinical 
experience. These are listed in table 7.6. 
Table 7.6: Additional exploratory questions added to the adapted BMQ 
Additional questions 
I sometimes worry that being on enoxaparin will limit the type of child birth delivery I can have 
Enoxaparin protects my unborn baby’s health 
The enoxaparin does not cause me any side-effects 
I sometimes worry that being on enoxaparin will limit the type of pain relief I can have at the time 
of child birth 
Having to take enoxaparin throughout pregnancy is not an issue for me, as long as it helps to 
protect mine and my unborn baby’s health 
Enoxaparin only works if taken regularly during pregnancy 
It is difficult for me to take my enoxaparin in exactly the way my doctor has told me 
I sometimes worry that being on enoxaparin during pregnancy will interfere with my ability to 
breastfeed when my baby is born 
Having to inject myself with enoxaparin daily is not an issue for me, as long as the health of my 
unborn baby is protected 
 
Finally, there was a space at the end of the questionnaire for the women to make any comments, 
should they wish. See appendix XI for final questionnaire used. 
7.2.2.2 Administration and completion of the questionnaire 
The questionnaire was given to the pregnant women at the time they consented into the study 
(during the antenatal period) and they were asked to return the completed questionnaire at one of 
their subsequent haematology clinic appointments. The timing of administering the questionnaire 
was very much driven by when women first attended the haematology clinic following referral. For 
the majority of women, this was following booking with the obstetric service and usually during the 
second trimester (typically gestational weeks 14-22). Women were advised that their responses 
would be kept confidential and would not be shared with the clinical team. 
7.2.3 Data Analysis 
Data from the questionnaire was coded, entered and analysed using IBM SPSS (version 18), 
Chicago, Illinois. Descriptive statistics were used to summarise the demographic (e.g. ethnicity) 
and clinical characteristics (e.g. indication for enoxaparin) of the cohort of women. 
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7.2.3.1 Calculation and classification of patients according to adherence 
Percentage adherence rates were calculated separately for both the antenatal and postnatal 
periods, following recruited women’s last clinic visit (eight weeks post-partum). Women were 
classed as adherent to enoxaparin for the antenatal and/or post-natal period, if they achieved an 
adherence rate > 80% [DiMatteo et al., 2004]. This was calculated for each individual woman, by 
dividing the total number of doses injected over the antenatal or postnatal period by the total 
number of doses prescribed over that respective time period. The number obtained was then 
multiplied by 100 to obtain a % adherence rate. The paired t-test was used to compare antenatal 
adherence rate with the postnatal adherence rate. 
In order to assess women’s beliefs about the enoxaparin prescribed, subscale scores for overuse, 
harm, necessity and concerns were calculated for the cohort of women as a whole. This involved, 
for example calculating a mean response for all the overuse questions from the tool. In this case, 
the subscale response from a particular woman could range from a minimum of 4 to a maximum 
of 20 (as there were four overuse questions). Therefore a score in the region of 4 indicates 
women’s lack of agreement with those questions and that she did not think doctors overuse 
medicines and a score in the region of 20 indicating that a woman did feel doctor’s overused 
medications. This was repeated for the other three subscales. 
Women’s adherence to enoxaparin in this study could be classified into two broad groups; women 
who were equally adherent to enoxaparin through both the antenatal and postnatal periods 
(optimal adherence group) and women who were adherent to enoxaparin through the antenatal 
period, but with a 5% or more decrease in adherence through the postnatal period (suboptimal 
adherence group). The BMQ subscales scores were additionally computed for these two groups 
separately and compared using the independent t-test.  
7.2.3.2 Necessity and concerns differential 
As first suggested by Clifford and colleagues [Clifford et al., 2006], the necessity-concerns 
differential was also computed for the cohort of women, and then separately calculated for the two 
groups (optimal and suboptimal groups) and compared. This necessity-concerns differential 
calculates the difference between the patient’s perceived necessity for treatment from their 
apparent concerns, and is strongly associated with a patient’s intention to adhere to treatment. 
Specifically, this was calculated by subtracting the average necessity subscale score from the 
average concern subscale score for each woman. A positive number indicates that the necessity 
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for treatment outweighs any concerns the patient may have, and vice versa, with a positive 
differential indicating a patient’s or group of patients’ intention to adhere to treatment. 
7.2.3.3 Relationships 
Section 2 of the questionnaire explored the relationship between the general necessity and 
concern questions of the BMQ and the respective pregnancy specific repeat question. Pearson’s 
correlation was utilised to assess whether each pair of questions was correlated and whether 
women agreed more with the pregnancy specific questions. 
7.2.3.4 Additional questions 
The additional questions added to the questionnaire were reported back as % agreement, with 
each statement. Voluntary comments made by women in the questionnaire were themed. These 
themed comments are listed in the results section.  
Statistical significance was considered at p<0.05. 
 
7.3 Results 
7.3.1 Demographic information and response rate 
In the wider population pharmacokinetic study, 123 patients contributed anti-Xa activities for 
pharmacokinetic modelling purposes. Of these subjects, four patients had two pregnancies during 
the study period and were therefore not re-administered the questionnaire during their second 
pregnancy. A further three patients who consented into the study and had anti-Xa activities 
measured, miscarried before the questionnaire was administered to them. Two patients did not 
speak English fluently and so were not asked to complete the questionnaire. Of the remaining 114 
patients administered the questionnaire, 8 did not return the questionnaire, response rate = 
92.98%. The mean age of the women who returned the questionnaire was 33.14 years (range 18-
46); Fifty-seven (53.77%) of the women were actively being treated for VTE or had suffered from 
thrombosis in the past. Thirty (28.3%) women had a history of recurrent miscarriage. Table 7.7 
summarises key information on the 106 women from the study who returned the questionnaire. 
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Table 7.7: Demographic details of the 106 women who returned the questionnaire 
Demographic Number (%) 
n=106 
Ethnicity 
     Caucasian 
     Black 
     Asian 





  7 (6.60) 
  9 (8.49) 
 
Indication      
     VTE prophylaxis 
     VTE treatment 
     Switched from long term warfarin* 
     Antiphospholipid syndrome 
     Other** 
 
 
 73 (68.9) 
   9 (8.5) 
   8 (7.5) 
   7 (6.6) 
   9 (8.5) 
Frequency of enoxaparin prescribed 
     Once a day 
     Twice a day 
     Once, followed by twice a day 
 
 88 (83.01) 
 16 (15.09) 
   2 (1.88) 
 
Prior experience of injecting LMWH during 
pregnancy 
     No 
     Yes 
 
 
 72 (67.92) 
 34 (32.07) 
Obstetric history (as a cohort) 
    Gravida 
    Parity 
    Miscarriages 






  19 
 
* The specific indications for the women switched from long term warfarin to enoxaparin during the index pregnancy were 
recurrent VTE (x2), symptomatic homozygous FVL (x1), Budd-Chiari (x3), paroxysmal nocturnal hamoglobinuria (x1), 
valvular atrial fibrillation (x1) 
** The specific indications for the women in this category include recurrent miscarriages in the absence of anti-
phospholipid syndrome (x5), stillbirth in previous pregnancy where post-mortem results indicated perivillous fibrin 
deposition, placental ageing and dysmaturity (x1), patent foramen ovale (x1),  history of IUGR and hypertension in 
previous pregnancies (x2) 
Adherence to enoxaparin 
A total of 21,914 antenatal doses of enoxaparin were prescribed for the 106 women (mean 211 
(range 18-455)), and 4,597 postnatal doses (mean 44 (range 0-114)). The cohort of women were 
found to be highly adherent (>80%) to the enoxaparin therapy; antenatally, mean percentage 
adherence 97.92%, postnatally mean percentage adherence 92.75%. Adherence to enoxaparin 
decreased in some women during the postnatal period (paired t-test, t=6.099, df=100, p=0.000). 
Women could be allocated into two broad categories with respect to their adherence to enoxparin, 
(i) women who were equally adherent to enoxaparin antenatally and postnatally with no significant 
change during the postpartum period (n=66, 64.7%) – optimal adherence group, (ii) women who 
were adherent to enoxaparin antenatally and postnatally, however, with at least a 5% drop in 
adherence during the postnatal phase (n=36, 35.3%) – suboptimal adherence group. These sub-
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groups will be referred to later on in the analysis. Four women had no further indication for 
enoxaparin postnatally and were not included in this component of the analysis. 
7.3.2 Necessity-concerns differential 
Cronbach’s alpha was calculated for the four established BMQ sub-scales, which revealed good 
internal consistency (Overuse=0.792, Harm=0.775, Necessity=0.800, Concerns=0.739). The 
mean scores from the four established BMQ subscales for the women questioned are shown in 
table 7.8. There was more agreement from the women regarding the specific necessity and 
concerns questions, compared to the general overuse or harm questions in the instrument, with 
an overall necessity-concerns differential of 2.13, indicating a strong intention to adhere to 
treatment in the cohort of women followed. 
Table 7.8: Mean BMQ sub-scales 
BMQ sub-scale Mean SD Min-Max 
Overuse 9.88 2.92 4 – 17 
Harm 8.06 2.62 4 – 16 
Necessity 14.07 3.82 5 – 25 
Concerns 11.94 3.69 5 – 20 
 
The mean BMQ subscale scores, when the women’s responses were subdivided by adherence 
rates as two groups are described in table 7.9: 
(i) Those who were equally adherent ante- and postnatal period (optimal adherence 
group) 
(ii) Those who were adherent antenatally, but had at least a >5% drop in adherence 
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Table 7.9: Differences in BMQ sub-scale scores between the optimal adherence and sub-optimal 
adherence groups 





































*independent t-test   **Group 1 – optimal adherence, Group 2 – sub-optimal adherence 
 
A significant difference was found between the necessity sub-scale mean scores, from those 
women in the optimal adherence group, compared to those women in the suboptimal adherence 
group (independent t-test, t=2.851, df=100, p=0.005). 
The mean necessity-concerns differential for the optimal and suboptimal adherence groups were 
3.26 and 0.60 respectively, (independent t-test, t=2.543, df=100, p=0.013), suggesting that the 
perceived need for enoxaparin was less in the latter group. 
Differences between different sub-groups? 
Differences in adherence rates were explored between Caucasian and the African-Caribbean 
population, between those women injecting enoxaparin once a day versus those women injecting 
twice a day and between those women with a  history of recurrent miscarriage versus those who 
did not. This analysis (independent t-test), revealed no significant different differences in the 
adherence rates between these sub-groups.  
Sub-scale scores (harm, overuse, necessity and concerns) were also compared between these 
sub-groups, the results of which are presented in tables 7.10, 7.11 and 7.12. 
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Table 7.10: Differences in subscale scores between the Caucasian and African-Caribbean 
population 
Subscale and ethnicity Mean SD Significant* 
Overuse       Caucasian 






Harm            Caucasian 






Necessity     Caucasian 






Concerns     Caucasian 







Even though significant differences exist between the Caucasian and African-Caribbean women’s 
beliefs about medicines in general (overuse and harm) and specifically about the enoxaparin 
(concerns), this did not translate into a difference in their adherence. 
Table 7:11: Differences in subscale scores between those women injecting once versus those 
women injecting enoxaparin twice a day 
Subscale and frequency Mean SD Significant* 
Overuse        Once a day 






Harm             Once a day 







Necessity      Once a day 






Concerns      Once a day 







No differences in sub-scale scores were found between those women injecting once versus those 
women injecting twice a day. 
Table 7.12: Differences in subscale scores between those women with a history of recurrent 
miscarriage compared to those women who had no history of recurrent miscarriage 
Subscale and miscarriages Mean SD Significant* 
Overuse         History 






Harm              History 






Necessity       History 






Concerns       History 
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Significant differences in the overuse, harm, and necessity subscale scores could be found 
between those women with no history, compared to those women with a history of recurrent 
miscarriage. Interestingly, those women with a history of recurrent miscarriage, one might expect 
to have a higher necessity subscale scores compared to those that did not, but the results did not 
reflect this. 
7.3.3 Necessity and concerns about enoxaparin  
In the adapted questionnaire, we asked the original BMQ questions from the necessity and 
concerns section of the questionnaire, and repeated seven of these questions in the context of 
pregnancy specifically to assess if the gravid state altered the women’s responses to the 
question. Table 7.13 lists the mean responses to these questions, along with the correlation 
relationship between each pair of questions.  
The majority of pairs of questions were well correlated. Two pairs, however, were not well 
correlated; the question exploring future health and future pregnancies and the question exploring 
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Table 7.13: Correlations between the necessity and concerns question pairs 
Necessity question pairs Mean SD r* 
My health at present depends on enoxaparin        






My life would be impossible without enoxaparin 






Without enoxaparin I would be very ill 






My health in the future depends on enoxaparin 






Enoxaparin protects me from becoming worse 






Concerns question pairs Mean SD r* 
Having to take enoxaparin worries me 






I sometimes worry about the long term effects of enoxaparin 







It was interesting to observe that when the questions are asked in the context of pregnancy, the 
women’s responses do change. The women agreed more with all the necessity and concerns 
questions, when asked specifically in the context of the gravid state. This suggests that the 
women have stronger necessity and concerns during pregnancy than outside of pregnancy. 
7.3.4 Additional questions 
In addition to the adapted BMQ questions, additional questions were asked in the questionnaire 
which were felt might be important factors for women prescribed antenatal enoxaparin. Table 7.14 
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Table 7.14: % agreement with the additional questions added to the adapted BMQ 
Question % agreement with 
statement 
General questions about medication use during pregnancy  
Before considering to take a medicine during pregnancy, I like to know about the 
safety of that medicine to me and my unborn baby 
97.2 
When deciding on whether to take a medicine whilst I am pregnant, I place a higher 
priority on the impact the medicine will have on the health of my unborn baby than to 
any effects the medicine may have on me 
84.8 
Most medicines are safe when taken during pregnancy if prescribed by a doctor 66.0 
OTC medicines from a chemist are safer than prescription only medicines during 
pregnancy 
2.9 
Specific questions about enoxaparin use during pregnancy 
Having to take enoxaparin throughout pregnancy is not an issue for me, as long as it 
helps to protect mine and my unborn baby’s health 
90.4 
Having to inject myself with enoxaparin daily is not an issue for me, as long as the 
health of my unborn baby is protected 
87.8 
Enoxaparin only works if taken regularly 66.1 
The enoxaparin does not cause me any side-effects 65.7 
Enoxaparin protects my unborn baby’s health 38.1 
I sometimes worry that being on enoxaparin will limit the type of child birth delivery I 
can have 
34.6 
I sometimes worry that being on enoxaparin will limit the type of pain relief I can have 
at the time of child birth 
31.5 
It is difficult for me to take my enoxaparin in exactly the way my doctor has told me 20.7 
I sometimes worry that being on enoxaparin during pregnancy will interfere with my 
ability to breastfeed when my baby is born 
14.3 
 
The results from the additional questions demonstrate how protective mothers are of their unborn 
child. The results also suggest that up to one third of women may have anxiety about what impact 
the enoxaparin may have on the type of pain relief and method of delivery they could have. 
Despite the fact that one-fifth of women agreed with the statement that it was difficult for them to 
take their enoxaparin in exactly the way the doctor had told them, the fact that they persisted, 
demonstrates the strong necessity beliefs the women had during pregnancy. 
7.3.5 Voluntary comments made by women 
Of the 106 women who completed the questionnaire, 33 women (31.13%) made a comment at 
the end of the questionnaire. Some of the comments were unrelated to the context of this study (8 
women). The remaining relevant comments were themed into three broad categories: 
 - 261 - 
(i) Necessity for injecting enoxaparin during pregnancy in order to protect them and/or 
their unborn baby’s health (14 women) 
(ii) Concerns or perceived harm associated with injecting enoxaparin (7 women) 
(iii) Suggestions for the future (4 women) 
Example comments from each theme are listed under each theme below. 
(i) Necessity for enoxaparin 
The following comments illustrate that although injecting enoxaparin is not a pleasant experience 
for women, their perceived necessity for it, particularly during pregnancy, overrides any concerns 
or pain associated with injecting enoxaparin. 
“I'm happy to take enoxaparin during pregnancy as a preventative measure. I don't like doing the 
injections but it’s manageable, and with my history it’s something I'm prepared to do to ensure a 
safe arrival of my baby.” (– Patient 3) 
“I am very thankful for enoxaparin and grateful it is available. It is not problem for me to take if it 
means I get my babies with me after so many lost babies.” (– Patient 15) 
 
“I'm happy the blood clots were detected in both my lungs. If I never went for that scan during my 
stay in hospital, i'd be very sick, possibly close to death, because these blood clots can kill if left 
untreated, they keep growing bigger and bigger until that’s it. Mine was found in both my lungs, 
one of the nurses said I was lucky to be alive. So taking my Clexane don't really worry me as long 
as it helps to keep the blood clot under control.” (– Patient 44) 
“As far as I am aware, enoxaparin is to ensure I remain well during pregnancy and do not have a 
DVT. Therefore it is paramount that my health is taken care of and reviewed. I feel more secure 
and less worried about my health now I am on this medication. I find the injections uncomfortable 
but a small price to ensure I have a healthy pregnancy.” (– Patient 56) 
“I don't have an issue with taking medication during pregnancy, if the unborn baby's health is not 
compromised. I believe I am on enoxaparin to prevent blood clots from forming (not that they 
definitely would appear, but to reduce the risk of them appearing).” (– Patient 73) 
“Definitely gives me piece of mind during pregnancy; without it I would feel very nervous about 
developing another DVT.”  (– Patient 76) 
 
“I took enoxaparin throughout my first baby's pregnancy. My son is now 2.5 years and he does 
appear to be normal.”  (- Patient 90) 
“Without enoxaparin I could be very ill (as never suffered a clot).” (– Patient 92) 
“I really do not like taking enoxaparin every night both because of physical discomfort, bruising 
and inconvenience. However, if it really is protecting mine and the unborn baby's health then I am 
willing to keep doing it.” (– Patient 93) 
“I do not mind taking enoxaparin because I know it will reduce my risk of developing a dvt. The 
injections sometimes sting and leave a bruise. I use the top of my leg as injection site because I 
do not like the idea of injecting into my stomach whilst pregnant (this is beacuse I only started 
injecting at 34 weeks when my stomach is very tight). I am glad that my risk of DVT was identified 
and treatment started.” (– Patient 120) 
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“My views may change as my pregnancy continues and I am still injecting everyday. Currently, I 
am delighted to be taking heparin, since this may protect me from miscarriage.” (- Patient 123) 
(ii) Concern or perceived harm  
The following comments were made by women who had specific concerns about the enoxaparin. 
The common theme which runs through these comments, is the unpleasant / painful nature of the 
enoxaparin. 
“It isn’t pleasant to inject. During my first pregnancy it was a bit traumatic the first time I injected, 
especially as it is quiet a painful injection. However, with practice and confidence it was no 
problem. I am happy to inject during pregnancy, but would not like to do this life-long.” (– Patient 16) 
 
“Be glad when its over.” (– Patient 30) 
“Since the month after taking enoxaparin I'm feeling like I’m having difficulties to breath.” (– Patient 
38) 
“I have no issues injecting if it safeguarding mine and the babies health but I lack some faith in the 
safety/side-effects/general effects of the medicine. Published information on Clexane seems to be 
contradictory.” (– Patient 42) 
“I sometimes worry that in the future they find that enoxaparin has a big side-effect for my baby, 
for example harmful for the heart or skin.” (– Patient 50) 
 
“Taking enoxaparin worries me ...because it’s painful.” (– Patient 89)   
  
“The problem I have is that I get severe pain for 30 minutes after the jab, and need to lie down. 
Early on, I decided I would cope better at night. My husband has to administer the injection as I 
am terrified of needles. I wish there was another way, other than injection of taking this drug! As I 
am having an elective c-section, I worry that my blood may cause problems during the operation 
and that if I stop the Clexane before the C-section, this will cause a problem for our baby. I have 
suffered with severe bruising around every needle mark, this also causes me concern.” (- Patient 
113)                                                     
 
(iii) Suggestions 
Four women made specific suggestions about the enoxaparin. The common theme which runs 
through these suggestion comments is to make it easier or more palatable to take the enoxaparin, 
with two women specifically asking for a tablet form of enoxaparin.  
“I do not have a problem doing injections and was aware of the possibility of the injections before 
becoming pregnant. However, I think other women might benefit from more time and support 
around the use of Clexane in their pregnancy.” (- Patient 28) 
“If there was a way to get injections for enoxaparin via an epi-pen type device it would be much 
more tolerable!” (– Patient 64) 
“If and when available in tablet/capsule form - it will be much easier to take.” (– Patient 108) 
“Since the introduction of enoxaparin many women in the UK have been able to have normal, 
healthy pregnancies which is a huge reassurance for me. The only down fall is that it only comes 
in injection form - it would be better if they had tablet form as well, as some women although 
being trained to do injections may not still feel comfortable doing so.” (- Patient 111) 
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7.4 Discussion 
This sub-study explored pregnant women’s views and adherence to LMWH therapy during 
pregnancy and the puerperium. We found women to be highly adherent to the enoxaparin therapy 
during both the antenatal (97.92%) and postnatal (92.75%) periods, although in a third of women, 
adherence decreased significantly postnatally. 
The high adherence rate observed in this study is perhaps not surprising. Colwell and colleagues
 
[2005], in the context of extended thromboprophylaxis with LMWH in orthopaedic surgery found 
that when properly instructed, patients can safely and efficiently self-administer the LMWH at 
home. This finding was also replicated by Watts and colleagues, who followed a small number of 
patients who had recently undergone lower limb arthroplasty and were prescribed LMWH for six 
weeks post surgery. They found that of the patients who could potentially self-inject at home, 85% 
were compliant to their prophylactic therapy [2006], and this has been further endorsed by the 
results of the recently published ETHOS registry [Bergqvist et al., 2012]. The aforementioned 
studies also primarily relied on self-reported adherence, by means of a patient diary. McLintock 
and colleagues are one of the few authors to explore the relationship between adherence to 
prescribed LMWH treatment and outcomes [2009]. In their study of high risk pregnant women with 
mechanical prosthetic heart valves in-situ, of the women found to suffer from thrombotic 
complications whilst prescribed enoxaparin treatment, non-compliance and sub-therapeutic anti-
Xa levels were implicated in each case, with the authors concluding that good compliance with 
treatment was associated with a low risk of valve thrombosis and good fetal outcomes.  
Others however have reported problems with self-administration of LMWH. Mengiardi and 
colleagues [2011] followed 213 non-pregnant patients injecting LMWH in the community and 
found a self-reported non-compliance rate of 17.1%, with 38.9% of patients stating that self-
administration of the injections required some effort. A similar finding was also reported by Spahn
 
[2002], who followed 207 patients following knee arthroscopy. Spahn reported problems with self-
injection in 34.8% initially and 6.3% the whole time.  
In this study, although some women reported some negative experiences about having to inject 
the enoxaparin, the majority appear to cope with self-administration. 
This study had higher adherence rates compared to the aforementioned studies, with apparently 
fewer problems. This may be in part due to the stronger beliefs about necessity over concerns 
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that the women had regarding the enoxaparin, as demonstrated by the necessity-concerns 
differential of the group of women overall. Another key reason for the high adherence rate may be 
in part due to the regular monthly follow-up these women had in the haematology clinic. This 
follow-up provided an opportunity to discuss and check for any problems, and when necessary to 
reinforce the importance of the LMWH therapy during the antenatal period; an opportunity which 
was lost to a certain degree during the postnatal period. 
It was interesting to observe that although adherence was relatively high during the antenatal 
period and for two-thirds of women maintained during the postnatal period, there was a group of 
women, where postnatal adherence dropped by >5%. On closer examination of the necessity-
concerns differential between these two groups, there was a clear difference between the groups, 
with the antenatal differential appearing to be able to predict postnatal adherence. The theme 
which emerges from this result is the protective behaviour of women toward their unborn baby. 
Once women are satisfied that a potential medicine is not doing any harm to their baby, they will 
inject it, if perceived by them to be necessary. In this study, 96.8% of women wanted to know to 
what extent any medicine they took could affect their unborn baby as well as them, with many 
(78.5%) placing a higher priority on the impact the medicine has on the unborn baby, compared to 
any impact the medicine may have on them; 91.4% of women in the study stated that having to 
inject enoxaparin was not an issue for them, as long as their own and their unborn baby’s health 
was protected. When this question was repeated, just enquiring about their unborn baby’s health, 
88.4% of women stated that having to inject enoxaparin was not an issue for them, as long as 
their unborn baby’s health was protected. This suggests a particular motivation for injecting the 
enoxaparin during the antenatal period was to protect the health of the unborn baby. It should 
therefore come as no surprise that for some women, once their baby is born, they were more 
likely to miss doses of enoxaparin.  
In many ways, the women’s belief is not completely wrong, because of the close physical 
relationship between a mother and child during the gravid period, however if this belief continues 
during the postnatal period, then the women’s perceived necessity for enoxaparin may decline 
and explains in part the reason why postnatally, there was a group of women (suboptimal 
adherence group), in whom adherence to enoxaparin dropped by >5% from their respective 
antenatal adherence rate. The necessity-concerns differential was significantly different between 
these two groups. This is further illustrated by the following comment:  
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“After delivery it was a lot more difficult to inject myself than during pregnancy, therefore I was 
more inclined to miss a dose.” (– Patient 10) 
 
The drop in adherence in some women during the puerperium have been observed in other 
clinical specialities, e.g. in the field of HIV [Ickovics et al., 2002; Vaz et al., 2007; Mellins et al., 
2008].
 
When asked informally in clinic by the principal researcher on why they might have missed doses 
postnatally, two reasons were most commonly cited; firstly, the challenges of motherhood 
following birth meant that often they simply forgot because their regular routine had been 
disrupted (unintentional non-adherence). Others reported that following birth, their perceived 
necessity for the enoxaparin was less (intentional non-adherence); as their baby had been born 
successfully, they were less worried if they missed a dose.  In their study of medication use in 
general amongst pregnant women, Sawicki and colleagues [2011] reported the two most 
commonly cited reasons for women non-adhering during pregnancy was forgetting to take and 
stopping medicine when they were feeling better. Though in Sawicki’s study, the reasons cited 
are by pregnant patients, clearly they resonate for our study population, as both unintentional and 
intentional non-adherence behaviours are exhibited by the women.  
The implication of incomplete adherence is not known. Small deviations in adherence may have 
little impact on the overall outcome, as has been observed during this study, where none of the 
women went on to suffer a thrombotic event. No reports in the literature exist which 
comprehensively define the point below which the desired preventative or desired therapeutic 
result is unlikely to be achieved, and this makes it difficult to know when non-adherence becomes 
clinically significant, and therefore which patients might benefit from more intensive adherence 
support. In the context of this study and the cohort of women followed, one has to aim for high 
adherence, as although resistance to therapy will not develop, as observed with antibiotic therapy 
in an infectious diseases setting, in this clinical context, one has to assume that the risk of 
developing a pathological thrombosis or miscarrying increases in the absence of treatment. Of the 
21,914 antenatal and 4,597 postnatal doses prescribed for the 106 women during the sub-study, 
456 (2.08%) were missed during the antenatal period and 333 (7.24%) were missed during the 
postnatal period. As the postnatal period was significantly shorter in terms of time, the number of 
missed doses per time was significantly more during the postnatal period, and whilst part of this 
non-adherence is linked to practical reasons of motherhood, it appears a significant reason for 
this in women whose adherence does fall during the postanatal period, is due to the women’s 
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perceived necessity for enoxaparin being less at this time point, due to baby being born 
successfully. 
 
These findings do have important practice implications. In the current Royal College of 
Obstetricians and Gynaecology guidelines for VTE prevention during pregnancy and the 
puerperium
 
[Royal College of Obstetricians and Gynaecologists, 2009], the threshold for initiating 
prophylaxis is lower during the puerperium than antenatally. This means that women not eligible 
for enoxaparin therapy antenatally become eligible postnatally, e.g. women having had a 
caesarean section (one week prophylaxis), or women who are asymptomatic heterozygous 
carriers of Factor V Leiden, will be prescribed LMWH (6 weeks prophylaxis). The observations 
from this study suggest that a key reason women adhere to enoxaparin is that they feel it protects 
their unborn baby’s health, it might not be too inconceivable that women prescribed prophylaxis 
cold, i.e. just during the post-natal period might not adhere to their treatment fully. Healthcare 
professionals, particularly those in contact with women during the early days following birth, 
requiring LMWH, should ensure patients have an opportunity to discuss prophylactic LMWH fully 
and are instructed on how to self-inject competently for those newly starting LMWH therapy and 
reinforce the necessity of adherence to LMWH therapy for those who had already been injecting 
antenatally, so that women gain maximal benefit postnatally. Future studies assessing adherence, 
should particularly focus on the post-partum population, as that is the time when adherence could 
be a particular problem for some women. 
7.4.1 Additional questions asked in the questionnaire 
The additional questions asked in the questionnaire were questions thought to be important 
factors to women injecting LMWH therapy during pregnancy and the puerperium. Some key 
issues which came out from this section included, one third of women agreeing with the statement 
which said that they sometimes worried that being on enoxaparin will limit the type of child birth 
delivery they could have, with a similar number worried that being on enoxaparin will limit the type 
of pain relief they could have at the time of child birth. 
Most of the women recruited in this study were asked to complete the questionnaire within a 
month or two of starting LMWH therapy. In the clinic setting of this study, discussions about child 
birth and options for pain relief are bought to the forefront during the third trimester. The findings 
from this study suggest that briefly discussing child birth and pain relief issues with women on 
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antenatal LMWH early on in their pregnancy might overcome any anxiety that some women may 
have, particularly as they can be managed. 
7.4.2 Limitations 
This sub-study is limited by the fact that the questionnaire was only administered once during the 
women’s pregnancy. Following the result that postnatal adherence may fall in some women, it 
would have been interesting to assess how women’s views may have changed as pregnancy 
progresses and following delivery; this should form the basis of future studies. It must be borne in 
mind, that this study was part of a wider pharmacokinetic modelling study of enoxaparin during 
the antenatal period. Therefore, the antenatal adherence rates reported might represent an over-
estimate of the true adherence rate in the real world, due to the fact that women knew enoxaparin 
(anti-Xa activity) was being monitored. Clinical experience from the study clinic setting suggests 
that women requiring LMWH in this setting are often highly motivated, as they wish for a 
successful obstetric outcome. Due to the pharmacokinetic nature of the wider study, women 
clearly non-adherent to enoxaparin had to be excluded. During the course of this study, this was 
found to be the case in 3 patients and so the questionnaire was not administered to them. It would 
have been interesting to see what their responses would have been to the questionnaire and 
assess where differences were, compared to the adherent cohort of women. Finally, though it was 
emphasised to the women participating that their responses would remain confidential and not 
shared with the clinical team, it is impossible to exclude the fact that some women may have 
responded with socially acceptable responses. 
7.4.3 Implications for practice and future work 
We found women to be highly adherent to LMWH during the antenatal and postnatal period, 
though in some women, adherence does drop postnatally. This drop in adherence is related to the 
women’s perceived individual necessity for the enoxaparin and how much they believed it 
protected their unborn baby’s health. Women indicated a strong desire to know about what 
potential effect a medication may have on them and their unborn child, with the results suggesting 
that women would take a medicine during the antenatal period, even if it caused them pain and 
discomfort, if they felt it was protecting the health of their unborn baby. In the cohort of women 
followed, their perceived necessity for enoxaparin therapy appeared to outweigh any concerns 
they had antenatally. It is important for healthcare professionals to understand patients beliefs 
and experiences about LMWH and reinforce the necessity of adherence to LMWH particularly 
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during the post-partum period when for some women, the risk of an adverse event is greater. 
Future work should explore if there are differences in women’s responses to the questions at 
different pregnancy and post delivery time points. It would also be interesting to assess the 
responses of women who are clearly non-adherent, to see if they respond as a group to certain 
questions in different ways. Furthermore, it would be interesting to explore how those women 
prescribed enoxaparin, just during the post-natal period adhere to thrombophylaxis prescribed, 
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Chapter 8  
8.1 Implications for clinical practice 
The research programme contained within this thesis raises and addresses the key issues of 
dosing enoxaparin (and other LMWH) for the management of antenatal VTE. This final chapter 
aims to frame the major findings from this thesis, within a clinical context, in order to optimise the 
use of enoxaparin (and other LMWH) for the management of antenatal VTE.  
8.1.1 Recommendations 
8.1.1.1 Once versus twice a day for the management of antenatal VTE? 
The primary aim of the research conducted in this thesis was to determine how the 
pharmacokinetics of enoxaparin is altered during the antenatal period, in order to determine the 
optimal dosing strategy for enoxaparin for the management of antenatal VTE. The key question 
being addressed was whether enoxaparin needed to be administered twice a day for this 
population, as currently recommended by national and international guidelines, or whether a once 
daily dose was more appropriate.  
The results from the population pharmacokinetic modelling aspects of the study clearly confirms 
that although enoxaparin CL increases during pregnancy, the current recommendation of 
increasing the dose/dosing frequency, adopted by key guidelines is not appropriate. This is 
because Vd also needs to be considered. The Vd increase during pregnancy, impacts on (and 
prolongs) the half-life of enoxaparin significantly with the progression of pregnancy. The clinical 
implications of this are that a once a day LMWH regimen for the treatment of VTE during 
pregnancy is appropriate for the majority of women and a different dosing regimen for enoxaparin 
is not required during the antenatal period.  
This recommendation is made with some confidence; this is because this is the largest 
pharmacokinetic study that has been undertaken with a LMWH, specifically designed to address 
this issue in an antenatal population. The studies which were published during the 1990’s, which 
form the basis of current practice recommendations used relatively low patient numbers and did 
not consider LMWH Vd. Once the Vd of enoxaparin is considered, the situation and subsequent 
recommendations change. Furthermore, this study is not the first to report the phenomenon of 
residual anti-Xa activity with the progression of pregnancy (which forms the basis of the once 
daily recommendation); others have also found this to be the case [Lebaudy et al., 2008]. In their 
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study, Lebaudy and colleagues report an increase in residual anti-Xa activity with the progression 
of pregnancy. Earlier studies assessing the PK of LMWH during the antenatal period, also 
demonstrated an increase in Vd, but because the respective groups were not formally assessing 
Vd and were more focussed on the LMWH CL, it appears not to have been considered [Sturridge 
et al., 1994; Hunt et al., 1997; Blomback et al., 1998; Casele et al., 1999].  
What specific changes should be made to current guidelines? 
The current RCOG guidelines state that for both dalteparin and enoxaparin, a twice daily dose of 
these agents should be used for the management of antenatal VTE. Interestingly, the third LMWH 
commonly used in the UK, tinzaparin, is only prescribed as a once a day LMWH outside of 
pregnancy and thus is already listed in the RCOG guidelines as a LMWH agent that can be used 
once daily for the antenatal population for the management of VTE, based on work by Smith and 
colleagues [Smith et al., 2004].  
The current RCOG guidelines should therefore be updated so that both dalteparin and enoxaparin 
should have once daily doses recommended for the management of VTE. Specifically, for 
enoxaparin, the simulation work was based on a dose banding strategy as described in table 8.1. 
Table 8.1: Weight banding used for the enoxaparin simulation work in this study  









The advantage of adopting a dose banding schedule as outlined in table 8.1 for enoxaparin is that 
it covers a wider weight range compared to the current RCOG guidelines, with respect to the 
upper end of the weight spectrum; an issue which will need to be considered more with the 
growing obese pregnant population in the UK [Modder and Fitzsimons, 2010]. Furthermore, like 
the current RCOG guidelines, dose-banding allows for body-weight increases during the course of 
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pregnancy, largely removing the issue of whether the dose of LMWH needs to be increased with 
the progression of pregnancy. Finally the dose-banding suggestions made in table 8.1 are 
practical, in that the manufacturers of enoxaparin produce pre-filled syringes in the doses 
suggested, thus making it possible for women to inject enoxaparin at home safely, without having 
to worry about drawing up a particular volume of the drug.  
If obsterticans / haematologists caring for this population retain concerns about using a once daily 
LMWH regimen from the start, then a dosing strategy which gives twice a day LMWH for the first 
2 weeks (or until the woman is stable), followed by a once daily regimen would seem reasonable. 
With respect to monitoring the LMWH, the results from this thesis suggest that most women 
would be expected to reach recommended 3 hour target anti-Xa levels on the once daily regimen, 
so that anti-Xa monitoring would not be necessary for the majority. However, the simulation work 
from this study revealed a proportion of women who will not have residual anti-Xa activity before 
the next dose is due. The clinical implication of not having a measurable anti-Xa activity is not 
known and is unlikely ever to be known, however, given the premise of the recommendations 
made in this thesis is that having a measurable anti-Xa activity allows once daily dosing of 
enoxaparin, it is therefore proposed, that the recommended monitoring of anti-Xa activity is 
changed during pregnancy, from the 3 hour anti-Xa activity measure (as recommended by 
RCOG) to trough anti-Xa activity for the management of VTE, in patients who clinicians feel need 
close monitoring, e.g. obese patients. This will ensure that any woman requiring a specific dose 
adjustment (following confirmation of adherence to LMWH) has a dose increase instigated on the 
basis of a meaningful anti-Xa activity, in this case trough activity, not peak. Monitoring of peak 
anti-Xa activity does seem inappropriate during the antenatal period; peak anti-Xa activity will 
inevitably drop with an increase in the Vd over the course of pregnancy and is not related soley to 
an increase in CL.  
The other key guidelines in the antenatal VTE field, is the ACCP guidelines, which state [Bates et 
al., 2012]: 
“If LMWH is used for the treatment of acute VTE in pregnancy, a weight-adjusted dosing regimen 
should be used. LMWH requirements may alter as pregnancy progresses because the Vd of 
LMWH changes and GFR increases in the second trimester. The latter has led some to 
recommend a bid LMWH dosing schedule. However, many clinicians use a once-daily regimen to 
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simplify administration and enhance compliance. Observational studies have not demonstrated 
any increase in the risk of recurrence with the once-daily regimen over the bid (bis in die – twice 
daily) regimen.” 
The current ACCP guidelines already appear to lean towards a once daily dosing strategy.  
To summarise, the results from this thesis suggest that it is appropriate to use a once daily dose 
of enoxaparin for the management of VTE, and the following recommendations / amendments are 
suggested to the current RCOG / ACCP guidelines: 
1. Table 1 in the RCOG VTE treatment guidelines should be revised so that enoxaparin 
(and dalteparin) once daily doses are recommended as an initial dosing strategy. The 
ACCP guidelines should just recommend a once daily dose for this indication. A caveat 
should be added to this recommendation that during the first two weeks of therapy (or 
until the woman is stabilised), clinicians may consider giving twice a day LMWH. 
2. The 3 hour anti-Xa monitoring which is listed as an option in the RCOG guidelines and 4 
hour monitoring in the ACCP guidelines, should be revised to suggest that trough anti-Xa 
activity is recommended in women where clinicians suspect a poor response to LMWH, 
with subsequent dose increase in those women with no anti-Xa activity registered at this 
time point. In the majority of women, such monitoring will not be required and clinicians 
should be mindful of adherence to enoxaparin when anti-Xa activity are drawn and 
interpreted. 
The implementation of the recommendations in this thesis might provide a significant challenge. 
Historically in medicine, even when land-mark clinical trials are published, there is often a lag time 
before wide-spread uptake and a change in clinical practice. For example, even though clinical 
studies from the 1980’s had demonstrated the benefits of aspirin and beta-blocker therapy in 
improving survival in patients with an acute ST-elevation myocardial infarction, the uptake of 
these interventions was slow [Davis et al., 1995; Pashos et al., 1994]. A significant change in 
clinical practice, particularly historical practice, can be complex, as it involves behaviour change 
[Jackevicius et al., 2001]. For a number of years, the twice daily regimen of LMWH has been 
recommended and used for the management of antenatal VTE, and although studies published in 
the past 5 years have demonstrated that up to 50% of patients are managed with a once daily 
LMWH regimen for antenatal VTE, for the full uptake of the recommendations in this thesis, will 
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require key opinions leaders in the UK and further afield to endorse the findings. This will require 
publishing and presenting the findings in key journals and at conferences and when appropriate, 
debating the findings, so that a new consensus can be reached and the situation can be moved 
forward for the benefit of women. 
8.1.1.2 Prophylactic dosing of LMWH 
As for the management of VTE, the study results in this thesis imply that a once daily regimen 
should be appropriate for the majority of prophylactic LMWH indications as well. The current 
RCOG guidelines suggest a once daily dose of enoxaparin (and other LMWH) for prophylactic 
indications, however they do stipulate that a possible twice daily dose of LMWH could be used in 
those patients who are obese (>90kg) (table 8.2). 
Table 8.2: Current RCOG prophylactic dosing recommendations for enoxaparin 
Weight (kg) Enoxaparin 
<50 20mg daily 
50-90 40mg daily 
91-130 60mg daily* 
131-170 80mg daily* 
>170 0.6mg/kg/day* 
High prophylactic (intermediate) dose 40mg 12-hourly 
*may be given in two divided doses 
There is no reason to believe that the obese population require a more frequent dose of 
enoxaparin (and other LMWH). During the course of the study in this thesis, a small number of 
obese women specifically requested to be managed with a once daily prophylactic dose (e.g. 
80mg once daily, as opposed to 40mg twice a day) and did not suffer any adverse effects. The 
findings from the adherence aspect of the study (chapter 7), suggest that some women find it 
difficult to perform daily injections; therefore a complete once daily strategy is suggested for this 
sub-group.  
The simulations from the prophylactic aspects in this thesis found that a proportion of women 
would not have a measurable trough anti-Xa activity with a once daily dose. Monitoring anti-Xa 
activity is currently not recommended in any of the guidelines for prophylactic indications and is 
unlikely to be beneficial in the prophylactic setting (unlike in the treatment setting). A better 
marker of efficacy needs to be established for prophylactic doses. This is where thrombin 
generation could serve a useful purpose. If it can be established what % inhibition of peak 
thrombin generation achieves a prophylactic effect at a pre-defined time point, then that could 
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potentially be used as a marker of the efficacy of prophylactic regimens and be used to guide 
future research addressing why LMWH is only ~60-70% effective in preventing VTE when 
prescribed for prophylactic indications. More recently, a novel approach has also been suggested 
by Mandema and colleagues [2011]. They suggest a model based approach to comparing the 
thromboprophylatic effect of different anticoagulants following orthopaedic surgery. In their study, 
a therapeutic index was created, which represented the ratio of the dose with an acceptable 
bleeding risk to the dose with a relevant risk reduction for VTE. Such model based approaches in 
the future, might also be used to help tackle the problem of what pharmacodynamic response 
produces an efficacious thromboprophylactic response.  
Getting the dosing of thromboprophylaxis correct is important. A recent cross sectional study has 
been completed by Revell and Smith [2011], evaluating 109 deliveries over a one week period at 
their district general hospital. Their aim was to quantify the number of women who would reach 
the threshold for antenatal and postnatal thromboprophylaxis, according to the current RCOG 
guidelines. They found that 7% of women met the threshold for antenatal thromboprophylaxis and 
41% met the threshold for postnatal thromboprohylaxis. The large numbers of women, particularly 
during the postpartum period eligible, illustrates why it is important to get the dosing strategy right. 
In summary, the current RCOG prophylactic guidelines should be amended for the obese 
population (those weighing >90kg), so that all women prescribed enoxaparin (and dalteparin) for 
prophylactic indications receive an appropriate once daily regimen. Women are also more likely to 
adhere to such a regimen and therefore gain maximal benefit from the prophylactic LMWH 
prescribed.  
8.1.1.3 Do obese patients require special consideration? 
Dosing of the obese population provides a particular challenge, due to uncertainty outside of 
pregnancy of whether the dose of LMWH should be increased in proportion to actual weight or 
whether it should be capped at a maximum dose. The current consensus is that LMWH dose 
should be increased with increasing body weight, but caution should be exercised when using 
actual body weight, as LMWH CL is highly correlated with lean body weight, which would be a 
better descriptor to use for dosing LMWH [Patel et al., 2011].  
The obese population does deserve special attention; recent reports suggest that the extremely 
obese population are more likely to bleed and suffer from complications during the antenatal 
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period, even when not prescribed LMWH. Therefore having to inject LMWH for a treatment or 
prophylactic indication could considerably increase the risk of bleeding in this population [Modder 
and Fitzsimons, 2010] and particular vigilance would seem appropriate for this population, until 
the underlying mechanisms are better understood. 
8.1.1.4 Adherence to LMWH during pregnancy and the puerperium 
The findings from the adherence sub-study of this thesis suggest that women are highly adherent 
to enoxaparin (>80%), during both the antenatal and the puerperium periods. However in a group 
of women adherence to enoxaparin fell following the birth of their baby. The results suggest that 
pregnant women’s antenatal beliefs around necessity and concerns of enoxaparin could predict 
their postnatal adherence. No statistically significant differences in adherence rates were found 
between Caucasian and African-Caribbean women, those women once versus those women 
injecting twice a day and also between those women who had a history of recurrent miscarriage 
compared to those women who did not. 
The findings from the adherence sub-study are important for two reasons. Firstly, they 
demonstrate that women will inject themselves with a parenteral medication during pregnancy, if 
they believe it is protecting their health and that of their unborn baby; demonstrating a protective 
behaviour towards their unborn baby. Additionally, if such a strong belief is carried through to the 
postnatal period, then such a belief could lead to non-adherence during the postnatal period. This 
finding does also imply that adherence could be an issue for women who are commenced on 
enoxaparin (LMWH) just during the postnatal period. The threshold for commencing LMWH 
prophylaxis is much lower during the postnatal period than antenatally, according to the current 
RCOG guidelines: 
 two or more risk factors (e.g. age >35, obese class III), : at least 7 days postnatal 
prophylactic LMWH 
 If persisting or >3 risk factors (e.g. age >35, obese class III, parity >2), consider extending 
thromboprophylaxis with LMWH 
The results in this thesis demonstrate that an important driver of adherence might be the 
protection of the baby in-utero. Therefore for those women who are simply prescribed 
thromboprophylaxis during the postnatal period, clinicians may find that adherence to LMWH is 
not complete and varies, as the perceived necessity may not be that strong. Further studies are 
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needed to explore this issue, as it could help optimise for how long thromboprophylaxis is offered 
in women during the puerperium, particularly as the numbers eligible during the post-partum 
period increases significantly [Revell and Smith, 2011]. 
8.1.2.1 Exceptions to once daily antenatal LMWH I: mechanical heart valves 
As discussed in chapter four, the antenatal management of women with prosthetic mechanical 
heart valves in-situ provides a particular challenge. The literature suggests that the risk of valve 
thrombosis and death is lowest with coumarin anticoagulants and highest with unfractionated 
heparin during pregnancy. Low molecular weight heparins can be used and the most 
comprehensive guidelines in the field (the ACCP [Bates et al., 2012]), state that if LMWH is used, 
that dosing should be twice a day and adjusted to aim for a 4 hour post injection anti-Xa of 1-1.2 
IU/mL. Following the findings from this thesis, the question to consider is whether a once daily 
dose of LMWH could be used, as suggested for the management of VTE. The PK changes 
reported in this thesis, will also apply to the mechanical heart valve pregnant population and so 
one would anticipate an increase in trough anti-Xa activity with the progression of pregnancy and 
the potential advantage that brings, supporting a once daily dosing strategy. However, the 
mechanical heart population is very different to the VTE population, in terms of risk. The literature 
is littered with case reports of women suffering apparent treatment failures whilst on therapeutic 
dose LMWH. In view of this, to suggest a once daily LMWH just on the basis of this study, 
particularly as none of the women in this study had a mechanical heart valve in-situ, would seem 
unwise. Further research specifically in this population is required before such a recommendation 
can be made. 
If the VTE treatment recommendations cannot be directly applied to the mechanical valve 
population, what can be learnt and applied from this thesis for the antenatal mechanical heart 
valve population? 
First, the Vd issue is important here. The ACCP guidelines [Bates et al., 2012] suggest that a 
twice daily dose of LMWH should be adjusted to maintain the 4 hour peak anti-Xa activity 
between 1-1.2 IU/mL. Given observed changes to Vd over the course of pregnancy, this strategy 
runs the danger of over-anticoagulation, as an inevitable drop in peak anti-Xa activity will occur, 
with a respective rise in the trough anti-Xa activity. This then potentially places the patient at risk 
of bleeding, if LMWH doses are aggressively increased in response to the drop in peak anti-Xa 
activity. Recent published reports suggest this to be the case [Saeed et al., 2011; Basude et al., 
 - 277 - 
2012], where as well as valve thrombosis being reported, epistaxis, vaginal spotting, and 
intracerebral haemorrhage were also reported by these studies and may be linked to clinicians 
trying to maintain the peak anti-Xa activity aggressively within the 1-1.2 IU/mL range. 
Haematology- obstetric experts are in the process of re-thinking this strategy; at the recent 
International Society of Thrombosis and Haemostasis conference, Dr Claire McLintock, an 
international expert on managing anticoagulation in women with mechanical heart valves during 
pregnancy, was invited to give the Shirley Johnsson memorial lecture [McLintock, 2012]. In her 
lecture, she discussed this issue and suggested that her practice is likely to alter in the future, 
with more of a focus on monitoring anti-Xa trough activity for women on a twice daily LMWH 
regimen for this indication. The research findings in this thesis would certainly support such a 
strategy; those women with low or negligible trough activities can have their dose increased, as 
opposed to a wholesale increase for all women. The challenge in part will be on knowing what is 
an acceptable anti-Xa trough activity. At the National Women’s Hospital and Auckland City 
Hospital, Dr McLintock specifically recommends the following monitoring schedule for enoxaparin; 
1mg/kg bd, peak (4 hours): 07-1.2 IU/mL and trough (12 hours): 0.4-0.7 IU/mL [Pavord and Hunt, 
2010].  
It is surprising that the literature over the last 10-15 years has reported a number of failures with 
the use of LMWH in this population, suggesting that treatment doses of LMWH are not effective 
during pregnancy. However, most reports have assumed that medication adherence to be 
complete in this population. McLintock and colleagues [2009] found that those mechanical valve 
patients who had poor adherence with LMWH had poorer outcomes compared to those who took 
their LMWH as prescribed. Medication adherence is complex and very patient specific; 
McLintock’s findings are unsurprising and given the findings outlined in this thesis (chapter 7), 
perhaps greater emphasis on adherence should be placed, before a conclusion that LMWH has 
failed is drawn. More emphasis and evidenced based support with adherence is required 
specifically in this situation, given the large risks involved, with reports continuing to be published 
in the literature exemplifying the risks involved [Nelson-Piercy and Greer, 2012]. 
In summary, a once daily recommendation of LMWH cannot be recommended for the mechanical 
heart valve population until further evidence from this specific population is obtained. A trough 
monitoring strategy seems a more appropriate anti-Xa activity monitoring strategy in this 
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population. Strategies supporting adherence to LMWH should be provided to women suspected 
of non-adherence, as this is more likely to lead to a successful outcome in these women.  
8.1.2.2 Exceptions to once daily antenatal LMWH II: antithrombin deficiency 
Women with antithrombin deficiency are at high risk of VTE and may require higher than usual 
prophylactic doses during pregnancy, particularly those with type-1 deficiency (reductions in both 
activity and antigen). AT deficiency is discussed here, because the pharmacological activity of 
LMWH is exerted by potentiating the effects of anti-thrombin, and so a deficiency could render the 
LMWH less effective. In a pregnancy setting this could be problematic, with few studies 
specifically exploring this issue. Practice has centred on giving a higher and more frequent dose 
of LMWH for this group of patients (40mg twice a day, as opposed to 40mg daily). The question of 
whether a once daily dose of LMWH could be used in this population is raised again (i.e. 80mg 
once daily as opposed to 40mg twice a day). The principal finding from this study that trough anti-
Xa activity increases in the antenatal population, will not be different for an antenatal antithrombin 
deficient pregnant woman. Given this, there is no reason to believe that a once daily prophylactic 
dosing strategy would be ineffective. However, due to the specific high risk nature of this 
population and because of the nature of LMWH mechanism of action, until further evidence in this 
area is available, it would be unwise to ignore the current suggested dosing regimen of twice daily 
dosing, where the majority of experience exists, although at King’s College Hospital, AT deficient  
women are managed with a once daily dose of LMWH. However, like previous discussions, the 
target peak anti-Xa activity should be re-considered, as one anticipates a drop with the 
progression of pregnancy, due to the increase in Vd. 
8.1.3 Management of treatment doses of LMWH at the time of delivery 
At some centres, like King’s College Hospital, standard practice for women who are on once daily 
treatment doses of LMWH is to divide the total daily dose of once daily enoxaparin, around 36 
weeks gestation; for example if a woman is prescribed enoxaparin 120mg once daily, then to 
prescribe 60mg twice a day. The rational for this, is that given the woman could go into labour at 
any time, splitting the dose to a twice daily regimen, reduces the chances of high peak 
concentrations being achieved at the time of delivery.  
The current RCOG guidelines for the management of VTE, specify how LMWH should be 
managed at the time of delivery [Royal College of Obstetricians and Gynaecologists, 2007]. 
Would a once daily dose of LMWH cause problems for women at the time of delivery? 
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For women who have a planned induction or planned caesarean section, once daily enoxaparin 
(or LMWH) should not present a problem, as they can be advised to omit their enoxaparin 
treatment dose 24 hours before surgery (i.e. omit the day before) or when induction booked.  
Women receiving once a day and twice a day treatment doses of LMWH waiting for spontaneous 
labour, present more of a challenge for both LMWH regimens, due to the uncertain nature of 
spontaneous labour making it difficult to know how to manage the LMWH, if an epidural is 
required. No plan can be formulated, as it will all depend on when the woman goes into labour to 
what needs to happen and what pain relief can be offered. Either way, a multi-disciplinary 
approach to support women in this position seems the most logical approach to adopt.   
8.1.4 Recommended future research priorities 
The recent availability of the novel oral anticoagulants in clinical practice, e.g. rivaroxaban and 
dabigatran, offer many advantages over existing anticoagulant treatments, e.g. oral formulation, 
and immediate onset of anticoagulant effect. However, their use during the ante- and post-natal 
periods is not established and is unlikely to be, for the foreseeable future. For these reasons, 
future antenatal research work should focus on LMWH use, with particular priorities being: 
a) Preventing thromboembolic complications in the mechanical heart valve population 
through better understanding and establishment of a trough target, to help guide 
clinicians on when a dose increase might be required. Establishing a minimum inhibitory 
concentration would be the challenge here and the global coagulation assays, e.g. 
thrombin generation, may have a role to play in establishing this. 
b) For women who suffer VTE in the first trimester, an important question to address is 
whether they really need LMWH for the full nine months at treatment dose LMWH, or 
whether the dose be reduced after 3 months. As the recurrence rate is so low once on 
treatment, conducting a clinical trial is likely to be futile, as 1,000’s of women would need 
to be recruited to demonstrate one intervention is better over another. Perhaps, the best 
way to address this question would be to observe the outcome of women who are given 
three months full intensity LMWH, followed by a reduction in dose; such a case series 
may help clinicians build up experience in this area of uncertainty.  
c) Women managed on once daily LMWH for the treatment of VTE, should be followed up 
across the UK, as a cohort study to confirm (or disprove) the findings from this thesis. 
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d) The obese antenatal population in the UK (and worldwide) is on the increase. Obesity is 
an independent risk factor for VTE, but reports suggest that obese women also suffer 
more bleeding (particularly at the time of delivery). Further study into why this might be 
the case would be welcome, as it would help clinicians to appropriately balance the risk of 
VTE with the risk of bleeding. 
 
8.1.5 Conclusion 
To conclude, the primary aim of programme of research of this thesis was to establish how the 
pharmacokinetics of enoxaparin are altered during pregnancy and thus determine what the 
optimal dosing strategy of enoxaparin is, for the management of VTE. Through applying the 
method of non-linear mixed effects modelling, mathematical models which estimated CL and Vd 
during pregnancy were developed (equations 8.1-8.4): 
CL = POPCL x GESTCL x (Wt/80)
1.06
       (8.1) 
Vd = POPVd x GESTV x (LBW/42)
1.25
       (8.2) 
where during pregnancy: 
GESTCL=1          (8.3) 
GESTV=(GEST/MGEST)
0.357
        (8.4) 
Simulations of women injecting once versus twice daily doses of enoxaparin demonstrated that 
for the majority of women, a once daily dose of enoxaparin would be appropriate for the 
management of antenatal VTE, due to a significant increase in the Vd, prolonging the half-life of 
enoxaparin. National and international guidelines should reconsider their current 
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 March 2010 
 
 
 King’s College Hospital NHS Foundation Trust 
King’s College Hospital 
Denmark Hill 
London SE5 9RS 
 
                                                                 Jignesh Patel 
                                                                                    Mobile tel: 07984949011 
                                                                                      Direct fax: 020 3299 4689 
                                                                                      Email: jig.patel@kcl.ac.uk 
 
Patient Information Sheet 
 
We would like to invite you to take part in a research study. Before you decide if you 
want to take part you need to understand why the research is being done and what it 
would involve for you. Please read the following information carefully. You may ask 
us if there is anything that is not clear or if you would like more information.  
 
Take time to decide whether you would like to take part or not. 
 
Title: Optimising the use of enoxaparin during the antenatal period  
 
 
Please read Part 1. If the information given there interests you and you are 
considering taking part in the study, please read the additional information in Part 2 
before making any decision. 
 
At your next appointment, a member of the research team will go through the 





Purpose of the study 
During pregnancy changes which occur in a woman’s body increases the chance of 
developing blood clots in the veins of the body. So pregnant women who are at high 
risk of getting these clots or already have these clots are given the medicine, 
enoxaparin. 
 
Enoxaparin works by reducing the stickiness of the blood, stopping these clots from 
forming. 
Currently it is not known how the amount of enoxaparin in the body changes as 
pregnancy progresses. It is important that we know how the amount of enoxaparin in 
the body changes during pregnancy, so that pregnant women receive the best dose of 
this medicine. 
 
The purpose of this study is to find out how being pregnant affects the amount of 
enoxaparin in the body so that we can make sure that pregnant women get the best 
dose of enoxaparin to reduce the chance of these blood clots developing.   
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Why have I been invited? 
You have been invited to take part in this study because you are having or about to 
have enoxaparin.  
 
 
Do I have to take part? 
No. It is up to you to decide. If you do decide to take part you are free to withdraw at 




What will happen to me if I take part? 
If you wish to take part in the study you will be asked to sign a consent form.  
 
During pregnancy  
During pregnancy you will be asked to inject the enoxaparin at a particular time of 
day. You will normally attend the haematology clinic every 4 weeks, where the doctor 
will normally measure enoxaparin activity in the blood through a blood test. 
 
If you decide to take part in this study, we will ask you to have two additional blood 
tests each time you visit the haematology clinic. These additional blood tests also 
measure the amount of enoxaparin in your blood, but they will be taken at different 
times during your clinic visit. This will help us to determine how the amount of 
enoxaparin is changing with time. 
 
All blood tests will be taken from a vein in your arm by a trained member of the 
research team. This blood test will be similar to other blood tests you may have had at 
your GP or other clinics. We will ask you if you prefer to have the blood taken from a 
particular arm. 
  
A small quantity of blood (one and a half tablespoons) will be taken at each clinic 
visit, as follows:  
 
 one table spoon of blood will be taken on arrival at clinic,  
 half a tea spoon of blood will be taken 1 hour later and,  
 a further half a tea spoon will be taken 3 hours after you arrived in clinic.  
 
In addition, at each clinic visit you will be weighed and will be asked about any 
changes in any medications you may be on. 
 
If you decide to participate in the study, it is expected that your appointment in the 
haematology clinic will last 3 hours in total each time – due to the additional tests 
being done.  
 
 
The following diagram shows what a typical visit to the haematology clinic will 
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On arrival You will see the researcher in clinic and the following information will be 




- asked about changes in medications 
- blood tests taken 
 
You will then be asked to inject your usual dose of enoxaparin in clinic 
 
  
1 hour later A blood test will be taken one hour later by the researcher. 
 
You will also see the haematology doctor – as part of routine clinical care 
 
  
3 hours after arriving 
in clinic 
Another blood test will be taken and you will be given the date and time 
of your next appointment  
 
 
During month 2, 5 and 8 of your pregnancy, we will also do additional tests, looking 
at how your blood is clotting. Three samples will be taken - at the same time as the 
other blood tests.  
At these clinic visits, a total of 2 tablespoons of blood will be taken – due to these 
extra tests being done. 
 
After your baby is born  
Once your baby is born, we will measure how your blood is clotting twice:  
 once whilst you are still in hospital following the birth of your baby, and 
 again 8 weeks after your baby is born. 
 
 
In addition during your pregnancy, you will also be asked to complete a short 
questionnaire which explores your views about having to take enoxparin during your 
pregnancy. 
This is being done, as currently very little information exists on what women’s views 
are, around having to inject enoxaparin during their pregnancy. 
 
Expenses and payment 
Travel costs will be provided for all visits to meet the research team that are not on 
the same day as your usual outpatient appointments at the haematology or antenatal 
clinic.  
 
Whilst you are waiting for all three blood tests to be taken at each clinic visit, we will 
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What are the possible disadvantages and risks of taking part in the study? 
As with any blood test, there could be discomfort and/or bruising at the site from 
where the blood is taken.  
 
Your clinic appointments will take longer than if you were not in the study.  
 
 
What are the possible benefits of taking part? 
The usual blood tests which you will have as part of your normal care will be taken in 
the haematology clinic – so you will not have to go to the blood test area of the 
hospital for these. 
 
The results from this study will give valuable information on the use of enoxaparin 
during the antenatal period. 
 
Overall, we cannot promise that the study will be of direct benefit to you.  
 
What happens when the research stops? 
You will continue to see the doctor at the haematology clinic. 
 
What if there is a problem? 
Any complaint about the way you are being dealt with during the study or any 
possible harm you might suffer will be dealt with. The detailed information on this is 
given in Part 2. 
 
Will my taking part in the study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be 






What if relevant new information becomes available? 
If any new information on this medicine becomes available, then your doctor will let 
you know. If this happens a member of the research team will discuss with you 
whether you should continue in the study. If you decide to continue in the study, you 
may need to sign a new consent form. If you decide to withdraw from the study, you 
will continue to see your usual doctor and the care you receive will not be affected. 
 
 
What will happen if I don’t want to carry on with the study? 
If you decide to withdraw from the study, please contact the research team. You are 
free to withdraw at any time, without giving a reason. Withdrawing from the study 
will not affect the care that you receive. If you wish, any stored blood that can be 
identified as yours will be destroyed. All data collected up to the time of your 
withdrawal from the study will be used. 
After entering the study, should you lose the ability to give consent you will be 
withdrawn from the study at this time. We will use any blood or information collected 
up to the time of your withdrawal from the study.  
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What if there is a problem? 
If you are worried about any part of the study, you should speak to a member of the 
research team (contact names and telephone numbers are at end of this sheet). 
If you remain unhappy and wish to complain formally, you can do this through the 
NHS Complaints procedure. Details can be obtained from the hospital. 
 
In the event that something goes wrong and you are harmed due to someone’s 
negligence, you may have grounds for legal action but you may have to pay for your 
legal costs.  
The normal National Health Service complaints mechanisms will be available to you. 
 
What will happen to any blood samples I give? 
All blood samples collected will be securely stored in a freezer at the hospital. Only 
members of the research team will have access to these samples. Each research 
sample will be identified with a unique number. It will only be possible for members 
of the research team to link the samples back to you. 
 
Samples will not be moved out of the UK; but they may be transferred to a different 
laboratory in the UK for testing if equipment at the hospital is unavailable e.g. 
breakdown of equipment. 
 
At the end of the study all blood samples will be destroyed. Should our team or 
another team of researchers wish to use the samples for any other work, ethical 
approval will be required and you must give further consent. 
 
What will happen to the questionnaire I complete? 
The information from the questionnaire will be entered onto a computer, so it can be 
analysed. The information from your completed questionnaire will be anonymised 
and will not be shared with your clinical team. 
 
Will genetic tests be done? 
No.  
 
What will happen to my data? 
All information collected during the study will be kept strictly confidential. Your 
data will be anonymised using a unique number.  
 
The data collected will only be used for this study. The data will be stored securely on 
a password protected computer at the hospital. Only members of the research team 
will be able to access the data.  
 
The data will be retained for 5 years and then destroyed. Use of the data in other 
studies will not be possible without further ethical approval and consent from you. 
 
Involvement of the General Practitioner (GP) 
We would like to inform your GP that you are taking part in this study. We will only 
inform your GP with your consent.   
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Informing your hospital doctor (referring doctor) 
We would like to inform your hospital doctor that you are taking part in this study. 
We will only inform your hospital doctor with your consent.  
 
What will happen to the results of the research study? 
If you decide to participate in this study, we will ask you if you wish to be informed 
of any results arising from the research. When results are obtained we will send you a 
letter providing an outline of the broad scientific results of the study, with references 
for any work that has been published in medical journals. 
 
It is hoped that results will be presented at scientific meetings and published in 
medical journals. At no time will it be possible to identify that you have taken part in 
this study.  
This study will be described in the researcher’s (Jignesh Patel) PhD thesis. 
 
Who is organising and funding the research? 
King’s College Hospital Foundation NHS Trust is sponsoring the research. 
The GSTFT/KCL National Institute of Health Research Biomedical Research Centre 
is funding the research. 
 
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, called a 
Research Ethics Committee to protect your safety, rights, wellbeing and dignity. This 
study has been reviewed and given favorable opinion by the Isle of Wight, 
Portsmouth and South East Hampshire Research Ethics Committee. 
 
Further information and contact details 
 
1) General information about research 
 
National Electronic Library for Health www.library.nhs.uk/trials 
The National Research Register (UK database of research projects) www.nrr.nhs.uk 
INVOLVE (Promoting public involvement in the NHS) www.invo.org.uk 
 
2) Sponsor and Funder’s website 
 
King’s College Hospital www.kch.nhs.uk and www.kingshealthpartners.org 
NIHR GSTFT/KCL Biomedical Research Centre www.biomedicalresearchcentre.org 
 
3) Specific information about this research study 
 
Jignesh Patel 07984949011  
Dr. Roopen Arya 020 3299 3570 
Dr. Raj Patel 020 3299 3418 
Mr. Michael S Marsh 020 3299 3629 
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King’s College Hospital NHS Foundation Trust 
King’s College Hospital 
Denmark Hill 
London SE5 9RS 
 
                                                                                     Mobile tel: 07984949011 




CONSENT FORM (version 2) 
  
Title of Study: Optimising the use of enoxaparin during the antenatal period 
 
Name of Researcher: Jignesh Patel  
       
Please initial each box                    
Initials
 
1. I confirm that I have read and understand the information sheet dated 17th 
March 2010 Version 3, for the above study. I have had the opportunity to 
consider the information and ask questions. 
     
2. I understand that my participation is voluntary and that I am free to withdraw at 
any time without giving any reason, without my medical care or legal rights being 
affected.  
  
3. I understand that relevant sections of my medical notes and data collected 
during the study may be looked at by individuals from the research team and 
also by regulatory research and ethical authorities in the NHS Trust, where it is 
relevant to my taking part in this research.  I give permission for these individuals 
to have access to my records.  
  
4. I agree to my GP being informed of my participation in the study.     
 
5. I agree to my hospital doctor (referring doctor) being informed of my 
participation in the study 
 
6. I am happy to complete the questionnaire as part of the study 
 
7. I agree to take part in the above study.     
   
____________________                    ________________                       _________________  
Name of Patient                          Signature                                        Date                                      
  
I confirm that I have explained the study to the participant and have answered their questions 
honestly and fully. 
 
____________________                 ________________                    _________________ 
Name of Person                          Signature                                       Date   
taking consent   
 
 
Patient would like information on the broad results of the study:   Yes   /   No 
 
When completed, 1 for patient; 1 for researcher site file; 1 (original) to be kept in medical notes 
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Appendix V: NONMEM control stream for the base model (model 1) 
 
$SIZES LIM6=2000000 
$PROB BASE PREGNANCY MODEL 
 
$INPUT ID AGE WT DAT1=DROP TIME AMT DOSE DVID DV MDV GEST TRI CRE CRCL LBW 
ETHN 
 
$DATA ..\final22.csv IGNORE=@ 
ACCEPT=(DVID.LE.1) 





TVCL  =THETA(1) 
TVV    =THETA(2) 
TVKA =THETA(3) 
 







;MODEL FOR RANDOM BETWEEN SUBJECT VARIABILITY 
CL  =TVCL*EXP(ETA(1)) 





















0.1                 ;PPVCL 
0.05 0.1         ;PPVV 
 
$SIGMA 
0.1                 ;PROPRUV 
0.2                 ;ADDRUV 
 
$EST MAX=9990 SIG=3 PRINT=1 METHOD=1 INT 
$COV PRINT=E 
 
$TABLE ID TIME AMT DOSE DVID DV MDV WT AGE CRE CRCL TRI CL V KA ETA1 ETA2 
IPRE TAD CWRES IWRE LBW ETHN GEST 
ONEHEADER NOPRINT FILE=final.fit 
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Appendix VI: NONMEM control stream for the base model with M3 error method 
 
$SIZES LIM6=2000000 
$PROB BASE PREGNANCY MODEL 
 
$INPUT ID AGE WT DAT1=DROP TIME AMT DOSE DVID DV MDV GEST=DROP TRI CRE 
CRCL 
 
$DATA final22M3.csv IGNORE=@ 
ACCEPT=(DVID.LE.1) 





TVCL  =THETA(1) 
TVV    =THETA(2) 
TVKA =THETA(3) 
 





;SCALE CONCENTRATIONS x 1000 to covert anti-Xa from IU/mL to IU/L 
SC=V*1000 
 
$ERROR                                                    ; M3 METHOD 
 
ADD=THETA(4)                                          ; ADDITIVE PART 
PROP=F*THETA(5)                                    ; CV PART 
SD=SQRT(ADD*ADD+PROP*PROP)           ; COMBINED ERROR MODEL 
LLOQ=0.01 
IF (DV.GE.LLOQ) THEN                              ; NON BQL VALUES 
     F_FLAG=0 
     Y=F+SD*EPS(1) 
ELSE                                                          ; BQL VALUES 
     F_FLAG=1 




(0.1,10)   
(1,15)     
(0.01,3)   
(0,1)                 ;SDADD 
(0,1)                 ;CVPROP 
 
$OMEGA BLOCK(2) 
0.1                   ;PPVCL 
0.05 0.1           ;PPVV 
 
$SIGMA 1 FIX 
 
$EST MAX=9990 SIG=4 PRINT=1 METHOD=1 INT LAPLACIAN NUMERICAL SLOW 
$COV PRINT=E 
 
$TABLE ID TIME AMT DOSE DVID DV MDV WT AGE CRE CRCL TRI CL V KA ETA1 ETA2 
CWRES 
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Appendix VII: NONMEM bootstrap code for the base model 
 
$SIZES LIM6=2000000 
$PROB BASE PREGNANCY MODEL 
 
$INPUT ID AGE WT DAT1=DROP TIME AMT DOSE DVID DV MDV GEST TRI CRE CRCL LBW 
ETHN 
 
$DATA ..\final22.csv IGNORE=@ 
ACCEPT=(DVID.LE.1) 





TVCL  =THETA(1) 
TVV    =THETA(2) 
TVKA =THETA(3) 
 





















(0.1,10)   
(1,15)     
(0.01,3)   
 
$OMEGA BLOCK(2) 
0.1                            ;PPVCL 
0.05 0.1                    ;PPVV 
 
$SIGMA 
0.1                            ;PROPRUV 
0.2                            ;ADDRUV 
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Appendix VIII: NONMEM control stream for the final pregnancy model 
 
$SIZES LIM6=2000000 
$PROB BASE PREGNANCY MODEL 
 
$INPUT ID AGE WT DAT1=DROP TIME AMT DOSE DVID DV MDV TRI CRE CRCL LBW BABY 
GEST ETHN MGEST 
 
$DATA ..\final23.csv IGNORE=@ 
ACCEPT=(DVID.LE.1) 






































(0.1,1)            ;POPCL 
(1,15)             ;POPV  
(0.01,3)          ;POPKA  
(0.445)           ;FACGESTV 
(-0.1)              ;FACGESTCL2 
(-0.5)              ;FACGESTV2 
(1.47)             ;FACLBWV 
(0.165)           ;FACWTCL 
 
$OMEGA BLOCK(2) 
0.1                 ;PPVCL 
0.05 0.1         ;PPVV 
 
$SIGMA 
0.1                 ;PROPRUV 
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0.03               ;ADDRUV 
 
$EST MAX=9990 SIG=3 PRINT=1 METHOD=1 INT 
$COV PRINT=E 
 
$TABLE ID TIME AMT DOSE DVID DV MDV WT AGE CRE CRCL TRI CL V KA ETA1 ETA2 
IPRE TAD CWRES GEST ETHN MGEST 
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Appendix IX: NONMEM bootstrap code for the final model 
 
$SIZES LIM6=2000000 
$PROB BASE PREGNANCY MODEL 
 
$INPUT ID AGE WT DAT1=DROP TIME AMT DOSE DVID DV MDV TRI CRE CRCL LBW BABY 
GEST ETHN MGEST 
 
$DATA ..\final23.csv IGNORE=@ 
ACCEPT=(DVID.LE.1) 































(0.1,1)           ;POPCL 
(1,15)            ;POPV 
(0.01,3)         ;POPKA  
(0.445)          ;FACGESTV 
(-0.1)             ;FACGESTCL2 
(-0.5)             ;FACGESTV2 
(1.47)            ;FACLBWV 
(0.165)          ;FACWTCL 
 
$OMEGA BLOCK(2) 
0.1                 ;PPVCL 
0.05 0.1         ;PPVV 
 
$SIGMA 
0.1                 ;PROPRUV 
0.03               ;ADDRUV 
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Appendix X: ‘R’ code for VPC of final model 
 
################################################### 
######### Enoxaparin in Pregnancy Study VPC  ########### 
################################################### 
 





# READ RAW DATA 
 
obdata          <- read.csv(file=paste("c:/nm72/nm7/run/","final23.csv", sep=""),header=TRUE) 
 
# READ SIM DATA 
 
simdata          <- read.table(file=paste("c:/nm72/nm7/run/",simdataname,"final450.fit", sep=""),  
header=FALSE,skip=0) 
 
tablerow<-c("ID", "TIME", "AMT", "DOSE", "DVID" , "DV", "MDV", "WT", "AGE","CRCL", "TAD", 
"GEST","ETHN", "REPI", "BABY", "TRI", "MGEST") 
 
dimnames(simdata)<-list(1:nrow(simdata),tablerow) 













png(filename = "Rplot%03d.png", width = 480, height = 480, units = "px", pointsize = 12, 
bg = "white", res = NA, family = "", restoreConsole = TRUE, 
type = c("windows", "cairo", "cairo-png")) 
 
################################ 









# Generate Percentiles  # 
######################### 
 
obdata$TIM<-round(obdata$TIME)                      
obdata$TAD<-round(obdata$TAD)                        
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data$TAD<=6,5,ifelse(simdata$TAD>6&simdata$TAD<=10,8,ifelse(simdata$TAD>10&simdata$T















time<-sort(unique(obdata$TIMBIN))                    
timesim<-sort(unique(simdata$TIMBIN))                
 
plot (timesim,simpercentile5, ylim=c(-0.005,0.025),type="n", axes=F,ylab="",xlab="",xlim=c(-1,40)) 
 
points (obdata$TAD,obdata$DV, pch=1, cex=0.75) 
 
lines (time,obpercentile95, lty="dashed",lwd=4, col="red") 
lines (time,obpercentile50, lty="solid",lwd=4, col="red") 
lines (time,obpercentile5, lty="dashed",lwd=4, col="red") 
 
lines (timesim,simpercentile95, lty="dashed",lwd=4,col="blue") 
lines (timesim,simpercentile50, lty="solid",lwd=2,col="blue") 
lines (timesim,simpercentile5, lty=2,lwd=4,col="blue") 
 
box() 
mtext(side=1,"Time After Last Dose (hr)",cex=0.75,line=3)                     
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Appendix XI: The adapted beliefs about medication questionnaire used in this study 
 
Participant Number:          
Understanding your views on having to take enoxaparin whilst you are 
pregnant 
 
You have been asked to complete this questionnaire, as you are currently having enoxaparin 
therapy during your pregnancy. 
Currently, very little information exists on pregnant women’s views about taking medicines, in 
particularly enoxaparin during pregnancy.  
As part of the enoxaparin in pregnancy study, we want to explore your views about medicines 
use, in particularly enoxaparin, during pregnancy and would like you to complete this 
questionnaire.  
The questionnaire comprises of two main sections. The first section will investigate your views 
about medicine use in general during pregnancy. The second section will investigate your views 
about enoxaparin therapy specifically. 
Instructions 
 In both sections, a series of statements have been made.  
 A 5-point rating scale is used, going from strongly agree to strongly disagree. Please consider 
each statement in turn and tick the box that best describes your views to that statement. 
 At the end of the questionnaire, there is an opportunity for you to write any other comments 
you may have 
 
Please answer every question. It will take approximately 10 minutes to complete. 
Your answers will be completely anonymous and will be kept confidential. 
There are no “right” answers to the questions – we are simply interested in your views. 
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Section 1: General questions relating to medicine use in general during 
pregnancy 
 
This section explores your views and concerns (if any) about taking medicines in general whilst 
you are pregnant. 
Please answer every question by ticking the box that best describes your views to each 
statement. 










Doctors use too many medicines during pregnancy 
 
     
G2 
Pregnant women who take medicines should stop their 
treatment for a while every now and again 
     
G3 
Most medicines are addictive 
 
     
G4 
Natural remedies are safer than medicines during 
pregnancy 
 
     
G5 
Medicines used during pregnancy do more harm than 
good 
 
     
G6 
All medicines are poisons when taken during 
pregnancy 
 
     
G7 
Doctors place too much trust on medicines during 
pregnancy 
 
     
G8 
If doctors had more time with patients they would 
prescribe fewer medicines during pregnancy 
     
A1 
Over-the-counter medicines from a chemist are safer 
than prescription medicines during pregnancy 
     
A2 
Before considering to take a medicine during 
pregnancy, I like to know about the safety of that 
medicine to me and my unborn baby 
     
A3 
Most medicines are safe when taken during pregnancy 
if prescribed by a doctor 
     
A4 
When deciding on whether to take a medicine whilst I 
am pregnant, I place a higher priority on the impact the 
medicine will have on the health of my unborn baby 
than to any effects the medicine may have on me 
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Section 2: Specific questions relating to enoxaparin during pregnancy 
This section explores your views and concerns (if any) specifically around enoxaparin during 
pregnancy.  
Please answer every question by ticking the box that best describes your views to each 
statement. 









My health at present depends on enoxaparin 
 
     
S2 
Having to take enoxaparin worries me 
 
     
S3 
My life would be impossible without enoxaparin 
 
     
S4 
Without enoxaparin I would be very ill 
 
     
S5 
I sometimes worry about the long term effects of 
enoxaparin 
 
     
S6 
The enoxaparin is a mystery to me 
 
     
S7 
My health in the future depends on enoxaparin 
 
     
S8 
The enoxaparin disrupts my life 
 
     
S9 
I sometimes worry about becoming too dependent on 
enoxaparin 
     
S10 
Enoxaparin protects me from becoming worse 
 
     
R1 
My current pregnancy depends on enoxaparin 
 
     
R2 
Having to take enoxaparin during pregnancy worries 
me 
 
     
R3 
My current pregnancy would be impossible without 
enoxaparin 
     
R4 
Without taking enoxaparin during this pregnancy I 
would be very ill 
     
R5 
I sometimes worry about the long term effects of 
enoxaparin 
on my unborn baby 
     
R6 
Any pregnancies in the future will depend on me 
taking enoxaparin 
     
R7 
Enoxaparin is protecting my pregnancy 
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I sometimes worry about that being on enoxaparin will 
limit the type of child birth delivery I can have 
     
SA2 
Enoxaparin protects my unborn baby’s health 
 
     
 
SA3 
The enoxaparin does not cause me any side-effects 
 
     
SA4 
I sometimes worry that being on enoxaparin will limit 
the type of pain relief I can have at the time of child 
birth 
     
SA5 
Having to take enoxaparin throughout pregnancy is 
not an issue for me, as long as it helps to protect 
mine and my unborn baby’s health 
     
SA6 
Enoxaparin only works if taken regularly during 
pregnancy 
 
     
SA7 
It is difficult for me to take my enoxaparin in exactly 
the way my doctor has told me 
     
SA8 
I sometimes worry that being on enoxaparin during 
pregnancy will interfere with my ability to breastfeed 
when my baby is born 
     
SA9 
Having to inject myself with enoxaparin daily is not an 
issue for me, as long as the health of my unborn baby 
is protected 
     
 










THANK YOU VERY MUCH FOR COMPLETING THIS QUESTIONNAIRE 
 
 
